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Abstract
Aim: This thesis aims to explore and investigate the level and process of adoption of
Antimicrobial Stewardship Programmes (ASPs) and factors influencing their
implementation in Saudi Ministry of Health (MOH) hospitals. The findings of this study
will provide hospitals and policy makers with evidence-based recommendations on
how barriers to ASPs adoption can be overcome, which will ultimately improve
antimicrobial use and reduce antimicrobial resistance (AMR).
Method: A mixed method approach was carried out using both qualitative and
quantitative research methods. Semi-structured interviews were conducted with
healthcare professionals in three Saudi hospitals to explore the enablers and barriers
to their adoption of ASPs. A survey was then developed based on these findings to
investigate the level of hospitals’ adoption of ASPs and factors influencing their
implementation at a national level. Further, a case study using in-depth interviews was
utilised to understand the process of ASP adoption in a Saudi hospital, and how
adoption challenges were addressed. Finally, a self-administered questionnaire was
used to examine patients’ knowledge and perceptions of antimicrobial use and
resistance, and to evaluate the institutional role of patient education on antimicrobial
use in two Saudi hospitals. The overall methodology of the research is summarised in
Figure I.
Results: Despite the introduction of a national ASP strategy, adoption of ASPs in
Saudi MOH hospitals remains low. Organisational barriers such as the lack of senior
management support, lack of supportive IT infrastructure and the shortage of ASP
team members hinder hospitals’ efforts to adopt ASPs. Further barriers relate to the
lack of formal enforcement by MOH and the physicians fears of patients' complications
and clinical liability. Patients admitted to Saudi hospitals lack knowledge and
perceptions of AMR, and the adoption of ASPs may improve hospitals’ role in patients'
education.
Conclusions: Despite the established benefits of ASPs, their adoption in Saudi MOH
hospitals remains low. Urgent action is needed to address the strategies priorities
associated with AMR, including access to antimicrobials, antimicrobial stewardship
III
and education and research. Policy makers are urged to consider making ASPs
adoption in hospitals a regulatory requirement supported by national guidelines and
surveillance programmes. It is essential to increase the provision of ID and infection
control residency and training programmes to meet the extreme shortage of ID
physicians, pharmacists, microbiologists and infection control practitioners. Higher
education institutions and teaching hospitals are required to introduce antimicrobial
prescribing and stewardship competencies into undergraduate Medical, Pharmacy,
Dental, Nursing and Veterinary curriculum, as well as introduction of AMR topics in
order to increase knowledge and awareness of ASPs and AMR. Collaboration
between ASPs adopting and non-adopting hospitals is essential to share
implementation experience, strategies and solutions to overcome barriers. Healthcare
specialised associations are needed to be part of AMR conversation and guide
healthcare professionals’ training and accreditation.
Multiple stakeholders should be actively part of the conversations around tacking
AMR. Primary care, secondary care, community pharmacies and policy makers should
strive to create a shared culture of responsibility among all healthcare partners to
improve antimicrobial therapy and reduce risks of AMR.
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Figure I: Overall methodology of the research
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1Chapter 1: Introduction
1.1 Antimicrobial resistance (AMR)
The world Health Organisation (WHO) defines Antimicrobial resistance (AMR) as “the
ability of a microorganism (like bacteria, viruses, and some parasites) to stop an
antimicrobial (such as antibiotics, antivirals and antimalarials) from working against it.
As a result, standard treatments become ineffective, infections persist and may spread
to others” (World Health Organisation, 2014, 2016a).
When microorganisms are exposed to antimicrobials for an inappropriate period of
time or repeatedly at ineffective doses, they develop resistance mechanisms to drugs.
The microorganisms or bacteria that develop drug resistance are sometimes referred
to as superbugs. AMR is one of the biggest threats to public health, and there is an
urgent need for different government sectors and societies to take appropriate actions
towards preventing AMR spread (World Health Organisation, 2016b).
It is essential to note that without appropriate measures to treat infectious diseases,
therapeutic procedures like organ transplantation, diabetes management, cancer
chemotherapy and major surgery such as hip replacements and caesarean sections
will be high risk interventions to be undertaken. The cost incurred in taking care of an
individual with AMR is higher than the cost incurred to treat a person with no AMR due
to additional tests, accompanied by expensive drugs and a longer period of care
(World Health Organisation, 2016b).
According to the Centers for Disease Control and Prevention (CDC), there are two
million illnesses and 23,000 deaths in the United States (U.S.) alone due to AMR every
year. These illnesses account for as much as $20 billion in direct healthcare costs and
up to $35 billion in lost working hours due to the patients being unproductive during
their sick days leave and hospitalisation (Centers for Disease Control and Prevention,
2013b).
In Europe, it is estimated that infection is present in 5-12% of hospital patients,
resulting 400,000 patients with AMR and leading to 25,000 deaths with a total cost of
2€1.5 billion annually (European Medicines Agency, 2016; World Health Organisation,
2014, 2016f).
A prior study that evaluated the outcomes of failure in antibiotic therapy for patients
with skin infections through a large USA multihospital database, found that
inappropriate antibiotic regimen was associated with a 3-fold rise in mortality rates. It
also resulted in patients receiving intravenous (IV) antibiotic therapy for 5.7 additional
days, with additional hospitalisation of 5.4 days  and a mean of $5,285 in additional
inpatient costs (Edelsberg, Berger, Weber, et al., 2008). Using a large U.S. multi-
institutional database, it was also shown that failure of initial empiric antibiotic therapy
for hospitalised patients with intra-abdominal infections led to 5.6 additional days of IV
antibiotic therapy and 4.6 additional hospital stay with additional inpatient cost of
$6,368 (Edelsberg, Berger, Schell, et al., 2008). A more recent study, in 11 tertiary-
care hospitals in South Korea, found that failure of initial antibiotic therapy to treat
community-onset intra-abdominal infections caused an additional 2.9 days of IV
antibiotic therapy and patients being hospitalised for an additional 5.3 days leading to
an additional inpatient cost of $3,287 (Chong et al., 2015).
It is estimated that worldwide mortality due to AMR will be the highest at 10 million
people a year, followed by cancer at 8.2 million, and other causes of death such as
diabetes, diarrhoeal diseases, road traffic accidents, measles, cholera, and tetanus
following at a distance respectively in the year 2050 (Figure 1.1). This will cause a
decrease of about 2% to 3.5 % in gross domestic product by 2050, and it will cost the
world up to $100 trillion (O’Neill, 2014, 2016).
Figure 1.1: Worldwide deaths from AMR infection and other causes in 2050
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31.2 AMR Surveillance
The WHO stressed the need to put in place a global surveillance system to support
the global action plan and research on AMR, and to strengthen the evidence base on
AMR and support national, regional and global actions (WHO, 2014). In response to
this call, the Global Antimicrobial Surveillance System (GLASS) was launched in
October 2015 working in collaboration with centres and existing AMR surveillance
networks (World Health Organisation, 2014, 2015b).
According to WHO (2018) report, Escherichia coli (E. coli), Klebsiella pneumoniae (K.
pneumoniae), Staphylococcus aureus (S. aureus) and Streptococcus pneumoniae (S.
pneumoniae) were reported as the greatest concerns in relation to hospital and
community acquired infections (WHO, 2018). In that, it was reported by some
countries that E. coli resistance is more than 50% to third-generation cephalosporins
and fluoroquinolones in 5 out of the 6 WHO regions, K. pneumoniae had more than
30% resistance rates to third generation cephalosporins in most WHO countries and
exceeded 60% in some countries, and Methicillin-resistant staphylococcus aureus
(MRSA) resistance rates exceeded 20% in all WHO regions, and was reported to be
more than 80% in some regions.
These high rates of AMR can be due to the increasing rates of antimicrobial
consumption worldwide. The rate of the global antimicrobial consumption increased
by 36% between 2000 and 2010. Cephalosporins and penicillins were responsible for
more than 60% of the total amount of antimicrobial consumption in 2010, which is an
increase of 41% when compared to 2000 (British Society for Antimicrobial
Chemotherapy, 2018; Center for Disease Dynamics Economics & Policy, 2015; Van
Boeckel et al., 2014). The use of antimicrobials is associated with the seasonal spread
of infectious diseases like influenza (Polgreen, Yang, Laxminarayan, & Cavanaugh,
2011). From 2000 to 2010, the usage of antimicrobials peaked in Western Europe and
North America between December and February, in June and July in South America,
and within the tropics in August and September (Sun et al., 2012). This is due to winter
flu seasons, heavy rains and monsoons as well as risks of infectious diseases (Van
Boeckel et al., 2014).
4According to the Center For Disease Dynamics and Policy (CDDEP), two main factors
have been attributed to the rise in antimicrobial consumption all over the world. The
first one is the increase in household income, which has enabled people to access
and afford antibiotics easily. Although this has positive effects such as saving lives, it
has a negative impact in case of inappropriate usage that leads to AMR. The second
factor is the increase in demand for animal protein and the application of antimicrobials
to boost the growth and development of animals and agriculture (Center for Disease
Dynamics Economics & Policy, 2015).
Having discussed the global patterns and trends of AMR, it essential to comprehend
its rate of surveillance. The next sub-headings will explore that in detail in two
advanced economies namely United Kingdom (UK) and U.S., and in the Gulf
Cooperation Council (GCC) countries.
1.2.1 AMR Rates and Surveillance in UK
Public Health England (PHE) established the English Surveillance Programme for
Antimicrobial Utilisation and Resistance (ESPAUR) in July 2013 in order to support
the UK 5-year AMR strategy. In collaboration with PHE, the National Health Service
(NHS) and other healthcare providers aim to adopt the surveillance of AMR,
antimicrobial consumption data, and support recommendations to enhance
antimicrobial use in general and hospital practice. Using Second Generation
Surveillance System (SGSS), a national database maintained by PHE, around 98% of
hospital microbiology laboratories in England are submitting data regarding
antimicrobial susceptibility testing results (Public Health England, 2015a, 2017). PHE
also developed an Electronic Reporting System (ERS) in May 2015 for hospital
laboratories in England to report cases of carbapenemase-producing Gram-negative
bacteria. As a result, 95% of laboratories are registered to the system and monthly
surveillance reports are produced to update rates of carbapenemase-producing Gram-
negative bacteria (Public Health England, 2017).
According to the ESPAUR report, E. coli is considered one of the most common
causes of bloodstream infection in UK and showed 15.6% increase between 2010 to
2014 (45 cases to 52 cases per 100,000 population). The incidence of K. pneumoniae
infections increased by 20.8% between 2009 and 2014 (7.7 to 9.3 incidence per
5100,000 population). On the other hand, the incidence of Klebsiella oxytoca (K.
oxytoca), Pseudomonas spp., Enterococcus spp., S. aureus and Acinetobacter spp.
stayed relatively constant. However, the incidence of S. pneumoniae decreased by
23.4% between 2010 and 2014 (7.7 to 5.9 per 100,000 population), most likely due to
the effect of the conjugate pneumococcal vaccine (Public Health England, 2015a).
In terms of resistance rates to antimicrobials, the 2014 data revealed that the rate of
E. coli resistance to co-amoxiclav was 42%, E. coli resistance to ciprofloxacin was
18.7%, K. pneumoniae resistance to piperacillin/tazobactam was 16.9% and and S.
aureus resistance to methicillin was 10% (Public Health England, 2015a, 2017). In
2016, E. coli resistance to ciprofloxacin was 18.1-18.7%, resistance to
piperacillin/tazobactam was 11.8%, and co-amoxiclav was 40.8% (Public Health
England, 2017).
The increased rates of AMR in UK can be attributed to the increase in antimicrobial
consumption. All antimicrobial use (hospital/retail) increased from 21,784 in 2000 to
22,767 standards unit per 1000 population in 2014 (Figure 1.2). Broad-spectrum
penicillins were the most used class of antibiotics and it increased from 6,874 in 2000
to 7,334 standards unit per 1000 population in 2014 and was accounted for 45% of
total antimicrobial prescribing in England in 2016, followed by Cephalosporins that
decreased from 1,747 to 777 standers unit per 1000 population in 2014 (Public Health
England, 2017; The Center for Disease Dynamics Economics & Policy, 2015b). In a
recent report by PHE, all antimicrobial prescribing reduced by 5% between 2012 and
2016 and broad-spectrum antibiotics (piperacillin/tazobactam and carbapenems) in
hospitals also reduced by 4% from 2015 to 2016 (Public Health England, 2017).
6Figure 1.2: Antibiotic use (hospital/retail) in UK 2000-2014 (The Center for Disease
Dynamics Economics & Policy, 2015b)
Information on antimicrobial consumption in UK is monitored through three different
systems including; 1) NHS Digital database for Antimicrobial (NHSDDA) consumption
in primary care, 2) Quintiles IMS for antimicrobial consumption in secondary care and
3) NHS Business Services Authority (NHSBSA) database for antimicrobial
consumption in dental care. In 2014, the most commonly prescribed antimicrobials in
England included: penicillins (45%), tetracyclines and macrolides (15%). The use of
tetracyclines increased significantly by 13% between 2010 and 2014 while
sulphonamides/trimethoprim increased by 5%. However, the use of beta-lactam
antibiotics decreased by 17%, anti-Clostridium difficile antibiotics decreased by 3%
and quinolones use decreased by 2%. These reductions were mainly in community
(Public Health England, 2015a). Whereas, within hospital settings, the consumption of
carbapenems increased by 36% and piperacillin/tazobactam increased by 55%
between 2010 and 2014 (Public Health England, 2015a). The total antimicrobial
consumption in primary and secondary care in 2016 was 21.4 defined daily dose per
1000 inhabitants per day that is 0.9% reduction from 2015. General Practice (GP)
setting prescribed 74% of antimicrobials, 11% were prescribed for hospital inpatients,
6% for hospital outpatients, 5% for patients in dental care and 3% in other community
settings (Public Health England, 2017).
71.2.2 AMR Rates and Surveillance in USA
In 1996, the National Antimicrobial Resistance Monitoring System (NARMS) was
established as a collaborative project of national and local public health departments,
the Food and Drug Administration (FDA), the U.S. Department of Agriculture (USDA),
and CDC. This national surveillance system monitors changes in AMR in ill people
(though the CDC), retail meats (through the FDA), and food animals (through the
USDA). The NARMS project provides information about emerging AMR and outcomes
of interventions developed to control the spread of AMR, in order to promote and save
public health. The data of this project are used by the FDA to develop regulatory
decisions to maintain the effectiveness of antimicrobials for both humans and animals
(Centers for Disease Control and Prevention, 2016b; Department of Health and
Human Services, 2012; Food and Drug Administration, 2016).
In 2013, CDC published a report summarising the top drug-resistant threats in the U.S
(Centers for Disease Control and Prevention, 2013a, 2016a). Threats were grouped
according to degree of concern: urgent, serious and concerning. The urgent threats
include: Clostridium difficile (C. difficile) (caused half a million infections and 15,000
deaths in 2015), Carbapenem-Resistant Enterobacteriaceae (CRE) (causes 9,000
drug-resistance infections and 600 deaths per year) and Drug –resistance Neisseria
gonorrhoeae annually (causes 188,600 resistance to tetracycline, 11,480 reduced
susceptibility to Cefixime, 3,280 reduced susceptibility to Ceftriaxone, and 2,460
reduced susceptibility to Azithromycin).
Compared to the UK, the U.S. antimicrobial use (hospital/retail) decreased from
25,716 in 2000 to 18,522 standards unit per 1000 population in 2015 (Figure 1.3).
Broad-spectrum penicillins were the most used class of antimicrobial and it decreased
from 8,771 in 2000 to 6,846 standers unit per 1000 population in 2015, followed by
cephalosporins that decreased from 4,659 in 2000 to 3,137 standers unit per 1000
population in 2015 (The Center for Disease Dynamics Economics & Policy, 2015b).
8Figure 1.3: Antibiotic use (hospital/retail) in USA 2000-2015 (The Center for Disease
Dynamics Economics & Policy, 2015b)
1.2.3 AMR Rates and Surveillance in GCC Countries
The GCC was established in 1981, including the following countries: Bahrain, Kuwait,
Oman, Qatar, Saudi Arabia and United Arab Emirates (UAE). The main language in
the GCC countries is Arabic. Citizens of the these countries can travel between the
GCC countries freely and without any restrictions (Secretariat General of the Gulf
Cooperation Council, 2016). The WHO groups its member states into 4 income groups
based on the list of income of the World Bank (low, lower-middle, upper-middle, and
high). All GCC countries are classified as high income countries (The World Bank,
2016; World Health Organisation, 2016c).
Some general information about GCC countries are summarised in Table 1.1 (Bahrain
Central Informatics Organisation, 2015; Federal Competitiveness and Statistics
Authority, 2016; Kuwait Public Authority for Civil Information, 2016; Oman National
Centre for Statistics and Information, 2016; Qatar Ministry of Development Planning
and Statistics, 2016; Saudi Central Department of Statistics & Information, 2015; Saudi
Ministry of Health, 2015; Secretariat General of the Gulf Cooperation Council, 2016).
9Table 1.1: General information about GCC countries
Country Total area Total population Total hospitals
Bahrain 769 Km2 1.3 million people (46% nationals,
54% foreign nationals)
25 hospitals (17 private and 8
government)
Kuwait 17,818 Km2 4.4 million people (30% nationals,
70% foreign nationals)
34 hospitals (21 government and
13 private)
Oman 309,500 Km2 4.5 million people (54% nationals,
46% foreign nationals)
70 hospitals (55 government and
15 private)
Qatar 11,500 Km2 2.5 million people (10% nationals,
90% foreign nationals)
14 hospitals (10 government and 4
private)
Saudi
Arabia
2.15 million
Km2
31 million people (68% nationals,
32% foreign nationals)
444 hospitals (308 government and
136 private)
UAE 83,600 Km2 8.1 million people (12% nationals,
88% foreign nationals)
115 hospitals (79 private and 36
government)
In contrast with UK and USA, there are no national surveillance systems for AMR and
antimicrobial use in GCC countries. Data on resistance pathogens in GCC countries
were obtained from published studies. Between 01/1990 and 04/2011, it was reported
that E. coli was presented in 44% (10,073/37,295) of total bacterial isolates, followed
by K. pneumoniae in 20% (4,709/37,295), and Pseudomonas aeruginosa (P.
aeruginosa) in 18.7% (4,287/37,295) of bacterial isolates (M. Aly & Balkhy, 2012).
GCC countries also have high rates of carbapenemase-producing gram negative
bacilli and Extended-spectrum B-lactamase (ESBL) mostly associates with
nosocomial infections (H. M. Zowawi, Balkhy, Walsh, & Paterson, 2013).
The use of antimicrobials in GCC countries was shown to be high and is increasing
over time, the consumption of all antimicrobials (Retail) in Saudi Arabia increased from
11,852 in 2000 to 17,173 standard units per 1000 population in 2015, while in UAE it
increased from 11,548 in 2000 to 16,886 standard units per 1000 population in 2015.
In Kuwait, it increased from 4,444 in 2000 to 4,729 standard units per 1000 population
in 2015 (The Center for Disease Dynamics Economics & Policy, 2015a). The
antimicrobial use (retail) is higher in Saudi Arabia in comparison with Kuwait and UAE
(Figure 1.4).
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Figure 1.4: Antibiotic use (retail) in Kuwait, Saudi Arabia and UAE in 2015 (The
Center for Disease Dynamics Economics & Policy, 2015b)
The emergence of AMR in GCC countries maybe due to lack of surveillance,
stewardship programmes, and poor infection control. There is no national reporting
system of antimicrobial consumptions in hospital settings in any GCC country. Also,
there is no national reporting system of antimicrobial consumption (retail or hospitals)
in Bahrain, Oman and Qatar.
1.3 Causes of AMR
One of the major causes of AMR is the uncontrolled use of antimicrobials. Regions
where antimicrobials can be obtained without official prescriptions or restriction and
without treatment guidelines have higher prevalence of AMR compared to regions
where legislations require people to acquire antimicrobials only if they have
prescriptions (World Health Organisation, 2016a).
One of the causes of AMR is the overuse or misuse of antimicrobials, as this will
increase the development of resistant organisms (Figure 1.5).
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Figure 1.5: Causes of AMR (World Health Organisation, 2016d)
According to WHO (World Health Organisation, 2015d, 2016b), AMR can be due to:
 Poor antimicrobial prescribing practice, such prescribing antimicrobials when
not needed.
 Inappropriate antimicrobial regimen, dose, duration or route of administration.
 Self-medication where antimicrobials can be obtained without prescriptions.
 Lack of policies and regulations for healthcare professionals regarding
antimicrobials use and infection control.
 Overuse and misuse of antimicrobials in agriculture and animal husbandry.
AMR microbes are presented in humans, animals, environment (water, air and soil)
and food, where they can easily spread between them (Figure 1.6). Lack of infection
control, poor sanitary conditions and improper food-handling increase the spread of
AMR (World Health Organisation, 2016b).
12
Figure 1.6: Methods of AMR spread (World Health Organisation, 2016d)
1.4 Actions to slow and prevent the development and spread of AMR
As mentioned earlier AMR is increasing due to the overuse and misuse of
antimicrobials, as well as weak infection prevention and control. Number of actions
(Figure 1.7) can be taken by different levels of society to slow and prevent the spread
of AMR and preserve the effectiveness of available antimicrobials (Center for Disease
Dynamics Economics & Policy, 2015; World Health Organisation, 2016a).
Figure 1.7: Strategies needed in national antimicrobial policies (Center for Disease
Dynamics Economics & Policy, 2015)
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Several action plans to tackle AMR have been undertaken including WHO global
action plan, UK five-year strategy, and U.S. national strategy for combating AMR, and
GCC strategic plan.
1.4.1 WHO Global action plan on AMR
Because of the AMR crisis, the May 2015 WHO assembly adopted a global action plan
on AMR. This action plan highlights the importance of a “one health” approach that
involves collaboration among international authorities and organisations, including:
human medicine, veterinary medicine, agriculture, environment, finance, and
consumers (World Health Organisation, 2015a). The goal and objectives of this action
plan are summarised in Table 1.2.
Table 1.2: WHO Global action plan on AMR
WHO Global action plan on AMR 2015
Goal The goal of the WHO action plan on AMR is to ensure continuity of successful
prevention and treatment of infectious diseases with safe and effective quality assured
medicines that are used in a responsible way, and accessible to all people. It is
expected that a national action plan on AMR will be developed by each country in line
with the WHO global plan.
Objectives  To improve understanding and awareness of AMR through effective
education, communication and training.
 To strengthen the evidence base and knowledge through research and
surveillance.
 To decrease the risk of infection through effective infection prevention
measures, sanitation and hygiene.
 To optimize the consumption of antimicrobials in human and animal health.
 To develop investments that consider the needs of all countries and to
increase and support investment in new medicines, vaccines, diagnostic tools
and other interventions.
1.4.2 UK Five-Year AMR Strategy
A cross-government 5-year AMR strategy was launched in 2013 and it was led by the
Department of Health (DoH), PHE, Department for Environment, NHS England and
Food and Rural Affairs (Defra). The 5 year national strategy, 2013 to 2018, takes ‘One
health’ approach covering people, agriculture, animals and environment with an
overall goal of slowing the development and spread of AMR (United Kingdom
Department of Health, 2013). Each nation in UK (England, Scotland, Wales and
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Northern Ireland) has a committee to oversee stewardship and ensure progress
toward the national strategy (Table 1.3). The aim of the UK government is to reduce
the rates of healthcare associated Gram-negative bloodstream infections and
inappropriate antimicrobial prescribing by 50% by March 2021 (against 2015/2016
data) (O’Neill, 2016; Public Health England, 2017).
Table 1.3: Committees overseeing stewardship and the national AMR strategy in UK
Nation Group Date
formed
Remit
England
Antimicrobial stewardship
subgroup (ASG) of the
Advisory Committee on
Antimicrobial Resistance and
Healthcare-Associated
Infection (ARHAI)
ESPAUR
2003
2013
Established as part of the Specialist Advisory
Committee on Antimicrobial Resistance (SACAR),
to focus on the prudent prescribing of
antimicrobial across the NHS.
Developed by PHE to bring together antimicrobial
utilization and resistance data, examine national
implementation of stewardship initiatives and
develop quality measures, methods to monitor
unintended outcomes of antimicrobial stewardship
and both public and professional behaviour
interventions.
Scotland
Scottish Antimicrobial
Prespring Group (SAPG) 2008
To lead and coordinate delivery of the Scottish
Management of Antimicrobial Resistance Action
Plan (ScotMARAP).
Wales
Wales Antimicrobial
Resistance Program
Surveillance Unit (WARP-SU)
2008
Currently focuses on reporting antimicrobial usage
and resistance data and coordinating nationwide
antimicrobial audits.
Northern
Ireland
Antimicrobial Resistance
Action Committee (ARAC)
2002
ARAC provides expert advice to the Department
of Health, Social Services and Public Safety
(DHSSPS) on all issues to do with antimicrobial
resistance and provides leadership on strategies
for tackling this issue.
Public engagement is an important element of the UK AMR strategy. The Antibiotic
Guardian (campaign) was developed by PHE, as one of the UK activities for the
European Antibiotic Awareness Day (EAAD) (18th of November each year) and World
Antibiotic Awareness Week (14-20 November) and to support the UK 5-year AMR
strategy. This campaign aims to engage and stimulate behaviour change, increase
knowledge about antibiotic use and resistance among healthcare workers and the
public (Public Health England, 2015a, 2017). Antibiotic Guardian professional and
public behaviour change and engagement campaign was developed by ESPAUR to
provide webinars and training for healthcare personnel and run a national campaign
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for the public to highlight the importance of appropriate antimicrobial use through
different activities including; junior and family Antibiotic Guardian digital badges,
posters with community pharmacies and badges for university students (Public Health
England, 2017). Engagement with different stakeholder including; The British Dental
Association, British Society for Antimicrobial Chemotherapy (BSAC), Care Quality
Commission, Faculty of General Dental Practice (UK), Health Education England,
National Institute and Care Excellence (NICE), the Royal Pharmaceutical Society and
UK Clinical Pharmacy Association, was one of the key activities in improving practice,
awareness and reducing inappropriate use of antibiotics (Public Health England,
2017). Moreover, the UK is cooperating with international surveillance organisations
such as; European Antimicrobial Resistance Surveillance Network (EARS-Net) and
GLASS to share AMR data, improve antimicrobial practice and reduce AMR rates
(Public Health England, 2017).
1.4.3 The USA national strategy for combating AMR
This action plan indicates priorities and organises investments to curb, detect and
monitor outbreaks of resistant microorganisms identified by CDC as urgent or serious
threats. The national strategy has 5 interrelated goals for the government to act in
collaboration with health care partners, public health, agriculture, food and safety,
veterinary medicine, and federal, academic, and industrial research (The White
House, 2014, 2015). The 5 goals of this strategy include:
1. Slowing the emergence of resistant bacteria and prevent the spread of resistant
infections.
2. Strengthening the national One-Health surveillance efforts to combat
resistance.
3. Advancing the development and use of rapid and innovative diagnostic tests
for identification and characterization of resistant bacteria.
4. Accelerate the research to develop new antibiotics, other therapeutics,
vaccines, and diagnostics.
5. Improving the international collaboration and capacities for prevention,
surveillance and antimicrobial research and development.
The U.S. government has embarked on initiatives to educate the public on
antimicrobial stewardship and increase awareness of the threat of AMR and
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appropriate antimicrobial use. CDC’s campaign ‘Get Smart About Antibiotics Week’
(14th to 20th of November each year), had an increase in public awareness and a 50%
rise in participating partners. In animal medicine there are some educational activities
such as ‘Get Smart on the Farm’ (Presidential Advisory Council on Combating
Antibiotic-Resistant Bacteria, 2016). The Task Force monitors progress towards
achieving the national plan outcomes. They provide annual updates on federal
government actions to control AMR, including success made in implementing the
national action plan, strategies for addressing challenges and obstacles, and
recommendations for new actions (The White House, 2014).
1.4.4 The strategic plan for combating AMR in GCC Countries
This plan was developed and approved by the GCC Center for Infection Control (GCC-
IC). In April 2015, the center released the GCC AMR strategic plan that represents the
views of experts and aligns with the 2015 WHO global action plan on AMR. This
strategic plan helps in developing a tailored national plan for each GCC country
(Balkhy et al., 2016). The goal, strategic aims and evaluation of the plan are
summarised in Table 1.4.
In response to this plan and the WHO calls, some of the GCC countries developed or
are developing their own national plans to combat AMR. The Saudi government
developed the national AMR action plan in 01/2017, and is in the process of
developing a national surveillance system for AMR after enrolling in GLASS since May
2017 in order to share AMR data, improve antimicrobial practice and reduce AMR
rates. In the UAE, the national AMR action plan is still under development, and the
country was enrolled in GLASS in April 2017. The national AMR action plan, in Bahrain
was approved in 2016 after enrolling in GLASS in October 2016. Oman approved its
national AMR action plan in May 2016 and enrolled in GLASS (World Health
Organisation, 2018). No data is available for Kuwait and Qatar.
Table 1.4: The strategic plan for combating AMR in GCC countries
The strategic plan for combating AMR in GCC countries
Goal To provide a roadmap for GCC states and authorities to have and provide
effective and timely actions to control AMR.
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Strategic aims 1. To develop and understand the magnitude of AMR in the GCC countries
among humans, animals, agriculture and the environment.
2. Preserve the limited and available effective antimicrobials for human
use.
3. Improve early identification of emerging Multidrug-Resistant Organisms
MDROs.
4. Reduce the spread of resistant pathogens through patients, animals,
and agriculture.
5. Encourage and support collaborative research initiatives regarding
AMR in humans, animals and environment.
Evaluation and
monitoring
 The GCC-IC will monitor the progress and challenges and share
experiences of implementation in annual workshops.
 A platform will be given to the GGC states to share and raise awareness
on the topic through the journal of Infection and Public Health.
A limited number of initiatives have been undertaken from GCC countries to educate
public and increase awareness of the threat of AMR and appropriate antibiotic use.
Only Kuwait and Saudi Arabia reported campaigns regarding AMR and antimicrobial
use. A national campaign for the use of antimicrobial was run in Kuwait, following WHO
recommendations. The campaign was launched in three phases starting in 2009 and
then in 2011 and 2012 targeting all healthcare workers and general public in all
government hospitals in Kuwait (Kuwaiti Infection Control Directorate, 2014). In Saudi
Arabia, the Ministry of Health (MOH) launched antimicrobials awareness campaigns
in its hospitals and shopping malls in accordance with the World Antibiotic Awareness
Week (14-20 November 2016), in order to increase awareness and improve
antimicrobial practice targeting both health care professional and the public (Saudi
Ministry of Health, 2016).
Table 1.5 brings together the national policies to combat AMR in the UK, US and GCC
countries.
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Table 1.5: Comparison of national AMR policies implementation in UK, USA and
GCC countries
Activity UK USA GCC
National strategy implementation in:
hospitals, community, veterinary, and
agriculture.  
Saudi 01/2017
Bahrain 2016
Oman 05/2016
Approval and support from high
authorities
  Saudi
Bahrain
Oman
Public health activities   Only in Kuwait and Saudi
Support research on AMR, IPC and
development of new drugs   No available data
National surveillance system to monitor
antimicrobial use and resistance rates   No available data
International collaboration to share data
and experience  
The following countries
were enrolled in GLASS but
no data is available yet:
Saudi 05/2017
UAE 04/2017
Bahrain 10/2016
Oman 05/2016
An identified body to monitor and report
progress and outcomes   No available data
Specific targeted outcomes to be
measured   No available data
From Table 1.5, it is clear that more actions are needed in the GCC countries to fully
implement the GCC plan on AMR in all sectors: hospitals, community, veterinary and
agriculture. One way to combat AMR is for each GCC country to develop its own
national plan to prevent and control inappropriate antimicrobial use in human, animals
and agriculture. Moreover, a national surveillance system is necessary to monitor
antimicrobial use and resistance in all sectors and to share data with different sectors,
update policies and monitor progress at the national level. For these initiatives to
succeed, higher authorities must be involved to facilitate and strengthen their
implementation, maintain high level of health services and increase awareness of
AMR.
A timeline of global key events on antimicrobials and AMR policies are summarised in
Figure 1.8.
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Figure 1.8: A timeline of global key events of antimicrobials and AMR policies
Several solutions have been proposed internationally to combat the growth of AMR
including rationing antimicrobial use on farms, practising antimicrobial stewardship,
reducing the inappropriate use of antimicrobials among outpatients (community), the
adoption of more rapid diagnostic tests, developing new drugs, and coordinating
schemes through the creation of national plans to address AMR. The previous
sections of this chapter addressed AMR, its impact and causes. It also reported the
patterns and trends in AMR globally and in UK, USA and GCC countries and gave
examples of some international plans to combat AMR.
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The next section will focus on one specific strategy to help combat AMR: ASPs,
including; definition, team members, strategies and potential outcomes.
1.5 Antimicrobial stewardship programmes (ASPs)
According to the Infectious Diseases Society of America (IDSA), ASPs seek to
improve the use of antimicrobial agents and achieve a corresponding reduction in
resistance that can arise through improper or excessive use of these agents (The
Infectious Diseases Society of America, 2016). Therefore, ASPs involve the
application of collective strategies to enhance the proper use of antimicrobial agents,
as well as minimise any adverse effects that may arise from their use. Also, ASPs
generally aim to reduce the toxicity and the costs associated with the use of
antimicrobials; these goals can be promoted through the selection of the right antibiotic
regimen, correct dose, duration of use, and how a given agent is administered
(Centers for Disease Control and Prevention, 2017; The Infectious Diseases Society
of America, 2016). The Society for Healthcare Epidemiology of America (SHEA) and
IDSA were the first to publish guidelines and clearly outline the concepts of ASPs
(Dellit et al., 2007), which have been crucial in developing coordinated institutional
programmes that enhanced antimicrobial stewardship.
1.5.1 ASPs team members
A successful ASP requires the collaboration of its team members (Table 1.6) with the
hospital infection control and pharmacy, as well as with the related therapeutic
committees. ASPs also require negotiation with the hospital administration regarding
authority, compensation and expected outcomes for the programme, and especially
the requisite infrastructure to track the institutional use of antimicrobials (Dellit et al.,
2007; MacDougall & Polk, 2005):
Table 1.6: ASPs team members and responsibilities
Team member Responsibility
ID physicians
Design, implement and ensure the successful functioning
of the programme. This is achieved through supervising
the therapeutic guidelines, antimicrobial restriction
policies and other measures that are deemed necessary,
as proven by evidence and practice.
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Clinical/hospital pharmacists
Play an important role in the ASP implementation as they
are the ones that process the medications and determine
the formulary of the particular hospital concerned. The
clinical pharmacists also give recommendations for the
review of the medication by infectious disease
specialists, hence calling for a specialised trained
pharmacist for the administration of this programme.
Clinical microbiologists
Provide the requisite data on ASP, and therefore their
timely reporting of the microbiology susceptibility test
data is important in the selection of the most appropriate
and focused antibiotic therapy.
Infection control staff and hospital
epidemiologist
Gather data on nosocomial infections and conduct
surveillance of the antimicrobial resistance.
Hospital managers
Provide the funding, frame policies for the ASP, and give
physicians the autonomous power to implement the most
appropriate ASP for the hospital. Therefore, the hospital
managers are critical, but passive supporters of a
successful ASP in any health care institution.
Earlier guidelines for implementing ASPs failed to include nurses or provide
information on the role of nurses in ASPs. For example, the landmark IDSA/SHEA
guideline for institutional ASPs recommends a multidisciplinary team comprising an
ID physician and a clinical pharmacist with training in infectious diseases as core
members, as well as clinical microbiologist, information system specialist, infection
control specialist, and hospital administrator (Dellit et al., 2007), with no involvement
of nurses. There is now increasing emphasis on the potential contribution nurses can
make to the management of antimicrobials in hospital settings which could impact on
the development of AMR (Edwards, Drumright, Kiernan, & Holmes, 2011).
Consequently, current guidelines such as, the PHE “Start Smart, then Focus”
recommends inclusion of a senior nurse in stewardship committee (Public Health
England, 2015b). Similarly, the 2017 CDC core elements of hospital ASPs states that
nurses can assure that cultures are performed before starting antibiotics in addition to
their routine duties of medication review which places them in a position to initiate
discussions of antibiotic treatment (Centers for Disease Control and Prevention,
2017). The aspects of antimicrobial management and potential contributions nurses
can make is summarised in Table 1.7 (Edwards et al., 2011; Sumner et al., 2018).
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Table 1.7: Roles of nurses in antimicrobial management
Aspect of antimicrobial management Potential contribution
Treatment specificity Could ensure treatment is in line with
microbiology results, and use of broad-spectrum
antimicrobials is limited where possible with
support and training
Duration of treatment Could ensure appropriate duration of
antimicrobial therapy in collaboration with
doctors and pharmacists
Route of administration Could identify opportunities for switching from
intravenous to oral antibiotics
Surgical prophylaxis Can ensure appropriate duration prophylactic
antimicrobials through discussion with doctors
and pharmacists
Timing of antimicrobial administration Can contribute to improvement antimicrobial
administration practices through ASP training
Therapeutic drug monitoring Can monitor blood results along with physicians
to ensure doses are in-line with recommended
guidance
Outpatient Antibiotic Therapy (OPAT) Can promote use of OPAT services through
engagement in decision making regarding
patient’s suitability
Although nurses have critical roles in ASPs, available literature shows little or no data
on participation of nurses or the effect of the nurses' role in ASPs (Sumner et al.,
2018). Given that nurses constitute the largest segment of the health care workforce
(Manning, Pfeiffer, & Larson, 2016), their potentials should be fully exploited in
ensuring appropriate use of antibiotics in healthcare settings.
1.5.2 ASP strategies
ASPs have become one of the most important infection control measures in the
attempt to ensure the judicious use of antimicrobials, through restriction on their use,
by means of educating prescribers, health personnel and patients, and by ensuring
the proper use of feedback (Mckenzie, Rawlins, & Mar, 2013). Details are provided
below for the core strategies (Table 1.8) and supplemental strategies (Table 1.9) for
ASPs (Dellit et al., 2007; Nathwani & Sneddon, 2015).
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Table 1.8: ASPs core strategies
ASPs core strategies
Prospective audit with intervention and
feedback (Back-end strategy)
Formulary restrictions and preauthorisation
(Front-end strategy)
This involves the review of patients taking
antimicrobial therapy and offering voluntary
recommendations. This strategy is widely
practiced, easily accepted and offers more
educational opportunities, although it is more
labour intensive.
This involves the restriction of certain class of
antibiotics and approval from ID physician before
such antibiotic is prescribed. This strategy
provides direct reduction in use and inherently
lowers the cost of restricted antibiotics.
Table 1.9: ASPs supplemental strategies
ASPs supplemental strategies
Streamlining / timely de-escalation of
therapy
Empirical antimicrobial therapy streaming or de-
escalation based on culture results to target the
causative pathogens can result in reduced
antimicrobial use and cost saving.
Dose optimisation Ensures provision of optimal therapy based on
each case/drug characteristics and causative
organism is essential in ASP.
Parenteral to oral conversion The conversion of antimicrobials from parenteral
to oral form reduces patients' hospitalisation time
and cost.
Guidelines and clinical pathways The enhancement of antimicrobial utilisation,
encourages prescription based on evidence, and
is facilitated by training and feedback.
Antimicrobial order forms Facilitates adherence to guidelines and is
effective in implementing ASP strategies.
Education Increases acceptance of ASP strategies and
influence change in antimicrobial use behaviour.
Education is facilitated by incorporation with
active intervention.
1.5.3 ASPs outcomes
ASPs promote the proper selection, duration, and dose of a given therapy using
microbial agents throughout the entire course of treatment (Hamilton et al., 2015). This
implies that the most significant benefit of this programme is the optimal use of therapy
geared towards the general improvement of the clinical outcomes (British Society for
Antimicrobial Chemotherapy, 2018; Hamilton et al., 2015). ASPs outcomes include:
reduction in inappropriate or excessive use of antimicrobials, reduction in AMR rates,
reduction in antimicrobial consumption cost, reduction in length of hospital stay and
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reduction in readmission rates. Key ASPs outcomes are summarised below with some
evidence-based studies (Table 1.10).
Table 1.10: ASPs outcomes
ASPs outcomes
Outcome Example Reference
Reduction in inappropriate use
of antimicrobials
ASP resulted in an immediate
17% reduction in broad-
spectrum antimicrobial use in
an intensive care unit (ICU), as
well as a 10% reduction in
broad-spectrum antimicrobial
use outside the ICU.
After the introduction of an ASP,
79.1% of the antibiotic uses
were found to be inappropriate
and reduced to 0%.
(K. a. Cairns et al., 2013),
Australia
(Amer, Akhras, Mahmood, &
Al-Jazairi, 2013), Saudi Arabia
Reduction in rates of resistant
bacteria such as: MRSA and
Clostridium difficile infections
(CDI)
ASP reduced CDI rate by
0.0047/100 bed-days per
month (P = 0.0081)
The results of an ASP showed
that the rate of MRSA
decreased by an average of 3%
each year from 1999 to 2002.
Implementation of the ASP in a
rural hospital resulted in the
reduction in the rate of CDI from
an average of 5.5 cases per
10,000 patient days to an
average of 1.6 cases per
10,000 patient days.
(Aldeyab et al., 2012), Ireland
(Martin et al., 2005), USA
(Yam, Fales, Jemison, Gillum,
& Bernstein, 2012), USA
Reduction in healthcare and
antimicrobials expenditures
Implementation of the ASP at a
community hospital led to a
reduction in the expenditures
on the use of antimicrobials by
26% from the previous year
spending, with a total cost
saving of $145,353.
Expenses on all antimicrobials
decreased by 24.7%, with a
total cost saving of $1,401,126
(Bartlett & Siola, 2014), USA
(Martin et al., 2005), USA
Reduction in length of stay
(LOS)
ASP reduced mean LOS from
6.2 days in the historical group (Pasquale et al., 2014), USA
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to 4.4 days in the intervention
group.
Reduction in readmission rate
ASP reduced 30-day
readmission rate from 16.71%
in the historical group to 6.5% in
the intervention group.
(Pasquale et al., 2014), USA
1.5.4 Barriers and facilitators to successful adoption and implementation of
ASPs
The successful adoption and implementation of ASPs can be affected by number of
factors. A study in the US that interviewed 15 ASP pharmacists and 6 physicians from
21 medical centres identified factors that can affect the successful implementation of
ASPs (Pakyz et al., 2014). These factors were classified into culture and resources.
Cultural factors included: communication process between staff and departments in
the organisation, relationships between ASP members and non-ASP members, and
conflict management. Resources factors included; information technology at the
organisation, the analysis and reporting of antimicrobials consumptions and
resistance, and the availability of personnel and expertise. A national survey was sent
to all general acute care hospitals in California which received 223 responses (53%
response rate). The study identified the following as barriers to ASPs: staffing
constraints, lack of funding, lack of formal proposal to establish the programme, lack
of administrative support, and lack of medical staff support (Trivedi & Rosenberg,
2013).
Another study in Australia that interviewed 17 healthcare professionals working in
hospitals identified the following as barriers to the adoption of ASPs: lack of
enforcement of ASPs policies, lack of adherence to prescribing guidelines, lack of up
to date knowledge about appropriate antimicrobial use among senior specialists, and
lack of resources including: ID physicians and pharmacists. The study also identified
the following as potential solutions to ASPs: good communication between
consultants, physicians and other healthcare professionals as a mean of education to
improve the practice, hospitals management  support and empowerment of the
programmes, provision of clinical ASP service and electronic decision support system
to practitioners, and involvement of pharmacists and nurses in antimicrobial therapy
process (Cotta et al., 2015).
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Having reviewed ASPs adoption barriers and facilitators, it will be interesting to outline
the current status of ASPs in the UK, US, and GCC countries.
1.5.5 ASPs in UK
In England, there are 3 national ASP toolkits: Start Smart then Focus for hospitals
(secondary care) (Public Health England, 2015b), the Treat Antibiotics Responsibly,
Guidance, Education, Tools (TARGET) toolkit for community (primary care) (Royal
College of General Practitioners, 2015) and Dental sector ASP toolkit (Public Health
England, 2017). These toolkits provide educational materials and programmes to
improve antibiotic practice. Moreover, in order to reduce unnecessary and
inappropriate antibiotic use, two antimicrobial stewardship initiatives were developed
by NHS: 1) Quality Premium (QP) in primary care from 2014/2015, and 2)
Commissioning for Quality and Innovation (CQUIN) in secondary care from
2016/2017. As a result, 88% of Clinical Commissioning Groups (CCGs) reduced all
antibiotics use to meet their objective and 83% reduced the consumption of broad-
spectrum antibiotics to the target level. In 2016/2017, of the CQUIN, 33%, 37% and
52% of NHS acute trusts reduced piperacillin/tazobactam, total antibiotic and
carbapenem consumption respectively to 2013/2014 levels (Public Health England,
2017).
The implementation of ASPs in primary and secondary care in UK was assessed by
PHE: 68% (100) of Acute NHS trusts and 41% (68) of CCGs participated in the PHE
survey. The national ASP policy for primary or secondary care was reviewed by 87%
of acute NHS trusts in 2014/2015 and 85% in 2016/2017 and 60% of CCGs. However,
implementation of an action plan to run ASP activities was done by only 46% of acute
NHS trusts in 2014/2015 and increased to 55.3% in 2016/2017, and 13% of CCGs.
The main results of the PHE assessment are outlined in Table 1.11 (Public Health
England, 2015a, 2017).
27
Table 1.11: Comparison of ASPs activities in secondary and primary care, England,
2014, 2017
1.5.6 ASPs in USA
The Centres for Medicare and Medicaid Services (CMS) introduced two important
actions regarding ASPs in USA hospitals including the CMS (Centers for Medicare
and Medicaid Services, 2016; Presidential Advisory Council on Combating Antibiotic-
Resistant Bacteria, 2016), and the Presidential Advisory Council on Combating
Antibiotic-Resistant Bacteria (Centers for Medicare and Medicaid Services, 2016;
Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, 2016):
 A condition of participation (CoP) that will request ASPs in inpatient settings to
be aligned with the CDC core elements of hospital ASPs.
 New infection control and prevention standards that will require ASPs in Long-
Term Care Facilities (LTCFs).
The implementation of ASPs in US hospitals was assessed by analysing the 2014
National Healthcare Safety network (NHSN) Annual Hospital Survey. Thirty-nine
percent (1,642/4184) of US hospitals reported having ASPs that met all the CDC 7
core elements of ASPs (Pollack et al., 2016); 45% (741) of the hospitals were large
hospitals with more than 200 beds, 37% (611) of hospitals were medium with 51 to
200 beds and 17% (290) of hospitals were small with 50 beds or less.
Secondary care: Acute
NHS trust n = 100
(2014/2015)
Secondary care:
Acute NHS trust n
= 116 (2016/2017)
Primary care:
Clinical
commissioning
groups n = 82
(2014/2015)
Existence of ASP
committee
94% 95.6% 18%
Written dedicated
antimicrobial policy
93% Not assessed 99%
Action plan/implemented
toolkit
46% 55.3% 13%
Written education and
training strategy
24% Not assessed 1%
Implemented audits within
ASP toolkit
74% Not assessed 15%
NICE ASP guidance
reviewed
Not assessed 93% Not assessed
NICE ASP baseline audit
completed
Not assessed 83% Not assessed
ASP local indicators
accessed on Fingertips
Not assessed 91% Not assessed
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1.5.7 ASPs in GCC countries
The implementation of ASPs in GCC countries hospitals was assessed in a regional
survey and response were only received from 47 hospitals in 4 GCC countries (2 from
Bahrain, 2 from Oman, 2 from UAE and 38 from Saudi Arabia). Sixty-two percent
(29/47) of the hospitals reported having ASPs in place (Enani, 2016). However, the
situation is unknown in other hospitals and other GCC countries.
Compared to UK and US, current status of ASPs in GCC counties is not clear. Thus,
a review of existing evidence on ASPs activities in the GCC countries is needed to
understand the situation of ASPs in the region and develop recommendations for
research and policy.
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Chapter 2: ASPs in GCC countries Hospitals: A Review of Existing
Evidence
2.1 Introduction
AMR is a global public health concern undermining efforts to treat infectious diseases,
resulting in increased morbidity and mortality, and adding avoidable costs to already
strained healthcare systems (World Health Organisation, 2016b). It is estimated that
rates of mortality will be at 10 million people a year due to AMR, followed by cancer,
road traffic accidents and other causes of deaths (O’Neill, 2014, 2016).
GCC countries are facing risks of inappropriate antimicrobial use and AMR with few
national guidelines and policies to monitor and control antimicrobial use and resistance
rates (M. Aly & Balkhy, 2012). Available reports indicate that rates of AMR are
increasing in the GCC countries with rare and novel resistance strains (Areeshi, Bisht,
Mandal, & Haque, 2014; El-Saed et al., 2013; Saber Yezli, Shibl, & Memish, 2015; H.
Zowawi et al., 2015; H. M. Zowawi et al., 2014). The risk of AMR is even more serious
in the GCC countries due to population mobility (MacPherson et al., 2009) - the high
number of expatriates in the region, as well as around 10 million people that travel
every year to Saudi Arabia for Hajj and Umrah, and the high number of tourists to the
UAE and other GCC countries (Azeem et al., 2014; Kapiszewski, 2006; Östholm-
Balkhed et al., 2013; H. M. Zowawi et al., 2013).
As mentioned earlier, ASPs are one of the main interventions to control the use of
antimicrobials and reduce AMR rates; however, the level of adoption of ASPs in GCC
countries is unclear. Thus, this review will aim to:
 explore the availability and the extent of ASPs adoption within GCC countries,
 identify factors that influence ASPs adoption, and the reported outcomes
 review the national policies of adopting or implementing ASPs within GCC
countries.
Understanding the current status of ASPs adoption in GCC countries will have several
implications not only for the public, but also for health care professionals and health
policy makers.
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2.2 Methods
2.2.1 Data Resources
Electronic databases of PubMed (MEDLINE), Embase, Scopus, CINAHL Plus, Ovid,
Google scholar, grey literature (government documents, conference papers, doctoral
thesis, evaluations and working papers), and official health authorities’ websites for
each GCC country were searched. Literature search ranged from year 01/1981 to
07/2017. References lists of retrieved articles and relevant review articles were
checked manually for further relevant studies. Table 2.1 shows the search terms that
were used. The search terms in the same group were combined using the Boolean
term OR, while the three groups of search terms were combined using the Boolean
term AND.
Table 2.1: Literature review search terms
ASP terms Strategies terms GCC terms
Antimicrobial stewardship program(s),
Antimicrobial stewardship programme(s),
Antimicrobial stewardship, Antimicrobial
control program(s), Antimicrobial control
programme(s), Antimicrobial
management, Antimicrobial stewardship
model, Antibiotic stewardship program(s),
Antibiotic stewardship programme(s),
Antibiotic stewardship, Antibiotic control,
Antibiotic management
Strategy (s), measure (s),
intervention(s), policy (s),
practice (s), protocol (s),
surveillance, procedure (s),
implementation, adoption,
recommendation
Gulf Cooperation Council,
Gulf countries, GCC,
Bahrain, Kuwait, Oman,
Qatar, Saudi Arabia, United
Arab Emirates.
2.2.2 Inclusion and Exclusion criteria
Studies were included if they meet the following criteria:
• Conducted in any GCC country (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia
and United Arab Emirates).
• Reported ASP in a hospital setting.
• Reported a national ASP/AMR policy.
• Published between 01/1981 and 07/2017.
• Published in English or Arabic language.
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Studies were excluded if:
• ASPs were studied in primary healthcare centres, dental centres, cancer
centres, and community pharmacies.
• Reported a single antibiotic policy intervention not part of ASP.
• Only reported consumption and resistance rates.
• Conducted on animals.
Two researchers screened all titles and abstracts independently to determine whether
the article met the inclusion criteria and should be retrieved. A third researcher
screened a random 10% sample to check the reliability of the screening. Any
discrepancies were resolved through discussion between the three researchers. The
first researcher then read and extracted data from the articles included in this review.
2.2.3 Quality assessment and data extraction process
The Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA)
standards (Moher, Liberati, Tetzlaff, & Altman, 2009) were used to extract data and
assess the quality of studies. Search results were exported to Mendeley, a free
reference manager and academic social network (Elsevier Inc.360 Park Avenue South
New York, New York 10010). Titles and abstracts were screened in order to retrieve
the full text of the article. As this is the first ever review of ASPs in GCC hospitals, all
papers/research found from the search were included.
2.3 Results
A total of 2,801 titles and abstracts were reviewed from the literature search. Nine
hundred and sixty-two duplicates were removed. After titles review, 1740 were
excluded, 48 after abstract review and 27 after full text review, leaving twenty-four
articles eligible for inclusion. Grey literature searching identified 7 further papers, and
2 National ASP/AMR policies, totaling 33 included papers as highlighted in Figure 2.1.
Of the 33 papers reviewed, 13 were from Saudi Arabia, five from Qatar, four from
Bahrain, four from Oman, three from Kuwait, two from UAE and 2 national AMR/ASP
strategies/guidelines one from the GCC and one from Saudi Arabia). All the included
papers are published in English language only.
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Figure 2.1: Literature review flow chart of data extraction and study selection
process.
Studies identified through
database searching = 2801
Studies screened for title =
1839
Studies abstract evaluated =
99
Full articles evaluated = 51
Included articles = 24
Included papers = 33
Studies removed after applying limits and removing duplicates =
962
Studies excluded after title screening = 1740 and included:
Studies not relevant to ASP and antibiotics (e.g.: management of
hepatitis, asthma, diabetes, arthritis, acne, hypertension,
meningitis, malaria, pneumonia and tuberculosis) = 1253
Studies reporting patterns of AMR rates = 253
Studies reporting patterns of antibiotic use/misuse = 115
Studies about antibiotic use/misuse not in GCC countries = 65
Studies reporting antibiotic use/misuse in primary/community or
dentistry settings = 54
48 articles were removed after abstract screening as they were:
Studies reporting patterns of AMR rates = 23
Single Antibiotic intervention not part of ASP = 9
Studies about antibiotic use/misuse not in GCC countries = 7
Studies about antibiotic use/misuse in community/primary care = 6
No access to full article = 3
27 articles were removed after evaluating full text as they were:
Studies evaluating/reporting antibiotic use/misuse= 14
Studies not in GCC countries = 8
Single Antibiotic intervention not part of ASP = 5
Grey literature: 7 papers
National ASP/AR policies: 2
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2.3.1 Existing hospital ASPs in GCC countries
Evidence of the existence of hospital ASPs was identified in all GCC countries.
Majority (13/33) of the reports were from Saudi tertiary hospitals and medical cities.
This was followed by Qatar (5/33) reports from tertiary and community hospitals;
Bahrain, 4 reports from military hospitals, Oman, 4 reports from tertiary hospitals,
Kuwait, 3 reports, one from government hospital and 2 reported Ministry of Health
(MOH) efforts to increase awareness about AMR among professionals, patients and
the public through national campaigns. Two reports were identified from the UAE and
they were from tertiary hospitals. A national strategic plan for combating AMR was
identified in GCC countries (Balkhy et al., 2016).
The main ASP strategies that were reported in GCC countries hospitals included:
guidelines and clinical pathways, prospective audit with intervention and feedback,
and formulary restriction and pre-authorisation. Other reported strategies include:
parenteral to oral conversion, streamlining/timely de-escalation of antimicrobial
therapy, and education of professionals and patients.
No evidence was found in relation to national surveillance systems in antimicrobial
consumption and AMR rates in any GCC country as part of ASPs initiatives.
In hospitals that reported ASP activities, ASP team was composed of only ID
specialists and consultants, and sometimes infection control nurses and specialists.
In few reports, pharmacists were monitoring antimicrobial consumption and giving
feedback on appropriate antimicrobial therapy. In Saudi hospitals, microbiologists
provided AMR rates data to hospital committees to update ASPs interventions based
on their resistance data.
Table 2.2 summarises the findings in relation to the evidence of existing ASPs,
strategies employed and composition of ASP team.
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Table 2.2: Evidence of ASPs in GCC countries hospitals
Country Authors Setting Study Type Existing ASPs Components of ASPs ASP Team
Bahrain
(AlAnsari,
AlAlawi,
AlQahtani, &
Darwish, 2013)
Outpatient
setting attached
to Bahrain
Military hospital
Audit of
antimicrobials used,
patients treated,
patient satisfaction
and total costs
comparison
Strategy to reduce the
risk of healthcare
associated infections
and patients' LOS
Outpatient parenteral
antimicrobial therapy:
Treatment policy and
protocol
ID physician,
Chief resident
family physician,
specialist nurse,
pharmacist
(S. Al Alawi,
Abdulkarim,
Elhennawy, Al-
Mansoor, & Al
Ansari, 2015)
Outpatient
setting attached
to Bahrain
Military hospital
retrospective
review of case
notes of patients
admitted to OAPT
clinic
Strategy to reduce the
risk of healthcare
associated infections
and patients' LOS
Establishing guideline and
protocol of ceftriaxone use in
OPAT treatment policy and
protocol. No involvement of
antibiograms
ID consultant,
family physician
and specialist
nurse
(Alqahtani, 2015)
(Conference
presentation)
400-bed
defence force
hospital
Before/after study Strategy to reduce Multi-
drug resistance bacteria
and antibiotic
consumption
Formulary restrictions and
preauthorization, local
antibiotic susceptibility
antibiogram, parenteral to
oral conversion, guideline
and clinical pathways,
antibiotic audit with
intervention and feedback,
education
AMS teams and
committees
(World Health
Organisation,
2016e) (WHO
report)
Country's
preparedness
and capacities
International
mission report
Hospitals have various
elements of ASPs since
2012.
No national plan for
detection and reporting
of AMR pathogens or
infections. No national
plan for ASPs at central
or facility level. No
centres implementing
ASPs.  No ASPs exist in
private hospitals or
primary care centres
AMS teams and committees,
antimicrobial use guidelines,
and staff training. Strong
NHRA control (National
Health Regulatory Agency).
AMS teams and
committees
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Country Authors Setting Study Type Existing ASPs Components of ASPs ASP Team
Kuwait (Al-Mousa & Aly,
2012)
The Directorate
of Infection
Control in
Kuwait
organised a
national
campaign to
encourage
judicious use of
antibiotics in
healthcare
settings during
the period 19–
26 March, 2009
Letter to editor and
campaign report on
ministry of health
website
Campaign to raise
awareness of doctors,
pharmacists, patients
and the public regarding
appropriate antibiotics
use called: ‘Wise use or
lose’.
Education activities to
healthcare professionals,
patient and public. Reminder
SMS communication to Drs
to use antibiotics wisely.
Posters displayed on hospital
corridors
Organised by
National
directorate of
infection control,
Scientific and
Awareness
committee. No
involvement of
teams within
hospitals in
design
(N. Y. Aly, Omar,
Badawy, Al-
Mousa, & Sadek,
2012)
9 government
hospitals
Audit of medical
records in 9
government
hospitals assessing
adherence to
hospital antibiotic
policy
National antibiotic policy
printed and distributed in
booklets to hospitals
since 2007. Hospitals
use the national policy
as basis for their local
antibiotic policy. Existing
antibiotic policy and
guidelines at national
and local levels.
Antibiotic policy contains
broad evidence-based
guidelines for the prescription
of antibiotics to ensure
appropriate prescribing
Organised by
National
directorate of
infection control,
Scientific and
Awareness
committee. No
involvement of
teams within
hospitals in
design
(Kuwaiti Infection
Control
Directorate, 2014)
(Government
online report)
Nationwide
Campaign
including: Audits
of adherence to
national/
hospital
antibiotic policy
(first one
reported by Aly,
2012. National
awareness
campaigns (1st
Campaign on
antimicrobial
resistance and
judicious use
targeting doctors in
the private sector
Antibiotic policy, audits
of adherence to policy.
National awareness
campaigns Education
workshop 14/11/12 to
private sector and
campaign activities in
government hospitals
and primary care
centres
Antibiotic policy
Audits of prescribing and
adherence to policy
Organised by
National
directorate of
infection control,
Scientific and
Awareness
committee. No
involvement of
teams within
hospitals in
design
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Country Authors Setting Study Type Existing ASPs Components of ASPs ASP Team
one reported by
Al-Moussa &
Aly, 2012).
Oman (Gunn, Ali, Abdo-
Rabbo, &
Suleiman, 2009)
Four major
hospitals
Retrospective
examination of
medical records of
patients admitted
for Lower Segment
Caesarean
Sections (LSCS)
The Ministry of Health
Antibiotic Chemotherapy
Policy & Guidelines
were published in 1998
and cover the use of
antibacterials in
prophylaxis and
treatment
most major hospitals in
Oman have
established their own “in
house” guidelines for almost
all antibiotic
use
Not identified
(Al-Abri, Al-
Maashani,
Memish, &
Beeching, 2012)
Tertiary hospital
(Royal Hospital)
Muscat
Retrospective case
study involving a
review of case
notes of 342
patients
CAP guidelines Guidelines and antimicrobial
use policy
Not identified
(Al Za’abi, Shafiq,
Al Riyami, & Ali,
2013)
Tertiary hospital
(Sultan Qaboos
university
hospital)
A review of
patients' medical
records of 365
patients
Antibiotic handbook
(antibiotic policy)
produced by the hospital
in 2006 is the primary
antibiotic protocol
Restricted Antibiotic-
Vancomycin
Antibiotic policy/ guidelines
and restricted antibiotics
Not identified
(Al-Maliky, Al-
Ward, Taqi,
Balkhair, & Al-
Zakwani, 2017)
Tertiary hospital
(Sultan Qaboos
University
hospital)
Observational study
involving 366
patients
Local infections
guidelines and
Restricted antibiotic
policy
Antimicrobial guidelines
restricted antibiotic policy Not identified
Qatar
(F. Y. Khan,
Matar, & Khudair,
2010)
Tertiary hospital
(Hamad General
Hospital)
Retrospective audit
of medical records
of 69 patients
Local infection guideline:
Guidelines for
management of CAP
local infection guideline
Not identified
(Abdel-Aziz et al.,
2013)
Tertiary hospital
(Hamad General
Hospital)
Retrospective
analysis of patient
data from different
surgical units in
hospital
Surgical antimicrobial
prophylaxis guidelines
Antimicrobial guidelines
Not identified
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Country Authors Setting Study Type Existing ASPs Components of ASPs ASP Team
(Pawluk, Black, &
El-Awaisi, 2015)
Primary/
community and
secondary care
Cross-sectional
survey targeting all
pharmacists
practicing in Qatar
Various ASP strategies
reported by pharmacist
in secondary care in
Qatar
Formulary restriction of
antibiotics, clinical practice
guidelines for infectious
diseases, audit and
feedback, IV to oral step-
down guidelines, patient
education, prescriber
education, protocols that
transfer authority from
prescribers to pharmacists,
antimicrobial cycling
Pharmacists
review medication
and feedback to
prescribers
(Garcell, Arias,
Fernandez,
Guerrero, &
Serrano, 2016)
Community
hospital (75-bed
facility)
Observational study
monitoring
antibiotic
consumption and
compliance with
policies (2012-
2015)
Hospital has an
established ASP
programme
Current strategies for
ASP in hospital
Antimicrobial prescribing
policy for therapeutic use and
surgical prophylaxis including
antibiotic stop orders,
switching from IV to oral
antibiotics and antibiotic
restriction. Prescribing
audits, antimicrobial
consumption monitoring,
feedback to medical staff and
management, data
dissemination, staff training
and development.
Pharmacists
monitor
consumption and
disseminate rates
to medical and
management
staff. Infection
prevention and
control committee
working closely
with Quality and
Patient Safety
committees.
(Guanche Garcell
et al., 2016)
Community
hospital (2013-
15)
Interventional study
to determine the
impact of ASP on
antimicrobial
related activities in
hospital
Existing, fully functional
ASP focusing on
appendectomies with
quality indicators
(compliance with timing,
selection and dose,
discontinuation of
antibiotic prophylaxis as
per protocol).
Staff education, monitoring
antimicrobial consumption
and providing feedback to
prescribers
Compliance with
antibiotic
prophylaxis was
monitored by an
infection control
practitioner.
Monitoring of
antimicrobial
consumption was
monitored by
pharmacists.
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Country Authors Setting Study Type Existing ASPs Components of ASPs ASP Team
Saudi
Arabia
(Jacobs et al.,
2003)
Riyadh Armed
forces hospital
Interventional study
involving 228
patients admitted to
ICU for
Percutaneous
Dilatational
Tracheostomy
Antibiotic protocol and
procedure guidelines
Microbiology/ antibiotic
protocol
Not identified
(Dib, Al-Tawfiq, Al
Abdulmohsin,
Mohammed, &
Jenden, 2009)
Tertiary hospital
Dhahran Health
Centre
Interventional study
with reviews of
medical records
pre-and post-
intervention
Hospital infection control
practices advisory
committee producing
antimicrobial use
guidelines, education
and feedback
Antimicrobial use guidelines,
education and feedback
Clinical
pharmacist review
and feedback to
prescriber
regarding
adherence to
guidelines.
Infectious disease
consultants used
in persistent use
cases
(Amer et al.,
2013)
Tertiary hospital
(KFSHRC)
Comparative
historically-
controlled study. 24
patients enrolled on
the active ASP arm
and 49 patients on
the historical
control arm
ASP implementation in
2011 including ASP
team, prospective audit
and feedback, and
education interventions.
Appropriateness of
prescribing assessed
against formulary
restrictions, adapted
international infection
guidelines. Verbal and
written reports to ICU
prescribers.
Proactive core strategies:
formulary restriction and pre-
approval strategies,
prospective audit and
feedback. Supplementary
strategies: education
interventions, guidelines,
antimicrobial order forms,
pharmacodynamics dose
optimisation, antimicrobial
cycling.
ASP team (ID/
Intensivist
physician and
ASP pharmacists)
(Malhani, Al-
ghamedi, &
Enani, 2014)
(conference
poster)
Medical City
(King Fahad)
Retrospective audit
of medical records
172 patients before
ASP
implementation and
Report on one ASP
strategy implementation
in hospital
Audit and feedback to
prescriber regarding IV to
oral switch and duration of
therapy
ASP team not
identified possibly
including
pharmacists
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Country Authors Setting Study Type Existing ASPs Components of ASPs ASP Team
205 patients' post-
implementation
(Al-Somai, Al-
Muhur, Quteimat,
& Hamzah, 2014)
Tertiary hospital
(King Abdullah
Medical City)
Makkah.
Pre- and post-study
to explore the
impact of
implementation of
antimicrobial policy
Antimicrobial policy Antimicrobial policy adapted
from international infectious
disease guidelines
Clinical
pharmacist, ID
consultant
(Al-Tawfiq,
Momattin, Al-
Habboubi, &
Dancer, 2015)
Dhahran Health
Centre 380-bed
general hospital
Interventional study
Selective reporting of
Gram-negative bacillus
susceptibility by clinical
laboratory services and
pharmacy,
considering local
resistance rates and
international guidelines.
Education activities
Cascade and restrictive
reporting. Formulary
restriction, guidelines and
education activities
Microbiologists-
microbiology lab
(Al-Harthi et al.,
2015)
University
hospitals,
private hospitals
and public
hospitals
A cross-sectional
self-administered
questionnaire
To investigate the
perceptions, attitude, and
prescribing practice among
clinicians about AR
Not identified
(AlAwdah et al.,
2015)
(Conference
poster)
Tertiary hospital
(Riyadh)
Pilot prospective
quality-
improvement
interventional study
in paediatric ICU a
Reported existence of
ASP. Formulary
restriction
Formulary restriction
ASP team
mentioned but not
identified. Most
likely including
clinical
pharmacist
reviewing
medication and
recommending
antimicrobial
optimisation
according to
restricted
formulary
recommendations
.
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Country Authors Setting Study Type Existing ASPs Components of ASPs ASP Team
(Haseeb et al.,
2015) (conference
paper)
Survey of ASPs
in Makkah
hospitals
Survey targeting
hospitals in Makkah
region
Existing elements of
ASP
Audit of antimicrobial use,
education and training, and
infection control and
surveillance. Most common
types of strategies were
formulary restrictions for
broad-spectrum
antimicrobials and use of
automatic stop orders to limit
empirical therapy of
antimicrobials in Makkah
hospitals
Not identified
(M. M. Alawi &
Darwesh, 2016)
1002-bed
tertiary care
university
hospital
Prospective
before/after
Audit, review and
restriction
Audit and review Number of
prescriptions and
dispensations, incidence of
Multi drug resistance (MDR)
and cost
Not identified
(Salahuddin et al.,
2016)
Specialist
hospital in
Riyadh (King
Faisal specialist
hospital)
Prospective cohort
study
Antibiotic protocol and
sepsis guidelines
De-escalation strategy and
Sepsis guideline adapted
from an international
guideline (2012)
Not identified
(Enani, 2016) Mainly in tertiary
hospitals
Regional survey
targeting healthcare
professionals in
hospitals involving
several GCC
countries.
Evidence of existing
ASPs in tertiary care
settings in Saudi Arabia.
Although the definition of
ASPs was not provided,
restricted list of antimicrobial
agents and antimicrobial
audits were the main
strategies reported
Not identified
(Alshukairi et al.,
2016)
Specialist
hospital (King
Faisal specialist
hospital,)
Jeddah
Pre-post
intervention study
De-escalation protocol
De-escalation protocol,
education and training of
nurses and physicians re
protocol, and auditing
adherence to protocol
Not identified
Tawam tertiary
hospital,
Report Existing functional ASP Pre-approval antibiotics
(restricted antimicrobials),
Microbiologists,
ID physicians, ID
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Country Authors Setting Study Type Existing ASPs Components of ASPs ASP Team
United
Arab
Emirates
(Hashmey et al.,
2013) (oral
presentation)
National
Oncology
referral centre
guidelines and pathways, IT
setting of infection control
antibiotic stewardship
worklist, prospective audit
with feedback
pharmacists,
Infection Control
Practitioners
liaising with IT
and Quality office.
(El Hassan et al.,
2014)
Mafraq hospital,
Abu Dhabi
Retrospective
review of data of
250 patients
Surgical antimicrobial
prophylaxis guidelines
Hospital guidelines on
surgical antimicrobial
prophylaxis and use of
bacterial antibiograms
Surgeons, clinical
pharmacists and
surgical nursing
staff. Med review
by pharmacists
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2.3.2 Barriers and facilitators to ASPs adoption in GCC countries hospitals
Barriers and facilitators to successful adoption of ASPs were addressed in 9 of the 33
retrieved reports. At the individual level, barriers to ASP adoption includes lack of
knowledge about appropriate antimicrobial therapy and AMR, lack of awareness of the
availability of antimicrobial polices and guidelines, lack of awareness and knowledge
of ASPs, lack of time and staff to make the required tests, lack of confidence to de-
escalate antimicrobial therapy when required and lack of confidence to prescribe other
antibiotics rather than what is usually prescribed. At the institutional level, barriers
were reported to hinder the adoption of ASP in GCC countries hospitals; lack of
expertise (ID specialists/consultants), lack of antibacterial agents, lack of educational
and training programmes on appropriate antimicrobial therapy and risks of AMR, lack
of microbiology equipment, and lack of management support. Also, lack of financial
resources to fund ASPs was reported as a barrier to ASPs in hospitals.
Factors that were reported to enhance ASP adoption were prescribers’ experience
and knowledge of appropriate antimicrobial therapy according to the Kuwaiti Infection
Control Directorate (Kuwaiti Infection Control Directorate, 2014), availability of written,
clear and accessible antibiotic policy (Gunn et al., 2009), as well as feedback and
discussions between prescribers and other healthcare professionals (Al-Tawfiq et al.,
2015).
Table 2.3 summarises the barriers and facilitators of successful ASPs adoption by
hospitals in GCC countries.
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Table 2.3: Identified barriers and facilitators to ASPs adoption in GCC countries hospitals
Country Authors Facilitators Barriers
Kuwait (Kuwaiti Infection
Control Directorate,
2014) (Government
online report)
Experience (in relation to age) and antibiotics
knowledge can lead to good antimicrobial
stewardship
Excessive antibiotics prescribing as reported by Drs include: lack
of time to perform the required investigation, fear of complication
and antibiotic resistance concerns.
Barriers to adherence to policy as reported by Drs include: non-
availability or poor distribution of the policy, neglect of reading the
policy, being incomplete or not updated and interrupted supply of
some antibiotics. Knowledge of types of resistant organisms &
isolation precautions
Oman (Gunn et al., 2009)
Those hospitals that had a consistent policy and
especially a written policy, made known to all
staff, had better outcomes as far as post-
operative infections
Many health workers considered the guidelines to be out-dated
Qatar (Pawluk et al., 2015) Not identified
Non-availability of an infectious diseases specialist is the most
prominent perceived barrier to implementation and expansion of
ASP
Training of pharmacists and pharmacy staff on elements of ASP
are also perceived barriers.
Saudi
Arabia
(Al-Tawfiq et al., 2015)
Alleviate prescribers concerns through
discussing evidence of intervention and
providing support. Held small group meetings
with targeted (main) prescribers and key/
influential prescribers to encourage physicians
to support ASP initiative
Many physicians were comfortable only with prescribing familiar
antibiotics, difficulty persuading physicians to prescribe specific
agents/ combinations, relevant microbiology not always available,
no incentive for prescribers to choose more appropriate antibiotics
(Al-Somai et al., 2014) Not identified
Maintaining antimicrobial control during time of Hajj in Makkah is a
challenge because of increased number of admitted patients and
increased antimicrobial use.
(Haseeb et al., 2015)
(conference paper)
Not identified Majority of the hospitals lacked local antimicrobial guidelines
based on hospital-wide antibiograms
(Salahuddin et al., 2016)
Not identified reluctance of physicians to de-escalate antimicrobial therapy in
complicated, sicker patients with drug resistance or fungal sepsis
(Enani, 2016) Not identified
Lack of programme funding and personnel as main barriers. Other
barriers include obstruction from prescribers, and administration,
lack of awareness of ASPs
(Alshukairi et al., 2016) Not identified High resistance rates in other centres and transfer of resistance to
specialist centres upon admission for last resort intervention
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2.3.3 Outcomes of hospital adoption of ASPs in GCC countries
A number of outcomes were used to evaluate ASPs in GCC countries. They include;
reduction of healthcare associated infections, reduction of inappropriate antimicrobial
prescribing, reduction in length of hospital stay and mortality rates, reduction of
expenditures of antimicrobials and reduction of AMR rates.
Most of the reported studies from Saudi Arabia used more than one outcome to assess
the ASPs interventions, while other studies in the rest of GCC countries used reduction
in inappropriate antimicrobial prescribing to assess ASPs interventions. The reduction
in AMR rates as an outcome of ASPs was only assessed in 2 studies from Saudi
Arabia.
The reduction in post-operative infections was reported in 6 studies (4 from Saudi, 1
from Oman and 1 from UAE), and in one of the studies the peri-operative infection
complications were reduced from 32% to 11% (Jacobs et al., 2003). Reduction in
C.difficile infection rates was reported in 2 studies (Al-Tawfiq et al., 2015; Hashmey et
al., 2013).
Only 5 studies reported reduction in antimicrobial expenditures. Four of the studies
were carried out in Saudi hospitals, and reported a reduction of up to half the cost of
antimicrobials budget (Al-Somai et al., 2014; Amer et al., 2013; Enani, 2016; Malhani
et al., 2014). The fifth study was carried out in UAE reporting a 40% reduction in
antimicrobial budget (Hashmey et al., 2013).
The reduction on the readmission rates and mortality rates were reported in only 3
studies ( Al Alawi et al., 2015; AlAnsari et al., 2013; and Amer et al., 2013). Two studies
from a military hospitals in Bahrain reported that the outpatient service including ASPs
interventions reduced hospital admissions (2 out of 101 in 2013 and 6 out of 97 in
2015) ( Al Alawi et al., 2015; AlAnsari et al., 2013). A study in Saudi hospital reported
a reduction in mortality rate from 33% to 17% due to the introduction of ASP (Amer et
al., 2013).
Only few studies reported the reduction in AMR rates as an outcome of ASPs. This is
can be due to the lack of involvement of microbiologists in ASPs. A reduction in AMR
rates was reported in a Saudi study, but an increase in the resistance rates to some
other heavily used alternative antibiotics were observed (Al-Tawfiq et al., 2015).
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Another study in a Saudi hospital reported no impact on AMR rates (Alshukairi et al.,
2016).
The reduction in broad-spectrum antibiotics was used to assess the impact of ASPs
in all the retrieved studies, with only one study reporting a decrease in the consumption
of cefuroxime (Guanche Garcell et al., 2016). The authors however reported that
reduction in consumption of Cephalosporins resulted in an increase in consumption of
Pencillins and Macrolides.
The reported outcomes of the adoption of ASPs by hospitals in GCC countries are
summarised in Table 2.4.
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Table 2.4: Outcomes of hospital adoption of ASPs in GCC countries
Country Authors Reduction of
inappropriate
prescribing
Reduction
of
healthcare
associated
infections
Reduction of
direct
antimicrobial
cost
Reduction LOS/
mortality metrics
Reduction of
antimicrobial
resistance
Reduction of Broad-
spectrum antibiotic use
Bahrain
(AlAnsari et al.,
2013)
Not measured Not
measured
Not measured Only 2 out of 101
patients were
admitted to hospital
Not measured High usage of Ceftriaxone
(S. Al Alawi et
al., 2015)
Not measured Not
measured
Not measured Only 6 out of 97
patients admitted to
hospital
Not measured increased use of broad-
spectrum antibiotics due to
resistance to first and
second line.
(World Health
Organisation,
2016e) (WHO
report)
Not measured Not
measured
Not measured Not measured Detection and
identification of
AMR
Not measured
Oman (Gunn et al.,
2009)
Not measured
Hospitals
that had a
consistent
policy and
especially
a written
policy, made
known to all
staff, had
better
outcomes as
far as post-
operative
infections
Not measured Not measured Not measured Not measured
(Al-Abri et al.,
2012)
80% adherence
to antimicrobial
treatment
guidelines of
CAP but
excessive IV
Not
measured
Not measured Not measured Not measured Not measured
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Country Authors Reduction of
inappropriate
prescribing
Reduction
of
healthcare
associated
infections
Reduction of
direct
antimicrobial
cost
Reduction LOS/
mortality metrics
Reduction of
antimicrobial
resistance
Reduction of Broad-
spectrum antibiotic use
use of
macrolides
(Al-Maliky et al.,
2017)
Not measured Not
measured
Not measured Not measured Not measured
High use of broad-spectrum
antibiotics (90% of
antibiotic prescriptions) due
to lack of adherence/
compliance with guidelines
and policy
Qatar (F. Y. Khan et
al., 2010)
Adherence to
guideline in 75%
of cases
Not
measured
Not measured Not measured Not measured Not measured
(Abdel-Aziz et
al., 2013)
Only 40% of
surgical patients
received the
right antibiotic
due to lack of
adherence to
hospital policy.
Not
measured
Not measured Not measured Not measured Not measured
(Garcell et al.,
2016)
Not measured Not
measured
Not measured Not measured Not measured
Reduction in use of
cephalosporins but rise in
use of other antibiotics
such as oral penicillin's and
IV macrolides.
(Guanche
Garcell et al.,
2016)
Appropriate
prescribing and
administration of
antibiotics
improved
Not
measured
Not measured Not measured Not measured
reduction in antimicrobial
use especially cefuroxime
Saudi
Arabia
(Jacobs et al.,
2003)
eliminated
inappropriate
prescribing
Reduced
perioperative
infective
complication
Not measured Not measured Not measured Not measured
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Country Authors Reduction of
inappropriate
prescribing
Reduction
of
healthcare
associated
infections
Reduction of
direct
antimicrobial
cost
Reduction LOS/
mortality metrics
Reduction of
antimicrobial
resistance
Reduction of Broad-
spectrum antibiotic use
s from 32%
to 11%
(Dib et al., 2009)
Education and
feedback to
prescriber
enhanced
adherence to
guidelines from
35% to 68%.
Not
measured
Not measured Not measured Not measured Not measured
(Amer et al.,
2013)
appropriate
empirical
antibiotics
improved from
31% to 100%
No impact on
C diff rates
half the total
cost of
antibacterial
agents
Reduction of hospital
stay 376 DDD
compared to 2404
DDD pre-ASP.
Deaths decreased
from 33% to 17%.
Not measured Not measured
(Malhani et al.,
2014)
(conference
poster)
Not measured Not
measured
Cost savings
reported as a
result of ASP
team
interventions
Not measured Not measured Not measured
(Al-Somai et al.,
2014)
ASP
interventions
resulted in 37%
reduction in
antimicrobial
consumptions
Not
measured
Reduction of
direct
antimicrobial
cost
Not measured Not measured Not measured
(Al-Tawfiq et al.,
2015)
Not measured
Reduced
C.diff rates Not measured Not measured
Reduction of
antimicrobial
resistance for
some organism-
antibiotic
combinations and
increase in
Not measured
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Country Authors Reduction of
inappropriate
prescribing
Reduction
of
healthcare
associated
infections
Reduction of
direct
antimicrobial
cost
Reduction LOS/
mortality metrics
Reduction of
antimicrobial
resistance
Reduction of Broad-
spectrum antibiotic use
resistance of the
heavily used
antibacterial
(piperacillin-
tazobactam)
(AlAwdah et al.,
2015)
(Conference
poster)
Improved
antimicrobial
prescribing in
relation to
reduced DOT
for major
antibiotics used.
Not
measured
Not measured Not measured Not measured Not measured
(Enani, 2016)
Two thirds
report the
outcome
Two thirds
report the
outcome
Two thirds
report the
outcome
60% report the
outcome
55% report the
outcome
Two thirds report the
outcome
(Alshukairi et al.,
2016)
Not measured Not
measured
Not measured Not measured
No significant
effect on
antimicrobial
resistance
Not measured
United
Arab
Emirates
(Hashmey et al.,
2013) (oral
presentation)
Not measured
Reduction in
c. diff
40% reduction
in consumption
and associated
costs
Not measured Reduction in MDR Reduction in use of broad-
spectrum antibiotics
(El Hassan et
al., 2014)
Low adherence
to hospital
guidelines
(32%) resulted
in inappropriate
SAP prescribing
Not
measured
Not measured Not measured Not measured Not measured
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2.4 Discussion
Findings of this review show varying level of adoption of ASPs and/or activities
directed at control of AMR in the GCC countries. This is similar to the findings of a
recent review on the impact of ASPs on antibiotic prescribing and prescribing
behaviours in some Middle Eastern countries (Nasr, Paravattil, & Wilby, 2017). In
2015, a strategic plan for combating AMR was developed for the GCC states. The plan
was developed in response to the WHO call for action against increasing rates of AMR.
This plan provides a guide for all GCC countries to develop effective and timely local
plans to monitor and control AMR (Balkhy et al., 2016). Prior to development of this
strategic plan however, the General Administration of Pharmaceutical care in Saudi
MOH had in 2013 developed pharmacy strategic plan. The strategic plan consisted of
a number of programmes, one of which was to initiate national ASP with aim of
establishing antimicrobial stewardship committee in MOH (Yousef Ahmed Alomi,
2017; Saudi Ministry of Health, 2014). This may explain why the majority of ASP
reports included in this review was from Saudi Arabia.
Although there is evidence of existing antimicrobial stewardship activities in the GCC
countries, most of the included studies did not define ASPs or provide their
components. There was also no evidence of follow up report on the progress of the
initiated programmes.
Antimicrobial stewardship guidelines such as, the IDSA/SHEA (Dellit et al., 2007) has
outlined strategies that may be employed to control antibiotic use in hospitals, as well
as composition of antimicrobial stewardship committee. In hospitals that reported
adoption of ASP, strategies employed were consistent with published guidelines,
although the ASP teams were mostly composed of ID specialists/consultants.
Surprisingly, lack of ID specialists/consultants was reported as one of the main barriers
to the adoption of ASPs by hospitals in GCC countries. For example, according to a
Saudi MOH report, the number of ID specialists/consultants in Saudi MOH hospitals
is only 57 (Saudi Ministry of Health, 2017a). This profession may not be attractive due
to the work environment and low payments compared to private sector (Manyisa &
van Aswegen, 2017). In the U.S. only 50-58% of US hospitals have access to ID
services (Reese, Gilmartin, Rich, & Price, 2014; Septimus & Owens, 2011). The ID
51
specialists/consultants leading ASPs need the help of pharmacists and microbiologists
to monitor and control the use of antimicrobials and provide recommendations to
prescribers and other healthcare workers on the appropriate use of antimicrobials
(Struelens, 2003). However, this review reveals that there is lack of involvement of
pharmacists and microbiologists in ASPs and antimicrobial therapy. To be successful
in ASPs adoption, a multidisciplinary team must be put in place to improve
antimicrobial therapy (Cairns et al., 2016; Schmitt et al., 2014).
The high influx of international travellers in and out of the GCC countries, especially,
Saudi Arabia, for Hajj and Umrah, was reported as one of the barriers. This is because
the number of hospital admissions increase dramatically during these periods, which
results in an increase in consumption of antimicrobials, and increased risk of AMR
development (Al-Somai et al., 2014). Other factors identified as barriers to the
adoption of ASPs included lack of knowledge, workload, prescribing behaviour and
lack of blame-free environment, and lack of resources. These factors are similar to the
findings of other studies (Hulscher, Grol, & Meer, 2010; Pakyz et al., 2014). It was also
reported in a systematic review that hospitals in the region lack blame-free
environment where reporting of errors is not practiced (Elmontsri, Almashrafi,
Banarsee, & Majeed, 2017).
From this review, a number of facilitators enable the adoption of ASPs by hospitals in
GCC countries including; knowledge and experience of prescribers, availability of
polices and guidelines, good communication between staff and departments, and
feedback to prescribers on antimicrobial therapy. These facilitators were identified in
previous studies, highlighting the importance of staff knowledge and experience,
availability of expertise and team work between staff to improve antimicrobial therapy
(Pulcini et al., 2014; Skodvin et al., 2015).
A Cochrane review of interventions to improve antibiotic prescribing practices for
hospital inpatients classified ASP outcomes into primary and secondary outcomes.
Primary outcomes include compliance with antibiotic guidelines or policies and
duration of treatment. Secondary outcomes include clinical outcomes such as,
mortality, length of hospital stay; microbial outcomes, including C. difficile infection and
colonisation or infection with antimicrobial-resistant bacteria (Davey et al., 2013,
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2017). The authors also report ASP interventions were effective in increasing
compliance with antibiotic policy and reducing duration of antibiotic treatment (Davey
et al., 2017); as well as reducing AMR and healthcare-associated infections, and
improve clinical outcomes (Davey et al., 2013). Outcomes used in assessing ASPs in
the GCC countries were in line with Davey et al. (2013; 2017) classification, however,
it was found that there were no changes in resistance rates, or a reduction was
observed in some organisms, and an increase in resistance was observed in other
organisms. This can be due to poor interventions, and/or lack of involvement of
microbiologists who should provide resistance patterns that helps in the development
and adoption of ASPs. Also, this can be due to inadequacy of testing methods for
antimicrobial susceptibility in hospitals in the region (Al-Tawfiq et al., 2015).
2.4.1 Limitations and future research
Although ASPs activities were explored previously in the region (Nasr et al., 2017),
this review is considered the first comprehensive review to explore the adoption of
ASPs in GCC countries hospitals. All study types and grey literature were reviewed in
order to increase the scope of evidence and provide a clear picture and understanding
on the level of adoption, barriers and facilitators, and outcomes of the adoption of
ASPs in the GCC countries. However, most of the reviewed studies did not define
ASPs or provide their components. As mentioned earlier, only little evidence was
identified with no follow up report or studies about the progress of programmes.
Therefore, further studies are required to evaluate ASPs for longer period and
understand how these programmes can be adopted and how barriers can be
overcome. Also, studies are required to explore the situation of antimicrobial use and
resistance in community pharmacies, private hospitals and primary healthcare
centres.
2.4.2 Implications for practice
The adoption of ASPs in GCC countries hospitals remains low due to the identified
barriers in this review. There is a need for each GCC country to develop a national
ASPs strategy to improve antimicrobial therapy and reduce AMR (Balkhy et al., 2016;
World Health Organisation, 2015a). Any national strategy should link to the GCC
regional strategy to share experiences and ideas, and improve practice.
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Communication and collaboration between organisations to share experiences and
ideas about the adoption of ASPs and how to overcome barriers can help to improve
organisational learning and practice. Also, collaboration between hospital
management and healthcare professionals is important to improve the adoption of
ASPs and enforce guidelines and recommendations. This is to be accompanied with
educational and training programmes about ASPs, appropriate antimicrobial use and
risks of AMR, in order to increase the knowledge and awareness of staff and facilitate
the adoption process.
2.5 Conclusion
AMR is increasing in the GCC countries very rapidly, with rare and novel resistant
strains, and one of the key measures to improve appropriate antimicrobial practice
and reduce rates of AMR is ASP. Despite the reported benefits of ASPs, their adoption
by hospitals in GCC countries remains low and underreported. A national surveillance
system should be introduced to report consumption and resistance rates to help in the
development of ASPs in the region. All of these should be done with the engagement
of all different stakeholders including; healthcare professionals, institutional and
regional levels, and national/governmental levels.
It is clear that studies are required at national levels to investigate the availability of
ASPs and barriers and facilitators for their implementation in GCC countries. It is
important to organise studies that will recommend changes to high authorities to
increase their awareness regarding AMR and ASPs, provide required resources,
enforce policies as well as periodic assessments to monitor the outcome of these
interventions.
2.6 Why Saudi Arabia
The focus of this thesis therefore is to explore and investigate the level, process and
factors influencing the adoption and implementation of ASPs in MOH hospitals in
Saudi Arabia, to provide hospitals and policy makers with evidence-based
recommendations on how to overcome the barriers to ASPs adoption in order to
improve antimicrobial practice and reduce AMR. Besides being a Saudi citizen,
sponsored by the Saudi government, worked as a hospital pharmacist in a Saudi
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hospital with no monitoring of antimicrobial use, able to get access to the data in the
country, and willing to contribute and improve the health practices in Saudi hospitals,
the following reasons are the main drivers for this research to be carried out in Saudi
MOH hospitals:
1. The only ASP guideline identified in all GCC countries is in Saudi Arabia
targeting MOH hospitals, but the implementation progress is not known.
2. Risks of AMR is more in Saudi Arabia due to the high number of expatriate
working in Saudi Arabia and their mobile in and out of the country, also due to
the high number of visitors from all over the world for Hajj and Umrah (around
10 million international visitors per year).
3. There are more published studies/reports from Saudi Arabia showing high AMR
rates.
4. The GCC-IC is located and monitored from Saudi Arabia, which is the guide for
infection control for all GCC courtiers.
5. Most of the reported papers in this review were from Saudi Arabia.
6. The healthcare system in Saudi Arabia is the biggest in the area with a total of
444 hospitals.
Therefore, the remaining part of this chapter discussed the health care system in Saudi
Arabia.
2.7 Research Context
2.7.1 Saudi Arabia
Saudi Arabia is a sovereign nation that is situated between the central portions of the
Arab Peninsula of South-West Asia (Al-Yousuf, Akerele, & Al-Mazrou, 2002). It is
bordered with Bahrain and the UAE to the east, Iraq to the north and northeast, Jordan
to the northwest, the Red Sea to the west, Yemen to the south and Oman to the
southeast (Figure 2.2). Saudi Arabia is composed of 13 regions, which are further
divided into governorates, in addition to the regional capitals.
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Figure 2.2: Saudi Arabia map
2.7.2 Saudi Arabia Healthcare System
The Saudi healthcare system is supervised by the MOH, which controls the operations
of public providers and monitors the private providers. The structure of the MOH public
health care system provides universal healthcare coverage in a two-tier framework:
1) 2,325 primary healthcare clinics and centres that mainly provide basic,
preventive, emergency and antenatal care, supported by mobile clinics that
serve rural or remote regions.
2) 274 hospitals and specialised facilities (63% of hospitals in Saudi)  that are
primarily situated in the urban areas (Saudi Ministry of Health, 2017a).
The MOH conduct the planning and development of health care, offering curative and
preventive health care, and the management of public hospitals. The MOH hospitals
are staffed by physicians (31,112), nurses (79,361), pharmacists (2,765), allied health
professionals (43,704) (Saudi Ministry of Health, 2017a). Despite the pre-eminence of
the MOH, there are several important health care providers in Saudi Arabia (Figure
2.3) (King Faisal Specialist Hospital & Research Centre, 2013; Saudi Ministry of
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Defense, 2015; Saudi Ministry of Health, 2013; Saudi Ministry of National Guard,
2015). The Ministry of health operates 63% (274) of the hospitals in Saudi Arabia.
Figure 2.3: Health care providers in Saudi Arabia
In the year 2016, a total of 137 million visits were made to healthcare facilities in Saudi
Arabia. Around 64 million visits (46%) were to MOH facilities, 50 million (36%) were to
private sectors, and 23 million (16%) were to other governmental hospitals. The total
number of hospitalised patients in 2016 were 3.4 million patients in all healthcare
facilities in Saudi Arabia. Around 1.7 million (50%) were hospitalised in MOH hospitals,
1.2 million (35%) were in private sectors, and 0.5 million (15%) were in other
governmental hospitals (Saudi Ministry of Health, 2017a).
The majority of MOH hospitals (79.5%) are general hospitals as shown in Table 2.5
(Saudi Ministry of Health, 2017a).
Table 2.5: Classification of Saudi MOH hospitals
Hospitals types Number
General 218(79.5%)
Psychiatric 18 (6.5%)
Obstetrics/Gynaecology and paediatrics 16 (6%)
Convalescence 7 (2.5%)
Eye 4 (1.4%)
63%
30%
3.5%
1.5% 1% 0.5% 0.5%
Health care providers in Saudi Arabia
Ministry of Health (274 hospitals)
Private sectors (136 hospitals)
Ministry of Defence (13 hospitals)
Ministry of National Guard (6
hospitals)
Ministry of Education (4 hospitals)
King Faisal Specialsit hospitals (3
hospitals)
Ministry of Interior (2 hospitals)
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Obstetrics/Gynaecology 3 (1%)
Paediatrics 3 (1%)
Chest 3 (1%)
Rehabilitation 2 (0.7%)
Total 274 (100%
In terms of external accreditation, several hospitals in Saudi Arabia have achieved the
Gold Seal of Approval® as entities that have attained the Joint Commission
International (JCI) accreditation. These include: academic medical centres, hospitals
and primary care providers. JCI identifies, measures and shares best quality and
patient safety practices with the world (Joint Commission International, 2015). The
partnership with JCI is mainly to ensure that these hospitals achieve excellence, which
applies from the point of accreditation, maintenance of the accreditation, updating of
standards and the offering of guidance that can help in improving performance that
JCI accreditations intended for (Joint Commission International, 2015).
In Saudi Arabia, only 15 of the hospitals owned by the MOH have the JCI accreditation,
as a result of concerted efforts by the hospitals to improve in their systems and the
adoption of measures, standards and specifications that comply with the
internationally acceptable requirements of the provision of healthcare (Saudi Ministry
of Health, 2012).
2.7.3 Health seeking behaviour in Saudi Arabia
The term ‘illness behaviour’ has been used to describe the way an individual perceives
symptoms, evaluate, and act when he recognises pain, discomfort or other signs of
organic malfunction (Young, 2004). Illness behaviour is sometimes referred to as
health behaviour, care-seeking behaviour or health seeking behaviour (HSB). HSB
has been defined as any activity an individual undertakes to define his/her state of
health and obtain suitable advice or treatment (Oberoi, Chaudhary, Patnaik, & Singh,
2016). HSB research looks at the ways people behave in relation to their health, as
well as factors that facilitate the use of formal health services (Mackian, 2003). A
number of studies have been carried out in different countries to investigate these
factors. Two main approaches have been employed in investigation of what facilitates
the use of health services, and what influences people to behave differently in relation
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to their health. The first approach focuses on the ‘end point’ (utilisation of the formal
system, or health care seeking behaviour); the second focuses on the ‘process’ (illness
response, or health seeking behaviour) (Mackian, 2003). Studies on utilisation of
formal health services have shown that the decision to engage with a particular
medical channel is influenced by a number of factors which lie between patients and
health services. These include geographical, social, economic, cultural and
organisational factors. Table 2.6 summaries the determinants of HSB (Mackian, 2003).
Table 2.6: Determinants of HSB
Category Determinant Details
Cultural Status of women Element of patriarchy
Social Age and sex
Socio-economic Household resources Education level
Maternal occupation
Marital status
Economic status
Economic Costs of care Treatment
Travel
Time
Type and severity of illness
Geographical Distance and access
Organisational Perceived quality Standard of drugs
Standard of equipment
Competence of staff
Attitudes of staff
Interpersonal process
In Saudi Arabia, healthcare is offered for free to Saudi citizens through more than 2300
PHCs and 270 hospitals (Almalki, Fitzgerald, & Clark, 2011; Saudi Ministry of Health,
2017a). In spite of the government investment in healthcare through the MOH, more
than 1.9 million (15.2%) and 1.7 million (13.4%) Saudis aged 15 years or older are
hypertensive and diabetic, respectively. A further, 57.8% and 43.6% of those affected
have not been diagnosed with hypertension and diabetes, respectively, while among
those diagnosed, 31.1% and 9% are not treated (El Bcheraoui, Basulaiman, et al.,
2014; El Bcheraoui, Memish, et al., 2014). In a study to identify barriers to healthcare
services in Saudi Arabia, it was concluded that individual characteristics (age, level of
education, type of disease) are more important than system-based characteristics in
healthcare-seeking practices (El Bcheraoui, Tuffaha, Daoud, Kravitz, et al., 2015).
59
With regards to antibiotics, socio-economic and geographical determinants have been
found to drive antibiotics use behaviour. Poor knowledge and unhealthy perception
about antibiotics have been identified among the general population and students in
Saudi Arabia. A study that aimed to determine the prevalence of self-prescription of
antibiotics in Saudi community found that 78.7% (536/681) of participant practice self-
prescription of antibiotics without seeing a doctor (Al Rasheed et al., 2016). Another
study in Riyadh, found out that 77.6% (253/327) of community pharmacies dispensed
antibiotics without a medical prescription (Bin Abdulhak et al., 2011). In a study aimed
to estimate the prevalence of self-medication with antibiotics among third year nursing
students, 35.44% (28/79) of the students practiced self-medication with antibiotics
(Khanam & Haj-ali, 2017). A related study also reported high prevalence (54.5%
(214/394)) of self-medication with antibiotics among female students in a Saudi
university (Al Barakh et al., 2016). These studies show that even among persons in
higher education, misuse of antibiotics is still common in Saudi Arabia; a multi-pronged
intervention, including educational campaign targeting different groups in the Saudi
population will therefore be required to stir health seeking and antibiotics use
behaviour in the right direction.
2.7.4 Country Cooperation Strategy for WHO and Saudi Arabia 2012-2016
The Country Cooperation Strategy for WHO and Saudi Arabia 2012-2016 was
intended to bring the help of WHO to support Saudi Arabia  in addressing its particular
local health challenges and priorities (World Health Organisation, 2013). This involves
the examination of the health needs of the nation within the context of its health sector,
socioeconomic status, and national policies and health strategies. WHO has
collaborated with the Saudi Arabian government to update its information on the health
sector, together with other players such as the Ministries of Health, Education,
Agriculture and Social Affairs. The United Nations Children's Fund (UNICEF) and GCC
have also committed to pursuing measures to support health initiatives and
programmes (World Health Organisation, 2013).
The Country Cooperation Strategy for WHO and Saudi Arabia 2012-2016 holds that
there is a need for improvement, especially in the strengthening of the WHO office
through a fund-in-trust arrangement. It also necessitates a timely response to requests
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for support and guidance, as well as the identification of technical expertise elsewhere
other than Saudi Arabia (World Health Organisation, 2013). This notwithstanding, the
WHO in collaboration with the Government of Saudi Arabia have enlisted four strategic
priorities for collaborative work (World Health Organisation, 2013):
 Strengthening the control of communicable diseases and health security.
 Strengthening the promotion of health and control of noncommunicable
diseases.
 Strengthening the health care delivery systems.
 Improvement of partnership for health development.
The Saudi government established the Expanded Programme for Immunisation (EPI)
to focus on the vaccination of preventable diseases (such as Measles, Mumps and
Rubella), which has contributed in the reduction of infection rates in the country. This
initiative has increased immunization coverage by approximately 90%, reducing
incidences of diseases that are targeted by the immunization (Saudi Ministry of Health,
2013).
2.7.5 AMR Rates and surveillance in Saudi Arabia
No national surveillance system for AMR and antimicrobial consumption exists in
Saudi Arabia. The following data regarding resistance pathogens were obtained from
a global surveillance report on AMR that was developed by WHO in 2014. The WHO
report produced the following data by reviewing all the available publications regarding
AMR in Saudi Arabia (World Health Organisation, 2014).
A study that was conducted in an adult ICU at a tertiary care centre which tested 392
isolates found that there is a 61% resistance of E. coli to third generation
chephalosprins (AlJohani et al., 2010). Another study found among 2530 isolates there
is a 74.1% resistance of E. coli to fluoroquinolones (Al-Tawfiq & Anani, 2009). It was
also found that K. pneumoniae resistance to Ceftriaxone is 59% among 96 isolates in
a general ICU in a tertiary care hospital (Saeed, Kambal, & El-Khizzi, 2010). MRSA
was presented in 92% of 112 isolates in a specialist hospital (Ahmad, 2010). In another
study in a tertiary care hospital in Riyadh, 46% Nontyphoidal Salmonella (NTS)
resistance to fluoroquinolones was found among 213 isolates (Somily et al., 2012).
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The increased rates of AMR in Saudi Arabia can be attributed to the increase in
antimicrobial consumption. All antimicrobial use (retail) increased from 11,852 in 2000
to 17,173 standards unit per 1000 population in 2015 (Figure 2.4). Broad-spectrum
penicillins were the most used class of antibiotic and it increased from 6,398 in 2000
to 9,571 standards unit per 1000 population in 2015, followed by Cephalosporins that
increased from 3,076 in 2000 to 4,041 standards unit per 1000 population in 2015 (The
Center for Disease Dynamics Economics & Policy, 2015b). Saudi Arabia is among the
top consumers of antimicrobials (retail) in GCC countries (Figure 1.4), and the
increasing emergence of AMR is likely to put the country on a fast track to the post-
antimicrobial era. The implementation of effective ASPs can potentially reduce the
spread of resistance and promote the rational use of antimicrobials. Another reason
for increased AMR rates is the sales of antimicrobial in community pharmacies without
official prescriptions as discussed earlier.
Figure 2.4: Antibiotic use (retails) in Saudi Arabia 2000-2015 (The Center for
Disease Dynamics Economics & Policy, 2015b)
A number of factors are associated with the emergence and spread of AMR and
infectious diseases in Saudi Arabia. The large number of international travellers, as
big number of different workers in health sectors and other sectors are non-Saudis. In
addition, the hosting of more than 10 million international visitors through the year for
Hajj and Umrah to Makkah and Madinah (Azeem et al., 2014; Kapiszewski, 2006;
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Memish et al., 2014; Saudi Ministry of Health, 2017a; H. M. Zowawi et al., 2013) is
among the factors that increase the risk of AMR spread, as travel and gatherings of
large number of people within a short period of time are considered risk factors for
acquiring and spreading of AMR bacteria and infectious diseases (Memish et al., 2014;
Östholm-Balkhed et al., 2013; Rogers, Aminzadeh, Hayashi, & Paterson, 2011).
Consequently, the Saudi MOH requires that people coming from some countries,
willing to make Hajj or Umrah and applying for an entry visa to get vaccines for the
following conditions: Yellow fever, meningococcal meningitis and poliomyelitis and the
seasonal influenza vaccine (Ministry of Health, 2016).
The Saudi MOH has released its 10 years strategic plan with the aim to improve health
care services in primary centres and hospitals. The goals of this plan include: adopt
an integrated and comprehensive approach to healthcare with focus on educational
and research activities; increase the quality of services and monitor performance;
recruit qualified healthcare personnel and develop human resources; develop
electronic health services and information systems; and optimise the use of resources
and develop ways for funding (Ministry of Health, 2009). Therefore, the Saudi MOH
has released the ASP plan to combat AMR in hospitals through the general
department of pharmaceutical care. The plan has 5 stages starting from year 2014 to
2018, each stage to involve more hospitals and strategies (Yousef A. Alomi, 2015).
However, there are no reports regarding the implementation or progress of the MOH
initiative.
The Saudi MOH guideline for ASPs implementation is the only ASP guideline in the
gulf area. However, the implementation progress of ASPs within hospitals is unknown,
therefor the aim of this thesis was to explore and investigate the level and process of
adoption of ASPs and factors influencing their implementation in Saudi MOH hospitals,
to provide hospitals and policy makers with evidence-based recommendations on how
to overcome the barriers to ASPs adoption in order to improve antimicrobial practice
and reduce AMR.
In the next section the research justification, questions, aim and objectives will be
presented.
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2.8 Research justification and rationale
AMR is a global public health concern undermining efforts to treat infectious diseases,
resulting in increased morbidity and mortality, and adding avoidable costs to already
strained healthcare systems. The irrational use of antimicrobials, and lack of ASPs are
major contributing factors to AMR.
Saudi Arabia is among the top consumers of antimicrobials (retail) in the world, and
the increasing emergence of AMR is likely to put the country on a fast track to the post-
antimicrobial era. The implementation of effective ASPs, especially in hospitals, can
potentially reduce the spread of resistance and promote the rational use of
antimicrobials.
A Saudi national guideline for ASPs implementation within MOH hospitals has been
developed. However, there is little data about the availability and implementation of
ASPs within hospitals. Thus, studies at national level are necessary to investigate the
level of implementation, and barriers to and facilitators of APSs adoption and
implementation. Steps should also be taken to recommend changes to high authorities
to support and facilitate ASPs adoption and implementation, as well as to implement
periodic assessments that monitor the progress and outcomes of these interventions.
This study, therefore, explores the barriers and facilitators for the adoption and
implementation of ASPs in Saudi MOH hospitals, from the perspectives of hospital
physicians, pharmacists, microbiologists, infection control practitioners, hospital
managers, nurses and policy makers; investigates the level of implementation and
factors influencing the adoption and implementation of ASPs in MOH hospitals on a
national level; and explores the adoption and implementation process of ASP in a
MOH hospital that has ASP in place and outline how the adoption and implementation
barriers could be removed.
Finally, due to lack of studies regarding public knowledge and perceptions regarding
AMR and appropriate antimicrobial use, and findings of the qualitative study (chapter
4) suggested that there is lack of patients' knowledge and perceptions regarding
antimicrobial use and AMR, patient’s knowledge and perceptions regarding
antimicrobial use and resistance were evaluated.
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2.9 Research questions
1. What is the level of ASPs implementation in Saudi MOH hospitals?
2. What are the barriers and facilitators for the adoption and implementation of
ASPs in Saudi MOH hospitals?
3. What is the process and steps of ASP adoption and implementation in a Saudi
MOH hospital?
4. What is the level of patients’ knowledge and perceptions regarding antimicrobial
use and resistance in Saudi MOH hospitals?
2.10 Research aim
The aim of this research is to explore and investigate the level and process of adoption
of ASPs and factors influencing their implementation in Saudi MOH hospitals, to
provide hospitals and policy makers with evidence-based recommendations on how
to overcome the barriers to ASPs adoption in order to improve antimicrobial practice
and reduce AMR.
2.11 Research Objectives
To achieve the research aim, the following objectives must be accomplished:
1. Explore the perspectives of physicians, pharmacists, microbiologists, infection
control practitioners, nurses, hospital managers and policy makers on the
barriers and facilitators of ASPs in Saudi MOH hospitals.
2. Investigate the level of implementation and factors influencing ASPs adoption
and implementation in Saudi MOH hospitals at national level.
3. Understand the process of ASP adoption and implementation (initiation,
adoption decision, and implementation) in a Saudi MOH hospital.
4. Evaluate the knowledge and perceptions regarding antimicrobial use and
resistance among adult hospital patients in Saudi MOH hospitals.
5. Produce evidence-based recommendations for successful adoption and
implementation of ASPs in Saudi MOH hospitals.
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Chapter 3: Research Methodology
This chapter explains the research methodology used in this thesis. It describes and
justifies the theoretical framework and research methods adopted in this thesis.
Further, it explains the research design and methods used to answer the research
questions and achieve the research objectives and aim. Finally, techniques to increase
the reliability and validity of this research were discussed as well as analysis of both
qualitative and quantitative data and ethical considerations in this research.
3.1 Theoretical Framework
The theoretical framework is the structure that holds, supports and describes the
research study theory that explains and justifies the research problem (Bryman, 2016;
Creswell, 2009). It informs and justifies the study design, sampling, setting, analysis
and interpretation in order to address the research objectives. The research
methodology and methods should be identified and justified for each research. The
research methodology involves the strategies, procedures and deign that are used to
achieve the desired outcome through a specific method. While, the methods include
the process of collecting and analysing data (Crotty, 1998).
The theoretical framework also justifies the researcher’s philosophical assumptions,
epistemology (knowledge and how to acquire it) and ontology (reality and how to view
it), behind the research (Bowling, 2009; Bryman, 2016). Although it is sometimes
referred as epistemology and ontology, it is usually referred to as a paradigm. The
research paradigm involves; concepts and assumptions that drives thinking and
research as well as methodology and methods of the research (I. B. Cohen, 1994;
Crotty, 1998).
3.2 Theoretical Paradigms
Theoretical paradigms include: positivism, constructivism, transformative,
pragmatism, critical and deconstructivism (Bowling, 2009; Creswell, 2009; Crotty,
1998; Mackenzie & Knipe, 2006). Positivism (Deductive approach) is associated with
quantitative methods and based on experimental and observational studies to test
hypothesis. On the contrary, constructivism/interpretivistivism (inductive approach) is
associated with qualitative methods and based on the concept that reality is multiple
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and constructed by the participants own experience and views to generate hypothesis.
On the other hand, critical/ transformativism is driven by demands to improve society
through political debates and actions. It discuses methodology and methods to assess
transformative theory usually through the use of mixed methods approach in order to
gain different points of view in relation to the research area. On the other side,
pragmatism approach follows multiple approaches and concentrates on the problem,
actions and situations by using both qualitative and quantitative methods in order to
understand the problem and achieve the results (Bowling, 2009; Creswell, 2009;
Crotty, 1998; Mackenzie & Knipe, 2006).
The framework of this thesis was developed bearing in mind the ability to answer the
research questions in order to achieve the research aim and objectives. From
reviewing the literature, there is increasing rates of antimicrobial resistance in Saudi
hospitals. Even though there is a national ASP strategy for MOH hospitals, the
adoption and implementation of ASP in this context is still unknown. Only few studies
reported the implementation of ASPs in some large Saudi hospitals. However, the
situation in other MOH hospitals that represent 60% of all hospitals in Saudi Arabia is
still unknown. In addition, studies have overlooked the adoption and implementation
of ASP in this context and none has yet to identify the barriers of adoption and how to
overcome them. Finally, it was identified from the qualitative study (Chapter 4) that
there is lack of knowledge and perceptions among patients in Saudi hospitals (without
ASPs) regarding appropriate antimicrobial use. Therefore, a pragmatic paradigm that
used both qualitative and quantitative methods (mixed-method approach) was
adopted in order to answer the research questions and achieve the research aim and
objectives.
A qualitative study was carried out in three Saudi MOH hospitals with the involvement
of policy makers at regional and national levels in order to explore adoption,
implementation, barriers and facilitators of ASPs in Saudi MOH hospitals. The
qualitative study was exploratory in nature to identify and understand the situation in
the three hospitals using semi-structured interviews in order to obtain more (in-depth)
data from participants. Complementing this, a quantitative study was carried out to
investigate the level of implementation, barriers and facilitators of ASPs adoption at
national level. This was followed by a qualitative study in a Saudi MOH hospital that
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has ASP in place in order to explore the process of adoption and implementation of
ASP and identify how to successfully overcome adoption barriers. Finally, a
quantitative study was conducted to evaluate the knowledge and perceptions of
antimicrobial use and resistance among adult hospital patients in Saudi MOH
hospitals.
3.3 Qualitative research
Qualitative research describes the phenomenon being studied in terms of words rather
than numbers. It is concerned with the qualities of social phenomena that are obtained
through direct and reactive observations (Creswell, 2009; Rice & Ezzy, 1999).
Qualitative data may be obtained through interviews, tape recording, recordings in a
diary, focus group techniques and life histories amongst other methods (Bowling &
Ebrahim, 2005; Smith, 2002). The advantage of this method is that it may be used in
instances when the researcher has little pre-existing knowledge about the subject
under investigation. It also offers the opportunity to deal with complicated or sensitive
issues in order to formulate an inductive or explorative hypothesis, instead of applying
the findings to a bigger population (Bowling, 2009). It is important to note that this
mode of research is used at the exploratory stage of a study and may be relevant to
investigations of public health, especially when that is reliant upon the understanding
of people (Rice & Ezzy, 1999). In essence, qualitative research helps in the
understanding and answering of the questions on ‘how’ and ‘why’, which makes it
ideally suited to determining the behaviour and thoughts of people (Smith, 2002).
Qualitative data can be collected through the use of interviewing technique. Research
interviews can be structured, unstructured or semi-structured (Bowling & Ebrahim,
2005). Structured interviews seek to find answers to specific questions and are asked
precisely the same way to each of the research participants, while unstructured
interviews are led by the participants who are allowed to provide their own stories in
their own words and without the involvement of the researcher. However, semi-
structured interviews entail the use of open and closed questions which have been
developed by the researcher before conducting the interviews and the questions are
flexible in response to participant comments.
68
Interviews are carried out face-to-face or remotely, such as by telephone. The
advantage of face-to-face interviewing is that the interviewer can probe for clarification,
offers less chance of error, and can include complicated and detailed questions.
However, this approach may be expensive, time-consuming, contain interviewer bias,
and produce data that is difficult to analyse. In contrast, telephone interviews are
efficient with regards to time, but are only restricted to use where there is a brief
questionnaire and with non-sensitive topics. The rate of response to this method is
typically low, especially when sensitive questions or topics are required (Bowling,
2009).
There are number of methods for qualitative research sampling including; 1)
Convenience sampling involves sampling of subjects (participants) for reasons of
convenience (easy to recruit, likely to respond, near at hand), 2) Purposive sampling
(judgement sampling) samples a group of settings or people with particular
characteristics (selection of particular respondents is made because they have
valuable knowledge on the researched topic), 3) Snowballing technique includes
asking an initial group of participants to recruit more participants relevant to the
research area, and 4) Theoretical sampling where sampling categories are developed
during the research process (Bowling, 2009).
3.4 Quantitative research
This term refers to the acquisition of data concerned with quantities and the
relationships between attributes. It therefore entails the collection and the analysis of
data that is highly structured in the positivist tradition. This approach is recommended
in situations where there is pre-existing knowledge that allows the use of standardised
methods of collecting data (Bowling, 2009; Creswell, 2009).
One of the most popular tools for collecting quantitative research data is the use of
questionnaires. The survey tools can be structured or semi-structured in nature
(Bowling, 2009; Smith, 2002). Structured questionnaires involve the use of
standardised questions that are presented to the respondents in the same way, while
semi-structured questionnaires involve the use of fixed questions but offers the
participant some flexibility to enable them raise other issues or offer other responses.
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The advantage of structured questionnaires is the ability to collect unambiguous data
that is easier to analyse due to the pre-coded questions. They can cover significantly
large populations than interviews, increasing generalisability, and are often more
popular in dealing with sensitive topics due to the anonymity they afford to
respondents. However, the pre-coded responses obtained through this method may
not be comprehensive and respondents may be forced to choose answers that may
not properly represent their views. Another disadvantage of this method is the inability
to ensure that the targeted participant will be the one to complete the questionnaire
(Bowling, 2009; Smith, 2002).
There are number of methods for quantitative research sampling including; 1)
unrestricted random sampling where members of the targeted population are
numbered and a number of them is selected randomly, numbers are replaced before
the next draw, so each unit can be selected more than once, 2) simple random
sampling which follows the unrestricted random sampling method, but without
replacing numbers of population before each draw, so each unit can be selected once,
3) systematic random sampling that involves selection of samples from a list, with this
method there is a risk of bias if the list of population is ordered as a trend can occur,
4) stratified random sampling where the targeted population is divided into strata
(layers)  (for example, nurses, pharmacists, microbiologists) and  sampling from the
layers is carried out using systematic or simple random sampling, 5) sampling with
probability proportional to size where units are stratified by size and a sample is
selected based on each size group, and 6) non-random sampling (quota sampling)
that is a stratified sampling method where the selection within geographical layer is
non-random (Bowling, 2009).
3.5 Mixed Method Research
The mixed method research uses both the qualitative and quantitative research
approaches. Table 3.1 highlights the different typologies suggesting how to use a
mixed method approach in actual research (Bowling & Ebrahim, 2005; Creswell,
2009).
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Table 3.1: Mixed method research strategies
3.6 Methodological design
The aim of this thesis is to develop evidence-based recommendations to improve
successful adoption and implementation of ASPs in Saudi MOH hospitals in order to
improve antimicrobial practice and reduce AMR (Figure 3.1). These evidence-based
recommendations were developed through a number of studies; 1) A systematic
literature review to explore the existing evidence on ASPs and activities in the GCC
region including Saudi Arabia (Chapter two), 2) Semi-structured interviews with
different healthcare professionals and policy makers to explore barrier and facilitators
for successful ASPs adoption and implementation in Saudi MOH hospitals (Chapter
four), 3) A national survey to investigate level of implementation and factors influencing
the adoption and implementation of ASPs in Saudi MOH hospitals (Chapter five), 4) A
case study (in-depth interviews) with core members of the ASP in a Saudi hospital that
has ASP in place to understand the process of ASP adoption and implementation and
how to overcome barriers (Chapter six), and 5) A survey to evaluate patients'
knowledge and perceptions of antimicrobial use and resistance (Chapter seven).
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Figure 3.1: Methodological design
3.7 Thesis Framework and Structure
A pragmatic approach was used in this research to explore and understand ASPs
adoption and implementation in Saudi MOH hospitals and produce evidence-based
recommendations for their successful adoption and implementation.
This research adopted a mixed-methods approach that uses semi-structured
interviews, supplemented by the distribution and completion of questionnaires. The
interviews enabled to capture of both verbal and non-verbal expressions, and
behaviours and emotions. The themes that emerged from the interviews were used to
design the national survey. These were used to elicit responses from a large number
of participants while ensuring that the different perspectives of participants are
obtained. The questionnaires are also preferred as a follow-up on the responses
offered by the semi-structured interviews, as well as enabling triangulation of the data
that has been collected by the semi-structured interviews (Bowling & Ebrahim, 2005).
In-depth interviews were also conducted in a Saudi MOH hospital that has ASP in
place in order to capture both verbal and non-verbal expressions, behaviours and
emotions of participants and gain in-depth data from participants regarding the
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adoption and implementation process of ASP and how adoption and implementation
barriers were overcome. A patient survey was also conducted in order to obtain
responses from a large number of participants and evaluate their knowledge and
perceptions regarding antimicrobial use and resistance.
This thesis has a total of eight chapters. Chapter one provides an overview of the issue
of AMR, actions to slow and prevent its development and spread and ASPs as one of
the solutions to prevent antimicrobial resistance. Chapter two encompasses a
systematic literature review regarding ASPs in the GCC countries hospitals. Chapter
three includes the theoretical framework of this thesis and different research theories
and approaches. It also describes the methods used in this research and the theory
behind it.
This research was carried out in two phases (as illustrated in Figure 3.2). Phase one
commenced with semi-structured interviews (Chapter four) with healthcare
professionals in three Saudi MOH hospitals and four MOH leaders, followed by a
national survey (Chapter five), developed from the qualitative study, that was sent to
all Saudi MOH hospitals. Phase two started with semi-structured interviews (Chapter
six) with participants involved in the process of ASP adoption and implementation in
the medical city, followed by self-administered questionnaires (Chapter seven) to
patients in two Saudi MOH hospitals. Chapter eight includes the overall discussion
interpreting the results of phase one and phase two studies, summary of the results,
recommendations and future research to improve ASPs implementation in order to
reduce rates of AMR and improve patients care and safety in Saudi MOH hospitals.
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Figure 3.2: Overview of research phases and methods
Research aim: To explore and investigate the level and process of adoption of ASPs and factors influencing their implementation in
Saudi MOH hospitals, in order to provide hospitals and policy makers with evidence-based recommendations on how to overcome the
barriers to ASPs adoption to improve antimicrobial practice and reduce AMR.
.
Phase 1 Phase 2
Objective 1
Explore barriers and facilitators of
ASPs adoption and implementation in
Saudi MOH hospitals
Objective 4
Evaluate knowledge and perceptions
regarding antimicrobial use and
resistance among hospital patients in
Saudi MOH hospitals
Semi-structured interviews
with 18 healthcare
professionals from 3 different
hospital settings and 4 MOH
leaders
Self-administered
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all Saudi MOH hospitals
(274)
Self-administered
questionnaires were
distributed to hospital patients
in 2 different hospital settings
Case study using semi-structured
interviews with participants
involved in the process of ASP
adoption and implementation in
the hospital
Produce evidence-based recommendations for successful adoption and implementation of ASPs in Saudi MOH
hospitals
Objective 3
Understand the adoption and
implementation process of ASP
(initiation, adoption decision,
implementation) in a Saudi MOH
hospital
Objective 2
Investigate the level of
implementation and factors
influencing the adoption and
implementation of ASPs in Saudi
MOH hospitals at national level
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3.8 Summary
Table 3.2 provides a summary of the research questions, methodology, rationale,
methods and the respective chapters.
Table 3.2: A summary of the research questions, methodology, rationale and methods
Research questions Methodology Rationale Methods Chapter
What are the barriers
and facilitators for the
adoption and
implementation of
ASPs in Saudi MOH
hospitals?
Qualitative
Explore barriers and
facilitators for ASPs
successful adoption
and implementation
in Saudi MOH
hospitals and
develop a national
survey (quantitative
tool) regarding
ASPs.
Semi-
structured
interviews
4
What is the level of
ASPs implementation
in Saudi MOH
hospitals?
What are the barriers
and facilitators for the
adoption and
implementation of
ASPs in Saudi MOH
hospitals?
Quantitative
Investigate the level
of implementation
and factors
influencing the
adoption and
implementation of
ASPs in Saudi MOH
hospitals at national
level.
Online self-
administered
questionnaire
5
What is the process
and steps of ASP
adoption and
implementation in the
medical city?
Qualitative
Qualitative study to
understand the
process of ASP
adoption and
implementation in
the medical city
In-depth
interviews
6
What is the level of
patients' knowledge
and perceptions
regarding antimicrobial
use and resistance in
Saudi MOH hospitals?
Quantitative
Evaluate the
institutional role of
patient education on
antimicrobial use and
resistance in Saudi
MOH hospitals.
Self-
administered
questionnaire
7
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3.9 Reliability
Refers to the consistency and reproducibility of the instrument and its degree of being
free from random error (internal consistency) (Bowling, 2009). Item equivalence and
convergence can be assessed by; 1) split half where the instrument is divided into two
parts and the correlations between the 2 are compared, and 2) Cronbach's alpha that
estimates reliability based on all correlations between all items within the scale (an
estimate of internal consistency, value range from 0 to 1). It is accepted that the minim
acceptable level for Cronbach's alpha (internal consistency reliability) is 0.7, while
others accept 0.5 (Bowling, 2009; Bryman, 2016).
Repeatability is assessed by; 1) inter-rater where the results obtained by 2 raters are
compared to measure to which extent they agree, and 2) test-retest that measures the
stability of the instrument over a period of time by repeating the administration of the
instrument at different time  where nothing else has changed (Bowling, 2009; Bryman,
2016).
To increase the reliability of this research the following steps were followed (Bowling,
2009);
 The interviewer was trained in order to avoid cases of biased interviewing
whereby the respondents are made to answer questions in a certain manner.
 The researcher was trained on the use of values and collection, analysis and
interpretation of data in order that they are logical to increase reliability.
 The researcher was careful to conceptualise proper methods, sampling
procedures and analysis techniques in order to ensure that the observed values
and the true values are consistent in order to increase reliability.
 The researcher was endeavoured to avoid, ambiguous wording of the
questions, interpretation of the questions by the respondents in an inconsistent
manner, or the inability of the respondents to offer accurate information that
may reduce the reliability of the data.
 The respondents were adequately informed that the interviews are not to
assess them to enable them freely participate in the research.
 Transcribed data were verified with the participants to ensure further reliability.
 The field data that included the audio recordings and the filed notes were
carefully reviewed by the investigator and supervisory team in order to
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categorise them. The investigator carried out the categorisation and further
approved by the supervisory team with regard to their reliability.
 Only the true results were reported without any need for overemphasis, in order
to have the true body of knowledge that increases reliability.
3.10 Validity
Validity assesses whether an instrument measures what it is meant to measure
(Bowling, 2009). There are two types of validity namely internal validity and external
validity. Internal validity refers to how well an experiment has been carried out to avoid
confounding or more than one possible variable acting at the same time (Bowling,
2009). On the other hand, external validity is the validity of the causal inferences
present in a specific research that is based on experiments. This relates to the extent
to which the results of a study can be generalised in other instances or to other people
(Bowling, 2009). There are different forms of validity including; 1) face validity that
refers to investigators assessments of the instrument to make sure it is clear,
reasonable, relevant and unambiguous, and 2) content validity that refers to the
assessment of the instrument (usually by a panel) to check the content of the
instrument and ensure it will measure what it is supposed to measure (Bowling, 2009;
Bryman, 2016).
To increase the validity of the study, the following steps were followed (Bowling, 2009);
 The researcher ensured that there are no faulty designs, methods, sampling
procedures and irrelevant techniques in the analysis of the data in order to
eliminate any differences between the observed values and the true values
which effectively increase validity.
 The data collection tools (interview schedules and surveys) were checked by
the investigator and supervisory team (face validity) as well as external experts
(content validity) to verify their relevance, reasonability and ambiguity in order
to increase their validity. This guaranteed that the content of the instrument is
logical, balanced and covers the scope and domain that is intended to be
measured.
 The researcher carried out a comparison with the most established methods
of collecting similar information.
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 The researcher incorporated questions that can easily be answered.
 The researcher ensured that the instruments cover all the issues that are
relevant to the topic through the incorporation of appropriate questions and
giving the respondents the opportunity to report on the issues assumed to be
most important.
 Transcribed data was verified with the participants to ensure further validity.
3.11 Determinants of ASPs adoption
A number of conceptual frameworks exist in the area of healthcare innovations
adoption and diffusion. One of the most prominent frameworks is the Generic
Implementation Framework (GIF) (Moullin, Sabater-Hernandez, Fernandez-Llimos, &
Benrimoj, 2015). It advocates that implementation of interventions (investigation,
protocol or programme) is influenced by number of factors, strategies and evaluations
which need to be considered during the process of implementation (Figure 3.3).
However, this framework did not determine/detailed those factors, strategies and
evaluations that may affect the process of implementation. Thus, this framework can
be used as a basis or a memory aid during the design/implementation of the
intervention and should be tailored based on the innovation, setting, user and
objective.
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Figure 3.3: Generic Implementation Framework (GIF) (Moullin et al., 2015)
Figure 3.4 highlights a conceptual framework on the determinants of diffusing,
disseminating, and implementing innovations in health organisations (Greenhalgh,
Robert, Macfarlane, Bate, & Kyriakidou, 2004). This framework advocates that a
number of factors affect implementation of healthcare innovations including:
innovation characteristics (e.g. compatibility, complexity, trialability, risk), assimilation
by the system, diffusion and dissemination of the process (e.g. networks, marketing,
expert opinion), system antecedents for innovation (structure, absorptive capacity for
new knowledge, receptive context for change), system readiness for innovation
(tension for change, support and advocacy, monitoring and feedback), outer context
(interorganisational networks and collaboration): (socio-political climate, incentives,
environmental stability, political directives), implementation and routinisation
(organisational structure, leadership and management, human resources issues,
funding, feedback), and linkage among the intervention stages (design stage and
implementation stage).
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Figure 3.4: Conceptual model for considering the determinants of diffusion,
dissemination and implementation of innovations in health services delivery and
organisation (Greenhalgh et al., 2004)
Another framework for the determinants of innovation within the healthcare
organisations was developed by (Fleuren, Paulussen, Dommelen, & Buuren, 2014;
Fleuren, Wiefferink, & Paulussen, 2004) (Figure 3.5). This framework grouped the
factors that can affect the implementation of healthcare innovations into four groups
including: the socio-political context characteristics (patient cooperation, patient
awareness, legislation and regulations), organisation characteristics (reinforcement
management, relationship with other organisations, collaboration between
departments, staff capacity, available expertise, financial resources, material
recourses, administrate support), user characteristics (support colleagues, skills,
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knowledge, ownership, task orientation,) and the innovation characteristics (clear
procedures, compatibility, trialability, relevance for patient, risks for patient,
complexity).
Figure 3.5: Framework representing the innovation process and related categories
of determinants (Fleuren et al., 2014, 2004)
The last two models are approximately consistent and represent same factors that can
affect the implementation process, however, the determinants of innovation within the
healthcare organisations model (Fleuren et al., 2004) is well-presented, more
organised,  easy to understand and interpret, has been updated recently (Fleuren et
al., 2014) and grouped the factors into four groups making it easy to analyse and
categorise themes and understand and interpret data.
Therefore, a framework representing the major phases in ASP processes and related
categories of determinants (Figure 3.6), has been developed based on the
determinants of innovation within the healthcare organisations model (Fleuren et al.,
2014, 2004) informing the analysis. The conceptual framework was also used to
develop the interviews schedules and survey questionnaires. Themes and subthemes
raised during the interviews and did not fit into this framework were incorporated and
added to the framework, so no emerging themes and subthemes to be missed.
Researchers looked for evidence of themes related to:
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1) Characteristics of the socio-political context, such as legislation, rules, and
patient characteristics.
2) Characteristics of the hospital such as leadership commitment and availability
of resources.
3) Characteristics of the healthcare professionals/hospital staff, such as skills,
support from colleagues and knowledge.
4) Characteristics of the ASP, such as advantages and disadvantages.
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Figure 3.6: ASP process and related categories of determinant
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3.12 Ethical considerations
This research adhered to Ethical Guidelines for Educational Research outlined by the
British Education Research Association (BERA 2011). The research obtained the
approval of the University of Hertfordshire Ethics Committee (Protocol number:
LMS/PGR/UH/02344) (Appendix one). Besides, official permissions were obtained
from the health authorities and participating hospitals in Saudi Arabia as described in
each study.
Participants were informed of their right to withdraw from the study at any time, without
requiring an explanation for doing so. In addition, they were informed that the data
they provide will be confidential and only used for research purposes. Data reporting
ensured that the participants remain anonymous and that their right of confidentiality
is consistently respected. To achieve this, their names, addresses and other details
were excluded from the research. Storage and usage of personal information were
undertaken in accordance with the UK Data Protection Act 1998.
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Chapter 4: ASPs in Saudi MOH hospitals: implementation, barriers
and facilitators: a qualitative study
4.1 Introduction
Available literature shows high rates of AMR in Saudi Arabia (M. Aly & Balkhy, 2012;
Shibl et al., 2014; S Yezli, Shibl, Livermore, & Memish, 2014; H. M. Zowawi, 2016; H.
M. Zowawi et al., 2013). From reviewing the literature (chapter two), it was noted that
while there is an ASP guideline for Saudi MOH hospitals (Yousef Ahmed Alomi, 2017;
Saudi Ministry of Health, 2014), the extent of implementing this guideline remains
unknown. In light of the high rate of resistance in the country, and risk of further spread
of resistance due to influx of visitors from all over the world for Hajj and Umrah, it is
essential to explore ASPs implementation to minimise the increase in AMR.
The objective of this qualitative study is to explore the perspectives of physicians,
pharmacists, microbiologists, infection control practitioners, hospital managers,
nurses and MOH leaders regarding:
 The adoption/implementation of ASPs in Saudi MOH hospitals.
 The barriers and facilitators of ASPs adoption and implementation in Saudi
MOH hospitals.
The findings of this qualitative study informed the development of a national survey
(Chapter five) to establish the status of ASPs in Saudi MOH hospitals and identify
barriers and facilitators to their successful implementation on a national level.
4.2 Methods
4.2.1 Design
To achieve the objectives of this study, semi-structured interviews were carried out.
4.2.2 Development and source of interview schedule
The interview schedule (Appendix two) was developed following a review of the
literature and discussion among the researcher and supervisory team, as well as
consultation with three ASP pharmacists (two from Saudi Arabia and one from the UK)
85
and two ID consultants (from Saudi Arabia). Questions in the schedule were all open-
ended to obtain in depth views or perspectives of study participants. The interview
schedule has two main sections, which primarily consist of open questions. Firstly, is
a section on background information (six questions), such as location of hospital,
number of beds, hospital type, position of healthcare professional, gender and years
of experience. Secondly, open-ended questions (14 questions) were used to explore
the available strategies to control antimicrobials in Saudi hospitals, and the associated
factors (barriers and facilitators) influencing the adoption and implementation of ASPs
in Saudi hospitals.
Background information questions were developed after discussion between the
researcher and supervisory team to explore participants demographic data (hospital
type, city, number of beds, position, gender and years of experience). Questions 1-7
were developed after discussion between the researcher and supervisory team to
explore characteristics and availability of ASPs in hospitals (available strategies, team
members, roles of members, frequency and nature of meetings, and effectiveness of
available strategies). Questions 8-14 were adapted from published tools (Cotta et al.,
2015; Pakyz et al., 2014) to explore factors (barriers and facilitators) influencing the
adoption and implementation of ASPs in hospitals.
The interview schedule was developed bearing in mind the four main domains of the
conceptual framework (Fleuren et al., 2014, 2004) to cover all different factors that can
affect the adoption and implementation of ASPs in hospitals. Questions 1, 4, 5, 6 and
7 was developed based on the domain: characteristics of the ASP to explore
characteristics and availability of ASPs in hospitals. Question 2 was developed based
on the domain: characteristics of healthcare organisation to explore the availability of
expertise in hospitals. Question 3 was developed based on the domain: characteristics
of healthcare workers to explore knowledge and skills of healthcare workers in regards
to ASPs. Questions 8-14 was developed to explore factors (barriers and facilitators)
influencing the adoption and implementation of ASPs in hospitals that can be under
any of the four different domains: characteristics of the socio-political context,
characteristics of the healthcare organisation, characteristics of the healthcare
workers and characteristics of the ASP. Probing questions were also asked based on
the responses of the participants to get more details.
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4.2.3 Validation of interview schedule
The following steps were taken to ensure validity of the interview schedule (Bowling,
2009; Smith, 2002): Face validity: the interview schedule was checked by the
researcher and the supervisory team to ensure their relevance, reasonability and that
no ambiguity exists. Content validity: three ASP pharmacists (two from Saudi Arabia
and one from the UK) and two ID consultants (from Saudi Arabia) checked the content
of the interview schedule to ensure that the content of the instrument is logical and
easy to understand.
4.2.4 Pilot study
The interview schedule was piloted with 16 different healthcare professionals from
three MOH hospitals including: an ID consultant, five hospital pharmacists, four clinical
microbiologists, four infection control practitioners and two hospital managers (Table
4.1), to ensure validity and practicality. After processing their feedback, appropriate
adjustments were made to the interview schedule. The outcomes of this pilot study
informed the following:
I) Conduct the interviews in the main language of the participant (Arabic or
English) in order to allow participants to express their thoughts easily and to get
in-depth data.
II) Explain the purpose of this study and ensure the privacy and confidentiality of
participants in order to obtain their trust and record the interviews.
III) Target other healthcare professionals that are involved in antibiotic therapy
(general physicians and nurses)
IV) Target policy makers on regional and national levels in order to capture different
viewpoints and understand the full picture of ASPs in Saudi hospitals.
Table 4.1: Demographic data of the pilot study participants
Number of participants
Male Female ID
Physician
Hospital
pharmacist
Microbiologist CEO/Medical
director
ICP
H
os
pi
ta
l
ty
pe
Local 2 2 0 1 0 1 2
Regional 4 1 0 2 2 1 0
Central 3 4 1 2 2 0 2
Total 9 7 1 5 4 2 4
ID: Infectious Diseases specialist/consultant, CEO: Chief Executive Officer, ICP: Infection Control
Practitioner (specialist/consultant)
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4.2.5 Setting
In Saudi Arabia, MOH provides approximately 60% of in-patient care. The three
participating hospitals were selected to represent three different types of general MOH
hospitals, in an effort to capture a representative sample of different healthcare
settings environments. These facilities can be broadly classified as: a local hospital
(50 beds), a regional hospital (180 beds) and a central hospital (380 beds). Leaders
from the general directorate of health affairs in a Saudi region (Infection control
department and pharmaceutical care department) and Saudi MOH (general
department of infection control and general department of pharmaceutical care) were
targeted.
4.2.6 Sampling and recruitment of participants
Purposive sampling was the method of sampling for this study, which involved
recruiting participants who have knowledge that is valuable to the research process
(Involved in ASPs and antimicrobial therapy). Participants were ID physicians, hospital
pharmacists, clinical microbiologists, infection control practitioners
(Specialists/consultants and nurses) and hospital managers (Chief Executive Officers
(CEOs) and Medical directors). These were chosen because they represent the team
members of the ASP, play a significant role in the adoption and implementation of
these programmes, and their combined efforts can improve infection control and
reduce antimicrobial resistance (Waters, 2015). Also, healthcare professionals dealing
with antibiotics (physicians and nurses) and policy makers at both regional and
national levels (infection control departments and pharmaceutical care departments)
were targeted in order to capture different viewpoints on antibiotics use and the current
policy initiatives in Saudi Arabia. Invitation letters (Appendix three) were sent to the
targeted participants, through the head of each department, to introduce the study,
obtain approval, and to schedule the interview.
4.2.7 Data collection
Interviews were conducted face-to-face in participants main language (Arabic or
English) and audio recorded (using Sony ICD-PX333 recorder) for later transcription.
Notes were taken during the interviews for non-verbal responses such as looking sad,
smiling, feeling angry, etc. Interviews were conducted in a quiet area (pharmacy
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meeting room) to avoid any interruptions. Consent forms (Appendix four) were
obtained from each participant. The interviews were conducted between January 2017
and February 2017. The recruitment of participants continued until no more new
themes emerged in the final three interviews. Reflexivity was considered during the
interviews and analysis, so the researcher's views and opinion do not influence the
participants responses.
4.2.8 Data analysis
The interviewer used a recorder to audio record all of the interviews for later verbatim
transcription and analysis. Transcripts were generated into Microsoft Word 2016 for
each of the recorded interviews and labelled with a unique code for each participant.
Themes and issues raised during the interviews were utilised to produce the codes,
which were then organised into a framework that formed the basis of the primary
coding structure. Interviews that were conducted in Arabic (15 out of 22) were
analysed and coded first, then, themes, subthemes and quotes from participants were
translated to English. Two independent researchers mapped and interpreted
interviews data to capture the emerging themes and avoid any bias that could
influence the analysis process. A third researcher screened a random sample (20% of
the interviews) to check the reliability of the coding. Any discrepancies were resolved
through discussion between the three researchers. A framework analysis using five
sequential components was undertaken for each interview (Braun & Clarke, 2006).
The five components of the analytical methodology are:
I) Familiarisation with the collected data.
II) Developing a thematic framework from the interviews and the themes emerging
from the data (through the identification of main topics and subtopics).
III) Indexing (coding the data) into themes.
IV) Charting by rearranging indexed data according to the thematic framework.
V) Mapping and interpreting data.
A framework representing the major phases in ASP processes and related categories
of determinants (Figure 3.6), was developed based on the determinants of innovation
within the healthcare organisations model (Fleuren et al., 2014, 2004) informing the
analysis. The conceptual framework was also used to develop the interview schedule.
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Themes and subthemes raised during the interviews and did not fit into this framework
were incorporated and added to the framework, so no emerging themes and
subthemes to be missed. Researchers looked for evidence of themes related to:
1) Characteristics of the socio-political context, such as; legislation, regulations,
patient cooperation, patient awareness benefits, financial burden on patient and
patient discomfort.
2) Characteristics of the healthcare facility, such as; decision-making process,
reinforcement management, relationship with other organisations, collaboration
between departments, staff turnover, staff capacity, available expertise,
financial resources, administrative support, time available, opinion leader,
feedback to user about innovation, material resources, and coordinator.
3) Characteristics of the healthcare workers, such as; social support colleagues,
social support supervisors, self-efficacy, knowledge, skills, work-related stress,
ethics problems, outcome expectations, ownership, expects patient
cooperation, expects patient satisfaction.
4) Characteristics of the ASP, such as; complexity, advantages, clear procedures,
compatibility, trialability, relevance for patient, risks for patient, frequency in the
use, perceived prevalence of health problem.
4.2.9 Trustworthiness of interview transcript
The following tests were used to ensure reliability (Bowling, 2009; Smith, 2002):
Inter-rater: two raters coded the transcribed interviews and the results were compared
to measure the extent to which they agree. A third researcher screened a random 20%
sample to check the reliability of the coding. Any discrepancies were resolved through
discussion between the three researchers. Further reliability was ensured through
verification of the transcribed data with the participants.
4.2.10 Ethical considerations
Official approvals were obtained from the General Directorate of Health Affairs in
AlBaha (Appendix five). The researcher obtained written consents (Appendix four)
from the participants and provided a participant information sheet explaining the nature
of the study and its objectives (Appendix six). All audio recordings were stored in
locked drawers and electronic files (password protected) stored on computer to which
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only the researcher/supervisors have access. Audio files and electronic/paper files of
the interviews' transcripts will be destroyed three years after completion of the writing
of thesis.
4.3 Results
All healthcare professionals (22/22) who were approached for recruitment had agreed
to participate in this study. Twenty two interviews were conducted with healthcare
professionals comprising physicians (n=5; 23%), nurses (n=4; 18%), hospital
pharmacists (n=3; 14%), hospital managers (n=2; 9%),  infection control practitioners
(ICP) (n=2; 9%), ID consultant (n=1; 5%), microbiologists (n=1; 5%), the head of the
infection control department in the health directorate office in a Saudi region (n=1;
5%), the head of the pharmaceutical care department in the health directorate office
in a Saudi region (n=1; 5%), a consultant clinical microbiologist at the general
department of infection control at MOH (n=1; 5%), a clinical pharmacist at the general
department of pharmaceutical care at MOH (the editor of the ASP guideline at the
Saudi MOH) (n=1; 5%). Approximate length of each interview was around 25 minutes.
Table 4.2 and Table 4.3 summarise demographic characteristics of participants and
their experience respectively.
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Table 4.2: Demographic data of participants
Number of participants
Male Female ID
Physician
Hospital
pharmacis
t
Microbiologist CEO/Medical
director
ICP Physicians Nurses
H
os
pi
ta
l
ty
pe
Local 3 1 NA 0 NA 1 1 1 1
Regional 2 2 NA 1 0 0 NA 2 1
Central 5 5 1 2 1 1 1 2 2
AlBaha
health
office
2 0 0 1 0 0 1 0 0
MOH 0 2 0 1 1 0 0 0 0
Total 12 10 1 5 2 2 3 5 4
Table 4.3: Years of experience of participants
Number of participants
Ye
ar
s 
of
ex
pe
rie
nc
e
≥ 2 years and  < 5 years 1
≥ 5 years and  < 10 years 8
≥ 10 years 13
92
Four main themes emerged from the collected data regarding ASPs in Saudi
MOH hospitals. They include: 1) adoption/implementation of ASPs in Saudi
MOH hospitals, 2) National AMR strategy in Saudi, 3) Barriers to ASPs
implementation in Saudi MOH hospitals, and 4) The potential facilitators of
ASPs implementation in Saudi MOH hospitals. Each will be discussed as
follows.
4.3.1 Adoption/implementation of ASPs in Saudi MOH hospitals
Participants from the three hospitals indicated there were no formal ASPs.
However, there was at least an antibiotic policy at the hospitals aimed at
controlling use of antimicrobials. This included restriction policy on antibiotics,
where antibiotics were grouped into three categories A, B, and C.
 Group A antibiotics (unrestricted antibiotics) were generally available
and free for use by all physicians in the hospital.
 Group B antibiotics (restricted antibiotics) were potentially toxic and
expensive antimicrobials. They were prescribed by the consultants or
their designees (specialist or resident) after informing the consultant and
under their responsibility. The consultant should countersign the order
of group B antibiotics if the resident or the specialist ordered it. There is
no need to complete a justification form in these cases.
 Group C antibiotics (reserved antibiotics) are potentially toxic and
expensive antimicrobials. They are reserved for severe sepsis or serious
infections caused by multi-drug resistant microorganisms. They are
prescribed by the consultant who is required to complete a justification
form.
There were guidelines for treatment for certain infections, including central
nervous system infection, gastrointestinal infections and respiratory system
infections, such as pneumonia. The prescribing guidelines were developed by
the Saudi MOH, but were not updated regularly by hospitals. However, some
personnel were not aware of hospital antibiotic policy and antibiotics were
dispensed without review or restrictions. The following quotes highlight
available strategies or policies to control antibiotics use in Saudi MOH hospitals:
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''According to our policy we make restriction for the antibiotic A, B, C OK, A
anybody can dispense any physician, B specialist, C consultant'' (Hospital
pharmacist 2)
''We have an antibiotic policy, which contains guidelines of empirical treatment
for any disease to its antibiotic'' (Hospital pharmacist 1)
4.3.2 National AMR strategy in Saudi Arabia
In response to the WHO call on members to develop and implement
comprehensive action plans on AMR, on 19/01/2017 the Saudi MOH launched
the national committee to combat AMR. The committee’s main responsibility is
to make guidelines, policies and programmes to control AMR, and to monitor
implementation of these policies or programmes at national level:
''….. has established a national committee represented by all government
agencies and non-governmental and civil society.'' (Consultant clinical
microbiologist 2)
The national committee consists of the following:
 The head of the health facilities Infection control department at MOH (the
chairman of the committee)
 A member from the health facilities Infection control department at MOH
(the rapporteur of the committee)
 A member from the ministry of Environment, Water and Agriculture
 A member from the GCC infection control centre
 A member from the National Centre for diseases prevention and control
 A member from the ministry of National Guard
 A member from the ministry of Culture and information
 A member from King Faisal specialist hospital and research centre
 A member from the ministry of defence, health services department
 A member from Saudi Commission for Health Specialties
 A member from the Saudi Central board for accreditation of healthcare
institutions
 A member from the Saudi Society for medical microbiology and
infectious diseases
 A member from the Saudi food and drug authority
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 A member from the medical cities in Saudi
 A member from the Saudi society for infectious diseases in children
 A member from a medical school in a Saudi university
 A member from the ministry of Interior, health services department
 A member from the Saudi society for sterilization and infection control
 A member from the general department of Laboratories and Blood bank
at MOH
 A member from the National Health Laboratory at MOH
 A pharmacist from the general Pharmaceutical care department at MOH
 A member from the Field Epidemiology program at MOH
 A member from the Communication and Relations department at MOH
 A member from the Ministry of Education
 A member from King Abdulaziz City for Science and Technology
 A member from the Health Licenses department at MOH
The committee has 5 subcommittees as highlighted in the following quote:
''….and from this large committee, there are 5 technical subcommittees:
awareness committee, the laboratory surveillance, infection control, antibiotic
stewardship, and the drug economy and research'' (Consultant clinical
microbiologist 2)
The national antibiotic stewardship subcommittee monitors the progress of
ASPs implementation through regional ASPs committees and hospital ASPs
committees.
''…and then there are committees in regions in health affairs directorates''
(Clinical pharmacist 5)
The regional antibiotic stewardship committee consists of the following:
 Consultant physician to be the head of the committee
 Pharmacist (the rapporteur of the committee)
 A member of the Infection control department at the region
 A member of the infectious disease department at the region
 A member of the drug information centre at the region
 A member of the IT department at the region
 A member of the Quality department at the region
To review
guidelines and
strategies and
monitor the work
at regional level
and report to the
national
committee
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Hospitals antibiotic stewardship committees consist of the following:
 A consultant physician to be the head of the committee
 A pharmacist to be the rapporteur of the committee
 A microbiologist
 A member of the Infection control department at the hospital
 A member of the infectious disease department at the hospital
 A member of the IT department at the hospital
 A member of the Quality department at the hospital
4.3.3 Barriers to ASPs implementation in Saudi MOH hospitals
Data regarding barriers to successful adoption and implementation of ASPs in
Saudi MOH hospitals were categorised into three main themes using the
innovation within the healthcare organisations model (Fleuren et al., 2014,
2004) described on page 80. Subthemes were developed from the codes.
They included I) characteristics of the socio-political context (Legislation and
regulation), II) characteristics of the healthcare organisation (Accountability,
administrative support, available expertise, collaboration between
staff/departments, financial resources, functional structure, recourses, staff
capacity/staff turnover and education and training) and III) characteristics of the
healthcare professionals (awareness, knowledge/skills and support from health
professionals/responsibility) (Table 4.4). The subtheme ''availability of
expertise'' was the most common subtheme identified by participants (19/22),
followed by education and training (17/22) and administrative support (15/22)
as seen in Figure 4.1.
Table 4.4: Themes and subthemes regarding barriers to successful adoption
and implementation of ASPs in Saudi MOH hospitals
Main themes Subthemes/ (Number of participants
identified each subtheme)
Characteristics of the socio-political
context
Legislation and regulation/ (15/22)
Characteristics of the healthcare
organisation
Accountability/ (13/22)
Administrative support/ (15/22)
Available expertise/ (19/22)
Collaboration between staff/departments/
(10/22)
Financial resources/ (5/22)
Functional structure/ (7/22)
To implement
guidelines and
strategies and
monitor the work in
the hospital and
report to the regional
committee
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Recourses (IT)/ (15/22)
Staff capacity/staff turnover/ (14/22)
Education and training/ (17/22)
Characteristics of the healthcare
professionals
Awareness/ (13/22)
Knowledge/skills/ (15/22)
Support from health
professionals/responsibility/ (9/22)
Figure 4.1: Subthemes identified from the interviews regarding barriers to
ASPs in Saudi MOH hospitals and the number of participants identified each
subtheme
I) Characteristics of the socio-political context
Legislation and regulation
The majority of participants (15/22) highlighted the lack of rule to question staff
about their inappropriate practices and there is fear of accusation of negligence
as barriers that prevent adoption of ASPs.
''There is no procedure, no procedure, there is no action that we can make…
we don’t have anything in our hands'' (Clinical pharmacist 4)
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''We discussed a few times with the administration, but in the end doctors
here fear to be accused of negligence'' (Infection control consultant 1)
II) Characteristics of the healthcare organisation
Subthemes identified under this theme included; accountability, administrative
support, available expertise, collaboration between staff/department, education
and training, financial recourses, functional structure, recourses (IT), and staff
capacity/staff turnover.
Accountability
Lack of questioning of inappropriate prescribing (13/22), non-compliance with
policy (11/22) and lack of feedback or follow up (8/22) were reported as some
of the barriers to the adoption of ASPs.
''…. there is no accountability, I mean, if you prescribed the patient five
antibiotics, no one will ask you why you have prescribed this'' (Physician 2)
''No one asks a physician why you have used such kind of combinations
relating to antibiotics'' (Microbiologist 1)
''There is no follow up or notification if someone broke the policy'' (Physician
5)
Administrative support
Most of the participants (15/22) believe that the lack of administrative support
and commitment is a major barrier to ASPs, and around half of the participants
(12/22) believe this is due to the lack of administrative awareness about the
benefits of ASPs and risks of AMR.
''There is lack of motivation, lack of support, ……support of leadership''
(Physician 3)
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''The administration isn't convinced itself to discuss the programme'' (Hospital
pharmacist 2)
Available expertise
Lack of professionals required to form antibiotic stewardship team were
reported by most of the participants (19/22) as one of the major barriers to the
adoption of ASPs. Healthcare professional were required to perform duties they
do not have sufficient expertise (5/22) as explained in the following quotes:
''Unfortunately, there is no clinical pharmacist here'' (Infectious Diseases
Consultant 1)
''…… the infection control in all hospitals, he is not a consultant or specialist in
Infection control, he is a surgeon or radiologist and he is told; he is the
Infection control doctor, …...and the hospital assigned him to cover this place
because the lack of expertise'' (Physician 4)
''I think if there is a clinical pharmacist, there is no ID consultant and vice
versa'' (Clinical pharmacist 3)
Collaboration between staff/departments
Nearly half of the participants (10/22) reported lack of inter-professional and
interdepartmental collaboration as barriers to the adoption of ASPs. Some
participants (8/22) believed that staff resistance or non-compliance with
guidelines are barriers to the adoption of ASPs.
''There is a gap in between the medical administration, the hospital
administration and the technical administrations'' (Hospital pharmacist 2)
''One patient is getting more than one antibiotic regimen, because doctors are
not discussing each other'' (Nurse 2)
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''They have sometimes resistance to our guideline by asking why we chose a
certain kind of medicine not that one they use'' (Clinical pharmacist 3)
Education and training
Lack of staff education and training was reported by majority of participants
(17/22) as a major barrier to ASPs adoption and implementation. Healthcare
professionals reported their unawareness of ASPs due to lack of training in
ASPs.
''…. training, even the definition itself, orientation and education on the
Stewardship, and people even don't know what is Stewardship'' (Consultant
clinical microbiologist 2)
''No, nobody from pharmacy, they are not educating'' (Nurse 1)
''We don’t have educational programmes to explain for us the guidelines of
antibiotics, no we do not have the system, it doesn't not exist'' (Physician 2)
Financial recourses
Some participants (5/22) reported lack of financial recourses as a barrier for
ASPs adoption.
''…. but I think the hospital, the hospital budget or the budget of the ministry of
health, are affecting all of us'' (Infection control specialist 3)
''…. the big problem that we faced is that there is no budget to print this''
(Clinical pharmacist 3)
Functional structure
Absence of the role of pharmacists to perform their duties and review and
discuss antibiotic therapy emerged as a barrier to the adoption of ASPs (7/22).
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''the role of the pharmacist is not activated, frankly they have no roles''
(Hospitals pharmacist 2)
Resources (Information Technology (IT))
The majority of participants reported the lack of IT (15/22) and
miscommunication in hospitals with IT support (5/22) as barriers to successful
adoption of ASPs.
''…. but most of hospitals don't have electronics so they can't tell us about
their consumption'' (Clinical pharmacist 3)
''There is another problem with IT now, if whenever doctors are entering from
here, sometimes pharmacy they cannot receive it in their computer'' (Nurse 4)
Staff capacity/staff turnover
Inadequate number of staff (14/22) as well as staff turnover (9/22) were found
to limit the adoption of ASPs.
''All people are busy and our number is not big, no one in us sees the other
unless in the monthly meetings, there is cooperation but we have overload,
and the number of staff is little'' (Physician 5)
''Persons who are, for example, responsible for the program, they leave
suddenly to continue their studies without making endorsement for the new
staff, so I start with someone new from the beginning'' (Clinical pharmacist 3)
III) Characteristics of the healthcare professional
Subthemes identified under this theme included awareness (of antibiotic
resistance and the need to control antibiotic use), knowledge/skills of
professionals required for successful adoption of ASPs, and refusal to accept
recommendations to change prescribing behaviour.
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Awareness
It was reported by several participants (13/22) that the lack of awareness of the
problem of antibiotic resistance across different staff is a barrier that will affect
the adoption of ASPs.
''… they don't know the danger of antibiotic resistance'' (Hospital pharmacist
2)
''There is no awareness related to stewardship program till
now'' (Microbiologist 1)
''The first thing is that doctors feel that this entire thing is a paper work''
(Infection control consultant 2)
Knowledge/skills
Inadequate knowledge of some staff about spectrum of antibiotics, doses and
combination were reported by number of participants (15/22) as some of the
problems associated with the adoption of ASPs.
''Now I face a problem, I have lack of knowledge, because I have freshly
graduated physicians, they have lack of knowledge'' (Hospital pharmacist 5)
''…. these doses have problems, and they are following an old regimen''
(Hospital pharmacist 2)
Support from health professionals/responsibility
Refusal to accept recommendations and non-compliance with antibiotic policy
were also reported (9/22) as some of the barriers to the adoption of ASPs.
Healthcare professionals explained their views as follows:
''Some doctors, we cannot tell all, really some are really stubborn.'' (Nurse 3)
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''I have seen that sometime there is very stubborn behaviour of the
physicians'' (Microbiologist 1)
4.3.4 Facilitators to ASPs implementation in Saudi MOH hospitals
Facilitators of ASPs in Saudi MOH hospitals were also categorised into two
main themes using the innovation within healthcare organisations model
(Fleuren et al., 2014, 2004). They included I) characteristics of the socio-
political context (Legislation and regulation) and II) characteristics of the
healthcare organisation (Accountability, administrative support, available
expertise, collaboration between staff/departments/organisations, education
and training, formal reinforcement by management, recourses, staff capacity
and staff turnover) (Table 4.5). The subtheme ''availability of expertise'' was the
most common subtheme identified by participants (19/22), followed by
education and training (18/22) and administrative support (15/22) as seen in
Figure 4.2.
Table 4.5: Themes and subthemes regarding facilitators to successful adoption
and implementation of ASPs in Saudi MOH hospitals
Main themes Subthemes/ (Number of participants
identified the subtheme)
Characteristics of the socio-political
context
Legislation and regulation/ (10/22)
Characteristics of the healthcare
organisation
Accountability/ (13/22)
Administrative support/ (15/22)
Available expertise/ (19/22)
Collaboration between
staff/departments/organisations/ (14/22)
Education and training/ (18/22)
Formal reinforcement by management/ (9/22)
Recourses (IT)/ (15/22)
Staff capacity/ (11/22)
Staff turnover/ (9/22)
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Figure 4.2: Subthemes identified from the interviews regarding facilitators to
ASPs in Saudi MOH hospitals and the number of participants identified each
subtheme
I. Characteristics of the socio-political context
Legislation and regulation
To successfully adopt ASPs in Saudi MOH hospitals, around half of the
participants (10/22) sited making ASPs a prerequisite for accreditation as a
facilitator as shown in the quote below:
''According to the third Edition of CBAHI standards, they are obligating them
to use the stewardship'' (Medical director 2)
''They (ASPs) are to be within the standers of accreditations. …..., and to be
obligatory'' (Hospital pharmacist 2)
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II. Characteristics of the healthcare organisation
Subthemes identified under this theme included; accountability, administrative
support, available expertise, collaboration between
staff/department/organisations, education and training, formal reinforcement by
management, opinion leader, recourses (IT), staff capacity and staff turnover.
Accountability
Participants in the interview (13/22) reported that a policy of interrogating and
holding people accountable for their prescribing behaviour will facilitate the
adoption of ASPs.
''You need to follow up people not applying policies, and ask them why not to
apply it?'' (Physician 1)
''There should be a procedure which is called warning'' (Hospital pharmacist
4)
Administrative support
The commitment and support of hospital administration was highlighted by
number of participants (15/22) as a facilitator for ASPs adoption as emphasised
in the quotes below:
''They are to be involved in the program and its implementation…. I mean we
need support from the administration'' (Hospital pharmacist 5)
''The administration can play a very good role. Like to have a regular follow-
up, …... administration should be playing a regular role in infection control
committee meetings'' (Microbiologist 2)
''I mean the administration should take the matter formally, the administration
is essential in this topic'' (Physician 1)
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Available expertise
To successfully adopt ASPs, a major facilitator that was reported by almost all
study participants (19/22) was the availability of the key experts required for the
implementation of the programme including ID specialists, clinical pharmacists,
infection control specialists and microbiologists.
''I think if they will assign clinical pharmacists, they will recruit more infectious
disease staff and to have qualified infection control practitioners. I think it will
be fully implemented'' (Medical Director 1)
''We want a specialist in infection control or studied infection control or ID
consultant'' (Physician 4)
Collaboration between staff/departments/organisations
Teamwork and multilayer collaboration, involving different professional groups
(pharmacists, physicians, infection control staff, microbiologists, nurses) within
hospitals; between hospitals that have ASPs and those that do not have; and
different stakeholders (MOH, Ministry of Agriculture) were highlighted as
facilitators for ASPs adoption and implementation by majority of participants
(14/22).
''Sending consultants who have been here for a long time to peripheral
hospitals, they stay there for a month, or two or three weeks at least and he
will work with them to teach them'' (Infection control practitioner 3)
''First of all, there should be some combined meetings, some combined
platform for all the physicians, nurses, technicians, pharmacists and like,
these should all be held at a single platform'' (Microbiologist 2)
Education and training
The majority of participants (18/22) reported staff education and training
regarding ASPs and hospital policies as a facilitator to successful ASPs
adoption.
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''there will be a workshop before we start, targeting all medical and nursing
staff, workshops to be held for a whole week or two containing the same
content, till we get the whole targeted staff'' (Hospital pharmacist 2)
''To increase education because the education is considered the main thing''
(Clinical pharmacist 3)
''there should be regular workshops, there should be some compulsion for
such workshops that should be arranged and everyone should be attending
those workshops'' (Microbiologist 2)
Formal reinforcement by management
Participants (9/22) reported that making ASPs a formal directive of the MOH,
empowering individual's hospital infection control committees (6/22) will
facilitate the adoption of ASPs. This is emphasized in the quote below:
''…. but if its implemented through the ministry, sure everybody will
follow'' (Nurse 2)
''The infection control committee should be empowered'' (Microbiologist 1)
Opinion leader
The need for opinion leader or champion who preferably should be a native was
identified as a facilitator for ASPs by some participants (4/22).
''You need a clever leader so he tries to unify different staff backgrounds, I
mean, he should be Saudi and encourage them to follow what he feels and he
believes that it will be for the benefit to the whole institution'' (Physician 3)
Resources (IT)
To implement ASPs, IT support and efficient communication system was
identified as a facilitator by several participants (15/22).
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''We need a good IT system and good internal communication system
between the concerned departments, the ID, the pharmacy and ward''
(Infection control consultant 2)
''ASP will not happen if you don't have a good IT system'' (Physician 2)
Staff capacity
Adequate number of staff (clinical/ hospital pharmacists, infectious diseases
physicians, microbiologists, nurses, infection control practitioners) required for
ASPs was highlighted as a facilitator of ASPs by number of participants (11/22).
''We need additional number for the follow up'' (Physician 5)
''We need to increase the number of Infectious disease, the staff of Infectious
disease, because we have only one doctor'' (Physician 4)
Staff turnover
It was reported by number of participants (9/22) that a period of stability for staff
appointed to stewardship role is a factor that would ensure implementation and
continuation of ASPs.
''We want a specialist in infection control or studied infection control or ID
consultant, and it is preferred that he remains in his position for a long period''
(Physician 3)
''We need a kind of stability, because this changing every month or two, there
is a new one, we need stability'' (Physician 1)
4.4 Discussion
The objectives of this qualitative study were to explore the adoption and
implementation of ASPs in Saudi MOH hospitals as well as identify the barriers
and facilitators to ASPs adoption and implementation in Saudi MOH hospitals.
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To my knowledge this is the first qualitative study regarding adoption,
implementation, barriers and facilitators of ASPs in Saudi MOH hospitals.
In recent years, there have been calls from international and national
organisations (Public Health England, 2015b; The White House, 2014, 2015;
United Kingdom Department of Health, 2013; World Health Organisation,
2015a) to implement ASPs in order to slow the development of AMR. Findings
of this study showed that there were no formal ASPs committees or
programmes in the participating hospitals. There were however prescribing
guidelines and policies (reserved and restricted antibiotic lists) aimed at
promoting judicious use of antibiotics in the participating hospitals. Interestingly,
the guidelines reported were developed by Saudi MOH with some of the
healthcare staff being unaware of their existence.
High prevalence of resistant bacteria has been reported in Saudi Arabia
(AlJohani et al., 2010; Areeshi et al., 2014; Balkhy et al., 2012; El-Saed et al.,
2013; Saber Yezli et al., 2015). AMR therefore poses serious health threat in
Saudi Arabia. The threat is particularly compounded by over 10 million pilgrims’
visits to the cities of Makkah and Madinah with increased risk of transmission
of AMR bacteria (Azeem et al., 2014; Balkhy et al., 2016; Kapiszewski, 2006;
H. M. Zowawi et al., 2013). As a consequence of this threat, and in line with
WHO call for national action plans against AMR, the Saudi MOH has recently
launched a national committee to combat antibiotic resistance. The committee’s
responsibility includes among others monitoring implementation of
programmes to control antibiotic resistance. The committee recommends
establishment of hospital antibiotic stewardship committees. Composition of
hospital stewardship committees, as described in previous guidelines (Barlam
et al., 2016; Centers for Disease Control and Prevention, 2014; Dellit et al.,
2007; Public Health England, 2015b) include consultant physician, pharmacist,
microbiologist, infection control expert, IT expert, and a member of the quality
department.
While the launching of a national antibiotic resistance strategy by the Saudi
MOH is a laudable step towards combating AMR, a number of barriers were
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identified in this study which would potentially prevent adoption and successful
implementation of ASPs in Saudi MOH hospitals. Also, a number of factors
were identified that would facilitate successful ASPs implementation. A
framework of the determinants of innovations within healthcare organisations
(Fleuren et al., 2014, 2004) was used to classify these barriers and facilitators.
The facilitators were a reverse of the barriers, and are therefore discussed as
corrective measures. The barriers to adoption and implementation included
characteristics of the socio-political context, characteristics of the healthcare
organisation, and characteristics of the healthcare professionals.
A key socio-political characteristic that would prevent adoption and
implementation of ASPs was the lack of legislation and regulation. In countries
with successful ASPs, especially the UK, the USA and France, implementation
of programmes or action plans directed at reducing AMR is now a requirement
for registration of healthcare providers (French Ministry of Health, 2011; Public
Health England, 2015b; Trivedi & Rosenberg, 2013). In the state of California,
for example, it is a legal requirement that all general acute care hospitals
develop programmes for evaluating judicious use of antibiotics and monitor
results using appropriate quality improvement committees (Trivedi &
Rosenberg, 2013). The law therefore requires hospital managers to establish
active ASPs. Successful adoption and implementation of ASPs in Saudi MOH
hospitals will require some form of legislation. As noted by study participants,
making ASP obligatory and a prerequisite for accreditation of hospitals will
facilitate ASPs.
Among the factors relating to the healthcare organisations that would prevent
successful adoption of ASPs were lack of accountability, lack of administrative
support, lack of expertise, lack of collaboration between staff/department, lack
of education and training, lack of IT resources and rapid staff turnover. These
barriers have been reported in previous studies (Cotta et al., 2015; James et
al., 2013; Johannsson et al., 2011; Pakyz et al., 2014). In a study conducted in
one of the GCC countries (Qatar) to identify antimicrobial stewardship activities,
pharmacist involvement and perceived barriers, the authors reported the
prominent barrier to implementation and expansion of ASPs was non-
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availability of infectious disease specialists as well as lack of training of
pharmacists and other healthcare professionals (Pawluk et al., 2015).
Successful adoption of ASPs will therefore require setting up a system that
ensures individuals are held accountable for their prescribing behaviour and/or
refusal to follow hospital prescribing guidelines. Successful implementation of
ASPs relies on adequate support of hospital administration. As a result, the first
published antibiotic stewardship guidelines, the IDSA/SHEA guidelines (Dellit
et al., 2007) recommend including a hospital administrator in the antibiotic
stewardship team. As noted by study participants in this study, administrative
involvement is required from planning and implementation of the programme,
and subsequent follow up to ensure its success. Part of role of hospital
administrators in ASPs include provision of funds for recruitment of experts
(clinical pharmacists, Infectious disease physicians), and other resources (such
as, IT) required for successful implementation of ASP (Dellit et al., 2007).
Individual MOH hospital administration therefore has critical roles to play if
ASPs are to be implemented.
One of the supplementary strategies of ASPs is education and training (Centers
for Disease Control and Prevention, 2014; Dellit et al., 2007). To successfully
adopt and implement ASPs in Saudi MOH hospitals, there is a need for
education and training programmes to create awareness among healthcare
professionals, nurses and other healthcare workers. As noted by study
participants, a before-training workshop with an element of compulsion is
required prior to start of the programme. Also, hospitals with established
programmes can act as preceptors and provide training for those that intend to
start ASP. Furthermore, a system that ensures consistency and stability of staff
on stewardship role should be in place. This will not only facilitate
implementation of the programme, but also ensure its continuity.
Barriers to adoption and implementation of ASPs also related the healthcare
professionals themselves, particularly noncompliance with antibiotic policies
where such policies are available. Successful adoption of ASPs will therefore
require joint meetings of professionals involved in ASPs. This will enhance
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professional relationship and collaboration. There is also a need for an opinion
leader or physician champion in individual hospital whose main role should be
‘selling’ the concept of antibiotic stewardship to team members and other
healthcare professionals. Previous qualitative studies have identified inter-
professional engagement and physician champion as facilitators of successful
ASPs implementation (Cotta et al., 2015; Pakyz et al., 2014).
4.4.2 Implications for practice
Identifying barriers and required facilitators to adopt and implement ASPs in
Saudi MOH hospitals will facilitate the implementation of the national ASP
policy developed by the Saudi MOH. It will give an insight on how adoption and
implementation barriers can be overcome, in order to adopt and implement the
national ASP policy easily and successfully, and improve antimicrobial practice,
reduce antimicrobial resistance and improve patients care.
For successful ASPs adoption and implementation in Saudi MOH hospitals,
ASPs implementation should be made obligatory for hospitals to get national
accreditation, hospitals leadership should provide enough support and
resources and ensure enforcement of guidelines, ensure the availability of
experts and adequate number of staff including ID consultants, clinical
pharmacists and microbiologists to implement and monitor the work, ensure
collaboration between staff, departments and organisations to discuss and
share ideas and experiences and improve the practice, provide educational and
training programmes for staff to increase their knowledge, skills and awareness
regarding ASPs and appropriate antimicrobial use, and provide IT support and
efficient communication system to facilitate daily tasks of the programme. The
role of pharmacists and microbiologists should not be underestimated in
antimicrobial therapy. Therefore, they should be involved in the process of
antimicrobial therapy and provide recommendations on appropriateness of
antimicrobial therapy to prescribers and nurses.
4.5 Conclusion
The objective of this qualitative study was to explore the implementation,
barriers and facilitators of ASPs in Saudi MOH hospitals. No formal ASPs
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existed in the participating hospitals and an antibiotic policy was available in
some hospitals as an effort to control the use of antibiotics although awareness
regarding this policy was low. The availability of administrative support,
competent personnel, educational programmes, effective inter-professional
collaboration & communication and information technology are key to the
successful implementation of ASPs. High authorities should make an action in
implementing national guidelines for antimicrobial use and resistance
surveillance, and make ASPs a regulatory requirement in Saudi hospitals.
This chapter explored implementation, barriers and facilitators of ASPs in three
Saudi MOH hospitals only, however the situation is unknown in other Saudi
MOH hospitals. Therefore, a quantitative study was carried out in the next
chapter in order to investigate the level of ASPs implementation and the barriers
and facilitators for their successful implementation at national level.
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Chapter 5: The Current Status of ASPs in Saudi MOH hospitals:
A National Survey
5.1 Introduction
In Chapter four, semi-structured interviews were conducted with healthcare
professionals in three Saudi MOH hospitals as well as with professionals in a
Saudi region health directorate office and at the Saudi MOH to explore the
adoption and implementation of ASPs, and factors influencing the adoption and
implementation of ASPs in Saudi MOH hospitals. The findings of the qualitative
study (chapter four) informed the development of this national survey to
establish the status of ASPs at national level.
5.1.1 Objective
This study aims to investigate the level of implementation and factors
influencing the adoption and implementation of ASPs in Saudi MOH hospitals
at national level.
5.1.2 Research questions
1. What is the level of ASPs implementation and availability of core
members of ASPs in Saudi MOH hospitals?
2. What are the factors (barriers and facilitators) influencing the adoption
and implementation of ASPs in Saudi MOH hospitals?
3. To what extend does the hospital type influence the adoption and
implementation of ASPs in Saudi MOH hospitals?
4. What are the perspectives of clinical pharmacists, hospital pharmacists,
pharmacy directors, infection control specialists/consultants, infection
control nurses, infectious diseases specialists/consultants and
microbiologists regarding factors influencing the adoption and
implementation of ASPs in Saudi MOH hospitals?
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5.2 Methods
5.2.1 Design
To achieve the objective of this study, a cross-sectional self-administered
survey was carried out.
5.2.2 Development and source of the national survey
The national survey (Appendix seven) was developed from the qualitative study
(chapter four) and following a comprehensive review of the literature and
discussion among the researcher and supervisory team. The survey has two
main sections, which primarily consist of closed-ended questions. Firstly, is a
section on background information (14 questions), such as location of hospital,
number of beds, hospital type and position of healthcare professional.
Secondly, Likert-type statements on factors influencing the adoption and
implementation of ASPs to address: intention to adopt and implement ASPs in
Saudi MOH hospitals (three items), legislation and regulations regarding the
adoption and implementation of ASPs in Saudi MOH hospitals (four items),
characteristics of hospitals (nine items) and characteristics of ASPs (twelve
items).
The national survey consists of four main domains, where three domains were
informed from the findings of the qualitative interviews (chapter four) and were
in line with the conceptual framework including; intention to adopt and
implement ASPs in hospitals, legislation and regulations regarding the adoption
and implementation of ASPs in hospitals, and characteristics of hospitals. The
fourth domain (characteristics of ASPs) was developed from the conceptual
framework (Fleuren et al., 2014, 2004).
The items in each domain were developed from the findings of the qualitative
interviews (chapter four), from the conceptual framework as well as from the
literature.
Question one was adapted from validated tools (Doron et al., 2013; Howard et
al., 2015). Question two was adapted from (Howard et al., 2015). Question
three was adapted from (Doron et al., 2013; Enani, 2016; Howard et al., 2015).
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Question four was adapted from (Doron et al., 2013; Enani, 2016). Question
five was adapted from (Cotta et al., 2014; Doron et al., 2013). Question six was
developed by the researchers. Questions seven, eight, nine, 10 and 11 were
adapted from (Doron et al., 2013). Question 12 was adapted from (Doron et al.,
2013; Enani, 2016; Howard et al., 2015). Question 13 was adapted from (Cotta
et al., 2014; Doron et al., 2013). Question 14 was adapted from (Doron et al.,
2013; Howard et al., 2015). Questions 15-21 were developed from the findings
of the qualitative interviews (chapter four) and from the conceptual framework
(Fleuren et al., 2014, 2004). Questions 22-25 were developed from the findings
of the qualitative interviews (chapter four) and from the conceptual framework
(Fleuren et al., 2014, 2004), and they are in line with the findings of previous
studies (Avent et al., 2014; Chen, Khumra, Eaton, & Kong, 2011; Howard et al.,
2015; Trivedi & Rosenberg, 2013). Questions 26, 28 and 29 were developed
from the findings of the qualitative interviews (chapter four) and from the
conceptual framework (Fleuren et al., 2014, 2004), and they are in line with the
findings of previous studies (Avent et al., 2014; Chen et al., 2011; Doron et al.,
2013; Enani, 2016; Howard et al., 2015; Johannsson et al., 2011; Trivedi &
Rosenberg, 2013). Questions 27 and 30 were developed from the findings of
the qualitative interviews (chapter four) and from the conceptual framework
(Fleuren et al., 2014, 2004), and they are in line with the findings of previous
studies (Enani, 2016; Howard et al., 2015). Questions 31-42 were developed
from the conceptual frameworks (Fleuren et al., 2014, 2004).
All questions were then reviewed by the researcher and supervisory team and
checked by three ASPs pharmacists (two from Saudi and one from UK), and
two ID consultants from Saudi.
The survey was developed in English (Appendix seven) and then translated
into Arabic (Appendix eight) through a forward and backward translation
process. The researcher translated the survey from English to Arabic. Then,
two independent researchers, who are bilingual (Arabic/English) speakers,
translated back the survey into English. Both Arabic and English versions of the
survey were compared. Any discrepancies were resolved through discussion
between the three researchers. The questionnaire statements were then
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entered into the SurveyMonkey online data collection tool for easier distribution
and analysis.
The survey consists of four sub-scales uses a five-point Likert scale ranging
across strongly disagree=1, disagree=2, neither disagree nor agree=3, agree=
4 and strongly agree=5. A total of 14 statements (Q1-Q14) examine
demographic information, such as location of hospital, number of beds, hospital
type and position of healthcare professional. The indications drawn from the
direction of scores across the four sub-scales are as follows: whenever the
survey scores increase, this means that healthcare professionals have a
positive attitude towards the adoption and implementation of ASPs in Saudi
MOH hospitals. In contrast, if the scores decrease, this means that the attitude
of healthcare professionals towards the adoption and implementation of ASPs
is negative and weak.
There are only two negative statement in this survey (item 36 and item 42). The
remaining items (26) are all positive. The total number of items in the four sub-
scales is 28. The participants required about 15 minutes to complete this
survey. Also, two items have been designed to check the reliability of the
participants. These are: ‘I work in one of the MOH hospitals’ and ‘I work in Saudi
Arabia’.
5.2.3 Pilot study of the instrument
The survey was piloted with a number of participants, including hospital
pharmacists, infectious diseases physicians, infection control practitioners and
microbiologists, to ensure its validity and practicality. Appropriate changes were
made in accordance with participants’ feedback to optimise the research tool.
The purpose of a pilot study is primarily to assess the degree of validity and
reliability of the research instrument. Validity and reliability are vital components
of quantitative and qualitative research (L. Cohen, Manion, & Morrison, 2000).
In the present study, a pilot study was carried out with 60 healthcare
professionals (including 37 pharmacists, 12 infection control
nurses/specialists/consultants, seven microbiologists, and four ID
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specialists/consultants) from hospitals belonging to the Saudi MOH (four
hospitals without ASPs and one hospital with ASP).
The pilot questionnaires were completed by a randomly selected sample. All
participants received a participant information sheet and a consent form. The
objectives of the pilot study are: 1) to draw on experts to ensure that the content
in the instrument is relevant to the aims of the study and research questions; 2)
to determine whether the organisation and structure of the instrument accords
with the aims of the research and research questions; 3) to ensure that the
sampling method selected is suitable; 4) to ensure that the data collected can
respond sufficiently to the research questions; 5) to check whether the timing
of the instrument is convenient for participants; and 6) to adjust statements and
questions that require clarification or are irrelevant.
5.2.4 Validation of the questionnaire
The following steps were taken to ensure validity of the questionnaire (Bowling,
2009; Smith, 2002):
a) Face validity: the questionnaire statements were checked by the
researcher and the supervisory team to ensure their relevance;
reasonability and that no ambiguity exists.
b) Content validity: three ASP pharmacists (two from Saudi Arabia and one
from the UK) and two ID consultants (from Saudi Arabia) checked the
content of the questionnaire to ensure that the content of the instrument
is logical and easy to understand.
c) Discriminant validity: to guarantee that the survey can distinguish
between the participants’ scores, which reflect their perspectives on the
adoption and implementation of ASPs, discriminatory validity is vital. To
test for this validity, the participants’ scores from the pilot study are
compiled in a list and the upper and bottom ends of the lists are
identified. Using a T-test, the scores are compared and mean scores are
calculated. The T-test reveals that the survey can effectively distinguish
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between the negative and positive views of participants regarding the
adoption and implementation of ASPs in Saudi hospitals. The researcher
has reviewed the results to identify any significant differences between
the healthcare professionals in Saudi MOH hospitals who scored highly
(M: 106.23, SD: 2.029, N=30) and those who recorded low scores (M:
79.83, SD: 4.42, N=30) in relation to the questionnaire scores (t =
(29.74), p=0.000). The review allows the researcher to categorise
participant responses. By conducting a visual inspection of the total low
and high survey scores reported by the study participants, a cut-off score
can be found (94.69). This score is necessary to identify participants’
positive and negative views of ASPs. A high score reflects that the
healthcare professionals member has a positive take on ASPs. In
contrast, reporting a low score indicates that the healthcare
professionals have a negative take on ASPs.
d) Internal Consistency: the correlation test in Table 5.1 shows whether
there is a significant correlation between the sub-scales of the survey in
relation to each other and the overall score of the survey.
Table 5.1. Pearson correlation between the summations of dimensions and
the total score of the survey (N: 60)
** Pearson correlation is significant at the 0.01 level (two-tailed).
The results of the analysis of the pilot study reveal that the sub-scales from (1)
-(4) have a significant and strong correlation between the dimensions of the
survey with each other and with the overall score of the survey between r≥0.35
and r=0.82. This shows a strong correlation between the summation of each
sub-scale and with total score.
Sub-Scales SS1 SS2 SS3 SS4 Total
Intention to adopt and implement ASPs (SS1) - .586** .616** .404** .745**
Context of ASPs (SS2) .586** - .584** .352** .690**
Role of hospital towards ASPs (SS3) .616** .584** - .676** .924**
ASPs (SS4) .404** .352** .676** - .828**
Total .745** .690** .924** .828** -
119
5.2.5 Reliability
The following tests were used to ensure reliability (Bowling, 2009):
split-half method and test-retest. These were administered to a group of
participants to ensure the stability of the measure over a period of time.
Cronbach’s alpha test was used to measure the internal consistency of the
instrument.
a) Split-half method: the split-half method divides the total items (28) into
two groups, the first group (14 items) is from Q15-Q28, and the second
group (14 items) is from Q29-Q42. This method then applies a
correlation between summations of both groups of the questionnaire.
The results show that there are good correlations between group (a) (M:
42.50, SD: 8.76) and group (b) (M: 50.53, SD: 6.33), where r=0.79,
p<0.001, N: 60.
b) Test-retest of the questionnaire: the survey was conducted again after
15 days among the same group (60 participants) who completed the
survey in its first application. The results of the Pearson correlation test
show there is a significant relationship between the first application (M:
93.03, SD: 13.74) and the second application (M: 93.08, SD: 12.68) of
the survey, such that r=0.93, p<0.001, N=60. The results of this test
indicate that the survey has good reliability, which makes it suitable for
the current study.
c) Cronbach’s alpha: reliability: the Cronbach’s Alpha method calculates
the reliability coefficients of all items within each scale of the survey and
the overall score of all items. The results of this test show that
Cronbach’s alpha coefficient (M: 93.03, SD: 13.74, N of items: 28) is
sufficient at a level of 0.81 and the instrument thus provides an
acceptable degree of reliability.
Furthermore, responses were received from more than one healthcare
professional from the same hospital. Therefore, responses from the same
hospital were compared (background information section), to check if the
120
answers of participants are correlating as a form of triangulation and for further
reliability and validity.
5.2.6 Sampling, setting and size of participants
This study utilised the sampling with probability proportional to size sampling
method, where the MOH hospitals were divided into groups or strata based on
the hospital type (general, psychiatric, obstetrics/gynaecology and paediatrics,
convalescence, eye, obstetrics, paediatrics, chest, and rehabilitation). Then the
researcher ensured to receive enough responses from each group based on its
proportion to the total number of hospitals, to ensure having a representative
sample (on-going analysis was carried out during that data collection process
and the research targeted the group of hospitals with few responses to receive
more response).
All MOH hospitals (274) were contacted targeting CEOs, Clinical pharmacists,
hospital pharmacists, infection control practitioners, ID physicians, medical
directors, microbiologists and pharmacy directors as they are the main
members of ASPs. CEOs and medical directors were required to respond to
the background questions (14 questions) only due to their time limitation. The
researcher also ensured to receive responses from all different healthcare
workers to have a representative sample, as on-going analysis was carried out
during that data collection process and the research targeted the group of
healthcare workers with few responses to receive more response.
Based on the total number of MOH hospitals in Saudi Arabia, 274 hospitals
(Saudi Ministry of Health, 2017a), sample size of 161 hospitals were required
(margin of error: 5%, confidence level: 95% and 50% response distribution).
The sample size was calculated using online SurveyMonkey® sample size
calculator.
5.2.7 Distribution methods
Invitation letters (appendix nine) were sent through internal E-mails to the
targeted participants in all the 274 MOH hospitals through the General
Directorate for Research and Studies at the Saudi MOH (targeting  CEOs and
121
medical directors), the general department of pharmaceutical care at the Saudi
MOH (targeting Clinical pharmacists, hospitals pharmacists and pharmacy
directors) and the general department of health facilities infection control at the
Saudi MOH (targeting infection control practitioners, ID physicians and
microbiologists). These letters introduced the study, and provided an online link
for the survey to be completed. Also, social media platforms were used to
distribute the survey to all Saudi MOH hospitals in order to increase response
rates. These included official WhatsApp numbers and the official Twitter
accounts of health regions offices and hospitals. Also, official E-mail accounts
of health regions offices and hospitals and phone calls were used.
5.2.8 Data collection and reminders
Responses were mapped to the list of all MOH hospitals in Saudi to identify the
responded hospitals (on-going analysis was carried out during that data
collection process and the research targeted the group of hospitals with few
responses to receive more response). So, the background questions (Q1, Q2,
Q3 and Q4) were used to identify the responded hospitals, which was mapped
to the list of all MOH hospitals to identify non-responded hospitals and response
rate. More than one response (multiple questionnaires) were received from
some participants working in the same hospital, all were included and analysed.
Reminders were sent to non-respondent hospitals at two weekly intervals.
Reminders were sent through internal E-mails and through the channels
described above. Data collection started from May 2017 to August 2017.
5.2.9 Data analysis
Data were extracted from the SurveyMonkey online data collection tool and
uploaded to the SPSS database (Version 23; SPSS Inc., NY, USA). Descriptive
analysis was conducted to answer the research questions by using frequencies,
percentages, mean and standard deviation. The minimum significance level
that is considered in this part of the study is 0.05, thereby aiding in the
determination of whether the similarities or differences between variables was
statistically significant. In addition to the descriptive analysis, based on the
distribution and nature of the data and as the data is normally distributed
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(Kolmogorov-Smirnov= 0.056, p= 0.2, and Shapiro-Wilk= 0.989, p= 0.154),
One-Way ANOVA analysis was used to explore the differences between
perspectives on the adoption and implementation of ASPs (dependant variable)
with the staff position and hospital type (independent variables). Moreover,
logistic regression analysis was applied to identify the significant factors
influencing the adoption of ASPs in hospitals, it was used to investigate the
significance of each factor (dependent variables) on the adoption of ASPs in
Saudi MOH hospitals. A T-test and correlations were used to examine the
validity and reliability of analysis.
5.2.10 Ethical considerations
Official permissions were obtained from the Saudi MOH (Appendix 10). The
researcher obtained online consents from the participants and provided an
online information sheet explaining the nature of the study and its objectives.
5.3 Results
5.3.1 Demographics of respondents
Of the 274 Saudi MOH hospitals, 147 hospitals (response rate 53.6%)
responded to the survey through 234 responses from different healthcare
professionals. Of the 234 surveys returned, 20 were excluded as they were
incomplete. A number of questionnaires were received from more than one
respondent in the same hospital. A total of 214 responses (including CEOs and
medical directors) were analysed for the background information of
participating hospitals and a total of 191 responses (excluding CEOs and
medical directors) were analysed to examine the factors influencing ASPs
adoption and implementation in Saudi MOH hospitals. Responses were mainly
from hospital pharmacists 33% (70/214) and pharmacy directors 26% (56/214)
as seen in Table 5.2. The low number of responses from ID physicians is due
to the shortage of ID physicians in Saudi (there are only 57 ID physicians in all
Saudi MOH hospitals (274 hospitals)) (Saudi Ministry of Health, 2017a).
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Table 5.2: Responses by profession
In terms of responses based on hospital type, 88% (129/147) of the responses
were from general hospitals as they represent 79.5% (218/274) of total MOH
hospitals as seen in Table 5.3.
Table 5.3: Responses by hospital type
Fourteen per cent (21/147) of responses were received from Riyadh, 10%
(15/147) were from Madinah, 9% (13/147) were from Aseer, 8% (12/147) were
from Eastern region and 8% (12/147) were from Qasim. A summary of
responses based on each Saudi region can be seen in Table 5.4.
Table 5.4: Responses by region
Profession Number of responses
CEOs 15 (7%)
Clinical pharmacist 20 (9%)
Hospital pharmacist 70 (33%)
Infection control nurse 12 (5%)
Infection control specialist/consultant 8 (4%)
ID specialist/consultant 17 (8%)
Medical director 8 (4%)
Microbiologist 8 (4%)
Pharmacy director 56 (26%)
Total 214 (100%)
Hospital type Total number Number of responded hospitals
General 218(79.5%) 129 (88%)
Psychiatric 18 (6.5%) 5 (3%)
Obstetrics/Gynaecology and
paediatrics
16 (6%) 9 (6%)
Convalescence 7 (2.5%) 1 (0.7%)
Eye 4 (1.4%) 1 (0.7%)
Obstetrics/Gynaecology 3 (1%) 0
Paediatrics 3 (1%) 0
Chest 3 (1%) 0
Rehabilitation 2 (0.7%) 2 (1.5%)
Total 274 (100%) 147
Region Number of MOH hospitals Number of responded hospitals
Al-Hasa 11 2 (1.3)
Al-Jouf 9 4 (3%)
Al-Qunfudah 5 1 (0.7%)
Al-Qurayyat 5 2 (1.3%)
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5.3.2 Level of ASPs implementation and availability of core members of
ASPs in Saudi MOH hospitals
Only 26% (39/147) of the hospitals reported the availability of ASPs within their
hospitals (33 general hospitals, 5 Obstetrics/Gynaecology and paediatrics
hospitals and 1 Rehabilitation hospital), with Only 31% (46/147) of the hospitals
having ID specialists/ consultants and 33% (48/147) employing antimicrobial
pharmacists, and 53% (78/147) of hospitals having microbiologists. However,
infection control practitioners were available in 96% (141/147) of the hospitals.
5.3.3 Factors (barriers and facilitators) influencing the adoption and
implementation of ASPs in Saudi MOH hospitals
To answer this research question, it was necessary to examine the
perspectives of healthcare professionals regarding the adoption and
implementation of ASPs in Saudi MOH hospitals. This study seeks to
investigate the barriers and facilitators that may influence hospitals to adopt and
implement ASPs to promote appropriate use of antimicrobials. This part of the
questionnaire examined the adoption and implementation of ASPs in Saudi
MOH hospitals in relation to four dimensions using the innovation within the
healthcare organisations model (Fleuren et al., 2014, 2004): a) intention to
adopt and implement ASPs; b) legislation and regulations to adopt and
Aseer 20 13 (9%)
Baha 10 5 (3.5%)
Bishah 7 4 (3%)
Eastern region 19 12 (8%)
Hafar Al-batin 7 5 (3.5%)
Hail 12 3 (2%)
Jeddah 13 10 (7%)
Jizan 21 6 (4%)
Madinah 19 15 (10%)
Makkah 9 5 (3.5%)
Najran 12 9 (6%)
Northern border 9 7 (5%)
Qasim 20 12 (8%)
Riyadh 42 21 (14%)
Tabouk 11 8 (5%)
Taif 13 3 (2%)
Total 274 (100%) 147
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implement ASPs; c) characteristics of hospitals; and d) characteristics of ASPs
(tables 5.5-5.8).
a) Intention to adopt and implement ASPs
Table 5.5: Intention to adopt and implement ASPs (N = 191)
Findings from this part demonstrate that 81% of healthcare professionals held
positive views regarding the intention of hospitals to adopt and implement ASPs
in Saudi MOH hospitals. Also, 80% of these healthcare professionals believe
that their hospitals have the intention to follow ASP guidelines on a regular
basis. Similarly, 72.7% state that their hospitals strongly recommend the
adoption and implementation of ASPs. Therefore, it seems that all the
healthcare professionals held positive views regarding the intention of ASPs
implementation and had faith in their hospitals in terms of the adoption and
implementation of ASPs.
b) Legislation and regulations to adopt and implement ASPs
Table 5.6: Legislation and regulations to adopt and implement ASPs (N = 191)
Statement
Relative Frequency Distribution
M
ean
Standard
D
eviation
Strongly
Agree
%
Agree
%
N
eutral%
D
isagree
%
Strongly
D
isagree
%
Q15/This hospital intends to adopt and implement ASP 45.5 36.1 14.7 2.6 1.0 4.23 .869
Q16/This hospital intends to follow ASP guidelines
regularly in the future
41.9 38.2 15.2 3.1 1.6 4.16 .904
Q17/This hospital would highly recommend the
adoption and implementation of ASPs in other hospitals
31.9 40.8 17.8 7.9 1.6 3.94 .977
Statement
Relative Frequency Distribution
M
ean
Standard
D
eviation
Strongly
Agree
%
Agree
%
N
eutral%
D
isagree
%
Strongly
D
isagree
%
Q18/Many of our patients would expect this hospital to
adopt and implement ASP.
10.5 46.6 24.6 12.0 6.3 3.43 1.038
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Findings from this part demonstrate that 57.1% of healthcare professionals
believed that their patients expect hospitals to adopt and implement ASPs, and
64.4% thought that their patients had a serious desire to see the adoption and
implementation of ASPs. However, 73.3% of healthcare professionals
displayed strong negative attitudes towards the fact that their hospitals have
not been pledged by legislative regulations to adopt and implement ASPs.
Similarly, 83% of the healthcare professionals surveyed reported that
compliance with the legislative regulations regarding ASPs is not enforced
strictly in Saudi MOH hospitals.
c) characteristics of hospitals
Table 5.7: Characteristics of hospitals (N = 191)
Q19/The legislative regulation pledges this hospital to
adopt and implement ASP.
0.5 7.9 18.3 52.9 20.4 2.15 .854
Q20/The compliance with the legislative regulations
regarding ASP is enforced strictly.
0.0 2.6 14.1 61.8 21.5 1.98 .680
Q21/Our patients would consider us to be forward
thinking by adopting and implementing ASP.
20.4 44.0 23.0 7.9 4.7 3.68 1.036
Statement
Relative Frequency Distribution
M
ean
Standard
D
eviation
Strongly
Agree
%
Agree
%
N
eutral%
D
isagree
%
Strongly
D
isagree
%
22/Senior management would provide resources
necessary for the adoption and implementation of ASP
in this hospital.
16.8 41.9 26.2 11.5 3.7 3.57 1.018
23/Senior management would provide necessary
support for the adoption and implementation of ASP in
this hospital.
15.7 45.0 24.6 10.5 4.2 3.58 1.012
24/Senior management would support adherence to
ASP in this hospital.
15.7 51.3 23.6 6.3 3.1 3.70 .918
25/Senior managers would be enthusiastic about
adopting and implementing ASP in this hospital.
18.8 45.5 22.0 11.0 2.6 3.67 .990
26/A specific person (or group) is available for
assistance with the adoption and implementation of
ASP in this hospital.
1.6 5.8 15.7 53.9 23.0 2.09 .869
27/We have the knowledge necessary to adopt and
implement ASP in this hospital.
0.5 2.1 12.6 61.3 23.6 1.95 .701
28/We have the resources necessary (e.g. experts and
staff) to adopt and implement ASP in this hospital.
0.5 3.1 14.1 54.5 27.7 1.94 .769
29/This hospital has the financial resources to adopt
and implement ASP.
8.4 27.7 30.9 22.0 11.0 3.01 1.131
30/This hospital has the technological resources to
adopt and implement ASP.
0.0 2.1 13.1 62.8 22.0 1.95 .659
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Findings on the characteristics of hospitals show that 58.7% of healthcare
professionals believed that their senior management would provide the
required resources to facilitate the adoption and implementation of ASPs in their
hospitals; 60.7% of healthcare professionals stated that their senior
management would provide the necessary support to adopt and implement
ASPs; 67% of healthcare professionals reported that their senior management
would support adherence to ASPs in their hospitals; and 64.3% said that their
senior managers would be enthusiastic about adopting and implementing ASPs
in their hospitals.
However, 76.9% of healthcare professionals strongly believed that there is no
specific person or group available to assist and facilitate the adoption and
implementation of ASPs in their hospitals; 84.9% reported that they lack the
necessary knowledge to adopt and implement ASPs in their hospitals; 82.2%
of the healthcare professionals surveyed felt they suffer from a shortage of the
necessary resources, such as experts and staff to adopt and implement ASPs;
and, similarly, 84.8% of the respondents stated that their hospitals lack the
required technological resources to adopt and implement ASPs in their
hospitals.
d) Characteristics of ASPs
Table 5.8: Characteristics of ASPs (N = 191)
Statement
Relative Frequency Distribution
M
ean
Standard
D
eviation
Strongly
Agree
%
Agree
%
N
eutral%
D
isagree
%
Strongly
D
isagree
%
31/Procedures for adopting and implementing ASP are
clear and understandable.
0.5 1.6 15.7 66.0 16.2 2.04 .656
32/I believe that it will be easy to adopt and implement
ASP in this hospital.
13.1 43.5 22.0 16.8 4.7 3.43 1.064
33/Overall, I believe that ASP will be easy to adhere to. 12.0 49.2 20.9 16.2 1.6 3.54 .955
34/I believe that it will be easy for staff to follow ASP
guidelines.
12.6 48.2 18.3 18.3 2.6 3.50 1.015
35/ASPs are adopted in other hospitals in the country. 14.1 49.7 31.9 3.7 0.5 3.73 .766
36/ASPs are not very visible in other hospitals. 6.8 33.0 51.3 8.9 0.00 2.62 .743
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Findings on the characteristics of ASPs show that 56.6% of the healthcare
professionals surveyed believed that the adoption and implementation of ASPs
in their hospitals will be easy; 61.2% stated that an ASP is easy to adhere to;
60.8% stated that staff can easily follow ASP guidelines; 63.8% believed that
ASPs are adopted in other hospitals in Saudi Arabia; 87.5% agreed that it is
essential to properly try out ASPs before adopting them; and 86.9% stated that
it is important to adopt ASPs on a trial basis long enough to see their benefits.
Similarly, 96.3% of healthcare professionals strongly agreed that ASPs can
improve antimicrobial use; 96.4% stated that ASPs can reduce antimicrobial
resistance; 97.4% strongly believed that ASPs improve patient safety; and
92.6% agreed that ASPs can improve patient care. However, 82.2% of
healthcare professionals strongly believed that the procedures for adopting and
implementing ASPs are unclear and difficult to understand; 39.8% found that
ASPs are not very visible in other hospitals, and 51.3% are undecided about
the visibility of ASPs in other hospitals in Saudi Arabia.
c) Summary
a) The findings in relation to the first-dimension show that most of the
healthcare professionals surveyed have a positive perception of the
possibilities of Saudi MOH hospitals to adopt and implement ASPs without any
difficulties. Also, they believed that their hospital can manage and follow ASP
guidelines without significant barriers.
b) Some of the healthcare professionals believed that their patients expect
hospitals to be interested in adopting and implementing ASPs to increase their
37/Before deciding whether to adopt ASPs, it will be
essential to be able to properly try them out.
28.3 59.2 8.9 3.1 0.5 4.12 .731
38/It is essential to adopt ASP on a trial basis long
enough to see their benefits.
39.3 47.6 7.3 4.2 1.6 4.19 .862
39/ASPs will improve antimicrobial use. 69.6 26.7 3.7 0.00 0.00 4.66 .547
40/ASPs will reduce antimicrobial resistance. 70.2 26.2 3.1 0.5 0.00 4.66 .566
41/ASPs will improve patient safety. 73.3 24.1 2.1 0.5 0.00 4.70 .533
42/ASPs will not improve patient care. 1.0 0.5 5.8 34.0 58.6 4.49 .724
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care and safety. However, others showed that there are huge barriers to the
adoption and implementation of ASPs because of lack of high authorities'
enforcement to adopt and implement ASPs, and lack of legislative regulations
to pledge ASPs in hospitals.
c) There are positive voices among the healthcare professionals in Saudi about
the characteristics of their hospitals in the adoption and implementation of
ASPs. They believed that their senior management are doing their best to
facilitate the development of ASPs in order to increase the benefit of their usage
through providing the required resources and support and increasing
awareness so that ASPs can form part of their medical system and enhance
medical safety and care among healthcare professionals and patients.
In contrast, other healthcare professionals showed their great concern about
the characteristics of hospitals in facilitating the adoption and implementation
of ASPs in Saudi MOH hospitals. They described some barriers to ASPs such
as lack of available experts or groups to assist the process of ASPs adoption
and implementation; lack of necessary awareness and knowledge about ASPs;
and shortage of experts and specialist staff to take responsibility about following
up the progress of ASPs in their hospitals.
d) A good number of the healthcare professionals surveyed showed a positive
perspective on the characteristics of ASPs. They believed the adoption and
implementation of ASPs is easy; it is simply to follow ASP guidelines; and it is
easy for ASPs to be adopted and used widely across Saudi Arabia. In addition,
they stated that it is important to pilot ASPs before any implementation in order
to see their impact and to be able to convince others about its benefits.
Similarly, the healthcare professionals believed that the adoption and
implementation of ASPs can effectively reduce antimicrobial resistance and
improve antimicrobial use. Similarly, the implementation of ASPs can improve
patient safety and patient care.
However, other healthcare professionals criticised the process of ASPs,
complaining that procedures for adopting and implementing ASPs are invisible,
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unclear and difficult to understand. These issues can act as obvious barriers in
the face of any progress of ASPs in Saudi MOH hospitals.
Table 5.9 shows the results of the logistic regression analysis applied to identify
the significant factors influencing the adoption of ASPs in Saudi MOH hospitals.
The results identified the following factors as significant for the adoption of
ASPs in Saudi MOH hospitals including; Patient demand (p= 0.002),
Usefulness of the programme (p= 0.002), and trialability of the programme (p=
0.013).
Table 5.9: Results of the logistic regression
Predictor B Coefficient Wald Statistic Significance
TM 1.737 6.996 0.515
PD 0.867** 4.068 0.002
SMS 0.973 7.065 0.079
OR -1.790* 5.935 0.050
EP 3.751** 10.303 0.029
TRI −2.180** 8.016 0.013
UN 1.127** 6.424 0.002
TM = Team Members; PD = Patient Demand; SMS = Senior Management Support; OR =
Organisation Readiness; EP= External pressure; TRI= Trialability; UN = Usefulness
5.3.4 Influence of the hospital type on the adoption and implementation
of ASPs in Saudi MOH hospitals
Several tests were used to strengthen and enrich the answers for the research
questions in the current study. One-way ANOVA analysis was used to examine
the differences between the level of adoption and implementation of ASPs and
the hospital type (general hospitals, general hospitals (referral), medical cities
(specialised), obstetrics/gynaecology and paediatrics, obstetrics/gynaecology,
paediatrics, eye, psychiatric, chest, convalescence, and rehabilitation). The
One-Way ANOVA analysis did reveal that there were no significant differences
between the adoption and implementation of ASPs and the type of hospital (F
= (6,184) = 1.20, p > 0.05, n = 191). Therefore, it seems that the independent
variable (hospital type) has no significant influence on the level of adoption and
implementation (dependent variable) of ASPs. This means that hospital type of
131
MOH hospitals has no impact on the level of adoption and implementation of
ASPs in Saudi MOH hospitals.
However, the One-Way ANOVA analysis revealed significant differences
between hospital type and the sub-scale ‘intention to adopt and implement
ASPs’, which consisted of the summation of three statements (Q15, Q16 and
Q17) (F = (6,184) = 2.63, p < 0.05, n=191). A significant difference was
identified through post-hoc analysis (Scheffe test). Specifically, medical cities
(specialised) have a more positive attitude towards the intention to the adoption
and implementation of ASPs (M = 14.33, SD = 0.77) compared with psychiatric
hospitals (M = 9.50, SD = 1.00). In addition, the results show the ranking of
hospitals in terms of their positive attitude towards the intention to adopt and
implement ASPs: medical cities (specialised) come in first place (M = 14.33,
SD = 0.77); followed by obstetrics/gynaecology and paediatrics (M = 13.10, SD
= 2.42); general hospitals (M = 12.22, SD = 2.29); central hospitals (referral) (M
= 12.12, SD = 3.29); convalescence (M = 12.00), rehabilitation (M = 11.67, SD
= 2.88); and psychiatric (M = 9.50, SD = 1.00).
In general, the hospital type did not have any influence on the adoption and
implementation process according to the healthcare professionals surveyed.
However, there is one significant difference between hospital type and the sub-
scale ‘intention to adopt and implement ASPs’, showing that ASPs are more
favoured by medical cities (specialised) as compared with psychiatrist
hospitals. This means that medical care and interest in terms of the intention to
adopt and implement ASPs are influence by hospital type and, unfortunately,
the healthcare professionals in psychiatrist hospitals are less concerned and
interested in ASPs.
5.3.5 Perspectives of healthcare professionals regarding factors
influencing the adoption and implementation of ASPs in Saudi MOH
hospitals
One-Way ANOVA analysis was used to examine the differences between the
level of adoption and implementation of ASPs and staff position (i.e. clinical
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pharmacists, hospital pharmacists, pharmacy directors, infection control
specialists/consultants, infection control nurses, ID specialists/consultants and
microbiologists). The one-way ANOVA analysis reveals that there are no
significant differences between the adoption and implementation of ASPs and
staff position (F = (6,184) = 1.71, p > 0.05, n = 191). Therefore, it seems that
the independent variable (staff position) has no significant influence on the level
of adoption and implementation (dependent variable) of ASPs. This means that
all healthcare professionals have similar perspectives regarding the adoption
and implementation of ASPs in Saudi hospitals.
However, One-Way ANOVA analysis revealed significant differences between
staff position and the sub-scale ‘intention to adopt and implement ASPs’ (F =
(6,184) = 2.79, p < 0.05, n=191). The results show the ranking of staff position
in terms of their positive attitude towards the intention to adopt and implement
ASPs: ID specialist/consultant comes in first place (M = 13.59, SD = 1.77);
followed by infection control nurse (M = 13.25 , SD = 2.09);  infection control
specialist/consultant (M = 13.13 , SD = 4.22); clinical pharmacist (M = 12.75 ,
SD = 1.62); microbiologist (M = 12.63, SD= 3.11), pharmacy director (M =
12.45 , SD = 2.18); and hospital pharmacist (M = 11.50, SD = 2.53).
Similarly, One-Way ANOVA analysis revealed significant differences between
staff position and the sub-scale ‘characteristics of hospital’ (F = (6,184) = 2.24,
p < 0.05, n=191). The results show the ranking of staff position in terms of their
positive attitude towards the characteristics of hospitals to adopt and implement
ASPs: infection control nurse comes in first place (M = 28.50, SD = 2.24);
followed by microbiologist (M = 27.25 , SD = 2.71);  infection control
specialist/consultant (M = 26.50 , SD = 1.85); hospital pharmacist (M = 25.53,
SD = 3.83); clinical pharmacist (M = 25.15, SD= 3.05), ID specialist/consultant
(M = 24.76 , SD = 3.36); and pharmacy director (M = 24.61, SD = 4.66).
In general, staff position does not significantly influence the adoption and
implementation of ASPs. This may indicate that all the healthcare professionals
held similar perspectives on ASPs in Saudi MOH hospitals. However, it seems
that infectious diseases specialists/consultants have a greater impact in both
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sub-scales: intention to adopt and implement ASPs and the characteristics of
hospitals.
5.4 Discussion
The objectives of this quantitative study were to investigate the level of
implementation and factors influencing the adoption and implementation of
ASPs in Saudi MOH hospitals at national level. To my knowledge this is the first
quantitative study regarding the level of implementation and factors influencing
the adoption and implementation of ASPs in Saudi MOH hospitals at a national
level. This will provide further empirical evidence on ASPs adoption in the
region.
Regarding the level of implementation of ASPs in in Saudi MOH hospitals,
finding of this study showed that implementation of ASPs was low with only
26% (39/147) of Saudi MOH hospitals reporting the availability of ASPs. While
there has been increasing calls on hospitals to implement ASPs (Public Health
England, 2015b; The White House, 2014, 2015; United Kingdom Department
of Health, 2013; World Health Organisation, 2015a), implementation of these
programmes varies between countries. For example, in a national survey of
4184 US hospitals, only 39% (1632/4184) reported having an ASP that met all
the CDC core elements for hospital ASPs (Pollack et al., 2016). In a UK-wide
survey to describe UK antimicrobial stewardship strategies however, 82%
(186/226) of the respondents reported having an antimicrobial management
team within their hospital (Tonna, Gould, & Stewart, 2014). Similarly, a cross-
sectional survey to evaluate the status of ASPs in Gulf Cooperation Council
(GCC) states found out that 62% (29/47) of participating hospitals have ASPs
in place (Enani, 2016). Internationally, a cross-sectional survey of 67 countries
reported that ASPs existed in 58% (383/660) of the participating hospitals
(Howard et al., 2015). These surveys indicate a positive response to the
national and international calls (Public Health England, 2015b; The White
House, 2014, 2015; World Health Organisation, 2015a) for containment of the
threat of AMR through judicious use of available antibiotics. On the other hand,
further improvements are still needed in such areas as, legislation and
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regulations, education and provision of required resources to increase the rate
of ASPs adoption.
The IDSA/SHEA antimicrobial stewardship guidelines were first published in
2007 recommending a multidisciplinary team comprising of an ID physician, a
clinical pharmacist with infectious diseases training as core members as well
as a clinical microbiologist, an infection control expert, a hospital
epidemiologist, and a hospital administrators for an optimal ASP (Dellit et al.,
2007). Findings of this study showed that only 31% (46/147), 33% (48/147) and
53% (78/147) of the hospitals had ID specialists/consultants, antimicrobial
pharmacists and microbiologists respectively. Currently, there are only 57 ID
physicians (Tropical medicine) (25 registrars and 32 consultants) in all Saudi
MOH hospitals (274 hospital) (Saudi Ministry of Health, 2017a). In a UK-wide
survey, antimicrobial pharmacists were presented in 95% (177/186) of UK
hospitals. Inadequate or lack of ID consultants, antimicrobial pharmacists and
microbiologists therefore is a major barrier to ASPs adoption in Saudi MOH
hospitals.
In this national survey, there was an overall positive attitude towards the
adoption and implementation of ASPs among healthcare professionals in the
Saudi MOH participating hospitals. Up to 80% of the healthcare professionals
agreed they have faith in their hospitals to adopt and implement ASPs, and
intend to follow ASPs guidelines. This is particularly important as successful
ASPs require cooperation and collaboration of healthcare professionals with
the antimicrobial stewardship team and hospital leadership (Pakyz et al., 2014).
Around 70% of participants also agreed to the willingness of senior
management to provide the necessary support to adopt and implement ASPs
in Saudi MOH hospitals. This is of great importance because successful
implementation of ASPs depends on strong management support.
Consequently, published antimicrobial stewardship guidelines recommend, not
only inclusion of a hospital administrator in the stewardship team, but also
support for the team by way of provision of required resources (Centers for
Disease Control and Prevention, 2014; Dellit et al., 2007; Pollack et al., 2016;
Public Health England, 2015b). Like participants in the qualitative study
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(chapter four), up to 87% of surveyed participants agreed that ASPs adoption
on a trial basis is necessary to observe the benefits of ASPs before full
implementation. Even though antimicrobial stewardship interventions have
been shown to reduce antibiotic use and cost, reduce AMR, and improve
clinical outcomes (Davey et al., 2017), lack of awareness/knowledge among
healthcare professionals in Saudi MOH hospitals on the problem of AMR and
benefits of ASPs was reported as a barrier to successful ASPs adoption and
implementation by 85% of respondents. This means there is need for the Saudi
MOH, as part of their AMR strategy to designate hospitals that have required
resources to pilot ASPs, and therefore serve as preceptors to other hospitals.
While there were overall positive views on the adoption and implementation of
ASPs, like the qualitative study (chapter four), 73% of participants in the survey
reported the lack of legislations as a barrier to the implementation of ASPs, 77%
reported lack of expertise, 82% reported lack of education and training, and
85% reported lack of IT resources as barriers to the adoption and
implementation of ASPs in Saudi MOH hospitals. These findings are in line with
previous studies (Avent et al., 2014; Chen et al., 2011; Enani, 2016;
Johannsson et al., 2011; Trivedi & Rosenberg, 2013), except the lack of
financial resources that was not reported as a major barrier in Saudi MOH
hospitals. This can be due to the increasing rates of the budget of the Saudi
MOH over the past years, as the budget increased by 100% between 2009 and
2016 (Saudi Ministry of Health, 2017b).
This national survey also sought to determine the extent to which hospital type
influences the adoption and implementation of ASPs in Saudi MOH hospitals.
Findings show there was no significant difference between the adoption and
implementation of ASPs and the type of hospital. This means the type of
hospital does not have impact on the adoption and implementation of ASPs. A
national survey to describe ASPs in US hospitals concluded that facilities of any
size can implement ASPs with hospital leadership support (Pollack et al., 2016).
While no difference existed between hospital type and adoption of ASPs, there
was significant difference between hospital type and the intention to adopt and
implement ASPs. Specifically, medical cities (specialised hospitals) had a more
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positive attitude towards the intention to adopt and implement ASPs than other
type of hospitals, including general and central hospitals. This can be due to
the availability of expertise (ID consultants and pharmacists) in those hospitals
who are the core members of ASPs.
Regarding the perspectives of the different stakeholders (clinical pharmacists,
hospital pharmacists, pharmacy directors, infection control
specialists/consultants, infection control nurses, ID specialists/consultants and
microbiologists) towards the adoption and implementation of ASPs in Saudi
MOH hospitals, there was no significant difference in their perspectives on the
adoption and implementation of ASPs. However, this study revealed significant
difference between staff position and their intention to adopt and implement
ASPs''. The results show infectious diseases specialists/consultants had more
positive attitude towards the intention to adopt and implement ASPs followed
by infection control nurses, infection control specialists/consultants, clinical
pharmacists, and microbiologists. This finding showed the importance of inter-
professional collaboration that could assist in implementing ASPs successfully.
Resistance or opposition from prescribers and other healthcare professionals
have been reported as one of the factors that hinder successful implementation
of ASPs (Chen et al., 2011; Doron et al., 2013; Howard et al., 2015; Pakyz et
al., 2014).
5.4.2 Implications for practice
In order to implement the national ASP guideline of the Saudi MOH, it is
important to identify barriers and facilitators for successful adoption and
implementation of ASPs to know how barriers can be overcome and provide
recommendations for professionals, hospitals and policy makers to improve
antimicrobial practice, reduce antimicrobial resistance and improve patient
care.
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5.5 Conclusion
The objectives of this national survey were to investigate the level of
implementation and factors influencing the adoption and implementation of
ASPs in Saudi MOH hospitals at national level. Less than a third of the hospitals
reported the availability of ASPs within their hospitals. Legislations and
regulations that require/enforce hospitals to implement ASPs, expertise (ID
consultants, antimicrobial pharmacists, microbiologists), IT resources and
educational programmes are key to successful implementation of ASPs in
Saudi MOH hospitals. senior management commitment to provide required
resource and support is essential to facilitate and empower the implementation
of ASPs.
This quantitative study and the previous qualitative study (chapter four)
identified lack of knowledge and awareness of staff regarding the availability of
ASPs in other Saudi hospitals and how ASPs can be implemented successfully.
Therefore, a case study was carried out in the next chapter in order to explore
the adoption and implementation process of an ASP in a Saudi MOH hospital
that has an ASP in place and identify how barriers were overcome in order to
provide recommendations for hospitals without ASPs to implement ASPs easily
and successfully.
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Chapter 6: ASP adoption and implementation process in a
Saudi MOH hospital: a case study
6.1 Introduction
The alarming rate of antibiotic resistance (Public Health England, 2015a; World
Health Organisation, 2014) and the association between antibiotic use and
development of resistance (Laxminarayan et al., 2013) have led to calls for
action plans and strategies to control antibiotic use in human and animal health.
One of the strategies to control increasing antibiotic resistance is ASPs, which
are well established especially in the USA (Pollack et al., 2016) and UK (Public
Health England, 2015a). Implementation of these programmes has been
associated with reduction in inappropriate antibiotic use (K. a. Cairns et al.,
2013); reduction in rates of resistant bacteria such as: MRSA and Clostridium
difficile infections (Aldeyab et al., 2012; Martin et al., 2005; Yam et al., 2012)
and reduction in antimicrobials expenditures (Bartlett & Siola, 2014).
Implementation of ASPs has also been associated with reduction in length of
hospital stay and rate of readmission (Pasquale et al., 2014).
A cross-sectional study that aimed to describe the prevalence of ASPs in GCC
states reported existence of ASPs in few hospitals (Enani, 2016). Findings of
Chapter four showed that there were no formal ASPs in the three Saudi MOH
hospitals that participated in the study, and less than a third of hospitals
(39/147) have ASPs (Chapter five). Participants in the study, however, reported
that if they receive training from hospitals with established programmes and
see how ASPs were adopted and implemented successfully in these hospitals,
they would be willing to adopt ASPs in their hospitals. Thus, the objective of this
chapter is to explore the adoption and implementation process of an
established ASP (initiation, adoption decision, implementation) that can serve
as a model or preceptor for Saudi MOH hospitals without ASPs with respect to:
i. Reasons/ initiatives behind ASP adoption and implementation in the
medical city
ii. Adoption and implementation phases of the ASP in the medical city
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iii. Characteristics of the ASP (team members, strategies and outcomes) in
the medical city
iv. Facilitators of successful implementation and barriers to smooth running
of the ASP in the medical city
6.2 Methods
6.2.1 Design
To achieve the objective of this study, in depth interviews were conducted in a
hospital with an established ASP. Also, content analysis of ASP hospital
documents was carried out to complement primary data.
6.2.2 Development and source of interview schedule
The interview schedule (Appendix 11) was developed following a review of the
literature and discussion among the researcher and supervisory team, as well
as consultation with three ASP pharmacists (two from Saudi Arabia and one
from the UK) and two ID consultants (from Saudi Arabia). Questions in the
schedule were all open-ended to obtain in depth views or perspectives of study
participants. The interview schedule has two main sections, which primarily
consist of open questions. Firstly, is a section on background information (3
questions), such as position of healthcare professionals, gender and years of
experience. Secondly, open-ended questions (12 questions) were used to
explore the components of the ASP in the medical city, members of the ASP
and their responsibilities, the adoption and implementation process of the ASP
in the medical city, and factors (barriers and facilitators) that influenced/are
influencing the adoption and implementation process of the ASPs in the medical
city.
Background information questions were developed after discussion between
the researcher and supervisory team to explore participants demographic data
(position, gender and years of experience). Questions 1-6 were developed after
discussion between the researcher and supervisory team to explore
characteristics and availability of ASPs in the medical city (available strategies,
team members, roles of members, frequency and nature of meetings, and
effectiveness of available strategies). Questions 7-10 were adapted from
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published tools (Cotta et al., 2015; Pakyz et al., 2014) to explore factors
(barriers and facilitators) influencing the adoption and implementation of ASPs
in the medical city. Questions 11 and 12 were developed after discussion
between the researcher and supervisory team to explore the adoption and
implementation phases of the ASP at the medical city (reasons to adopt, stages
of adoption and implementation, timeframe, outcomes, and policies).
The interview schedule was developed bearing in mind the four main domains
of the conceptual framework (Fleuren et al., 2014, 2004) to cover all the
different factors that affected the adoption and implementation process of the
ASP in the medical city. Questions 1, 3, 5, 6 and 12 was developed based on
the domain: characteristics of the ASP, to explore characteristics and
availability of ASPs in hospitals. Question 2 was developed based on the
domain: characteristics of healthcare organisation, to explore the availability of
expertise in hospitals. Question 4 was developed based on the domain:
characteristics of healthcare workers, to explore knowledge and skills of
healthcare workers in regards to ASPs. Questions 7-11 was developed to
explore the factors (barriers and facilitators) influencing the adoption and
implementation process of the ASP in the medical city that can be under any of
the four different domains: characteristics of the socio-political context,
characteristics of the healthcare organisation, characteristics of the healthcare
workers and characteristics of the ASP. Probing questions were also asked
based on the responses of the participants to get more details.
6.2.3 Validation of interview schedule
The following steps were taken to ensure validity of the interview schedule
(Bowling, 2009; Smith, 2002): Face validity: the interview schedule was
checked by the researcher and the supervisory team to ensure their relevance,
reasonability and that no ambiguity exists. Content validity: three ASP
pharmacists (two from Saudi and one from the UK) and two ID consultants
(from Saudi Arabia) checked the content of the interview schedule to ensure
that the content of the instrument is logical and easy to understand.
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6.2.4 Setting
This study was conducted at a 1500-bed tertiary medical city in Saudi Arabia
with an established ASP. The programme was implemented in January 2016.
The hospital has Coronary Care Unit (CCU), Cardiac Surgery Intensive Care
Unit (CSICU) and provides cardiac, haematology, oncology, neuroscience,
medical and specialised surgery services.
6.2.5 Sampling and recruitment of participants
Purposive sampling was the method of sampling for this study, which involved
recruiting participants who have knowledge that is valuable to the research
process. Participants in the study were the core members of the ASP and
included an ID consultant (Director of the ASP), a clinical pharmacist (Manager
of the ASP), a consultant clinical microbiologist, an infection control consultant
and the CEO of the medical city. They play a significant role in the adoption and
implementation of ASPs and the combined effort of the team can improve
infection control and reduce antimicrobial resistance (Waters, 2015). Invitation
letters (Appendix 12) were sent to the five targeted participants, through the
head of the clinical pharmacy department (the manager of the ASP at the
hospital), who was the first contact in the medical city, to introduce the study,
obtain approval, and to schedule interviews.
6.2.6 Data collection
Interviews were conducted face-to-face in participants main language (Arabic
or English) and audio recorded (using Sony ICD-PX333 recorder) for later
transcription. Notes were taken during the interviews for non-verbal responses
such as looking sad, smiling, feeling angry, etc. Interviews were conducted in
a quiet area (pharmacy meeting room) to avoid any interruptions. Consent
forms (Appendix four) were obtained from each participant. The interviews were
conducted in July 2017. Reflexivity was considered during the interviews and
analysis, so the researcher's views and opinion do not influence the
participants' responses.
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6.2.7 Data analysis
The interviewer used a recorder to audio record all of the interviews for later
verbatim transcription and analysis. Transcripts were generated into Microsoft
Word 2016 for each of the recorded interviews and labelled with a unique code
for each participant. Themes and issues raised during the interviews were
utilised to produce the codes, which were then organised into a framework that
formed the basis of the primary coding structure. Interviews that were
conducted in Arabic (3 out of 5) were analysed and coded first, then, themes,
subthemes and quotes from participants were translated to English. Two
independent researchers mapped and interpreted interviews data to capture
the emerging themes and avoid any bias that could influence the analysis
process. A third researcher screened a random sample (40% of the interviews)
to check the reliability of the coding. Any discrepancies were resolved through
discussion between the three researchers. A framework analysis using five
sequential components was undertaken for each interview (Braun & Clarke,
2006). The five components of the analytical methodology are:
I) Familiarisation with the collected data.
II) Developing a thematic framework from the interviews and the themes
emerging from the data (through the identification of main topics and
subtopics).
III) Indexing (coding the data) into themes.
IV) Charting by rearranging indexed data according to the thematic
framework.
V) Mapping and interpreting data.
A framework representing the major phases in ASP processes and related
categories of determinants (Figure 3.6), was developed based on the
determinants of innovation within the healthcare organisations model (Fleuren
et al., 2014, 2004) informing the analysis. The conceptual framework was also
used to develop the interview schedule. Themes and subthemes raised during
the interviews and did not fit into this framework were incorporated and added
to the framework, so no emerging themes and subthemes to be missed.
Researchers looked for evidence of themes related to:
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1) Characteristics of the socio-political context, such as; legislation,
regulations, patient cooperation, patient awareness benefits, financial
burden on patient and patient discomfort.
2) Characteristics of the healthcare facility, such as; decision-making
process, reinforcement management, relationship with other
organisations, collaboration between departments, staff turnover, staff
capacity, available expertise, financial resources, administrative support,
time available, opinion leader, feedback to user about innovation,
material resources, and coordinator.
3) Characteristics of the healthcare workers, such as; social support
colleagues, social support supervisors, self-efficacy, knowledge, skills,
work-related stress, ethics problems, outcome expectations, ownership,
expects patient cooperation, expects patient satisfaction.
4) Characteristics of the ASP, such as; complexity, advantages, clear
procedures, compatibility, trialability, relevance for patient, risks for
patient, frequency in the use, perceived prevalence of health problem.
6.2.8 Trustworthiness of interview transcript
The following tests were used to ensure reliability (Bowling, 2009):
Inter-rater: two raters coded transcribed interviews and the results were
compared to measure the extent to which they agree. A third researcher
screened a random 40% sample to check the reliability of the coding. Any
discrepancies were resolved through discussion between the three
researchers. Further reliability was ensured through verification of the
transcribed data with the participants.
6.2.9 Ethical considerations
Official permissions were obtained from the participating medical city (Appendix
13). The researcher obtained written consent (Appendix four) from the
participants and provided a participant information sheet explaining the nature
of the study and its objectives (Appendix 14). All audio recordings were stored
in locked drawers and electronic files (password protected) stored on computer
to which only the researcher/supervisors have access. Audio files and
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electronic/paper files of the interviews' transcripts will be destroyed three years
after completion of the writing of thesis.
6.3 Results
All the core members of the ASP at the medical city (5/5) who were approached
for recruitment had agreed to participate in this study. Five in-depth interviews
(three in English and two in Arabic) were conducted with the core members of
the ASP team. Length of interviews were two hours and 15 minutes (over two
days) with the clinical pharmacist, 45 minutes with the ID consultant, 36 minutes
with the CEO, 29 minutes with the consultant clinical microbiologist and 15
minutes with the infection control consultant. Also, content analysis of 35 ASP
hospital documents was carried out.
Four main themes emerged from the data regarding ASP at the medical city
(Table 6.1). They include: 1) Initiatives behind ASP adoption and
implementation at the medical city, 2) ASP adoption and implementation
phases at the medical city, 3) Characteristics of the ASP at the medical city
(core members, strategies and expected outcomes), and 4) Factors enhanced
the adoption and implementation, and barriers to smooth running of the ASP at
the medical city.
Table 6.1: Themes and subthemes regarding ASP at medical city
Main themes Subthemes
Initiatives behind ASP adoption and
implementation at the medical city
ASP adoption and implementation
phases at the medical city
Adoption phase
Implementation phase
Characteristics of the ASP at the medical
city
Core members
Strategies
Expected outcomes
Factors enhanced the adoption and
implementation of ASP at the medical
city
Administrative support
Collaboration between staff/departments
Reinforcement management
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Barriers to smooth running of the ASP at
the medical city
Financial resources
IT resource
Staff capacity
6.3.1 Medical city initiatives of ASP adoption and implementation
At the medical city, ASP is part of the Patient Safety Portfolio (PSP). PSP was
launched to promote safe environment for patients and staff. It discusses and
finds solutions for issues that are presented at the medical city and can affect
patient safety. The PSP consists of 10 patient safety strategic “programmes”
(as highlighted in Figure 6.1). ASP is one of the portfolio programmes
established to solve the issues of increasing rates of multidrug resistant
organisms (MDROs) and increased healthcare cost due to inappropriate use of
antimicrobials, with the aim of optimising patient management, and achieving
reduction in morbidity, mortality and healthcare cost. Quotes from some
participants regarding initiatives behind ASP adoption and implementation at
the medical city are provided below:
''The misuse and abuse and cost and the increase in multidrug-resistant
organism is worsening, that also, really encouraged us and we pushed
strongly with the support of the leaders that we should start an antimicrobial
Stewardship program'' (Infectious diseases consultant 1)
''We have complex situation, we have neurology, oncology, so complex is
there, so we should take the lead in implementing something evidenced
based, also there was increasing rates of multi-drug resistance, due to people
coming with complex cases'' (Chief executive officer 1)
''Motivation to start this program was because we have a lot of multidrug
resistant and it was talked about it a lot in the medical board'' (Clinical
pharmacist 1)
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Figure 6.1: Patient safety portfolio programmes at the medical city (The
medical city, 2016)
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6.3.2 ASP adoption and implementation phases at the medical city
The process of ASP adoption and implementation at the medical city had two
main phases namely a) creation of the program and b) running of the
programme.
A. ASP adoption process (creation of the program):
The process commenced with a request from the patient safety committee to
implement ASP at the medical city. This was followed by the recruitment of a
locum ID clinical pharmacist with experience in ASP implementation for a 3-
month period. The responsibility of the locum ID pharmacist was to review the
situation in the medical city and provide recommendations on how to establish
and run the programme. He was also expected to provide insight on how to
overcome barriers or other obstacles that can be faced during the initiation
process. Following this, a multidisciplinary team was formed and tasked with
setting up the programme and monitoring results. The responsibilities and
accountability were assigned among the ASP core members in the adoption
and implementation process, which was followed by the development of ASP
policies. An antimicrobial restriction form was developed, and a pilot phase was
performed with ID physicians, physicians and pharmacists, to validate the form.
The approval from the medical records committee for the restriction form to be
used in the patient files was obtained. The approval for the ASP policies was
also obtained from higher authorities including; pharmacy department, infection
control department, microbiology department, ID department, Pharmacy and
Therapeutics (PNT) subcommittee, other participating departments and finally
the CEO to make sure that everyone is ready to run the programme.
The next step was to conduct ASP educational and training campaign (in Arabic
and English) through workshops, posters, grand rounds, presentations,
brochures, newsletter, media (Twitter), staff contest and booths targeting all
departments and staff.  Public awareness of antibiotics misuse was also
conducted. The goals of the campaign were to increase awareness of antibiotic
resistance and ASPs, encourage best practices among hospital staff and avoid
further emergence and spread of antibiotic resistance. Some of the educational
148
materials used in the campaign are provided in Figures 6.2, 6.3, 6.4, and Table
6.2.
B. ASP Implementation Plan:
The plan was to start the implementation (running) of the ASP in few wards with
few antimicrobial consumptions. However, with employment of more ID
specialists, the ASP team decided to run the programme in all wards at the
same time. Hospital leadership commitment and enforcement was very critical
during the adoption and implementation process and facilitated the programme
progress. Quotes from study participants regarding the implementation process
are as follows:
''at the beginning, we got the order that we need to do antimicrobial
Stewardship program, …. Secondly, we recruited an ID clinical pharmacist,
we started to do first the policy……. Then, we did restriction form as one part
of the antimicrobial stewardship program strategies and we did the workflow
for the restriction form. Then we got the approval from the medical record
committee'' (Clinical pharmacist 1)
''We did the committees, antimicrobial sub-committee and we established the
members, so we can make the policy, and after policy we started with
education'' (Infectious diseases consultant 1)
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Figure 6.3: A poster about ASP campaign (The medical city, 2016)
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Figure 6.4: ASP and the medical city logos that were printed on some T-shirts
(The medical city, 2016)
Table 6.2: Some tweets that were used in the medical city twitter account
about ASP (The medical city, 2016)
The 2 core strategies of the
#Antimicrobial_Stewardship are formulary
restriction and Prospective audit and
feedback #AntibioticResistance
 ﻲﻓ نﺎﺗﯾﺳﺎﺳﻻا نﺎﺗﯾﺟﯾﺗارﺗﺳﻻا
 فرﺻ دﯾﯾﻘﺗ ﺎﻣھ ﺔﯾوﯾﺣﻟا_تادﺎﺿﻣﻟا_ةرادا_ﺞﻣﺎﻧرﺑ#
ﻟا و ،ﺔﯾوﯾﺣﻟا تادﺎﺿﻣﻟا مﯾﯾﻘﺗﻟا و ﻲﻌﻗوﺗﻟا ﻖﯾﻗدﺗ
#AntibioticResistance
#Antimicrobial_Stewardship program goals
are to decrease bacterial resistance to
antibiotics, reduce antibiotics consumption,
and reduce healthcare costs
#AntibioticResistance
ﯾﺣﻟا_تادﺎﺿﻣﻟا_ةرادا_ﺞﻣﺎﻧرﺑ# فادھأ ﺔﻣوﺎﻘﻣ لﯾﻠﻘﺗ ﻲھ ﺔﯾو
 تادﺎﺿﻣﻟا كﻼﮭﺗﺳا لﯾﻠﻘﺗ ،ﺔﯾوﯾﺣﻟا تادﺎﺿﻣﻠﻟ ﺎﯾرﺑﺗﻛﺑﻟا
 ﺔﯾﺑطﻟا ﺔﯾﺎﻋرﻟا ﺔﻔﻠﻛﺗ لﯾﻠﻘﺗ و ،ﺔﯾوﯾﺣﻟا
#AntibioticResistance
Dear doctor, reduce #AntibioticResistance
by keeping your patients’ vaccination up to
date #I_am_a _Steward
ﻠﻗ ،بﯾﺑطﻟا يزﯾزﻋ دﻛﺄﺗﻟﺎﺑ ﺔﯾوﯾﺣﻟا تادﺎﺿﻣﻟا دﺿ ﺔﻣوﺎﻘﻣﻟا ل
 دﺋﺎﻗ_ﺎﻧا# كﺎﺿرﻣ مﯾﻌطﺗ نﻣ#AntibioticResistance
Dear doctor, to prevent
#AntibioticResistance prescribe the right
antibiotic at the right dose for the right
duration #I_am_a _Steward
 ﺔﯾوﯾﺣﻟا تادﺎﺿﻣﻟا دﺿ ﺔﻣوﺎﻘﻣﻟا ﻊﻧﻣإ ،بﯾﺑطﻟا يزﯾزﻋ
 ةدﻣﻠﻟ ﺔﺑﺳﺎﻧﻣﻟا ﺔﻋرﺟﻟﺎﺑ ،بﺳﺎﻧﻣﻟا يوﯾﺣﻟا دﺎﺿﻣﻟا فرﺻﺑ
 دﺋﺎﻗ_ﺎﻧا# ﺔﺑﺳﺎﻧﻣﻟا#AntibioticResistance
Dear nurse, the most important factor to
detect antibiotic sensitivity in blood cultures
is the volume of blood drawn #I_am_a
_Steward #AntibioticResistance
 تادﺎﺿﻣﻟا ﺔﯾﺳﺎﺳﺣ فﺎﺷﺗﻛﻻ مھﻻا لﻣﺎﻌﻟا ،ضرﻣﻣﻟا يزﯾزﻋ
 دﺋﺎﻗ_ﺎﻧا# بوﺣﺳﻣﻟا مدﻟا ﺔﯾﻣﻛ وھ مدﻟا ﺔﻋرزﻣ ﻲﻓ ﺔﯾوﯾﺣﻟا
#AntibioticResistance
Dear nurse, draw blood specimen for
antibiotic sensitivity before administering
any antibiotics #I_am_a _Steward
#AntibioticResistance
 ﺔﯾﺳﺎﺳﺣﻟ ﺔﺻﺻﺧﻣﻟا مدﻟا ﺔﻧﯾﻋ بﺣﺳا ،ضرﻣﻣﻟا يزﯾزﻋ
 ضﯾرﻣﻠﻟ يوﯾﺣ دﺎﺿﻣ يأ ءﺎطﻋإ لﺑﻗ ﺔﯾوﯾﺣﻟا تادﺎﺿﻣﻟا
 دﺋﺎﻗ_ﺎﻧا##AntibioticResistance
A timeline of the key steps of the ASP adoption and implementation phases at
the medical city are summarised in Figure 6.5.
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Figure 6.5: A timeline of the major steps of the ASP adoption and
implementation phases at the medical city
6.3.3 Characteristics of the ASP at the medical city
A) ASP core members and their roles at the medical city
The core members of the ASP at the medical city constituted of an ID consultant
and specialists, antimicrobial lead pharmacist and clinical pharmacists,
consultant clinical microbiologist and infection control consultant. Each team
member has a specific role, and they work in cooperation with each other.
''The team of the antimicrobial stewardship program is the ID who is the
chairman, the clinical pharmacist the coordinator, other clinical
pharmacists…...ah we have microbiology specialist, she's consultant, we have
infection control doctor'' (Clinical pharmacist 1)
Infectious diseases consultant and specialists:
The ID consultant is the chairman of the ASP committee and director of the
ASP, he discusses ASP progress and needs with higher authorities. The ID
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specialists review antimicrobial therapy during ward rounds and give
recommendations on appropriate antimicrobial therapy.
''As an ID consultant, we review everyday forms. So, any antibiotic restricted
prescribed, we go and review the form then we go back to the patient file and
check why this patient is using this antibiotic, if we couldn't find anything on
the file, we call the prescriber, discuss with them what's the justification of
using restricted antibiotic, if there's no justification, we'll just restrict this
antibiotic then they will choose or deescalate to another antibiotic'' (Infectious
diseases consultant 1)
Antimicrobial lead pharmacist and other clinical pharmacists:
Antimicrobial lead pharmacist is the manager of the ASP, receives and reviews
daily reports for patients on antibiotics. Other clinical pharmacists review
antimicrobial therapy during ward rounds and provide recommendations for ID
physicians.
''I review patients who are new or old and then if it's new, I will try to find the
restriction form, if for some reasons, it was missed, I will communicate with
the pharmacy, I will communicate with the nursing with the physician to write
the restriction form'' (Clinical pharmacist 1)
Consultant clinical microbiologist:
The consultant clinical microbiologist produces yearly antibiogram, Cascade
reporting, daily reports about positive cultures, and sends them to ID
physicians, clinical pharmacists and infection control practitioners.
''So as the microbiologist here, we generate the antibiotics susceptibility test
for the organisms isolated from clinical specimens, and then we release it on
the hospital information system. I send an email at the end of the day with all
the positive cultures that we have reported that day'' (Consultant clinical
microbiologist 1)
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Infection control consultant:
The Infection control consultant monitors healthcare-associated infections
(HAIs) rates, rates of infections, Incident rates of MDROs, shares and
discusses the data with other staff and committee's members.
''As an infection control, we are mainly monitoring healthcare associated
infection rates, we see the incidence rates of different multidrug resistant
organisms, like the MRSA, VRE, carbapenem resistance, etc'' (Infection
control consultant 1)
B) ASP strategies at the medical city
Evidence based guidelines are used in the medical city to ensure safe practice
and positive outcomes. Strategies employed are based on the IDSA and CDC
guidelines (Centers for Disease Control and Prevention, 2014; Dellit et al.,
2007) as described in the quotes below:
''We followed the IDSA guidelines for antimicrobial stewardship and also
CDC'' (Clinical pharmacist 1)
The two core strategies (restriction and preauthorisation, and prospective audit
with intervention and feedback) of ASPs are implemented. A list of restricted
antimicrobials was developed based on local antibiogram and MDROs
surveillance reports. A sample of antibiotic restriction form and the process of
authorisation and approval of restricted antibiotics are provided in Figures 6.6
and 6.7 respectively. Prospective audit of antimicrobial use with direct
interaction and feedback to the prescriber is performed by either an infectious
diseases physician or a clinical pharmacist with infectious diseases training.
This is integrated with the formulary restriction at the medical city, where the
infectious disease physician and the assigned pharmacists are always in
contact with the medical team regarding patients on antibiotics. The assigned
pharmacists are responsible for documenting the daily follow ups or
recommendations on the patients' files under the title: “ASP Pharmacy
Assessment”.
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The main supplemental ASP strategy employed at the medical city is education
and seen as a fundamental component for ASP success at the medical city.
The purpose of the participation in the Antibiotic Stewardship Program
Awareness Week that was conducted at the medical city was to fulfil this
component of ASP, with the intention of making all the medical city staff
participate actively in the ASP. ASP core members launched a campaign titled:
“I am a Steward”. The medical city staff were requested to visit the campaign’s
booth to sign up and become a “STEWARD”. Other supplemental strategies
include: guidelines and clinical pathways, streamlining or de-escalation of
therapy, dose optimisation/adjustment and parenteral to oral conversion.
''So, restriction policy, this is of course the main thing, and then we added the
prospective audit and feedback. Also, the pharmacy regarding the dosing, so,
this is dose optimization. …. then we also thought about the guidelines.… ''
(Clinical pharmacist 1)
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PATIENT LABEL
ANTIMICROBIAL RESTRICTION FORM
Date: Unit:
FILLED BY PHYSICIAN
Ordering Physician:
Contact Number:
ID Number:
Signature (or stamp):
Culture withdrawn BEFORE antimicrobials therapy:
□ Yes □ No Date:
Culture withdrawn AFTER antimicrobials therapy:
□ Yes □ No Date:
Restricted Antimicrobial
□ Teicoplanin □ Voriconazole
□ Linezolid □ Posaconazole
□ Tigecycline □ Caspofungin
□ Meropenem □ Micafungin
□ Imipenem □ Anidulafungin
□ Amikacin □ Amphotericin B
□ Colistin
Date Hospital of Admission:
Indication (please specify infection SOURCE)
Justify not using narrower spectrum of activity
Prescribing Rational
□ Pathogen-directed therapy
□ Empiric therapy
□ Prophylaxis
Estimated Duration of Therapy:
Contact ID Bravo for approval “0515165026 ”
ID Physician Approval Status
□ Approved □ ID was not contacted
yetFILLED BY PHARMACIST
Pharmacist:
Dose Concurrent Antimicrobials (other than
restricted):
Pharmacist Comments
Culture
Source
Date Organism Comment
Labs
Tmax within 48 hours: UA:WBC:
Neutrophil:
ProCT:
CXR:
FILLED BY INFECTIOUS DISEASE PHYSICIAN
ID Physician:
ID Physician Recommendations and Rationale
□ Approved □ Not Approved
Re-evaluation of approval for the restricted antimicrobial after ………. Days
Comments:
Figure 6.6: The medical city antimicrobial restriction form (The medical city,
2016)
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Figure 6.7: Antimicrobial Restriction Workflow at the medical city
Ordering physician
 Fill out the antimicrobial restriction form
 Deliver the form to pharmacy ASAP
 Order restricted antibiotic for the
estimated duration of therapy
 Contact ID for approval
Assigned pharmacist
 Review and complete the form no later than 18
hours after the pharmacy has received the form
 Deliver the form to the ID consultant
 ID will review forms by 9:30 am and 2 pm
ID specialist
• Review the form/order and reach a decision
before order expiration
• Contact the ordering physician to discuss the
case (if ID was not contacted before)
• If no response from the ordering physician,
ID will contact the pharmacy to follow up with
the ordering physician
• ID can decide if a formal consultation is
required for approval
Assigned Pharmacist
• If ID approved, make sure that the duration of order
matched the duration of therapy approved by ID.
• If ID did not approve the restricted antibiotic after 24
hours during weekdays and after 72 hours if ordered
on Thursday after 12 pm, hold restricted antimicrobial
agent and inform physician
• If ID is not available, continue the order until ID can
review it.
• Re-assess the patient daily for dose adjustment, de-
escalation or adverse drug reaction
• Document recommendation in the patient file, if
applicable
• Sign off on the patient whenever the restricted
antimicrobial is discontinued
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C) Expected outcomes of the ASP at the medical city
The expected outcomes of the ASP at the medical city are to reduce rates of
AMR, MDROs, inappropriate antimicrobial use, and expenditure of
antimicrobials. Quotes from some participants regarding expected ASP
outcomes at the medical city are shown below:
''…...the goal was to reduce the consumption of antibiotics ….'' (Consultant
clinical microbiologist 1)
''We measure it by DOT, …. second, is antibiogram and patient outcome is
the most important, and also cost'' (Infectious diseases consultant 1)
The medical city achieved the expected results of the ASP intervention
including reduction of resistance rates through the increase of Enterobacter
spp. isolates susceptibility to cefepime from 39% (19/48) in 2015 to 66% (35/53)
in 2016 and to piperacillin/tazobactam from 48% (23/48) to 64% (34/53).
A.baumanni isolates susceptibility also increased to colistin  from 69% (62/90)
to 97% (78/80) and to trimethoprim/sulfamethoxazole from 32% (29/90) to 62%
(50/80). E.coli isolates susceptibility increased to piperacillin/tazobactam from
47% (129/274) to 77% (242/314). S.aureus isolates susceptibility to
clindamycin increased from 45% (50/112) to 76% (91/120). A summary of the
increased rates of bacterial isolates susceptibility to some antibiotics due to
ASP are summarised in Table 6.3.
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Table 6.3: A summary of rates of bacterial isolates susceptibility to some antibiotics in the medical city for 2015 and 2016
Antimicrobial agents
Piperacillin/
tazobactam
Colistin Trimethoprim/
sulfamethoxazole
Cefepime Ciprofloxacin Gentamicin Clindamycin
Bacterial isolates 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016
E. coli (percentage
susceptible/number
of isolates)
47%
(129/274)
77%
(242/314)
37%
(101/274
40%
(126/314
45%
(123/274
48%
(151/314
33%
(90/274)
36%
(113/314
71%
(194/274
65%
(204/314
A.baumannii 69%
(62/90)
97%
(78/80)
32%
(29/90)
62%
(50/80)
28%
(25/90)
22%
(18/80)
20%
(18/90)
22%
(18/80)
24%
(22/90)
34%
(27/80)
Enterobacter spp. 48%
(23/48)
64%
(34/53)
52%
(25/48)
72%
(38/53)
39%
(19/48)
66%
(35/53)
60%
(29/48)
75%
(40/53)
56%
(27/48)
79%
(42/53)
S. aureus 86%
(96/112)
94%
(112/120
62%
(69/112)
75%
(90/120)
75%
(84/112)
86%
(103/120
45%
(50/112)
76%
(91/120)
S.epidermidis 39%
(34/86)
58%
(52/89)
20%
(17/86)
20%
(18/89)
46%
(40/86)
53%
(47/89)
MRSA 47%
(22/47)
69%
(35/51)
55%
(26/47)
71%
(36/51)
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In addition, the implementation of the ASP reduced the consumption of all
antimicrobials (Tigecycline, Colistin, Meropenem and Imipenem) by 18.9% (Table
6.4) as the total consumption of all antimicrobials (Tigecycline, Colistin,
Meropenem and Imipenem) for the 6 months period between 07-12/2015 (before
the implementation of the ASP) (Table 6.5) was 7,773.5 Days of Therapy (DOT)
and decreased to 6,305.1 DOT for the 6 months period between 01-06/2016
(Table 6.6) (after the implementation of the ASP).
Table 6.4: Antimicrobials consumption before and after the implementation of the
ASP at the medical city
Table 6.5: Antimicrobials consumption before the implementation of the ASP (07-
12/2015)
Medication Total DOT (07-12/2015)
Before ASP
Total DOT (01-06/2016)
After ASP
Tigecycline 1,039.8 624.5
Colistin 2,080.9 1,417.2
Meropenem 2,287.2 2,597.3
Imipenem 2,365.6 1,666.1
TOTAL 7,773.5 6,305.1 (-18.9%)
Unit Medication DOT
07/2015
DOT
08/2015
DOT
09/2015
DOT
10/2015
DOT
11/2015
DOT
12/2015
Total DOT
(07-
12/2015)
ICU Tigecycline 277.5 142.4 162.3 201.2 174.4 38.5 996.3
Colistin 197.2 238.9 201.2 402.3 302.4 214.3 1,556.3
Meropenem 137.9 110.3 258.1 421.4 176.0 252.7 1,356.4
Imipenem 347.3 237.4 271.9 145.4 284.8 139.2 1,426
Haematology Tigecycline 0.0 0.0 0.0 0.0 0.0 37.4 37.4
Colistin 0.0 56.3 0.0 168.8 123.4 51.6 400.1
Meropenem 38.5 56.3 134.7 168.8 123.4 338.1 859.8
Imipenem 170.7 146.4 36.5 18.1 26.8 122.8 521.3
Oncology Tigecycline 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Colistin 5.0 0.0 8.3 34.5 15.7 7.3 70.8
Meropenem 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Imipenem 67.3 80.1 111.7 44.5 36.9 19.3 359.8
CCU Tigecycline 0.0 0.0 0.0 1.5 0.0 4.6 6.1
Colistin 3.6 2.0 0.0 1.5 14.3 32.3 53.7
Meropenem 1.8 13.8 0.0 1.5 1.6 52.3 71.0
Imipenem 0.0 2.0 6.5 3.0 27.0 20.0 58.5
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Table 6.6: Antimicrobials consumption after the implementation of the ASP (01-
06/2016)
This study also assessed patients' experience of antibiotic use during their
hospital stay in order to evaluate the institutional role of patients' education as
part of ASP. A total of 74 responses were analysed. Participants characteristics
includes; 62% (46/74) of participants were male and 38% (28/74) were female,
46% (34/74) of participants were between the age of 21 and 30 years, and 48.6%
(36/74) of participants hold bachelor degrees. Table 6.7 highlights the use of
antibiotics by patient during hospital stay.
Table 6.7: Patients’ use of antibiotics during hospital stay (N = 74)
Statement
Relative Frequency
Distribution
M
ean
Standard
D
eviation
Agree
%
D
o not
Know
%
D
isagree
%
F1- My doctor/pharmacist told me that I am being
treated with antibiotics. 12.16 8.11 79.73 1.32 0.68
F2- I was told about how to take the antibiotic. 77.03 5.41 17.57 2.59 0.77
F3- This hospital is strict when it comes to
prescribing antibiotics. 39.19 37.84 22.97 2.16 0.78
F4- This hospital provides information on
antibiotic resistance. 27.03 22.97 50.00 1.77 0.85
Unit Medication DOT
01/2016
DOT
02/2016
DOT
03/2016
DOT
04/2016
DOT
05/2016
DOT
06/2016
Total DOT
(01-
06/2016)
ICU Tigecycline 243.1 87.6 91.3 85.1 65.0 0.0 572.1
Colistin 432.7 294.2 214.1 135.2 99.1 31.3 1,206.6
Meropenem 539.7 403.8 179.6 148.6 82.1 0.0 1,353.8
Imipenem 267.4 78.2 202.1 203.7 338.5 0.0 1,089.9
Haematology Tigecycline 0.0 37.5 0.0 0.0 0.0 0.0 37.5
Colistin 33.9 42.2 40.2 21.9 0.0 0.0 138.2
Meropenem 299.4 121.8 85.4 255.5 54.7 0.0 816.8
Imipenem 113.0 0.0 72.9 21.9 189.1 0.0 396.9
Oncology Tigecycline 0.0 10.3 4.6 0.0 0.0 0.0 14.9
Colistin 16.9 9.3 9.1 31.7 2.8 2.6 72.4
Meropenem 45.0 79.4 47.5 132.4 0.0 0.0 304.3
Imipenem 33.7 0.0 26.5 17.3 72.6 0.0 150.1
CCU Tigecycline 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Colistin 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Meropenem 57.9 33.9 19.3 0.0 11.3 0.0 122.4
Imipenem 0.0 0.0 16.1 13.1 0.0 0.0 29.2
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F5- My hospital stay improved my awareness of
antibiotic resistance. 36.49 18.92 44.59 1.92 0.90
The findings indicate that 77% of patients had been informed about how to take
their antibiotic. Around, 40% of patients agreed that the hospital is strict when it
comes to prescribing antibiotics. However, 80% of patients agreed that their
doctors and pharmacists did not tell them that they were treated with antibiotics.
Only 27% of patients believed that they received information about antibiotic
resistance during their hospital stay. Similarly, 36.5% showed that their hospital
stay did not improve their awareness of antibiotic resistance.
6.3.4 Facilitators to the successful adoption and implementation of ASP at
the medical city
Data regarding the factors that enhanced successful implementation and barriers
to the smooth running of the ASP in the medical city were categorised into one
main theme (Characteristics of the healthcare organisation) using the innovation
within the healthcare organisations model (Fleuren et al., 2014, 2004) described
in page 80. Subthemes were developed from the codes.
Subthemes of the factors that enhanced successful adoption and implementation
included; administrative support, collaboration between staff/departments and
reinforcement management.
Administrative support
Hospital leadership commitment and support was reported by participants (4/5)
as one of the most critical determinants that facilitated ASP adoption and
implementation in the medical city.
''There is a lot of commitment from the administration and the leadership''
(Clinical microbiologist 1)
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''The CEO himself was the one insisted that we have to start antimicrobial
stewardship up and running within one month. He said, "I want the policies to be
ready, I want the project portfolio to be ready". Here, it was very good
administrative support to be honest with you'' (Clinical pharmacist 1)
Collaboration between staff/departments
Participants (5/5) reported that inter-professional and interdepartmental
collaboration and communication as a key facilitator for the successful adoption
and implementation of ASP. This was evident from the following viewpoints:
''There is good communication….so usually pharmacy will call us then we get
the form, in the form also we added the prescriber name, with phones, with
contact so we can communicate easily'' (Infectious diseases consultant 1)
''But now we are one team, we have group in WhatsApp and it's named
antimicrobial stewardship and we follow our patients there'' (Clinical pharmacist
1)
Reinforcement management
Participants (5/5) reported that formal reinforcement by management to adopt and
implement ASP facilitated the process of ASP implementation. Some of the
quotes in support of this included:
''When we were talking about antibiotic stewardship, the idea was to be one of
the projects under the program of medication, but I told them no, it needs to be
done, antibiotic stewardship, independently, I mean stands out, to be very
obvious and very evident'' (Chief executive officer 1)
''I think it’s only about enforcement about this programme that it has to be done.
It has to be done this way, it has to be done within this time frame. This is all
that we really needed'' (Clinical pharmacist 1)
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Although ASP has been successfully adopted and implemented at the medical
city, certain factors impede the smoothing of the programme, including financial
resources, IT resource and staff capacity.
Financial resources
Lack of financial resources was reported by some participants (3/5) as a barrier
that prevented recruitment of more ID consultants and lack of some microbiology
kits as shown in the quotes below:
''the recruitment, we had problems with financial supporting and recruiting more
IDs, recruiting more people'' (Clinical pharmacist 1)
''We all know that there is financial constraint currently and even some basic
items we are not getting regularly'' (Clinical microbiologist 1)
Resources (IT)
Inefficient IT system prevented smooth running of the programme (4/5). In
particular, the available system does not allow adequate and effective data
collection as reported below:
''…. the health information system in the hospital was not supported enough and
until now, we have this problem of getting accurate data from the system. So, a
lot of our data collected manually, it takes a lot of time and man power''
(Infection control consultant 1)
''We have some limitations in the electronic medical system or HIS (Healthcare
Information system), that it cannot be generated automatically, they have to do it
manually'' (Clinical pharmacist 1)
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Staff capacity
Inadequate number of staff (including ID consultants, clinical pharmacists and
clinical microbiologists) was reported by participants (3/5) as a factor that is
preventing smooth running of the ASP.
''If we talk about numbers, we don’t have, we are working with one ID
consultant, and four assistants only'' (Infectious diseases consultant 1)
''One of the biggest problems that we had, and we still I think struggle with, this
the microbiology lab, our microbiology lab has only one clinical consultant,
clinical microbiologist'' (Clinical pharmacist 1)
6.4 Discussion
To my knowledge this is the first case study to explore the process of adoption
and implementation of an established ASP in a Saudi MOH hospital. In order to
promote adoption and implementation of ASPs, governmental and professional
bodies have produced guidelines to help hospitals (Barlam et al., 2016; Centers
for Disease Control and Prevention, 2014; Dellit et al., 2007; Duguid &
Cruickshank, 2011; National Institute for Health and Care Excellence, 2015;
Public Health England, 2015b). These guidelines outline the basic elements that
make a good ASP.
Findings of this study indicated that ASP in the medical city resides within the
patient safety governance (patient safety portfolio). The IDSA/SHEA (Dellit et al.,
2007) and Australian (Duguid & Cruickshank, 2011) guidelines recommend that
ASP resides within the hospital’s quality improvement and patient safety
governance structure and be included within the hospital’s quality and safety
strategic plan. Inclusion of ASP in the patient safety portfolio showed that the
medical city is in line with the global recommendations.
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Successful implementation of ASP relies on a stewardship team or committee.
The IDSA/SHEA guidelines (Dellit et al., 2007) as well as the other guidelines
recommend establishment of a multidisciplinary team. Adoption and
implementation of ASP in the medical city began with a review and
recommendations from ID pharmacist on how to establish ASP followed by
formation of multidisciplinary team. Composition of team and stewardship
strategies employed is in line with the recommendations of the IDSA/ SHEA and
CDC guidelines.
The primary goals of ASPs are to improve patient outcomes and minimise
unintended consequences of antibiotic use, including development of resistance
and C. difficile infection (Dellit et al., 2007). Outcomes that have been used to
assess the effectiveness of ASPs include antibiotic consumption in Defined Daily
Dose (DDD) (''the assumed average maintenance dose per day for a drug used
for its main indication in adults'') (World Health Organisation, 2003) or DOT
(number of days that patient receives at least one dose of an antibiotic summed
for each antibiotic), rates of resistant bacteria and C. difficile, antimicrobials
expenditures, length of hospital stay and rate of readmission (Aldeyab et al., 2012;
Bartlett & Siola, 2014; Martin et al., 2005; Yam et al., 2012). In line with
recommendations for hospitals to monitor their antimicrobial stewardship
activities, the stewardship team in the medical city monitors antibiotic
resistance/rates of MDROs through the hospital anti-biogram, consumption of
antimicrobials through the monthly reports in DOT, and cost savings of
antimicrobials through the pharmacy financial reports. The ASP team decided to
exclude C. difficile infection as an outcome of the ASP from their policy. This is
because Saudi Arabia including the medical city has a very low incidence of C.
difficile infection that can be considered not significant (Al-Tawfiq & Abed, 2010;
Shajan, Hashim, & Michael, 2014). The medical city achieved the expected
results of the ASP intervention. Also, the implementation of the ASP reduced the
consumption of all antimicrobials. The ASP outcomes reported in this study are
in line with the findings of previous studies (Al-Tawfiq et al., 2015; AlAwdah et al.,
2015; K. a. Cairns et al., 2013; Jenkins et al., 2015; Vettese et al., 2013).
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Patients’ experience of antibiotic use during their hospital stay was also assessed
in order to assess the institutional role of patients' education as part of ASP. The
findings indicate that patients did not receive enough information about antibiotics
use and risks of resistance during their stay in hospitals. Further research is
required to evaluate and compare the situation with hospitals without ASPs to
measure if there are any significant differences between hospitals with ASPs and
hospitals without ASPs.
This study identified a number of facilitators that enabled the medical city to adopt
and implement ASP successfully. These included strong administrative support,
reinforcement management, and inter-professional collaboration and
communication. The responsibility for ensuring adoption and implementation of
ASPs lies with the hospital administration. Consequently, ASPs guidelines
(Centers for Disease Control and Prevention, 2014; Dellit et al., 2007; Duguid &
Cruickshank, 2011; National Institute for Health and Care Excellence, 2015)
recommend hospital administration should provide dedicated resources needed
for stewardship activities.
Seven key elements were identified as important factors for the successful
implementation of ASP in a multi-site NHS Trust (Cooke, Franklin, Lawson,
Jacklin, & Holmes, 2004); which also accounted for the successful
implementation of ASP in the medical city. One of the elements described was
strong leadership. In that Trust, the authors reported that medical director
endorsed the existence of the antibiotic stewardship steering committee and
supported its work, including authorising the committee to review antibiotic use
and implement new initiatives on behalf of the Trust. In this study, participants
reported the CEO of the hospital was the driving force behind the implementation
of the ASP in the medical city. Apart from giving directives for implementation of
the programmes, the CEO took the lead and participated in weekly patient safety
rounds that included questions about antibiotic prescribing.
The second element reported by (Cooke et al., 2004) was dedicated individuals
with responsibility for leading on antibiotic use. In the medical city, members of
the ASP team have specific responsibilities. The chairman of the team (ID
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consultant) for example, liaises with hospital administration regarding the
progress and needs of the programme; the lead clinical pharmacist as well as
other clinical pharmacists carries out daily review of patients on antibiotics, while
the consultant clinical microbiologist produces yearly antibiogram, cascade
reporting, and daily reports about positive cultures. Although members of the
team have specific role and responsibilities, they work collaboratively to ensure
success of the programme.
The third element that was important for successful implementation of ASP in the
multi-site NHS Trust was integration into pre-existing structures within the trust,
in their case, the Drugs and Therapeutics committee. The English stewardship
guideline (Start Smart, then Focus) recommends antimicrobial stewardship
activities should be reported to the hospital board through Director of Infection
Prevention and Control or the Drugs and Therapeutic Committee (Public Health
England, 2015b), while IDSA/SHEA  and Australian guidelines recommend that
ASP resides within the hospital’s quality improvement and patient safety structure
(Dellit et al., 2007; Duguid & Cruickshank, 2011). In the medical city, ASP resides
within an existing hospital structure, the patient safety portfolio, adoption and
implementation progress of the ASP was reported to the patient safety committee,
while outcomes and updates are discussed with the pharmacy and therapeutic
committee. Integrating ASP within an existing structure ensures accountability
and efficiency.
The fourth element the authors reported was important to their success was
education and training. The medical city team embarked on a massive
educational campaign (through workshops, posters, grand rounds, presentations,
brochures, newsletter, social media) to create awareness of antibiotic resistance
and the role of antimicrobial stewardship in controlling resistance. Education and
training is a persuasive or passive antimicrobial stewardship strategy that has
been shown to independently increase compliance with antibiotic policies, and
enhance the effect of restrictive strategies (Davey et al., 2017).
Another element reported was harnessing of existing resources (senior registrars)
to obtain desired results. In the medical city, other clinical pharmacists and ID
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specialists who were not necessarily core members of the ASP team were actively
involved in antibiotic review and referrals to ID consultant when a restricted
antibiotic is prescribed. Lack of ownership has been reported as one of the
barriers to the implementation of ASPs (Pakyz et al., 2014), harnessing of existing
resources ensures ownership of the programme among different healthcare
professional.
(Cooke et al., 2004) also reported communication and obtaining local data on
prescribing patterns and resistance were key elements of their programme.
Although ASP in the medical city is relatively new, the stewardship committee
aims to monitor antibiotic resistance rates as consumption of antimicrobials as
outcomes of their programme. While ASP has been successfully implemented in
the medical city, a number of factors however inhibit the smooth running of the
programme, principal of which are inefficient IT resources, funding and staff
constraints.
The medical city's ASP model closely resembles the model described by (Cooke
et al., 2004). Saudi MOH hospitals without ASPs could therefore emulate the
example set by the medical city, or as suggested by participants of the study in
Chapter four, hospitals planning to start the programme can send their staff to
understudy the medical city model. While this could enhance adoption and
implementation of ASPs in such hospitals, hospital administrators of such
hospitals must also take note the factors that prevent the smoothing running of
the programme.
6.4.2 Implications for practice
The information acquired in this research is vital in understanding the adoption
and implementation process of ASP in a healthcare facility in Saudi Arabia in order
to promote and spread ASPs in Saudi hospitals. It gave an insight on how
adoption and implementation barriers can be overcome, in order to adopt and
implement the national ASP policy easily and successfully, and improve
antimicrobial practice, reduce antimicrobial resistance and improve patients care.
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6.5 Conclusion
The objective of this case study was to explore the adoption and implementation
process of an established ASP (initiation, adoption decision, implementation) in a
Saudi MOH hospital that can serve as a model or preceptor for MOH hospitals
without ASPs. Leadership support was identified as one of the main drivers to
facilitate the adoption and implementation process of ASP at the medical city,
through providing required human, financial and IT resources and by including
the ASP duties in the daily tasks and annual evaluation reports of related staff.
The availability of experts in antimicrobial use and ASPs was vital in developing
and running of the program, monitoring and reporting outcomes and educating
and training other healthcare workers. Education and training through different
approaches showed a big impact on ASP progress and was one of pillars of the
medical city strategy at the start of the ASP adoption process. Moreover, following
evidence-based guidelines that have been developed by leading institutions was
key to the successful ASP adoption and implementation at the medical city.
Training and residency programs for different health specialities are really
important and there are big demands by healthcare professionals to increase the
number of these programs to increase the learning chance and improve
healthcare services.
This chapter and previous chapters (four & five) explored and investigated the
situation of ASPs in Saudi MOH hospitals from the point of view of healthcare
professionals, and it was emphasised by number of participants that there is poor
knowledge and practice among some patients regarding antimicrobial use and
resistance. Also, in this chapter (six), patients experience of antibiotic use during
their hospital stay were assessed in order to evaluate the institutional role of
patients' education as part of ASP. Therefore, the next chapter evaluated patients'
knowledge and perceptions on antimicrobial use and resistance in a Saudi MOH
hospitals with ASP and in a Saudi MOH hospital without ASP.
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Chapter 7: knowledge and Perceptions regarding antimicrobial
use and resistance among adult hospital patients in Saudi MOH
hospitals
7.1 Introduction
The rise in AMR has been recognised as a major public health problem that
threatens effective prevention and treatment of infectious diseases (World Health
Organisation, 2014). Inappropriate use of antimicrobials has been identified as
one of the main driver of AMR (Laxminarayan et al., 2013). The UK National
Institute for Health and Care Excellence (NICE) defines inappropriate
antimicrobial use as “the way in which people may misuse antimicrobials that they
have been prescribed or supplied with, and which may result in the antimicrobials
becoming ineffective in treating infections” (National Institute for Health and Care
Excellence, 2017).
An earlier study assessing knowledge, behavior and attitude toward antibiotics
use among adult Jordanians identified the different ways people misuse
antibiotics. These included using antibiotics for treatment of common cold and
cough, using antibiotics as analgesics, keeping antibiotics at home for emergency
use, use of antibiotics as prophylaxis against infections, use of left-over antibiotics
without physicians’ consultation, and use of antibiotics based on a relative advice
(Shehadeh et al., 2012). Patients’ and public misuse of antimicrobials therefore is
a major driving force in development of AMR. This has led to international and
national campaigns (Antibiotic Awareness Week) to raise public and professional
awareness of AMR (Earnshaw et al., 2009; World Health Organisation, 2015c).
In Chapter four of this thesis, it was found that patients were quick to demand,
and insistent on having antibiotics prescribed for treatment of common cold or
sore throat; and would often not complete the course of prescribed antibiotic. The
objective of this study therefore is to assess patients' knowledge and perceptions
of antimicrobial use and resistance to evaluate the institutional role of patients'
education about appropriate antimicrobial use. This chapter will answer the
following research questions:
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1. What are the patients' knowledge and perceptions regarding antimicrobial
use and resistance in Saudi MOH hospitals?
2. What is the difference between patients' knowledge and perceptions
regarding antimicrobial use and resistance in a hospital with ASP and a
hospital without ASP?
7.2 Methods
7.2.1 Design
To achieve the objective of this study, a cross-sectional self-administered survey
was used.
7.2.2 Development and source of the survey
The questionnaire statements (Appendix 15) were adapted from validated tools
(André, Vernby, Berg, & Lundborg, 2010; Awad & Aboud, 2015; Oh et al., 2011),
and following a comprehensive review of the literature and discussion among the
researcher and supervisory team. The survey has two main sections, which
primarily consist of closed questions. Firstly, is a section on background
information (four questions), including hospital, gender, age and level of
education. Secondly, Likert-type statements on knowledge and perceptions
regarding antimicrobial use and AMR to address: access to antibiotics (three
items), effect of antibiotics (six items), antibiotic resistance (six items), doctor's
habits and patient/doctor relationship (six items) and patients' use of antibiotics
during hospital stay (five items).
The items in each domain were adapted from validated tools and following
discussions among the researcher and supervisory team. Questions one, two,
three, B1, C1, C2, C5 and C6 were adapted from (André et al., 2010; Awad &
Aboud, 2015; Oh et al., 2011). Questions B2, B4, C3, C4, D2 and D4 were
adapted from (Oh et al., 2011). Questions B3, E1 and E2 were adapted from
(André et al., 2010; Awad & Aboud, 2015). Question D1, D6, E3 and E4 were
adapted from (Awad & Aboud, 2015). Questions D3, D5, E5, E6, F1-F5 were
developed by the researcher and supervisory team.
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All questions were then reviewed by the researcher and supervisory team and
checked by two ASPs pharmacists from Saudi and one ID consultant from Saudi.
The survey was developed in English (Appendix 15) and then translated into
Arabic (Appendix 16) through a forward and backward translation process. The
researcher translated the survey from English to Arabic. Then, two independent
researchers, who are bilingual (Arabic/English) speakers, translated back the
survey to English. Both Arabic and English versions of the survey were compared.
Any discrepancies were resolved through discussion between the three
researchers.
The survey consisted of five sub-scales based on a three-point Likert scale,
ranging across Agree=1, neither disagree nor agree=2 and Disagree =3. There
were eleven negative statements in this survey. The remaining items (15) were
positive. The total number of items in the five sub-scales was 26. Furthermore,
two items were designed to check the reliability of the participants. These were:
‘If a family member is sick, I will give him/her my antibiotic’ and ‘I will give my
antibiotic to a family member if needed’.
The indications drawn from the direction of scores across the five sub-scales are
as follows: whenever the survey scores increased, this meant that patients’
knowledge and perceptions regarding antimicrobial use and resistance was high
and the institutional role of patients’ education was active and good. In contrast,
if the scores decreased, this meant that the knowledge and perceptions of
patients towards antimicrobial use and resistance was low and the institutional
role of patients’ education was negative and poor.
The participants required about 15 minutes to complete this survey. The
researcher set the mean of the total perspectives of the knowledge and perception
of patients towards the antimicrobial use and resistance in Saudi MOH hospitals
at 52.46. Those with positive and good knowledge and perception towards ASPs,
the ‘agreement/positive group’, were above the mean of 52.46, while those with
negative knowledge and perception, the ‘disagreement/negative group’, were
below the mean.
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7.2.3 Pilot study of the instrument
The survey was piloted with a number of patients representing two hospitals, one
with ASP and one without ASP. Appropriate changes were made in accordance
with participants’ feedback to optimise the research tool. The purpose of a pilot
study is primarily to identify the degree of validity and reliability of a research
instrument. Validity and reliability are vital components of quantitative and
qualitative research (L. Cohen et al., 2000). In the present study, a pilot study was
carried out with 52 patients from the two hospitals. A total of 52 responses were
analysed, 57.7% (30/52) responses were from the hospital without ASP and
42.3% (22/52) were from the hospital with ASP. Participants characteristics
includes 59.6% (31/52) of participants were male and 40.4% (21/52) were female,
44.2% (23/52) of participants were between the age of 21 and 30 years, and
57.7% (30/52) of participants hold bachelor degrees.
7.2.4 Validity of the questionnaire
The following steps were taken to ensure validity of the questionnaire (Bowling,
2009; Smith, 2002):
a) Face validity: the questionnaire statements were checked by the
researcher and the supervisory team to ensure their relevance;
reasonability and that no ambiguity exists.
b) Content validity: two ASP pharmacists (from Saudi Arabia) and one ID
consultant (from Saudi Arabia) checked the content of the questionnaire
to ensure that the content of the instrument is logical and easy to
understand.
c) Discriminant validity: A T-test was conducted to allow comparison of the
scores and determination of the mean scores. The T-test confirmed that
the survey could successfully differentiate participants’ positive and
negative perspectives regarding antimicrobial use and resistance in Saudi
hospitals. The researcher reviewed the results to identify any significant
differences between patients’ good and positive knowledge and
perceptions towards antimicrobial use and resistance in Saudi MOH
hospitals who scored highly (M: 66.00, SD: 2.209, N=26) and those who
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recorded low scores (M: 46.12, SD: 4.376, N=26) in relation to the
questionnaire scores (t = (20.68), p=0.000). The review allowed the
researcher to categorise participant responses. By conducting a visual
inspection of the total low and high survey scores reported by the study
participants, a cut-off score was determined. This score was necessary to
identify participants’ positive and negative views towards antimicrobial use
and resistance. A high score indicated that the patients had a positive
knowledge and perception towards antimicrobial use and resistance. In
contrast, a low score indicated that the patients had a negative knowledge
and perception towards antimicrobial use and resistance.
d) Internal Consistency: the correlation test will show whether there is a
significant correlation between the sub-scales of the survey in relation to
each other and the overall score of the survey as highlighted in Table 7.1.
Table 7.1. Pearson correlation between the summations of dimensions and the
total score of the survey (N: 52)
** Pearson correlation is significant at the 0.01 level (two-tailed).
The results of the analysis of patients’ perspectives on antimicrobial use and
resistance revealed that the sub-scales from (1) -(5) had a significant and strong
correlation between the dimensions of the survey with each other and with the
overall score of the survey between r≥0.28 and r=0.89, except one insignificant
correlation between effects of antibiotics (SS2) and doctors’ habits (SS4), which
was 0.25. This indicated a strong correlation in general between the summation
of each sub-scale and with the total score.
Sub-Scales SS1 SS2 SS3 SS4 SS5 Total
Access to antibiotics (SS1) - .559** .398** .286* .602** .743**
Effects of antibiotics (SS2) .559** - .320* .251 .662** .739**
Antibiotics resistance (SS3) .398** .320* - .308* .490** .695**
Doctors’ habits (SS4) .286* .251 .308* - .499** .636**
Patients’ use of antibiotics (SS5) .602** .662** .490** .499** - .890**
Total .743** .739** .695** .636** .890** -
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7.2.5 Reliability
The split-half method and the test-retest method were the two types of tests
performed to confirm reliability (Bowling, 2009). Several participants were
subjected to this test to make sure that the measure was stable over an interval
of time. The internal consistency of the tool was assessed via Cronbach’s alpha
test.
a) Split-half method: the split-half method divided the total items (26) into two
groups; the first group (13 items) was from B1-D4, and the second group
(13 items) was from D5-F5. A correlation was then applied between the
summations of both groups of the questionnaire. The results showed that
there were good correlations between group (a) (M: 27.10, SD: 5.710) and
group (b) (M: 28.96, SD: 5.924), where r=0.80, p<0.001, N: 52.
b) Test-re-test of the questionnaire: the survey was conducted again after 7
days among the same group (52 participants) who completed the survey
the first time. The results of the Pearson correlation test showed there was
a significant relationship between the first application (M: 56.06, SD: 10.61)
and the second application (M: 57.25, SD: 10.49) of the survey, such that
r=0.79, p<0.01, N=52. The results of this test indicated that the correlation
between the first and second survey performance was significant, whilst
also showing only a very small difference between the two performances,
meaning the survey had good reliability, making it suitable for the current
study.
c) Cronbach’s alpha: the Cronbach’s Alpha method was used to calculate the
reliability coefficients of all items in the survey. The results of this test
showed that Cronbach’s alpha coefficient (M: 56.06, SD: 10.61, N of items:
26) was sufficient at a level of 0.86 and the instrument thus provided an
acceptable degree of reliability.
7.2.6 Sampling, setting and size of participants
Purposive/ convenience sampling was the method of sampling for this study. The
two hospitals described below were selected to represent a MOH hospital without
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ASP and a MOH hospital currently adopting ASP, in an effort to capture a
representative sample of different hospital patients. These facilities can be
broadly classified as: a central hospital (380 beds) and a tertiary medical city
(1500 beds). All patients being treated with antimicrobials in medical departments
were targeted. Minor patients (under 21 years of age) and psychiatric patients
were excluded. A total of up to 200 participants were targeted from each hospital
comprising a total of 400.
7.2.7 Distribution method and data collection period
Invitation letters (Appendix 17) were given to targeted patients through the
antibiotic pharmacist at each hospital. These letters introduced the study with a
copy of the survey to complete. Data was collected from June to August 2017.
7.2.8 Data analysis
Data were coded, entered manually into Microsoft Excel 2016, and uploaded to
the SPSS database (Version 23; SPSS Inc., NY, USA). Descriptive analysis was
conducted to answer the research questions by using frequencies, percentages,
mean and standard deviation. The minimum significance level that was
considered in this part of the study was 0.05, thereby aiding in the determination
of whether the similarities or differences between variables were statistically
significant. In addition to the descriptive analysis, based on the distribution and
nature of the data and as the data is normally distributed (Kolmogorov-Smirnov=
0.047, p= 0.2, and Shapiro-Wilk= 0.985, p= 0.110), One-Way Anova analysis was
used to explore the differences between perspectives on antimicrobial use and
resistance (dependent variable) with the hospital type, age and level of education
of participants (independent variables). A T-test and correlations were used to
examine the validity and reliability of analysis.
7.2.9 Ethical considerations
Official permissions were obtained from the General Directorate of Health Affairs
in AlBaha (Appendix five), and from the medical city (Appendix 13). The
researcher obtained written consents (Appendix 18) from the participants and
provided a participant information sheet explaining the nature of the study and its
objectives (Appendix 19 & 20).
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7.3 Results
7.3.1 Demographics of respondents
Of the 400 distributed questionnaires, 176 responses were collected (Response
rate of 44%). Twenty-six were excluded as they were incomplete. A total of 150
responses were analysed, 50.7% (76/150) responses were from the hospital
without ASP and 49.3% (74/150) were from the hospital with ASP. Participants
characteristics includes 52.7% (79/150) of participants were male and 47.3%
(71/150) were female, 44% (66/150) of participants were between the age of 21
and 30 years (Figure 7.1), and 48.7% (73/150) of participants hold bachelor
degrees (Figure 7.2).
Figure 7.1: Distribution of patients’ age groups
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Figure 7.2: Distribution of patients’ educational level
7.3.2 Patients' knowledge and perceptions regarding antimicrobial use and
resistance in Saudi MOH hospitals
This part of the questionnaire examined the perspectives of patients regarding
antimicrobial use and resistance in Saudi MOH hospitals in relation to five
dimensions: 1) Access to antibiotics; 2) Effects of antibiotics; 3) Antibiotics
resistance; 4) Doctors’ habits and the relationship between doctors and patients;
and 5) Patients’ use of antibiotics during hospital stay (see tables 7.2-7.6).
1) Access of patients to antibiotics
Table 7.2: Access of patients to antibiotics (N = 150)
Statement
Relative Frequency
Distribution
M
ean
Standard
D
eviation
Agree %
D
o not
Know
 %
D
isagree
%
B1- Left-over antibiotics are good to keep at home in
case they might be needed later on.
79.3 8 12.7 1.3
3
0.69
B2- If a family member is sick, I will give him/her my
antibiotic.
20.7 1.3 78 2.5
7
0.814
B3- It is good to be able to get antibiotics from
relatives, friends or pharmacy without having to see
a doctor.
17.3 3.3 79.3 2.6
2
0.766
48.70%
30.70%
16.70%
3.30% 0.70%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
Bachelor High
school
Less than
high school
Master PhD
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The findings in this section showed positive perception and good knowledge
about getting antibiotics, as 78% of patients were against giving any antibiotics
that were not prescribed by a doctor to any family member. Likewise, 79.3% were
against getting any sort of antibiotics from relatives or friends without prescription.
However, 79% of patients exhibited an unhealthy perception towards dealing with
antibiotics, preferring to keep left-over antibiotics at home for future use.
2) Effects of antibiotics
Table 7.3: Effects of antibiotics (N = 150)
Statement
Relative Frequency
Distribution
M
ean
Standard
D
eviation
Agree
%
D
o not
Know
%
D
isagree
%
C1- When I get a cold, I will take antibiotics to help
me get better quickly.
48 6 46 1.98 0.973
C2- If I feel better after a few days, I will stop taking
my antibiotics before completing the course of
treatment.
63.3 2.7 34 1.71 0.945
C3- Antibiotics are indicated to relieve
pain/inflammation.
55.3 20 24.7 1.69 0.843
C4- Antibiotics are used to stop fever. 47.3 19.3 33.3 1.86 0.890
C5- Antibiotics are effective against bacteria. 52 41.3 6.7 2.45 0.619
C6- Antibiotics are effective against viruses. 51.3 40.0 8.7 1.57 0.649
The findings in this section showed that 52% of patients believed that antibiotics
were generally effective against bacteria, which was a positive outcome.
However, the majority of patients held wrong beliefs about the effects of
antibiotics. 48% of patients believed that antibiotics could help them to get better
quickly when they got a cold, 63.3% of patients thought that they could stop using
antibiotics before completing the course of treatment if they felt better after a few
days; 55.3% of patients believed wrongly that antibiotics were intended to relieve
pain and inflammation; 47.3% of patients stated that antibiotics were used to bring
down fever; 51.3% believed wrongly that antibiotics were effective against
viruses. Surprisingly, 40%-41% of patients admitted that they did not know if
antibiotics were effective against bacteria and viruses.
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To conclude, the above findings show a significant lack of awareness and
knowledge among Saudi MOH hospitals patients about the effects of antibiotics
and safe usage.
3) Antibiotic resistance
Table 7.4: Antibiotic resistance (N = 150)
Statement
Relative Frequency
Distribution
M
ean
Standard
D
eviation
Agree
%
D
o not
Know
%
D
isagree
%
D1- Antibiotic resistance can be due to using
antibiotics when they are not necessary.
40.7 32.7 26.7 2.14 0.811
D2- Antibiotic resistance can be due to not
completing the full course of antibiotic.
5.3 10.7 84 1.21 0.53
D3- Antibiotic resistance can be due to using
antibiotics without physician prescription (self-
medication).
48.7 20.7 30.7 2.18 0.875
D4- Antibiotic resistance can be due to using the
same antibiotic with a different brand.
24 44.7 31.3 1.93 0.743
D5- Antibiotic resistance is a problem in Saudi today. 9.3 18 72.7 1.37 0.65
D6- Antibiotic resistance is a problem in the rest of
the world today.
38 52 10 2.28 0.636
The findings in this section revealed that 40.7% of patients showed a reasonable
awareness about the reason for the occurrence of antibiotic resistance, which can
be due to using antibiotics when they are not necessary. However, 84% of
patients refused to accept that antibiotic resistance could be due to not completing
the full course of antibiotic, revealing a lack of health and medical awareness
about antibiotic medication.
Moreover, 48.7% of patients showed good understanding that antibiotic
resistance could be due to using antibiotics without physician prescription (self-
medication). However, this figure meant that there were about 52% of patients
who either did not know or refused to accept this fact. Similarly, 38% of patients
showed that they were aware that antibiotic resistance was a problem in the rest
of the world today, however, about 62% of patients did not realise the risk and
spread of antibiotic resistance at a global level.
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31.3% of patients refused to believe the fact that antibiotic resistance could be
due to using the same antibiotic from a different brand, but 44.7% of patients did
know about this issue. 72.7% of patients did not believe that antibiotic resistance
is a current problem in Saudi Arabia. This reflected the risks that patients exposed
themselves to when they were against the medical facts and they were not careful
when dealing with antibiotics. The lack of medical awareness about the causes of
antibiotic resistance was clear among patients and the Saudi MOH should
address this issue and encourage hospitals to adopt ASPs and conduct public
campaigns in order to increase awareness about antibiotics use and resistance.
4) Doctors’ habits and the relationship between doctors and patients
Table 7.5: Doctors’ habits and the relationship between doctors and patients (N
= 150)
Statement
Relative Frequency
Distribution M
ean
Standard
D
eviation
Agree
%
D
o not
Know
%
D
isagree
%
E1- I trust the doctor’s decision if she or he decides
not to prescribe antibiotics.
78.7 7.3 14 2.65 0.715
E2- I trust the doctor’s decision if she or he decides to
prescribe antibiotics.
80 6.7 13.3 2.67 0.702
E3- Doctors often take time to consider carefully
whether antibiotics are needed or not.
45.3 17.3 37.3 2.08 0.909
E4- Doctors often prescribe antibiotics because the
patients expect it.
38 25.3 36.7 1.99 0.867
E5- A doctor who does not prescribe antibiotics when
the patient thinks s/he should is a bad doctor.
14 4.7 81.3 2.67 0.709
E6- I consult another physician to prescribe
antibiotics if my physician refuses to do so.
26 4 70 2.44 0.878
The findings in this section showed that 78.7%-80% of patients had good trust in
their doctors when they decided to prescribe or not to prescribe antibiotics for
them. Similarly, 45.3% of patients believed that their doctors often took time to
consider carefully whether antibiotics were needed or not. Positively, 81.3% of
patients believed that a doctor who does not prescribe antibiotics when the patient
thinks s/he should is not a bad doctor, while 70% of patients believed that there
was no need to consult another physician to prescribe antibiotics if their physician
refused to do so.
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5) Patients’ use of antibiotics during hospital stay
Table 7.6: Patients’ use of antibiotics during hospital stay (N = 150)
Statement
Relative Frequency
Distribution
M
ean
Standard
D
eviation
Agree
%
D
o not
Know
%
D
isagree
%
F1- My doctor/pharmacist told me that I am being
treated with antibiotics.
12.7 4 83.3 1.29 0.68
F2- I was told about how to take the antibiotic. 65.3 8 26.7 2.39 0.881
F3- This hospital is strict when it comes to prescribing
antibiotics.
34.7 34 31.3 2.03 0.814
F4- This hospital provides information on antibiotic
resistance.
22.7 14.7 62.7 1.60 0.835
F5- My hospital stay improved my awareness of
antibiotic resistance.
32 11.3 56.7 1.75 0.912
The findings in this section showed that 65.3% of patients had been informed
about how to take their antibiotic. Similarly, 34.7% of patients agreed happily
when their hospital was strict when it came to prescribing antibiotics. However,
83.3% of patients were strongly upset with their doctors and pharmacist because
they did not inform them that they were being treated with antibiotics. Similarly,
62.7% of patients stated that their hospitals did not provide them with information
on antibiotic resistance and 56.7% of patients showed that their hospital stay did
not improve their awareness of antibiotic resistance. This means that patients do
not receive enough information about antibiotics use and risks of resistance while
they are staying in hospitals. Patients may expect their knowledge and awareness
to be improved during their hospital stay if the healthcare professionals pay
attention and supply health education about the effects of antibiotics and the risk
of its misuse among healthcare professionals and patients.
In summary, the findings associated with the first research question revealed that
most participants exhibited favourable knowledge and perceptions about
reasonable use of antibiotics for themselves, relatives, and friends, without
prescription. 50% of participants considered that antibiotics have efficiency
against bacteria. 70-80% of participants trusted their doctors’ decision with regard
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to provision or refusal of antibiotic prescriptions. 65.3% of the participants who
were hospitalised reported that they had been instructed on antibiotic usage, and
34.7% of participants confirmed their satisfaction with the strict policy
implemented by their hospital with respect to antibiotic prescriptions.
On the other hand, use of antibiotics was inappropriately perceived by 79% of
participants, who stated that they kept left-over antibiotics to use at a later date.
Furthermore, 40-64% of participants were poorly knowledgeable about the effects
and safe usage of antibiotics. A proportion of 38% of participants were of the
opinion that doctors should prescribe antibiotics in order to satisfy patients’
expectations. Around 60% of participants were unaware and uninformed about
the risks of using antibiotics when not necessary.
84% of participants did not believe that lack of completion of a course of antibiotic
could give rise to antibiotic resistance, revealing that they were not
knowledgeable about antibiotics. Similarly, 72.7% of participants refused the idea
that the issue of antibiotic resistance existed in Saudi Arabia. Such a view could
have major implications, as patients could behave inappropriately with regard to
antibiotic usage, disregarding medical facts. The significant issue of patient
awareness regarding the effects of antibiotics should be dealt with by the Saudi
MOH, and in particular it should promote the adoption of ASP and public
campaigns among a larger number of hospitals to make patients more aware
about the use of antibiotics, both at home and in the hospital.
7.3.3 Patients' knowledge and perceptions regarding antimicrobial use and
resistance in a hospital with ASP and a hospital without ASP
The findings revealed significant differences between patients' knowledge and
perceptions regarding antimicrobial use and resistance in the hospital with ASP
(M: 54.30, SD: 4.30, N=74) and in the hospital without ASP (M: 50.67, SD: 6.43,
N=76) in relation to the total of questionnaire scores (t = (4.05), p=0.000). These
significant differences were in favour of the patients who registered in the hospital
that has ASP. This meant that patients registered in the hospital where ASP took
place showed more positive knowledge and perceptions towards antimicrobial
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use and resistance than patients who were registered in hospital where ASP was
not implemented.
The table below (Table 7.7) shows that only two sub-scales had significant
differences in the knowledge and perceptions of patients registered in a hospital
with ASP and patients registered in a hospital without ASP. The findings revealed
significant differences between patients' knowledge and perceptions in the sub-
scale ‘Access to antibiotics’ in the hospital with ASP (M: 6.89, SD: 1.32, N=74)
and those who registered in the hospital without ASP (M: 6.17, SD: 1.84, N=76)
in relation to the total of sub-scale scores (t = (2.74), p>0.01). This meant that
patients in the hospital with ASP were more aware and knowledgeable of how to
use and get access to antibiotics at home and among their family members,
friends and relatives than patients in the hospital without ASP.
Furthermore, the findings showed significant differences between patients'
knowledge and perceptions in the sub-scale ‘Patients’ use of antibiotics during
hospital stay’ in the hospital with ASP (M: 9.77, SD: 2.48, N=74) and in the
hospital without ASP (M: 8.38, SD: 2.40, N=76) in relation to the total of sub-scale
scores (t = (3.485), p>0.01). This meant that patients in the hospital with ASP
were told about the issue of antibiotic resistance and were also informed about
how to use the antibiotics by their doctor and pharmacist; by contrast, patients in
the hospital without ASP were much less well-informed.
Table 7.7: T-test on the difference between the patients’ knowledge and
perceptions in a hospital with ASP and a hospital without ASP (N=150)
PTSDMeanHospital
Type
Patients’
knowledge and
perceptions
.00702.741.326.89With ASPAccess to
antibiotics 1.846.17Without ASP
.12101.5602.3111.55With ASPEffects of
antibiotics 2.1410.99Without ASP
.38800.8661.7211.24With ASPAntibiotics
resistance 2.0710.97Without ASP
.07501.7952.0814.84With ASPDoctors’ habits
2.5314.16Without ASP
.00103.4852.489.77With ASPPatients’ use of
antibiotics during
hospital stay 2.408.38
Without ASP
0.0004.0494.3054.30With ASPTotal
6.4350.67Without ASP
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Gender influence:
The findings revealed significant gender-based differences between female
patients (M: 56.55, SD: 3.69, N=71) and male patients (M: 48.78, SD: 4.72, N=79)
in terms of knowledge and perceptions regarding antimicrobial use and
resistance, in relation to the total questionnaire score (t = (11.14), p=0.000). This
meant that female patients showed more knowledge and positive perceptions
towards antimicrobial use and resistance than male patients. It seems that female
patients were more careful about their health and safety and understanding the
importance of the advice from healthcare professionals about using antibiotics in
the hospital and at home.
Age influence:
In addition, One-Way ANOVA analysis was used to explore the impact of age
group on patients’ knowledge and perceptions regarding antimicrobial use and
resistance in Saudi MOH hospitals. The findings did not show any significant
differences in patients’ knowledge and perceptions regarding antimicrobial use
and resistance between different age groups (from 21 years to 80 years).
Educational influence:
One-way ANOVA analysis was used to examine the impact of patients’ level of
education on their knowledge and perceptions towards antimicrobial use and
resistance (Less than high school; High school; Bachelor; Master; and PhD). The
One-Way ANOVA analysis did reveal that there were significant differences
between the patients’ knowledge and perception towards antimicrobial use and
resistance and their level of education (F = (4,145) = 3.33, p < 0.05, n = 150).
Therefore, it seems that the patients who achieved a higher level of education,
such Master’s Degree, Bachelor’s Degree and High School, showed more
knowledge and perceptions towards using the antibiotics than the patients with a
lower educational level, such as Secondary School.
In summary, the findings associated with the second research question reveal
that, by comparison to patients in the hospital without ASP, patients in the hospital
with ASP exhibited more favourable knowledge and perceptions towards and
were better informed not only about antibiotic use and resistance, but also about
how to gain access to antibiotics at home and among relatives and friends.
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Furthermore, compared to patients in the hospital without ASP, the patients in the
hospital with ASP had greater awareness and knowledge about antibiotic use
during hospitalisation and they received more information about the problem of
antibiotic resistance and how to take the antibiotics.
With regard to the influence of gender, the findings indicated that female patients
were more aware and had more knowledge and perceptions about antibiotic use
and resistance by comparison to male patients.
With respect to the influence of the level of education, the findings revealed a
greater knowledge and positive perceptions about the use of antibiotics among
participants with a higher level of education, such as Master’s Degree, Bachelor’s
Degree and High School. By contrast, participants who finished only Secondary
School were less aware and less knowledgeable. On the other hand, in terms of
age, participants in different age groups (from 21 to 80 years of age) did not differ
much with regard to knowledge and perceptions toward antibiotic use and
resistance.
7.4 Discussion
The objectives of this quantitative study were to assess patients' knowledge and
perceptions regarding antimicrobial use and resistance to evaluate the
institutional role of patients' education. Findings of this study showed very poor
knowledge and unhealthy perceptions about antimicrobial use and resistance
among study participants. For example, almost half of the surveyed patients
perceived that antibiotics could help them get rid of common cold quickly; and
about 80% believed it was adequate to keep left-over antibiotics at home for future
use. There were also misconceptions that antibiotics were effective in treating
fever, viral infections and relieve of inflammation. This is in line with previous
studies reporting that patients use antibiotics as analgesics, keep antibiotics at
home for emergency use, and use of left-over antibiotics without physicians’
consultation (Awad & Aboud, 2015; Oh et al., 2011; Shehadeh et al., 2012).
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Furthermore, this study found that a good proportion of the surveyed patients
(84%) were unaware of the local and global problem of antibiotic resistance, and
that resistance could result from non-completion of a full course of antibiotic. This
is in contrast with (André et al., 2010) who reported a high proportion (80%) of
Swedish public perceive that bacteria could become resistant to antibiotics. These
findings show a lack of patients/ public awareness of the link between antibiotic
use/ misuse and the development of resistance (Laxminarayan et al., 2013).
Consequently, the Saudi national AMR strategy launched in January 2017
(described in Chapter four) will be more effective when patients and the public are
fully engaged through public enlightenment programmes and educational
campaigns. In addition, this study found that most of the patients treated with
antibiotics were not informed of what medicines they were taking, and hospitals
did not make patients aware of the problem of antibiotic resistance. Therefore,
individual hospitals need to have educational programmes for patients; also
treating physicians, pharmacists and nurses should educate all patients
prescribed antibiotics on the dangers of misuse and risks of AMR.
With respect to patients' knowledge and perceptions of antimicrobial use and
resistance in a hospital with ASP and a hospital without ASP, findings of this study
showed that patients in the hospital with ASP were more knowledgeable about
antibiotic use than those in the hospital without ASP. Information on antibiotic use
and resistance were given to patients in the hospital with ASP in contrast to the
hospital without ASP. In Chapter six of this thesis, it was noted that extensive
educational and training campaign (in Arabic and English) targeting both the
hospital staff, patients and general public were carried out prior to the
implementation of ASP. Such educational campaign is needed in hospitals
intending to start the programme. This will create awareness of the problem of
AMR among patients and the public who hold some misconceptions about
antibiotics, and often do not complete the course of prescribed antibiotics.
In this study, patients with higher education were more knowledgeable about
antibiotic use, and were more aware of the problem of antibiotic resistance than
patients with lower educational levels. (Oh et al., 2011) had previously reported
educational level as one of the demographic characteristics that is significantly
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associated with knowledge and attitudes toward antibiotic use. In view of the
threat of AMR poses in Saudi Arabia, the Saudi Ministry of Education should work
towards embedding antimicrobial prescribing and stewardship competencies into
undergraduate Medical, Pharmacy, Dental, Nursing and Veterinary curriculum, as
well as introduction of antibiotic resistance topics. Antimicrobial stewardship
principles are already included in most of the undergraduate healthcare and
veterinary degrees in the UK (Castro-Sánchez, Drumright, Gharbi, Farrell, &
Holmes, 2016). A survey of health education institutions to assess implementation
rate of the competencies (infection prevention and control, AMR and
antimicrobials, the prescribing of antimicrobials, antimicrobial stewardship and
monitoring and learning) showed the average implementation rate for all
universities and courses was 67% for all the dimensions (National Health
Services England, 2016). Learning from the UK example will be a right step in the
right direction for Saudi Arabia.
7.4.2 Implications for practice
In order to improve patients' perceptions and knowledge regarding appropriate
antimicrobial use and risks of resistance, high authorities should address this
issue and encourage hospitals to adopt ASPs and conduct public campaigns in
order to increase awareness about antibiotics use and resistance, change
patients' perceptions and culture regarding inappropriate antibiotic use, and
control and monitor access to antibiotics in primary and secondary care, to
improve antimicrobial practice, reduce antimicrobial resistance and improve
patient care.
Patients' education regarding their antimicrobial therapy (nature, treatment and
complications) is essential in the treatment process. This can be promoted
through counselling patients taking antimicrobials, public health campaigns and
media. Also, education of family members about appropriate use of antimicrobials
and risks of AMR is important, in order to improve adherence to antimicrobial
therapy and correct any wrong perceptions and practices among relatives and
friends.
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7.5 Conclusion
The objective of this quantitative study is to assess patients' knowledge and
perceptions of antimicrobial use and resistance and to evaluate the institutional
role of patients' education. It is clear from the results of this study that there are
poor knowledge and perceptions regarding antimicrobial use and resistance
among hospital patients in Saudi Arabia. Patients showed wrong perception
towards getting access to antibiotics, they also showed lack of knowledge on the
effects of antibiotics, lack of awareness and knowledge about causes of antibiotic
resistance was also identified among participants, and finally patients identified
that there is lack of information from hospital staff regarding antimicrobial use and
risks of resistance especially in the hospital without ASP. On the other hand, good
relation and trust was identified between patients and doctors when it comes to
antibiotic therapy. Finally, patients in the hospital with ASP showed a better
understanding and knowledge towards antimicrobial use and resistance than
patients in the hospital without ASP. This shows that there is need to improve
patients' educational programmes and campaigns on appropriate antibiotic use
and risks of antibiotic resistance, and spread ASPs among hospitals to improve
antimicrobial therapy and patients safety.
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Chapter 8: Overall Discussion
8.1 Introduction
The aim of this thesis was to explore and investigate the level and process of
adoption of ASPs and factors influencing their implementation in Saudi MOH
hospitals. This is particularly timely since Saudi Arabia, among other Arab Gulf
countries, is experiencing soaring levels of AMR and rapid emergence of novel
and rare multi-drug resistant strains. This does not only have health and economic
implications in the region, but could further globalise AMR and spread the rare
resistant strains to other parts of the world given that Saudi Arabia hosts around
10 million pilgrims and visitors for Hajj and Umrah every year and is home to one
of the largest expatriate populations in the world (Azeem et al., 2014;
Kapiszewski, 2006; Memish et al., 2014; Saudi Ministry of Health, 2017a; H. M.
Zowawi et al., 2013).
Despite the extensive literature addressing the adoption of ASPs in healthcare
settings, little is known about the levels of ASPs adoption in the Arab Gulf region
including Saudi Arabia, and the factors influencing their adoption that are
particular to the Middle Eastern/ Saudi context. Therefore, this thesis had set out
to enhance our understanding of ASPs in Saudi Arabia by looking at the factors
that facilitate/ hinder Saudi hospitals’ adoption of ASPs.
While the contributions to this area of research are appreciated, a large bulk of
the literature does not address the context specific factors that drive ASPs in the
Middle Eastern/ Saudi context and the factors that may influence innovation
adoption in its healthcare settings. Despite the well-documented benefits of ASPs
adoption in addressing inappropriate antimicrobials use (K. a. Cairns et al., 2013;
Davey et al., 2017; Jorgensen et al., 2018; Wong-Beringer, Nguyen, Lee, Shriner,
& Pallares, 2009) and reducing rates of AMR (Aldeyab et al., 2012; Davey et al.,
2017; Martin et al., 2005; Yam et al., 2012), adoption of these strategies is still
slow in healthcare settings of developing countries (Enani, 2016; Howard et al.,
2015), and some developed countries (Howard et al., 2015; Pollack et al., 2016;
Public Health England, 2015a, 2017). Various barriers to adoption have been
identified. These include characteristics of the socio-political context such as lack
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of regulations and legislation to adopt ASPs; characteristics of the healthcare
organisation such as lack of administrative support, lack of expertise, lack of
educational and training programmes, lack of IT systems, and lack of financial
resources; characteristics of the healthcare professional such as lack of
knowledge and skills and lack of ownership; and characteristics of the ASP being
adopted such as trialability, clarity and advantages (Avent et al., 2014; Chen et
al., 2011; Cotta et al., 2015; Enani, 2016; Johannsson et al., 2011; Pakyz et al.,
2014; Trivedi & Rosenberg, 2013).
In Saudi Arabia, the MOH supervises the healthcare system including both private
and public providers. It delivers care through 274 hospitals and specialised
facilities which constitute 63% of hospital care provision and serves around 32
million people (Saudi Ministry of Health, 2017a). In response to the concerning
levels of AMR in the country and in the region, the GCC countries introduced the
strategic plan for combating AMR in 2014 (Balkhy et al., 2016), stemming from
the WHO mandate to combat AMR at all levels (World Health Organisation,
2015a). Following that, Saudi Arabia has so far been the only country within the
GCC region to introduce a national ASP guideline in 2014 (Saudi Ministry of
Health, 2014). The progress of the implementation of this national ASP guideline
is detailed in the recent review by Alomi (Yousef Ahmed Alomi, 2017). This has
been highlighted in chapter 2, our review of existing evidence of ASPs adoption
in the GCC region. We further highlighted that ASPs do exist in some hospitals in
the region, and that Saudi tertiary hospitals and the large medical cities tend to
be the main adopters of ASPs. This is not surprising given that when the national
strategy was first introduced in 2014, it aimed to establish ASPs in tertiary MOH
hospitals within the capital Riyadh first, then expanding further to other larger
MOH hospitals (medical cities) within other localities (Yousef Ahmed Alomi,
2017). This centralised governance of ASPs could explain the slow levels of
adoption in secondary hospitals, and could also explain the low level of adoption
of ASPs in hospitals in other GCC member states, especially as their perspective
MOHs are yet to introduce a national ASP guideline or strategy. Noteworthy, the
WHO has supported several low and middle-income countries (LMIC)
governments to decentralise healthcare services and devolve funding services to
local authorities. However, failure of local governments to raise funds to support
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local health services may jeopardise the optimum delivery of such services
(Sreeramareddy & Sathyanarayana, 2013). Regional activation and delivery of
ASPs within healthcare settings may be a potential approach to fastening the
establishment of ASPs in Saudi hospitals, but the feasibility of such approach is
uncertain, especially in the absence of local success examples.
In our review (Chapter two), we also identified the reported barriers to ASPs
adoption in hospitals within the GCC region. These fall within three of the four
sets of characteristics detailed in (Fleuren et al., 2014, 2004) framework of
innovation within the healthcare organisation. First, characteristics of the socio-
political context such as the lack of rules and legislations, especially since that
Saudi has only recently introduced the national ASP strategy. Second,
characteristics of the hospital such as the lack of senior management support,
staff recruitment, and scarcity of resources especially IT and microbiology
equipment. Third, characteristics of the healthcare professionals/hospital staff,
such as physicians sense of potential clinical liability, their levels of knowledge
and awareness of appropriate antimicrobial use and resistance, and the limited
support from colleagues due to the common “working in slios” mentality.
These were further confirmed when healthcare professionals and staff from three
MOH hospitals as well as regional and MOH central directorate were interviewed
(chapter four) in relation to the factors that may facilitate or hinder ASPs adoption
in healthcare settings. The same picture emerged when participants from MOH
hospitals at a national level responded to the national survey (chapter five) to
confirm senior management support, ASP team members and ASP benefits as
significant factors affecting ASPs adoption in their organisations.
The poor enforcement of ASPs policies from the MOH and at hospital level has
been blamed for lack of adherence to ASP guidelines and policies. The MOH
antimicrobial stewardship committee could consider enforcing the policy as part
of their nationwide effort to establish ASPs in hospitals. This will not only allow
hospital management to set clear objectives, institutional mechanisms to monitor
and ensure adherence to policies, and a long-term road-map for ASPs adoption
and implementation, but also reduce physicians’ anxiety and fears in relation to
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potential clinical liability. However, a certain degree of autonomy has to be
maintained to reflect local patient demand and characteristics (Blume, van Weert,
Busari, & Delnoij, 2017).
The majority of the identified barriers were related to the healthcare organisation
itself. These included the availability of IT infrastructure (including electronic
prescribing), senior management support, shortage of ASP team members, the
disintegrated multi-disciplinary teams and the lack of education and training.
Unlike the high levels of adoption of electronic prescribing and data management
systems in hospitals here in the UK and many other European countries,
electronic prescribing and the availability of a sophisticated IT system in hospitals
in Saudi Arabia is still lagging. Electronic health records and clinical decision
support systems improve clinicians’ daily antimicrobial stewardship tasks (Kullar
& Goff, 2014), and the lack of these systems is causing the reluctance of hospitals
to adopt novel applications and practices such as ASPs. Although electronic
prescribing has been reported to be in use in hospitals in all GCC countries
(Enani, 2016), it is likely to be only adopted in advanced tertiary or military
hospitals. UEA has only recently (March 5th 2018) announced that all healthcare
facilities across the country (public and private) must only deal in printed and
electronic prescriptions within six months of the announcement, suggesting the
end of the hand-written prescription (Ministry of Health and Prevention, 2018;
UAE News 24/7, 2018).
Senior management support has been suggested as a significant factor affecting
hospitals’ adoption of ASPs. This is part of the culture within hospitals in Saudi
and others in the region, where managers tend to be mainly reactive rather than
pro-active, and their role largely involves response to and ensuring compliance
with rules and regulations set out by government (Balasubramanian &
Sundarakani, 2017). Healthcare professionals suggest senior management
support as a strong predictor of ASPs adoption. Like in the case of IT innovation
adoption for example, managers who are aware of the seriousness of AMR and
previous experience of ASPs are more likely to adopt the innovation. These
managers are convinced with the benefits of ASPs, are motivated to adopt them,
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can form partnerships with ASP team members, and can sustain the confidence
and the stability throughout the innovation adoption journey (Ingebrigtsen et al.,
2014).
The shortage of ASP team members is a significant barrier to ASPs adoption in
hospitals. The lack of ID specialists and clinical pharmacists has been frequently
stated. However, nurses' role in ASPs management is rarely addressed. Although
their role in antimicrobial stewardship has not been very well developed,
guidelines form UK, and the US clearly refer to staff nurses being part of the
multidisciplinary ASP teams (Centers for Disease Control and Prevention, 2017;
Edwards et al., 2011; Public Health England, 2015b; Sumner et al., 2018).
Further, nurses are uniquely positioned to successfully implement ASPs
(Edwards et al., 2011) in that nurses are central communicators between
physicians, pharmacy, microbiology labs, discharge planners and consultants.
They are also a primary source of information for patients during their hospital
stay, including information about the appropriate use of antimicrobials and
reducing the emergence of AMR (Olans, Olans, & Demaria, 2016). Nurses should
be offered education and training, and empowered to participate in ASP teams,
beyond their traditional role of infection control (Olans et al., 2016).
This lack of involvement of nurses in antimicrobial stewardship within Saudi
hospitals can explain the disintegration reported as a further barrier to ASPs
adoption. But it can also be explained by the nature and characteristics of the
workforce within Saudi healthcare organisations.
The language barrier has been blamed for poor communication amongst
healthcare staff, given that healthcare professionals consist of a large proportion
of expats (A. F. Almutairi, Gardner, & McCarthy, 2013; Elsheikh, Alqurashi,
Wahba, & Hodhod, 2018). This can also have implications on the communication
between healthcare professionals and patients (K. M. Almutairi, 2015). Further,
healthcare professionals from different countries bring different beliefs and
practices to Saudi healthcare settings (Badrinath, Ghaza-Aswad, Osman,
Deemas, & Mcllvenny, 2004), and in the absence of strict enforcement of policies
and regulations, there is no standardised practice and this could have serious
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implications on the quality and safety of care delivered to patients (Bahnassi,
2016). While the value of diversity is somewhat recognised, the Saudi
government and others in the region are attempting to address the heavy
dependence on foreign healthcare workforce through the Saudisation (Elsheikh
et al., 2018), and other workforce nationalisation  strategies in the GCC states
(Randeree, 2012).
Expat nurses make up around 70% of the nursing profession in Saudi Arabia
(Saudi Ministry of Health, 2017a). The picture is similar in other GCC states
despite the existence of nursing education and the modest governments’ efforts
to encourage uptake of this training by GCC nationals. However, the contribution
of nurses to clinical care remains under-recognised by hospital administration and
physicians and a complete absence of career progression structures (Hibbert, Al-
Sanea, & Balens, 2012).
Moreover, because of the culture norms in Saudi Arabia, and the dominance of
male representation in the workplace especially at strategic levels, male
healthcare professionals have more interactions and socialisation with colleagues
than females, presenting more opportunities for them for professional
development especially in relation to education and training on antimicrobial
stewardship (M. U. Khan, Shah, Ahmad, & Fatokun, 2014); hence, the female
healthcare professionals may not have as much opportunities as their male
counterparts. Other characteristics of healthcare professionals that hinder the
adoption of ASPs are physicians attitudes towards multi-disciplinary teams
(MDTs) especially with nurses, as some of the physicians feel uncomfortable as
nurses suggest changes or stopping of medications (Silbermann et al., 2013).
Not surprising that these were reported in all the three participating hospitals
(chapter four) which are all under the supervision of the MOH, reflecting a shared
organisational climate. Given the potential influence of the organisational climate
on hospitals’ performance (Zhou, Bundorf, Le Chang, Huang, & Xue, 2011), it is
imperative that these barriers are addressed strategically at ministry level as well
as at hospital level before ASPs can be successfully adopted.
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The adoption of ASPs has mainly been investigated in public/ government
hospitals and little is known about ASPs adoption in the private sector, which
according to the limited literature is still lagging. In the private sector, physicians
and consultants tend to be more autonomous, and there is greater opportunity for
involvement from nurses and pharmacists (Cotta et al., 2015). This may increase
the chances of private hospitals adopting ASPs quicker if enforcement is central.
Interestingly, all participants perceived ASPs to be extremely beneficial in
addressing inappropriate antimicrobial use and resistance. So, the fourth set of
characteristics within Flueren et al. framework relating to the characteristics of the
innovation, in this case ASP, do not affect Saudi hospital’s decision to (or not to)
adopt ASPs. Healthcare professionals in Saudi Arabia recognise the benefits of
ASPs adoption and they did not identify any issues relating to the programme
itself. This is similar to previous findings (Steinberg et al., 2016; Venugopalan et
al., 2016).
The medical city is a 1500-bed tertiary medical city. It is one of the few MOH
hospitals with an established ASP since January 2016. The hospital adopted ASP
as part of an initiative to improve the patient safety portfolio of the organisation.
In addition to the national ASP strategy, the medical city had to introduce and
enforce their own ASP strategy, without waiting for MOH implementation of the
programme which was still at its infancy at the time. This does not only fasten the
process of adoption and implementation, but provides the institution with
autonomy over monitoring and performance targets. Leadership was paramount
to the adoption and implementation of ASP at the medical city, as the hospital
board required frequent updates on antimicrobial stewardship activities. Staff
there further emphasised the commitment, engagement and support of senior
management as significant facilitators of ASP adoption. This is not surprising
since similar factors have been proposed for the adoption of ASPs here in NHS
trusts (Cooke et al., 2004).
To overcome the scarcity of ID consultants, the medical city recruited a clinical
pharmacist who was tasked to undertake a clinical pharmacist-led adoption of
ASP. This strategy has proven to be an effective approach to overcome the
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limitation of resources and expertise in several countries including US (Meyer et
al., 2016; Waters, 2015), UK (Dunn, O’Reilly, Silke, Rogers, & Bergin, 2011) and
Pakistan (Haque et al., 2018). While there was great collaboration between
physicians and pharmacists under this initiative, nurses’ involvement remained
within the traditional remit of infection control. This lack of optimum utilisation of
skills and expertise within the organisation may have contributed to the high
workload and the shortage of staff perceived by participants.
Not surprisingly, the availability of IT infrastructure further hinders ASP adoption
efforts. In the absence of electronic prescribing, the medical city struggle to
capture prescribing patterns and antimicrobials consumption data.
It is recognised that Hajj presents further challenges to Saudi hospitals especially
the ones like the medical city in Makkah (a holy city and the main pilgrimage
destination). Al Somai et al. describes how antimicrobial consumption increases
dramatically during Hajj and the difficulty to sustain antimicrobial stewardship
during the pilgrimage season (Al-Somai et al., 2014). This problem is further
exacerbated by the lack of an efficient IT system within hospitals to improve
prescribing practice and ensure patient safety.
Saudis and other patients within the GCC region seek healthcare when they are
ill, and do not routinely engage in preventive healthcare (El Bcheraoui, Tuffaha,
Daoud, AlMazroa, et al., 2015; El Bcheraoui, Tuffaha, Daoud, Kravitz, et al.,
2015). This behaviour could worsen the problem of AMR for three reasons: First,
there is unrestricted access to antibiotics facilitated by various community
enablers who include trained private pharmacists and untrained pharmacy
attendants (Bin Nafisah et al., 2017).
Second, the lack of public awareness of appropriate antimicrobial use and
resistance in Saudi Arabia (Bin Nafisah et al., 2017) and other GCC states
(Alhomoud et al., 2017; Awad & Aboud, 2015), calling for a more active role of
MOH to provide health education to Saudis (El Bcheraoui, Tuffaha, Daoud,
AlMazroa, et al., 2015). Here is the UK for example, PHE is an executive agency
of the DOH which is responsible for protecting and improving people’s health and
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wellbeing, and reducing health inequalities. Annual awareness initiatives such as
Antibiotic Awareness Week target patients with information in various forms to
highlight the issue of resistance and promote appropriate use of antibiotics (Public
Health England, 2015a, 2017).
Third, prescribers behaviour in relation to potential clinical liability, patients
expectations, their knowledge and level awareness as well as poor enforcement
of guidelines (Al-Homaidan & Barrimah, 2018). When patients were invited to
complete the patients survey (chapter seven) on their level of knowledge and
perceptions of antimicrobial use and resistance, and their antibiotics usage and
practices, most patients' knowledge and perceptions were low, and they
demonstrated incorrect practices that contribute to AMR. This is in agreement
with previous findings (Awad & Aboud, 2015; Oh et al., 2011; Shehadeh et al.,
2012). However, it was found that overall, patients who were staying at the
medical city, an ASP adopting hospital, demonstrated better levels of knowledge
and perceptions of appropriate antimicrobial use and resistance, compared to the
patients staying at a hospital without an established ASP. Although ASP is an
institutional programme rather than a patient-facing practice, the outcomes of
ASP adoption should address patients’ knowledge and perceptions regarding
antimicrobials use. In other words, the outcomes of adoption of ASPs should
translate into improved patients’ use of antimicrobials, especially during their
hospital stay. Like in the case of smoking cessation interventions, hospitalisation
offers an ideal opportunity to deliver health promotion message and educate
patients on appropriate antimicrobials use and resistance as patients are more
likely to be receptive of such messages, and are more likely to adhere to advice
given by hospital staff (Mellon et al., 2016). This is also a key strategic objective
set out in the World Health Assembly action plan to tackle AMR (World Health
Organisation, 2015a).
GCC member states share a number of geographical, historical, cultural and
political characteristics that make the issue of AMR more regional than local (M.
Aly & Balkhy, 2012; Center for International and Regional Studies, 2017). The
similar rates of AMR across the region and the familiarity of the reported barriers
hindering the adoption of ASPs in GCC hospitals make the recommendations
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drawn from this research not only relevant to Saudi hospitals, but also Bahrain,
Kuwait, Oman, Qatar and UAE.
8.2 Conclusion
The aim of this research was to explore and investigate the level and process of
adoption of ASPs and factors influencing their implementation in Saudi MOH
hospitals, in order to provide evidence-based recommendations for their
successful adoption and implementation. The availability of legislations and
regulations that require and enforce hospitals to implement ASPs, administrative
support, competent personnel, educational programmes, expertise (ID
consultants, antimicrobial pharmacists, microbiologists), effective inter-
professional collaboration & communication and IT resources are key to the
successful implementation of ASPs. Policy makers could take the findings of this
research to help in implementing national guidelines for antimicrobial use and
resistance surveillance, and make ASPs a regulatory requirement in Saudi
hospitals.
Leadership support was identified as one of the main drivers to facilitate the
adoption and implementation process of ASP through providing required human,
financial and IT resources and by including the ASP duties in the daily tasks and
annual evaluation reports of related staff. Training and residency programmes on
ASPs, infectious diseases and infection control for different health specialities has
been found to be critical to the success of ASPs since there is big demands by
healthcare professionals to improve healthcare courses. There is also need to
improve patients' educational programmes and campaigns on appropriate
antibiotic use and risks of antibiotic resistance, and spread ASPs among hospitals
to improve antimicrobial therapy and patients' safety.
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8.3 Research contribution to knowledge
What is already known regarding this topic (Figure 8.1):
 The issue of increasing rates of AMR is a public health concern worldwide,
but more in Saudi Arabia, due to the high number of expatriates working in
the country and high number of visitors every year for Hajj and Umrah.
 It is also a more serious issue due to lack of national strategies to control
and monitor the use of antimicrobials and resistance rates.
 Only few studies reported the availability of ASPs in big and advanced
hospitals in Saudi, however, the situation in other hospitals are still
unknown.
 Barriers of successful adoption of ASPs have been identified in some
studies worldwide and could include lack of expertise, lack of financial
resources, lack of leadership support and lack of educational and training
programmes.
 Lack of knowledge and awareness among patients regarding appropriate
antimicrobial use and risks of AMR were identified in some studies
worldwide.
What this research adds to existing knowledge (Figure 8.1):
 Identified the level of adoption of ASPs in Saudi MOH hospitals (chapter
four and five).
 Investigated barriers and facilitators of ASPs in GCC countries (through
the systematic review (chapter two)), and in Saudi MOH hospitals (chapter
four and five).
 Explored how to adopt ASP in a Saudi MOH and how barriers can be
overcome for successful adoption of ASPs in the Saudi context (chapter
six).
 Identified outcomes of ASPs in GCC countries (through the systematic
review), and in a Saudi MOH hospital (chapter six).
 Patients in the hospital with ASP showed better knowledge and
perceptions regarding antimicrobial use and AMR than patients in the
hospital without ASP (chapter seven).
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Figure 8.1: Research contribution to knowledge
8.4 Strengths and limitations of the research
8.4.1 Strengths
 To the knowledge of the researcher, this is the first research to explore the
situation of ASPs and identify factors influencing their adoption in Saudi
MOH hospitals and explore the adoption process of an ASP in a Saudi
MOH hospital.
 The findings of the systematic review (chapter two) identified gaps in
knowledge regarding ASPs in Saudi hospitals, that were used to develop
the aim and objectives of this research.
Problem: increasing rates of
AMR
Solution: adoption of ASPs
Known: little evidence about
ASPs in Saudi hospitals
Contribution:
1. Identified the level of adoption of
ASPs in GCC countries (through the
systematic review), and in Saudi
MOH hospitals
2. Investigated barriers and facilitators
of ASPs in GCC countries (through
the systematic review), and in Saudi
MOH hospitals
3. Explored how to adopt ASP in a
Saudi MOH hospital
4. Identified outcomes of ASPs in GCC
countries (through the systematic
review), and in a Saudi MOH
hospital
5. Patients in the hospital with ASP
have better perceptions regarding
antimicrobials and AMR
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 The systematic review search was carried out in both Arabic and English
languages in order to identify all the available information and gain in-depth
understanding of the topic.
 The researcher used a mixed methods approach (a qualitative and a
quantitative methods) as a method of triangulation in order to enhance the
validity and reliability of the research findings.
 A sequential exploratory method was used which involved the use of a
qualitative tool followed by a quantitative tool, that was developed from the
findings of the qualitative study, this is to increase the generalisability of
the findings and apply the findings to a wider population.
 The researcher explored and investigated the situation of ASPs in Saudi
MOH hospitals from the point of view of different healthcare professionals
including, ID specialists/consultants, hospitals pharmacists,
microbiologists, infection control practitioners/ specialists/consultants,
nurses, physicians (healthcare providers), hospitals leaders, and MOH
leaders (decision-makers).
 The findings of the qualitative study (chapter four) informed the
development of the national survey (chapter five).
 The use of social media platforms such as WhatsApp and Twitter to
distribute the national survey link improved the response rate.
8.4.2 Limitations
 This research explored the situation of ASPs in Saudi MOH hospitals only,
so the findings of this research may not be applied to other types of
hospitals.
 The main limitation of the qualitative study (chapter four) was that the
sample size was relatively small, therefore, generalisability cannot be
ensured. However, to overcome this limitation, interviews were conducted
with different healthcare professionals from different hospital settings and
with policy makers on regional and national levels to attempt to capture the
views of personnel from different settings and levels.
 The main limitation of the quantitative study (chapter five) was the
response rate (53.6%) which is always one of the main limitations of
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surveys. Although, reminders were sent at two weeks intervals to increase
response rate, and different methods were used to distribute the survey
link.
 No responses were received from obstetrics/gynaecology, paediatrics and
chest hospitals for the national survey, therefore the findings of the study
cannot be applied to these hospitals.
 Although, a national approval was obtained from the Saudi MOH to
conduct the survey in all Saudi MOH hospitals, some hospitals requested
to apply for their own approvals which was not applicable due to the time
frame of this research.
 The reliability of online self-administered surveys is lower than other
methods of survey administration, as the identity of respondents cannot be
ensured due to the physical absence of the researcher from the
respondent. However, the online link of the survey (chapter five) was sent
through official channels to ensure that the link will reach the targeted
participants and no other people.
 The case study (chapter six) was conducted in a hospital with some
resources that may not be available in other hospitals, so resources and
hospital structure in other hospitals should be considered before applying
the findings of this study.
 Lack of IT resources hindered the electronic collection of some data
regarding outcomes of the ASP at the medical city (chapter six), as data
were collected manually at some departments, which resulted in workload
and in some data being unavailable.
 The patients' survey (chapter seven) was conducted only in two hospitals,
therefore the findings of the study may not be applied to other hospitals.
8.5 Recommendations
The prevalence of multi-drug resistant pathogens in Saudi Arabia, coupled with
the widespread inappropriate use of antimicrobials put the country on a fast track
to the pre-antibiotic era. This is particularly alarming since the country hosts one
of the largest expatriate populations in the world, and is a destination to millions
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of travellers for annual and seasonal pilgrimage rituals; increasing the risk of
spreading AMR to most countries in the world.
Urgent action is needed to address the strategies priorities associated with AMR,
including access to antimicrobials, antimicrobial stewardship and education and
research. A key context to also consider here is Hajj and the need to reduce the
risk of globalising AMR during this mass gathering.
Access
It is imperative that patients have access to antimicrobials that could improve
health and save lives. But a balance has to be achieved to secure access whilst
restricting excess and inappropriate use. The main drivers of AMR in Saudi
include inappropriate and overuse of antimicrobials resulting from lack of
knowledge by both patients and clinicians on the subject, gaps in existing policies
on tackling AMR and lack or poor implementation of relevant policies. The
establishment of a national antimicrobial stewardship plan and the recent
introduction of legislation to prohibit the sale of antimicrobials over the counter are
encouraging initiatives to reduce inappropriate and excessive use of antibiotics.
However, if healthcare professionals are now aware of such initiatives, and
regulations are not enforced, these efforts are likely to be futile. Therefore:
 Policy makers are required to commit to implement the national AMR
strategy by establishing effective ASPs at national and regional levels both
in hospitals and community care settings.
 Having ASPs should become a regulatory requirement for accreditation of
hospitals in Saudi Arabia.
 The MOH is also required to restrict access to antimicrobials over the
counter through enforcing the recently introduced legislations.
 Higher education institutions and teaching hospitals are required to
introduce antimicrobial prescribing and stewardship competencies into
undergraduate Medical, Pharmacy, Dental, Nursing and Veterinary
curriculum, as well as introduction of AMR topics in order to increase
knowledge and awareness of ASPs and AMR.
 The Saudi commission for Health Specialities, in partnership with higher
education institutions, teaching hospital and even international
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collaborators is urgently required to increase the provision of ID and
infection control residency and training programmes to meet the extreme
shortage of ID physicians, pharmacists, microbiologists and infection
control practitioners. The availability of specialised staff to form ASP teams
is a key determinant of successful adoption and implementation of ASPs
in Saudi hospitals.
 The Saudi Food & Drug Administration (FDA) is required to restrict the
marketing of antimicrobials especially the ones that are reserved for
resistant/ life-threatening infections. This strategy can control the
accessibility of antimicrobials and reduce their inappropriate use.
Stewardship
Reducing the inappropriate use of antimicrobials in Saudi hospitals has been
recognised by the Saudi MOH as a top priority, through the establishment of a
national ASP strategy and the planned implementation across hospitals in the
kingdom. However, due to the gravity of AMR, urgent and fast actions are required
to accelerate ASPs adoption and improve prescribing practices. To achieve this,
it is essential that the following actions are put in place:
 Disseminating of good practice by establishing collaboration between
ASPs adopting and non-adopting hospitals to share implementation
experience, strategies and solutions to overcome barriers.
 Establishing regional surveillance systems that feed into a national
surveillance programme that is able to monitor resistance rates and inform
infection prevention and control practices. Laboratory-based surveillance
is probably the most efficient method, but the MOH has to invest in
laboratory infrastructure, and certainly robust information systems to
support the surveillance programme.
 Investing in health information systems that support prescribing decisions,
improve communication and data sharing, and enable tracking of
antimicrobial consumption not only in secondary care, but also primary
care including the private sector. Data will inform local and national
strategies to reduce AMR.
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 Enrolling in the GLASS programme to share antimicrobials consumptions
and resistance rates internationally in order to be part of the global
decision-making and to drive the national plan.
The MOH has already adopted the AWaRe model (Access, Watch and Reserve)
when categorising antimicrobials in their guidelines, and Saudi hospitals have
these guidelines in place but they are not adhered to, as they are poorly enforced
by the Ministry as well as the hospital management. A proper implementation of
these guidelines requires:
 Close collaboration between the MOH, hospital management,
professional regulators and healthcare professionals; and
 Hospitals providing a comprehensive and compulsory educational and
training programme about ASPs, appropriate use of antimicrobials and
risks of AMR to all new staff including physicians, pharmacists,
microbiologists and nurses
Reducing inappropriate use of antimicrobials can also be achieved through
improving the provision of preventative measures to reduce the spread of
infections and optimise the role of vaccines in improving public health. Further,
national campaigns and enhanced advertising through multimedia and social
media channels can increase the public’s awareness and knowledge of AMR and
how to preserve antimicrobials. This can be similar to the UK Antibiotic Guardian
that supports the UK AMR national strategy, the EAAD and the World Antibiotic
Awareness Week.
Research
Although the literature relating to antimicrobial stewardship is rich, little is known
about the adoption and implementation of ASPs in the context of the Middle East.
It is imperative that antimicrobial stewardship is explored in Saudi Arabia and
other countries in the region, mainly because, the region may become a “hot spot”
of rare and virulent strains of resistant microbes; and these may find their way to
every other country in the world. Multi-disciplinary research, linking all sectors of
healthcare is needed to provide insightful recommendations towards intelligent,
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integrated and mindful approaches to reduce the inappropriate use of
antimicrobials. For that:
 Healthcare specialised associations (such as the newly established Saudi
Clinical Pharmacy Association) are needed to be part of AMR conversation
and guide healthcare professionals’ training and accreditation.
 A centre in MOH is needed to share expertise, ideas, experiences, and
solutions on a national level to provide implementation tools and resources
to help hospitals to adopt ASPs.
 Learning from failures is important, and therefore, introducing Failure Mode
and Effects Analysis (FMEA) as a routine practice in hospitals and at a
national level will ensure policies and procedures are regularly reviewed
and updated to improve implementation
 Funding of research activities, networking across disciplines and sharing
research ideas and solutions will ensure that local problems have local
solutions and are applicable to the local population.
Multiple stakeholders should be actively part of the conversations around tacking
AMR. Primary care, secondary care, community pharmacies and policy makers
should strive to create a shared culture of responsibility among all healthcare
partners to improve antimicrobial therapy and reduce risks of AMR.
It is recommended that efforts to implement ASPs should follow a step-wise
approach; starting at regulation level, then prescribing policies and practices in
healthcare settings, parallel to integrating microbiology services and diagnostics
to prescribing formularies and decisions, then at pharmacy dispensing levels and
strengthening the role of pharmacists in curbing inappropriate prescribing, then
should end at improving the appropriate use of antimicrobials by the end user.
The Saudi MOH has already started rolling the programme in both secondary and
tertiary hospitals centrally (mainly in Riyadh) then regionally, then locally.
However, no plans have yet been announced regarding the primary care sector,
but these are urgently needed not to render the national ASP programme futile.
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The timeline to implement antimicrobial stewardship recommendations should be
agreed with stakeholders to take into account agreed milestones and length of
interventions; bearing in mind that a “one size fits all” approach may not be
feasible and may undermine the success of ASPs implementation. Evaluation of
outcomes of ASPs interventions should be both patient and pathogen-based.
These evidence of effectiveness in turn, could support the optimal design and use
of ASPs interventions.
The recommendations of this research will be shared with the Saudi MOH (the
infection control department and the pharmaceutical care department) and
healthcare professionals who participated in this research.
8.6 Future Research
To advance research in this area, future research could:
 Explore the situation and factors influencing ASPs in other governmental
hospitals (such as Ministry of National Guard, Ministry of Defence, Ministry
of Education and Ministry of Interior Hospitals), private hospitals, primary
healthcare centres (PHCs) and community pharmacies.
 Explore the adoption and implementation process of ASPs in other Saudi
MOH hospitals, other governmental hospitals, private hospitals, PHCs and
community pharmacies in order to gain a better understanding of the
situation of ASPs in different hospitals types and provide recommendations
to relevant organisations accordingly.
 Assess patients' knowledge and perceptions regarding antimicrobial use
and resistance in other MOH hospitals, governmental hospitals, private
hospitals, community pharmacies and among the general public in order
to gain a better understanding of the situation in different settings and
provide recommendations at a national level.
 Develop, run and assess public health campaigns to educate the general
public and patients on the appropriate use of antimicrobials and risks of
AMR.
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8.7 Reflection on the Research Process
Reflexivity is the process of critically reflecting on the researcher himself, his role
in the research, relation with the research topic and research environment. It
critically explores the researcher's personal experience in relation to the research
environment and context. This is essential to understand the influence of the
researcher's characteristics and experiences on the research process and
methods.
My educational background and work experience as a full-time hospital
pharmacist at a central MOH hospital in a Saudi region has provided me with
knowledge and skills that helped me to start this project. My previous work
experience in a Saudi MOH hospital showed me the issue of the overuse and
misuse of antimicrobials and the lack of surveillance of antimicrobials and AMR
rates in Saudi hospitals. This was the motivation to start reading about
international experiences in controlling the overuse and misuse of antimicrobials,
which identified ASPs as one of the solutions to monitor the use of antimicrobials.
As a previous member of the Saudi MOH, ethical approvals from the participating
hospitals and the Saudi MOH were successfully obtained, as I used my network
to help obtain hospital and MOH approvals.
Throughout this research, I have improved my research skills and learnt the
different methodological approaches needed to answer specific research
questions. I have also learnt about what method to use to answer a research
question and why, the different methods to collect qualitative and quantitative
data, how to analysis them, sampling methods, reliability and validity of data, this
was done through reading different research articles and through the generic
research training courses offered by the UH. The regular meetings and feedback
from my supervisors, improved my personality, research and writing skills, critical
thinking and communication skills.
This PhD journey has been a life learning experience. It has improved my
knowledge, research skills, communication and network in the UK and Saudi,
which opens doors for future research and collaboration. I am really thankful for
the support and encouragement of my sponsors, university, supervisors,
participants and colleagues at the Saudi MOH who helped me immensely to
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collect data for this project and achieve the objectives of this research. My only
hope is that this project will inform policy makers and healthcare professionals to
make ASPs adoption and implementation a reality in Saudi hospitals.
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Appendix 2: Qualitative study interview schedule
Interview schedule
Good morning/afternoon and welcome. I would like to thank you for taking the time to
join this interview.
The aim of this session is to explore the prevalence and characteristics of
antimicrobial stewardship practices and barriers and facilitators for their
adoption to promote and monitor the judicious use of antimicrobials in Saudi
hospitals.
This interview is part of my PhD research at the University of Hertfordshire to examine
the adoption of antimicrobial stewardship programs in Saudi hospitals.
The interview should take around (15) minutes to complete.
Please note that today’s discussion will be audio recorded and transcribed verbatim to
ensure the full interpretation of your contribution. Only the research team, comprising
of me (Mr Saleh Alghamdi), and the supervisory team comprising of Dr Ilhem Berrou,
Dr Nada Atef Shebl and Dr Zoe Aslanpour, will have access to this recording and
transcript.
Once the interview is transcribed I will send you a copy to make sure you are happy
with the interview content and to check that we have not missed anything.
There are no right or wrong answers to the questions I am going to ask. Please feel
free to share your opinion or experience.
Onto the questions,
Part A
1. Hospital………………………….
2. City………………………………
3. Bed capacity……………………..
4. Current position?
Infectious diseases physician o
Clinical/hospital pharmacist o
Microbiologist o
Chief executive officer/medical officer o
Infection control practitioner/nurse o
5. Gender?             Male                  Female
6. Years of experience?
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Part B
1. What antimicrobial stewardship practices are you employing at your hospital to
promote and monitor the judicious use of antimicrobials?
2. Who are the members involved in these practices?
3. What is the role of each member?
4. How often do those members meet?
5. How effective are those practices in promoting and monitoring the judicious use of
antimicrobials? Why?
6. What policies or recommendations are implemented in your practice to help combat
resistance/ or help reduce antimicrobial resistance?
7. Who do you report resistance data to?
8. Have you faced any difficulties (e.g. non-acceptance of recommendations from
HCWs, lack of resources/personnel for the program) in implementing antimicrobial
stewardship practices? If yes, what happened and how was the situation handled?
9. Can you give an example of meeting an antimicrobial stewardship practice specific
outcome, what was the situation, and what enabled success?
10. Can you give an example of NOT meeting an antimicrobial stewardship practice
specific outcome, what was the situation, and what were the reasons for not being
successful?
11. Which antimicrobial stewardship practices are MORE likely to be accepted/effective
at your hospital to promote and monitor the judicious use of antimicrobials? Why?
12. Which antimicrobial stewardship practices are LESS likely to be accepted at your
hospital to promote and monitor the judicious use of antimicrobials? Why?
13. What do you think the main challenges/barriers are going to be in adopting
antimicrobial stewardship practices to promote and monitor the judicious use of
antimicrobials in your hospital?
14. What are the required facilitators for the adoption of antimicrobial stewardship
practices to promote and monitor the judicious use of antimicrobials in your hospital?
Are there any other issues that you feel we haven’t talked about that you would like to
mention?
I would like to thank you for participating in today’s discussion.
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Appendix 3: Qualitative study invitation letter
Subject: Invitation to participate in a research study
Dear Sir/Madam
I am a PhD student at the department of Pharmacy, Pharmacology and Postgraduate
Medicine at the University of Hertfordshire. My research aims to examine the adoption
of antimicrobial stewardship programmes in Saudi hospitals.
I will be grateful if you agree to participate in an interview regarding antimicrobial
stewardship practices in your hospital. The information you provide during the
interview is strictly confidential. Further information on my study is available in the
attached information sheet. This research has been approved by my university ethics
committee and your hospital.
The interview will last approximately (15) minutes and will be conducted in the meeting
room of your department. Please note that there is no incentive for participating in this
interview, and you have the right to withdraw from the study at any time.
If you agree to participate in this study, please sign the attached consent form and
return to your head of department with this letter indicating a time that is convenient
for you.
Date.................. Time..................
Truly yours,
Saleh Alghamdi
PhD student
Department of Pharmacy, Pharmacology and Postgraduate Medicine
University of Hertfordshire
College Lane Campus
Hatfield, United Kingdom
AL10 9AB
s.alghamdi2@herts.ac.uk
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Appendix 4: Written Consent Form
UNIVERSITY OF HERTFORDSHIRE
ETHICS COMMITTEE FOR STUDIES INVOLVING THE USE OF HUMAN PARTICIPANTS
(‘ETHICS COMMITTEE’)
FORM EC3
CONSENT FORM FOR STUDIES INVOLVING HUMAN PARTICIPANTS
I, the undersigned [please give your name here, in BLOCK CAPITALS]
……………………………………………………………………………………………………………
of [please give contact details here, sufficient to enable the investigator to get in touch with
you, such as a postal  or email address]
…..………………………………………………………………………………………………………
hereby freely agree to take part in the study entitled;
The Adoption of Antimicrobial Stewardship Programmes in Saudi MOH hospitals
…………………………………………………………………………………………………………
1 I confirm that I have been given a Participant Information Sheet (a copy of which is
attached to this form) giving particulars of the study, including its aim(s), methods and design,
the names and contact details of key people and, as appropriate, the risks and potential
benefits, and any plans for follow-up studies that might involve further approaches to
participants.   I have been given  details of my involvement in the study.  I have been told that
in the event of any significant change to the aim(s) or design of the study I will be informed,
and asked to renew my consent to participate in it.
2 I have been assured that I may withdraw from the study at any time without disadvantage
or having to give a reason.
3 In giving my consent to participate in this study, I understand that voice, video or photo-
recording will take place.
4 I have been told how information relating to me (data obtained in the course of  the study,
and data provided by me about myself) will be handled: how it will be kept secure, who will
have access to it, and how it will or may be used.
5 I understand that if there is any revelation of unlawful activity or any indication of non-
medical circumstances that would or has put others at risk, the University may refer the
matter to the appropriate authorities.
6 I have been told that I may at some time in the future be contacted again in connection with
this or another study.
Signature of participant……………………………………..…Date………………………….
Signature of (principal) investigator……Saleh Alghamdi……Date…………………………
Name of (principal) investigator…..SALEH ALGHAMDI………………………………………
241
Appendix 5: General directorate of health affairs in Albaha region Ethics
Approval
Kingdom of Saudi Arabia
Ministry of Health
General Directorate of health affairs Al-Baha
To the university of Hertfordshire in the United Kingdom
Upon the request of Mr Saleh Alghamdi, a PhD student in pharmacy at the
university of Hertfodshire, Uk, to conduct his research, titled (The Adoption of
Antimicrobial Stewardship Programmes in Saudi Arabia hospitals), in AlBaha
hospitals.
We inform you that this request is accepted.
Best regards,
General Director of health affairs in AlBaha region
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Appendix 5: General directorate of health affairs in Albaha region Ethics
Approval
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Appendix 6: Qualitative study participant information sheet
UNIVERSITY OF HERTFORDSHIRE
ETHICS COMMITTEE FOR STUDIES INVOLVING THE USE OF HUMAN PARTICIPANTS
(‘ETHICS COMMITTEE’)
FORM EC6: PARTICIPANT INFORMATION SHEET
Title of study
The Adoption of Antimicrobial Stewardship Programmes in Saudi Arabia hospitals
Introduction
You are being invited to take part in a study.  Before you decide whether to do so, it is
important that you understand the research that is being done and what your involvement will
include.  Please take the time to read the following information carefully and discuss it with
others if you wish.  Do not hesitate to ask us anything that is not clear or for any further
information you would like to help you make your decision.  Please do take your time to
decide whether or not you wish to take part.
Thank you for reading this.
What is the purpose of this study?
The aim of this study is to explore the perspectives of physicians, pharmacists,
microbiologists, infection control nurses and hospital administrators regarding:
 The prevalence and characteristics of antimicrobial stewardship practices in Saudi
MOH hospitals.
 The barriers and facilitators for their adoption to promote and monitor the judicious
use of antimicrobials in Saudi MOH hospitals.
Do I have to take part?
It is completely up to you whether or not you decide to take part in this study.  If you do decide
to take part you will be given this information sheet to keep and be asked to sign a consent
form.  Agreeing to join the study does not mean that you have to complete it.  You are free to
withdraw at any stage without giving a reason.  A decision to withdraw at any time, or a
decision not to take part at all, will not affect any treatment/care that you may receive (should
this be relevant).
Are there any age or other restrictions that may prevent me from participating?
You can participate in the study if you are one of the following:
 Infectious diseases (ID) physicians.
 ID/hospital pharmacists.
 Clinical microbiologists.
 Infection control nurses.
 Chief Executive Officers
 Medical directors.
 Physician
 Nurse
How long will my part in the study take?
If you decide to take part in this study, you will be involved in it for around (15) minutes. You
are free to withdraw at any stage without giving a reason.
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What will happen to me if I take part?
If you decide to take part in this study, you will be given this information sheet to keep and be
asked to sign a consent form. You will then attend the interview. Your approval to participate
in the study does not mean that you have to complete it. You are free to withdraw at any
stage without giving a reason. Withdrawing from the study will not be held against you in any
way.
What are the possible disadvantages, risks or side effects of taking part?
There will be no risks or side effects.
What are the possible benefits of taking part?
You will contribute to realize the current situation about infection control and antimicrobial
stewardship practices and barriers and facilitators for their adoption in Saudi hospitals.
How will my taking part in this study be kept confidential?
The data you provide will be confidential and only used for research purposes. Data reporting
will also ensure that you remain anonymous and that your right of confidentiality is consistently
respected. To achieve this, your name, address and other details will be excluded from the
research. Storage and usage of personal information will be undertaken in accordance with the
Data Protection Act 1998 and the EU Directive 95/46 on Data Protection. All audio recordings
will be stored in locked drawers and electronic files (password protected) stored on computer
to which only the researcher/supervisors will have access. Audio files and electronic/paper files
of the interviews transcripts will be destroyed 3 years after completion of the writing of thesis.
What will happen to the data collected within this study?
The data you provide will be confidential and only used for research purposes. Data reporting
will also ensure that you remain anonymous and that your right of confidentiality is consistently
respected. To achieve this, your name, address and other details will be excluded from the
research. Storage and usage of personal information will be undertaken in accordance with the
Data Protection Act 1998 and the EU Directive 95/46 on Data Protection. All audio recordings
will be stored in locked drawers and electronic files (password protected) stored on computer
to which only the researcher/supervisors will have access. Audio files and electronic/paper files
of the interviews transcripts will be destroyed 3 years after completion of the research.
Who has reviewed this study?
This study has been reviewed by:
The University of Hertfordshire Health and Human Sciences Ethics Committee with Delegated
Authority
The UH protocol number is LMS/PGR/UH/02344
Who can I contact if I have any questions?
If you would like further information or would like to discuss any details personally, please get
in touch with me, in writing, by phone or by email:
Saleh Alghamdi, Principal investigator, s.alghamdi2@herts.ac.uk 00447799914477 or
0550465081
Dr Ilhem Berrou / Principal supervisor / i.berrou@herts.ac.uk
Although we hope it is not the case, if you have any complaints or concerns about any
aspect of the way you have been approached or treated during the course of this
study, please write to the University’s Secretary and Registrar.
Thank you very much for reading this information and giving consideration to taking
part in this study.
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Appendix 7: National Survey (English version)
Hospital Survey on Antimicrobial Stewardship Programmes
This survey asks for your opinions about the barriers and facilitators that may influence your
hospital to adopt and implement antimicrobial stewardship programmes to promote appropriate
use of antimicrobials. It may take up 10 minutes to complete. All information provided will be
strictly confidential and will only be used for the purposes of this research.
Thank you in advance for your co-operation and taking time out of your busy schedule to
participate in this study.
By completing and returning this questionnaire you are giving your consent to participate in
the study and for your responses to be used for the purpose of this research project.
This survey has been reviewed and approved by the General Directorate for Research and
Studies at the Saudi Ministry of Health.
Please do not hesitate to ask any questions or mention any concerns, you can contact the
principal investigator, Mr Saleh Alghamdi. s.alghamdi2@herts.ac.uk
You can complete this questionnaire Online on the following link
https://www.surveymonkey.co.uk/r/772244
Antimicrobial stewardship programmes (ASPs): are hospital based programmes
dedicated to improving antibiotic use, optimise the treatment of infections and reduce
adverse events associated with antibiotic use. These programmes help clinicians
improve the quality of patient care and improve patient safety through increased
infection cure rates, reduced treatment failures and increased frequency of correct
prescribing for therapy and prophylaxis. They also significantly reduce hospital rates
of Clostridium difficile Infection and antibiotic resistance (Centers for Disease Control
and Prevention, 2014).
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Section 1: Background Information
This information will help in the analysis of the survey results
1. Where is your hospital?
□ Aseer □ Hail □ Najran □ Tabouk
□ Al-Jouf □ Jizan □ NorthernBorder □ Taif
□ Baha □ Madinah □ Qasim □ Jeddah
□ Eastern Region □ Makkah □ Riyadh □ Al Qurayyat
□ Hafar Al-Batin □ Al Qunfudah □ Al-Hasa □ Bishah
2. Please identify the Governorate where this hospital is located:……………………
3. What is the number of beds in your hospital?..............................
4. Please indicate if your hospital is:
□ General hospital □ Central hospital (Referral) □ Medical city (specialised)
□ Obstetrics/Gynaecologyand paediatrics □ Obstetrics/Gynaecology □ Paediatrics
□ Eye □ Psychiatric □ Chest
□ Convalescence □ Rehabilitation
5. What is your staff position in this hospital?
□ Clinical pharmacist
□ hospital pharmacist
□ Pharmacy director
□ Infection control specialist/consultant
□ Infection control nurse
□ Infectious diseases specialist/consultant
□ Microbiologists
□ Other (please specify) ……………………………………….
6. In your staff position, do you typically have direct interaction/ contact with
patients taking antimicrobials?
□ Yes, I typically have direct interaction/ contact with patients taking
antimicrobials
□ No, typically I do NOT have direct interaction/ contact with patients taking
antimicrobials
7. Do you have an infectious diseases specialist/ consultant in your hospital?
□ Yes □ No □ I don’ t know
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8. Do you have an infection control practitioner in your hospital?
□ Yes □ No □ I don’ t know
9. Do you have a microbiologist in your hospital?
□ Yes □ No □ I don’ t know
10. Do you have an antimicrobial pharmacist in your hospital?
□ Yes □ No □ I don’ t know
11. Have you heard about antimicrobial stewardship programmes before?
□ Yes □ No □ I don’ t know
12. Do you have an Antimicrobial Stewardship Programme (ASP) in your hospital?
□ Yes □ No □ I don’ t know
13. If no, would you support your hospital’s intention to adopt ASP?
□ Yes, in the next year
□ Yes, in the next 3 to 5 years
□ No
□ I don’ t know
14. If you answered (yes) to question number 12, is any of the staff below involved
in the antimicrobial stewardship programme (ASP) in your hospital? (Please
tick all that apply)
□ Chief executive officer
□ Medical officer
□ Clinical pharmacist
□ hospital pharmacist
□ Pharmacy director
□ Infection control specialist/consultant
□ Infection control nurse
□ Infectious diseases specialist/consultant
□ Microbiologists
□ Other (please specify) ……………………………………….
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Section 2: The adoption and implementation of antimicrobial stewardship programmes
(ASPs) in your hospital
The following questions ask you about your opinions of attributes that may or may not
influence your hospital’s intention to adopt and implement antimicrobial stewardship
programmes.
Strongly
agree
Agree Neutral Disagree Strongly
disagree
Intention to adopt & implement ASPs
15. This hospital intends to adopt and implement ASP
16. This hospital intends to follow ASP guidelines
regularly in the future
17. This hospital would highly recommend the adoption
and implementation of ASPs in other hospitals
Context
18. Many of our patients would expect this hospital to
adopt and implement ASP
19. The legislative regulation pledges this hospital to
adopt and implement ASP
20. The compliance with the legislative regulations
regarding ASP is enforced strictly
21. Our patients would consider us to be forward
thinking by adopting and implementing ASP
The hospital
22. Senior management would provide resources
necessary for the adoption and implementation of
ASP in this hospital
23. Senior management would provide necessary
support for the adoption and implementation of
ASP in this hospital
24. Senior management would support adherence to
ASP in this hospital
25. Senior managers would be enthusiastic about
adopting and implementing ASP in this hospital
26. A specific person (or group) is available for
assistance with the adoption and implementation of
ASP in this hospital
27. We have the knowledge necessary to adopt and
implement ASP in this hospital
28. We have the resources necessary (e.g. experts
and staff) to adopt and implement ASP in this
hospital
29. This hospital has the financial resources to adopt
and implement ASP
30. This hospital has the technological resources to
adopt and implement ASP
ASPs
31. Procedures for adopting and implementing ASP are
clear and understandable
32. I believe that it will be easy to adopt and implement
ASP in this hospital
33. Overall, I believe that ASP will be easy to adhere to
34. I believe that it will be easy for staff to follow ASP
guidelines
35. ASPs are adopted in other hospitals in the country
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I would like to receive the results of this survey □ Yes □ No
Please complete the following section if you would like to receive the results of this survey
Name:
E-mail:
Please feel free to add any comments about Antimicrobial stewardship programmes at
your hospital or in Saudi Arabia
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………..……
………………………………..
Please feel free to add any comments about the survey
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
…………………………………………………………………………………………………..………
………………………………..
Thank you for taking part in this survey
36. ASPs are not very visible in other hospitals
37. Before deciding whether to adopt ASPs, it will be
essential to be able to properly try them out
38. It is essential to adopt ASP on a trial basis long
enough to see their benefits
39. ASPs will improve antimicrobial use
40. ASPs will reduce antimicrobial resistance
41. ASPs will improve patient safety
42. ASPs will not improve patient care
052
)noisrev cibarA( yevruS lanoitaN :8 xidneppA
ﺔ ﻓﻲ اﻟﻣﺳﺗﺷﻔﯾﺎتﺑراﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺣولإﺳﺗﺑﯾﺎن
semmargorP pihsdrawetS laiborcimitnA no yevruS latipsoH
اﻟﺗﻲ ﺗؤﺛر ﻋﻠﻰ ﻗرار اﻟﻣﺳﺗﺷﻔﻰ ﻓﻲ ﺗﺑﻧﻲ ھذا اﻹﺳﺗﺑﯾﺎن ﯾﺳﺄل ﻋن أراﺋﻛم ﺣول اﻟظروف اﻟﻣﺳﺎﻋدة و اﻟﻌواﺋﻖ
ﻣن أﺟل ﺗﻌزﯾز اﻹﺳﺗﺧدام اﻷﻣﺛل ﻟﻠﻣﺿﺎدات اﻟﺣﯾوﯾﺔ. ھذا اﻹﺳﺗﺑﯾﺎن إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔﺑراﻣﺞوﺗﻧﻔﯾذ
ﺟﻣﯾﻊ اﻟﻣﻌﻠوﻣﺎت اﻟﻣﻘدﻣﺔ ﻓﻲ ھذا اﻹﺳﺗﺑﯾﺎن ﺳﺗﻌﺎﻣل ﺑﻣﻧﺗﮭﻰ اﻟﺳرﯾﺔ و ﺳوف دﻗﺎﺋﻖ.01ﺳﯾﺳﺗﻐرق ﻗراﺑﺔ 
ﺗﺳﺗﺧدم ﻓﻘط ﻣن أﺟل أھداف ھذا اﻟﺑﺣث.
ﻓﻲ ھذه اﻟدراﺳﺔ.ﺷﻛرا ﻟﻛم ﻣﻘدﻣﺎ ﻋﻠﻰ ﺗﻌﺎوﻧﻛم و إﯾﺟﺎد اﻟوﻗت ﻣن ﺟدوﻟﻛم اﻟﻣزدﺣم ﻟﻠﻣﺷﺎرﻛﺔ
ﻣن ﺧﻼل إﺳﺗﻛﻣﺎل و إرﺟﺎع ھذا اﻹﺳﺗﺑﯾﺎن, أﻧت ﺗﻌطﻲ ﻣواﻓﻘﺗك ﻋﻠﻰ اﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ و ﻋﻠﻰ إﺳﺗﺧدام 
إﺟﺎﺑﺎﺗك ﻣن أﺟل ھذا اﻟﻣﺷروع اﻟﺑﺣﺛﻲ
اﻟﻣواﻓﻘﺔ ﻋﻠﯾﮫ ﻣن ﻗﺑل اﻹدارة اﻟﻌﺎﻣﺔ ﻟﻠﺑﺣوث و اﻟدراﺳﺎت ﺑوزارة اﻟﺻﺣﺔ ھذا اﻹﺳﺗﺑﯾﺎن ﺗﻣت ﻣراﺟﻌﺗﮫ و 
اﻟﺳﻌودﯾﺔ.
اﻟرﺟﺎء ﻋدم اﻟﺗردد ﻓﻲ اﻟﺳؤال أو اﻹﺳﺗﻔﺳﺎر ﻋن أي ﻣﻌﻠوﻣﺔ. ﺗﺳﺗطﯾﻊ اﻟﺗواﺻل ﻣﻊ اﻟﺑﺎﺣث اﻟرﺋﯾﺳﻲ, ﺻﺎﻟﺢ 
ku.ca.streh@2idmahgla.sاﻟﻐﺎﻣدي, ﻋن طرﯾﻖ
اﻟرﺟﺎء إﻛﻣﺎل اﻹﺳﺗﺑﯾﺎن ﻋن طرﯾﻖ اﻟراﺑط:
442277/r/ku.oc.yeknomyevrus.www//:sptth
ھﻲ ﺑراﻣﺞ ﻓﻲ اﻟﻣﺳﺗﺷﻔﯾﺎت ﻣﺧﺻﺻﺔ ﻟﺗﺣﺳﯾن إﺳﺗﺧدام اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ, ﺑراﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ: 
ﺗﺣﺳﯾن ﻋﻼج اﻟﻌدوى و ﺗﻘﻠﯾل اﻷﺿرار اﻟﻣﺗﻌﻠﻘﺔ ﺑﺈﺳﺗﺧدام اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ. ھذه اﻟﺑراﻣﺞ ﺗﺳﺎﻋد اﻷطﺑﺎء 
ﻟﺗﺣﺳﯾن ﺟودة رﻋﺎﯾﺔ اﻟﻣرﺿﻰ و ﺗﺣﺳﯾن ﺳﻼﻣﺔ اﻟﻣرﺿﻰ ﻣن ﺧﻼل زﯾﺎدة ﻣﻌدﻻت ﻋﻼج اﻟﻌدوى, اﻧﺧﻔﺎض ﻓﺷل 
و زﯾﺎدة ﺗﻛرار اﻟوﺻف اﻟﺻﺣﯾﺢ ﻟﻠﻌﻼج و اﻟوﻗﺎﯾﺔ. ﻛﻣﺎ أﻧﮭﺎ ﺗﻘﻠل إﻟﻰ ﺣد ﻛﺑﯾر ﻣن ﻣﻌدﻻت اﻟﻣﺳﺗﺷﻔﻰ ﻣن اﻟﻌﻼج 
dna lortnoC esaesiD rof sretneC(و ﻣﻘﺎوﻣﺔ اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ eliciffid muidirtsolCﻋدوى 
.)4102 ,noitneverP
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: ﻣﻌﻠوﻣﺎت ﻋﺎﻣﺔ: ھذه اﻟﻣﻌﻠوﻣﺎت ﺳوف ﺗﺳﺎﻋد ﻓﻲ ﺗﺣﻠﯾل ﻧﺗﺎﺋﺞ ھذا اﻷﺳﺗﺑﯾﺎن1اﻟﺟزء 
. أﯾن ﯾﻘﻊ اﻟﻣﺳﺗﺷﻔﻰ اﻟذي ﺗﻌﻣل ﻓﯾﮫ؟1
ﻋﺳﯾر□ ﺣﺎﺋل□ ﻧﺟران□ ﺗﺑوك□
اﻟﺟوف□ ﺟﺎزان□ اﻟﺣدود اﻟﺷﻣﺎﻟﯾﺔ□ اﻟطﺎﺋف□
اﻟﺑﺎﺣﺔ□ اﻟﻣدﯾﻧﺔ اﻟﻣﻧورة□ اﻟﻘﺻﯾم□ ﺟدة□
اﻟﻣﻧطﻘﺔ اﻟﺷرﻗﯾﺔ□ ﻣﻛﺔ اﻟﻣﻛرﻣﺔ□ اﻟرﯾﺎض□ اﻟﻘرﯾﺎت□
ﺣﻔر اﻟﺑﺎطن□ اﻟﻘﻧﻔذة□ اﻷﺣﺳﺎء□ ﺑﯾﺷﺔ□
. اﻟرﺟﺎء ﺗﺣدﯾد اﻟﻣﺣﺎﻓظﺔ اﻟﺗﻲ ﯾﻘﻊ ﻓﯾﮭﺎ اﻟﻣﺳﺗﺷﻔﻰ:.......................................2
. ﻣﺎ ھو ﻋدد اﻷﺳرة ﻓﻲ اﻟﻣﺳﺗﺷﻔﻰ اﻟذي ﺗﻌﻣل ﻓﯾﮫ؟.......................................3
ھل اﻟﻣﺳﺗﺷﻔﻰ اﻟذي ﺗﻌﻣل ﻓﯾﮫ:.4
ﻣﺳﺗﺷﻔﻰ ﻋﺎم□ ﻣﺳﺗﺷﻔﻰ ﻣرﻛزي )ﻣرﺟﻌﻲ(□ ﻣدﯾﻧﺔ طﺑﯾﺔ )ﺗﺧﺻﺻﯾﺔ(□
ﻧﺳﺎء و وﻻدة و □ ﻧﺳﺎء و وﻻدة□ أطﻔﺎل□
أطﻔﺎل
ﻋﯾون□ ﻧﻔﺳﯾﺔ□ ﺻدرﯾﺔ□
ﻧﻘﺎھﺔ□ ﺗﺄھﯾل□
. ﻣﺎ ھو ﻣﻧﺻﺑك اﻟوظﯾﻔﻲ ﻓﻲ ھذا اﻟﻣﺳﺗﺷﻔﻰ؟5
ﺻﯾدﻟﻲ ﺳرﯾري□
ﺻﯾدﻟﻲ□
ﻣدﯾر اﻟﺻﯾدﻟﯾﺔ□
أﺧﺻﺎﺋﻲ/إﺳﺗﺷﺎري ﻣﻛﺎﻓﺣﺔ ﻋدوى□
ﻣﻣرض ﻣﻛﺎﻓﺣﺔ ﻋدوى□
إﺳﺗﺷﺎري/أﺧﺻﺎﺋﻲ أﻣراض ﻣﻌدﯾﺔ□
أﺧﺻﺎﺋﻲ أﺣﯾﺎء دﻗﯾﻘﺔ□
أﺧرى )اﻟرﺟﺎء اﻟﺗﺣدﯾد(.................................□
. ﻣن ﺧﻼل وظﯾﻔﺗك, ھل ﻋﺎدة ﻟدﯾك ﺗﻌﺎﻣل ﻣﺑﺎﺷر ﻣﻊ اﻟﻣرﺿﻰ اﻟذﯾن ﯾﺗﻧﺎوﻟون ﻣﺿﺎدات ﺣﯾوﯾﺔ؟6
ﻣﺿﺎدات ﺣﯾوﯾﺔ., ﻋﺎدة ﻟدي ﺗﻌﺎﻣل ﻣﺑﺎﺷر ﻣﻊ اﻟﻣرﺿﻰ اﻟذﯾن ﯾﺗﻧﺎوﻟون ﻧﻌم□
, ﻋﺎدة ﻟﯾس ﻟدي ﺗﻌﺎﻣل ﻣﺑﺎﺷر ﻣﻊ اﻟﻣرﺿﻰ اﻟذﯾن ﯾﺗﻧﺎوﻟون ﻣﺿﺎدات ﺣﯾوﯾﺔ.ﻻ□
. ھل ﯾوﺟد إﺳﺗﺷﺎري/أﺧﺻﺎﺋﻲ أﻣراض ﻣﻌدﯾﺔ ﻓﻲ اﻟﻣﺳﺗﺷﻔﻰ اﻟذي ﺗﻌﻣل ﻓﯾﮫ؟ 7
ﻧﻌم□ ﻻ□ ﻻ أﻋﻠم□
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. ھل ﯾوﺟد ﻣﻣﺎرس ﻣﻛﺎﻓﺣﺔ ﻋدوى ﻓﻲ اﻟﻣﺳﺗﺷﻔﻰ اﻟذي ﺗﻌﻣل ﻓﯾﮫ؟ 8
ﻧﻌم□ ﻻ□ ﻻ أﻋﻠم□
. ھل ﯾوﺟد إﺳﺗﺷﺎري/أﺧﺻﺎﺋﻲ أﺣﯾﺎء دﻗﯾﻘﺔ ﻓﻲ اﻟﻣﺳﺗﺷﻔﻰ اﻟذي ﺗﻌﻣل ﻓﯾﮫ؟ 9
ﻧﻌم□ ﻻ□ ﻻ أﻋﻠم□
. ھل ﯾوﺟد ﺻﯾدﻟﻲ ﻣﺿﺎدات ﺣﯾوﯾﺔ ﻓﻲ اﻟﻣﺳﺗﺷﻔﻰ اﻟذي ﺗﻌﻣل ﻓﯾﮫ؟ 01
ﻧﻌم□ ﻻ□ ﻻ أﻋﻠم□
. ھل ﺳﻣﻌت ﻋن ﺑرﻧﺎﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻣن ﻗﺑل؟11
ﻧﻌم□ ﻻ□ ﻻ أﻋﻠم□
اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻓﻲ اﻟﻣﺳﺗﺷﻔﻰ اﻟذي ﺗﻌﻣل ﻓﯾﮫ ؟. ھل ﯾوﺟد ﺑرﻧﺎﻣﺞ إدارة 21
ﻧﻌم□ ﻻ□ ﻻ أﻋﻠم□
. إذا أﺟﺑت ب )ﻻ( ﻟﻠﺳؤال اﻟﺳﺎﺑﻖ, ھل ﺳوف ﺗدﻋم ﻧﯾﺔ اﻟﻣﺳﺗﺷﻔﻰ اﻟذي ﺗﻌﻣل ﻓﯾﮫ ﻟﺗﺑﻧﻲ ﺑرﻧﺎﻣﺞ إدارة 31
اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ؟
ﻧﻌم ﺧﻼل اﻟﺳﻧﺔ اﻟﻘﺎدﻣﺔ□
ﻧﻌم ﺧﻼل اﻟﺛﻼث اﻟﻰ ﺧﻣس ﺳﻧوات اﻟﻘﺎدﻣﺔ□
ﻻ□
ﻻ أﻋﻠم□
, ﻣن ﻣن اﻟﻣوظﻔﯾن أدﻧﺎه ﯾﺷﺎرﻛون ﻓﻲ ﺑرﻧﺎﻣﺞ إدارة اﻟﻣﺿﺎدات 21إذا أﺟﺑت ب )ﻧﻌم( ﻟﻠﺳؤال رﻗم . 41
اﻟﺣﯾوﯾﺔ ﻓﻲ اﻟﻣﺳﺗﺷﻔﻰ اﻟذي ﺗﻌﻣل ﻓﯾﮫ؟ )اﻟرﺟﺎء إﺧﺗﯾﺎر ﺟﻣﯾﻊ اﻹﺟﺎﺑﺎت اﻟﻣﻣﻛﻧﺔ(
اﻟﻣدﯾر اﻟﺗﻧﻔﯾذي□
اﻟﻣدﯾر اﻟطﺑﻲ□
ﺻﯾدﻟﻲ ﺳرﯾري□
ﺻﯾدﻟﻲ□
ﻣدﯾر اﻟﺻﯾدﻟﯾﺔ□
أﺧﺻﺎﺋﻲ/إﺳﺗﺷﺎري ﻣﻛﺎﻓﺣﺔ ﻋدوى□
ﻣﻛﺎﻓﺣﺔ ﻋدوىﻣﻣرض □
إﺳﺗﺷﺎري/أﺧﺻﺎﺋﻲ اﻷﻣراض اﻟﻣﻌدﯾﺔ□
352
أﺧﺻﺎﺋﻲ أﺣﯾﺎء دﻗﯾﻘﺔ□
أﺧرى )اﻟرﺟﺎء اﻟﺗﺣدﯾد(.................................□
: ﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑراﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻓﻲ اﻟﻣﺳﺗﺷﻔﻰ اﻟذي ﺗﻌﻣل ﻓﯾﮫ.2اﻟﺟزء 
ﺗؤﺛر ﻋﻠﻰ رﻏﺑﺔ اﻟﻣﺳﺗﺷﻔﻰ اﻟذي ﺗﻌﻣل ﻓﯾﮫ ﻓﻲ ﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑراﻣﺞ إدارة اﻷﺳﺋﻠﺔ اﻟﺗﺎﻟﯾﺔ ﺗﺳﺄل ﻋن أراﺋك ﺣول اﻟﻌواﻣل اﻟﺗﻲ ﻗد ﺗؤﺛر أو ﻻ
اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ.
ﻻ أواﻓﻖ 
ﺑﺷدة
أواﻓﻖ  أواﻓﻖ ﻣﺣﺎﯾد ﻻ أواﻓﻖ
اﻟﻧﯾﺔ ﻟﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑرﻧﺎﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﺑﺷدة
ھذا اﻟﻣﺳﺗﺷﻔﻰ ﯾﻧوي ﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑرﻧﺎﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ.51
ھذا اﻟﻣﺳﺗﺷﻔﻰ ﯾﻧوي إﺗﺑﺎع ﻗواﻧﯾن ﺑرﻧﺎﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﺑﺈﻧﺗظﺎم ﻓﻲ .61
اﻟﻣﺳﺗﻘﺑل
ھذا اﻟﻣﺳﺗﺷﻔﻰ ﺳوف ﯾوﺻﻲ ﺑﻘوة ﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑراﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ .71
ﻓﻲ ﻣﺳﺗﺷﻔﯾﺎت أﺧرى
اﻟﺳﯾﺎق
ﺑرﻧﺎﻣﺞ إدارة اﻟﻌدﯾد ﻣن ﻣرﺿﺎﻧﺎ ﯾﺗوﻗﻌون ﻣن ھذا اﻟﻣﺳﺗﺷﻔﻰ ﺗﺑﻧﻲ و ﺗﻧﻔﯾذ .81
اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ
اﻷﻧظﻣﺔ اﻟﺗﺷرﯾﻌﯾﺔ ﺗﻠزم ھذا اﻟﻣﺳﺗﺷﻔﻰ ﺑﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑرﻧﺎﻣﺞ إدارة اﻟﻣﺿﺎدات .91
اﻟﺣﯾوﯾﺔ
اﻹﻟﺗزام ﺑﺎﻷﻧظﻣﺔ اﻟﺗﺷرﯾﻌﯾﺔ ﺑﺧﺻوص ﺑرﻧﺎﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻣﻔروض .02
ﺑﺷﻛل ﺻﺎرم
و ﺗﻧﻔﯾذ ﺑرﻧﺎﻣﺞ إدارة ﻣرﺿﺎﻧﺎ ﺳوف ﯾﻌﺗﺑرون أن ﺗﻔﻛﯾرﻧﺎ إﻟﻰ اﻷﻣﺎم ﺑﺗﺑﻧﻲ .12
اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ
اﻟﻣﺳﺗﺷﻔﻰ
اﻹدارة اﻟﻌﻠﯾﺎ ﺳوف ﺗوﻓر اﻟﻣوارد اﻟﺿرورﯾﺔ ﻣن أﺟل ﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑرﻧﺎﻣﺞ إدارة .22
اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻓﻲ ھذا اﻟﻣﺳﺗﺷﻔﻰ
اﻹدارة اﻟﻌﻠﯾﺎ ﺳوف ﺗوﻓر اﻟدﻋم اﻟﺿروري ﻣن أﺟل ﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑرﻧﺎﻣﺞ إدارة .32
ﻓﻲ ھذا اﻟﻣﺳﺗﺷﻔﻰاﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ
اﻹدارة اﻟﻌﻠﯾﺎ ﺳوف ﺗدﻋم اﻹﻟﺗزام ﺑﺑرﻧﺎﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻓﻲ ھذا .42
اﻟﻣﺳﺗﺷﻔﻰ
اﻟﻣدراء ﺳوف ﯾﻛوﻧون ﻣﺗﺣﻣﺳﯾن ﺑﺧﺻوص ﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑرﻧﺎﻣﺞ إدارة .52
اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻓﻲ ھذا اﻟﻣﺳﺗﺷﻔﻰ
ﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑرﻧﺎﻣﺞ ﯾوﺟد ﺷﺧص )أو ﻣﺟﻣوﻋﺔ( ﻓﻲ ھذا اﻟﻣﺳﺗﺷﻔﻰ ﻟﻠﻣﺳﺎﻋدة ﻓﻲ .62
إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻓﻲ ھذا اﻟﻣﺳﺗﺷﻔﻰ
ﻟدﯾﻧﺎ اﻟﻣﻌرﻓﺔ اﻟﺿرورﯾﺔ ﻟﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑرﻧﺎﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻓﻲ ھذا .72
اﻟﻣﺳﺗﺷﻔﻰ
ﻟدﯾﻧﺎ اﻟﻣوارد اﻟﺿرورﯾﺔ )ﻣﺛل: اﻟﻣﺗﺧﺻﺻﯾن و اﻟﻣوظﻔﯾن( ﻟﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑرﻧﺎﻣﺞ .82
اﻟﻣﺳﺗﺷﻔﻰإدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻓﻲ ھذا 
ھذا اﻟﻣﺳﺗﺷﻔﻰ ﻟدﯾﺔ اﻟﻣوارد اﻟﻣﺎﻟﯾﺔ ﻟﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑرﻧﺎﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ.92
ھذا اﻟﻣﺳﺗﺷﻔﻰ ﻟدﯾﺔ اﻟﻣوارد اﻟﺗﻘﻧﯾﺔ ﻟﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑرﻧﺎﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ.03
ﺑرﻧﺎﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ
اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ واﺿﺣﺔ و ﻣﻔﮭوﻣﺔإﺟراءات ﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑرﻧﺎﻣﺞ إدارة .13
أﻋﺗﻘد أﻧﮫ ﻣن اﻟﺳﮭل ﺗﺑﻧﻲ و ﺗﻧﻔﯾذ ﺑرﻧﺎﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻓﻲ ھذا .23
اﻟﻣﺳﺗﺷﻔﻰ
ﺑﺷﻛل ﻋﺎم, أﻋﺗﻘد أﻧﮫ ﻣن اﻟﺳﮭل إﺗﺑﺎع ﺑرﻧﺎﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ.33
أﻋﺗﻘد أﻧﮫ ﺳوف ﯾﻛون ﻣن اﻟﺳﮭل ﻋﻠﻰ اﻟﻣوظﻔﯾن إﺗﺑﺎع ﻗواﻧﯾن ﺑرﻧﺎﻣﺞ إدارة .43
اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ 
ﺑراﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻣﺗﺑﻧﺎه ﻓﻲ ﻣﺳﺗﺷﻔﯾﺎت أﺧرى ﻓﻲ اﻟﻣﻣﻠﻛﺔ.53
ﺑراﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻏﯾر واﺿﺣﺔ ﻓﻲ اﻟﻣﺳﺗﺷﻔﯾﺎت اﻷﺧرى.63
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أود اﻟﺣﺻول ﻋﻠﻰ ﻧﺗﯾﺟﺔ ھذا 
اﻹﺳﺗﺑﯾﺎن
ﻻ□ﻧﻌم□
اﻟرﺟﺎء إﻛﻣﺎل اﻟﺟزء اﻟﺗﺎﻟﻲ إذا ﻛﻧت ﺗرﻏب ﻓﻲ اﻟﺣﺻول ﻋﻠﻰ ﻧﺗﯾﺟﺔ ھذا اﻹﺳﺗﺑﯾﺎن
اﻹﺳم:
اﻹﯾﻣﯾل:
ﺷﻛرا ﻹﻛﻣﺎﻟك ھذا اﻹﺳﺗﺑﯾﺎن.
إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ, ﻣن اﻟﺿروري اﻟﻘدرة ﻗﺑل إﺗﺧﺎذ اﻟﻘرار ﺑﺗﺑﻧﻲ ﺑرﻧﺎﻣﺞ.73
ﻋﻠﻰ ﺗﺟرﺑﺗﮫ
ﻣن اﻟﺿروري ﺗﺑﻧﻲ ﺑرﻧﺎﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻟﻔﺗرة ﺗﺟرﯾﺑﯾﺔ ﻛﺎﻓﯾﺔ ﻟرؤﯾﺔ .83
ﻓواﺋده
ﺑراﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﺳوف ﺗﺣﺳن إﺳﺗﺧدام اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ.93
ﻣﻘﺎوﻣﺔ اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔﺑراﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﺳوف ﺗﻘﻠل .04
ﺑراﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﺳوف ﺗﺣﺳن ﺳﻼﻣﺔ اﻟﻣرﺿﻰ.14
ﺑراﻣﺞ إدارة اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻟن ﺗﺣﺳن رﻋﺎﯾﺔ اﻟﻣرﺿﻰ.24
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Appendix 9: National survey invitation letter
Subject: Invitation to participate in a research study
Dear Director of Pharmacy
I am a PhD student at the department of Pharmacy, Pharmacology and Postgraduate
Medicine at the University of Hertfordshire. My research aims to examine the adoption
of antimicrobial stewardship programmes in Saudi hospitals.
I will be grateful if you agree to complete a questionnaire regarding antimicrobial
stewardship practices in your hospital. The information you provide in this
survey is strictly confidential. Further information on my study is available in the
attached information sheet. This research has been approved by my university ethics
committee, and Saudi Ministry of Health.
The questionnaire will take approximately (15) minutes to complete. Please note that
there is no incentive for completing this questionnaire, and you have the right to
withdraw from the study at any time.
Please complete the questionnaire Online on the following link:
https://www.surveymonkey.co.uk/r/772244
Truly yours,
Saleh Alghamdi
PhD student
Department of Pharmacy, Pharmacology and Postgraduate Medicine
University of Hertfordshire
College Lane Campus
Hatfield, United Kingdom
AL10 9AB
s.alghamdi2@herts.ac.uk
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Appendix 10: Saudi MOH Ethics Approval Notification
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Appendix 10: Saudi MOH Ethics Approval Notification
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Appendix 11: Case study interview schedule
Case study Interview schedule
Good morning/afternoon and welcome. I would like to thank you for taking the time to
join this interview.
The aim of this session is to explore and understand the adoption of Antimicrobial
stewardship programme (initiation, adoption decision, implementation) in your hospital.
This interview is part of my PhD research at the University of Hertfordshire to examine
the adoption of antimicrobial stewardship programs in Saudi hospitals.
Please note that today’s discussion will be audio recorded and transcribed verbatim to
ensure the full interpretation of your contribution.
Once the interview is transcribed I will send you a copy to make sure you are happy
with the interview content and to check that we have not missed anything.
There are no right or wrong answers to the questions I am going to ask. Please feel
free to share your opinion or experience.
The interview should take around (20-30) minutes to complete.
Onto the questions,
Part A
1. Current position?
2. Gender?            O  Male                  O   Female
3. Years of experience?
Part B
1. What antimicrobial stewardship practices are you employing at your hospital
to promote and monitor the judicious use of antimicrobials?
2. Who are the members involved in these practices?
3. How often do those members meet?
4. What is your role in the programme?
5. How effective are those practices in promoting and monitoring the judicious
use of antimicrobials? Why?
6. How do you report resistance data?
7. Can you give an example of meeting an antimicrobial stewardship practice
specific outcome, what was the situation, and what enabled success?
8. Can you give an example of NOT meeting an antimicrobial stewardship
practice specific outcome, what was the situation, and what were the reasons
for not being successful?
9. What were the main challenges/barriers that faced you in adopting ASP in
your hospital?
10. What were the required facilitators/solutions for the adoption of ASP?
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11. Can you describe step by step the adoption process of ASP at your hospital
(initiation, adoption decision, implementation)?
 Motivation/reasons to adopt
 Time frame
 Barriers
 Facilitators
 Outcomes
 Meetings
 Monitoring and reporting of Antibiotic use and resistance
 Updating policies
 Dissemination of ASP and outcomes
 Different stages
12. What international policies/guidelines did you follow to implement ASP at
your hospital?
Are there any other issues that you feel we haven’t talked about that you would like to
mention?
I would like to thank you for participating in today’s discussion.
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Appendix 12: Case study invitation letter
Subject: Invitation to participate in a research study
Dear Sir/Madam
I am a PhD student at the department of Pharmacy, Pharmacology and Postgraduate
Medicine at the University of Hertfordshire. My research aims to examine the adoption
of antimicrobial stewardship programmes in Saudi hospitals.
I will be grateful if you agree to participate in an interview regarding the adoption
of antimicrobial stewardship programmes (initiation, adoption decision,
implementation) in your hospital. The information you provide during the
interview is strictly confidential. Further information on my study is available in the
attached information sheet.
This research has been approved by my university ethics committee and your hospital.
The interview will last approximately (20-30) minutes and will be conducted in the
meeting room of your department. Please note that there is no incentive for
participating in this interview, and you have the right to withdraw from the study at any
time.
If you agree to participate in this study, please sign the attached consent form and
return to your head of department with this letter indicating a time that is convenient
for you.
Date.................. Time..................
Truly yours,
Saleh Alghamdi
PhD student
Department of Pharmacy, Pharmacology and Postgraduate Medicine
University of Hertfordshire
College Lane Campus
Hatfield, United Kingdom
AL10 9AB
s.alghamdi2@herts.ac.uk
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Appendix 13: King Abdullah Medical City (KAMC) Ethics Approval
Notification
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Appendix 14: Case study participant information sheet
UNIVERSITY OF HERTFORDSHIRE
ETHICS COMMITTEE FOR STUDIES INVOLVING THE USE OF HUMAN PARTICIPANTS
(‘ETHICS COMMITTEE’)
FORM EC6: PARTICIPANT INFORMATION SHEET
Title of study
The Adoption of Antimicrobial Stewardship Programmes in Saudi Arabia hospitals
Introduction
You are being invited to take part in a study.  Before you decide whether to do so, it is
important that you understand the research that is being done and what your involvement will
include.  Please take the time to read the following information carefully and discuss it with
others if you wish.  Do not hesitate to ask us anything that is not clear or for any further
information you would like to help you make your decision.  Please do take your time to
decide whether or not you wish to take part.
Thank you for reading this.
What is the purpose of this study?
The aim of this study is to explore the adoption of Antimicrobial stewardship programmes
(initiation, adoption decision, implementation) in your hospital.
Do I have to take part?
It is completely up to you whether or not you decide to take part in this study.  If you do decide
to take part you will be given this information sheet to keep and be asked to sign a consent
form.  Agreeing to join the study does not mean that you have to complete it.  You are free to
withdraw at any stage without giving a reason.  A decision to withdraw at any time, or a
decision not to take part at all, will not affect any treatment/care that you may receive (should
this be relevant).
Are there any age or other restrictions that may prevent me from participating?
You can participate in the study if you are one of the following:
 Infectious diseases (ID) physicians.
 ID/hospital pharmacists.
 Clinical microbiologists.
 Infection control nurses.
 Chief Executive Officers.
 Medical directors.
How long will my part in the study take?
If you decide to take part in this study, you will be involved in it for around (20-30) minutes.
You are free to withdraw at any stage without giving a reason.
What will happen to me if I take part?
If you decide to take part in this study, you will be given this information sheet to keep and be
asked to sign a consent form. You will then attend the interview. Your approval to participate
in the study does not mean that you have to complete it. You are free to withdraw at any
stage without giving a reason. Withdrawing from the study will not be held against you in any
way.
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What are the possible disadvantages, risks or side effects of taking part?
There will be no risks or side effects.
What are the possible benefits of taking part?
You will contribute to understand ASP adoption (initiation, adoption decision, implementation)
in Saudi hospitals in order to improve future practices.
How will my taking part in this study be kept confidential?
The data you provide will be confidential and only used for research purposes. Data reporting
will also ensure that you remain anonymous and that your right of confidentiality is consistently
respected. To achieve this, your name, address and other details will be excluded from the
research. Storage and usage of personal information will be undertaken in accordance with the
Data Protection Act 1998 and the EU Directive 95/46 on Data Protection. All audio recordings
will be stored in locked drawers and electronic files (password protected) stored on computer
to which only the researcher/supervisors will have access. Audio files and electronic/paper files
of the interviews transcripts will be destroyed 3 years after completion of the writing of thesis.
What will happen to the data collected within this study?
The data you provide will be confidential and only used for research purposes. Data reporting
will also ensure that you remain anonymous and that your right of confidentiality is consistently
respected. To achieve this, your name, address and other details will be excluded from the
research. Storage and usage of personal information will be undertaken in accordance with the
Data Protection Act 1998 and the EU Directive 95/46 on Data Protection. All audio recordings
will be stored in locked drawers and electronic files (password protected) stored on computer
to which only the researcher/supervisors will have access. Audio files and electronic/paper files
of the interviews transcripts will be destroyed 3 years after completion of the writing of thesis.
Who has reviewed this study?
This study has been reviewed by:
The University of Hertfordshire Health and Human Sciences Ethics Committee with Delegated
Authority
The UH protocol number is LMS/PGR/UH/02344
Who can I contact if I have any questions?
If you would like further information or would like to discuss any details personally, please get
in touch with me, in writing, by phone or by email:
Saleh Alghamdi, Principal investigator, s.alghamdi2@herts.ac.uk 00447799914477
0550465081
Dr Ilhem Berrou / Principal supervisor / i.berrou@herts.ac.uk
Although we hope it is not the case, if you have any complaints or concerns about any
aspect of the way you have been approached or treated during the course of this
study, please write to the University’s Secretary and Registrar.
Thank you very much for reading this information and giving consideration to taking
part in this study.
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Appendix 15: Patients' questionnaires (English)
Patient’s perceptions on antimicrobial use and resistance in Saudi hospitals.
The aim of this survey is to evaluate the knowledge and awareness regarding
antimicrobial use and resistance among hospital patients in Saudi hospitals. Please do
not identify yourself or other individuals.
By completing and returning this questionnaire you are giving your consent to
participate in the study and for your responses to be used for the purpose of this
research project.
The questionnaire should take around (10) minutes to complete.
Part A
1. Gender? O  Male O  Female
2. What is your age group?
o 21-30 years
o 31-40 years
o 41-50 years
o 51-60 years
o 61-70 years
o 71-80 years
3. What level of education have you achieved? ...................................
4. What is your condition for taking antibiotics? ………………………
Part B
B. Access to antibiotics: Please read carefully each statement regarding
access to antibiotics and tick, Agree, Don’t agree or Don’t know.
Agree Don’t agree Don’t know
1. Left-over antibiotics are
good to keep at home in
case they might be needed
later on.
o o o
2. If a family member is sick,
I will give him/her my
antibiotic.
o o o
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3. It is good to be able to get
antibiotics from relatives,
friends or pharmacy without
having to see a doctor.
o o o
4. I will give my antibiotic to a
family member if needed. o o o
C. Effect of antibiotics: Please read carefully each statement regarding
effect of antibiotics and tick, Agree, Don’t agree or Don’t know.
Agree Don’t agree Don’t know
1. When I get cold, I will take
antibiotics to help me get
better quickly. o o o
2. If I feel better after a few
days, I will stop taking my
antibiotics before completing
the course of treatment.
o o o
3. Antibiotics are indicated to
relieve pain/inflammation. o o o
4. Antibiotics are used to stop
fever. o o o
5. Antibiotics are effective
against bacteria. o o o
6. Antibiotics are effective
against viruses. o o o
D. Antibiotics resistance: Please read carefully each statement and tick,
Agree, Don’t agree or Don’t know.
Agree Don’t agree Don’t know
1. Antibiotic resistance can
be due to using antibiotics
when they are not necessary.
o o o
2. Antibiotic resistance can
be due to not completing the
full course of antibiotic.
o o o
3. Antibiotic resistance can
be due to using antibiotics
without physician prescription
(self-medication).
o o o
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Agree Don’t agree Don’t know
4. Antibiotic resistance can
be due to using the same
antibiotic with a different
brand.
o o o
5. Antibiotic resistance is a
problem in Saudi today. o o o
6. Antibiotic resistance is a
problem in the rest of the
world today.
o o o
E. Doctor’s habits and the patient/doctor relationship: Please read
carefully each statement and tick, Agree, Don’t agree or Don’t know.
Agree Don’t agree Don’t know
1. I trust the doctor decision if
she or he decides not to
prescribe antibiotics.
o o o
2. I trust the doctor decision if
she or he decides to
prescribe antibiotics.
o o o
3. Doctors often take time to
consider carefully whether
antibiotics are needed or not. o o o
4. Doctors often prescribe
antibiotics because the
patient expects it. o o o
5. A doctor who doesn’t
prescribe antibiotics when
the patient thinks s/he
should, is a bad doctor.
o o o
6. I consult another physician
to prescribe antibiotics if my
physician disagreed to do so.
o o o
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F. Patients’ use of antibiotics during hospital stay: Please read carefully
each statement and tick, Agree, Don’t agree or Don’t know
Agree Don’t agree Don’t know
1. My doctor/pharmacist told
me that I am being treated
with antibiotics.
o o o
2. I was told about how to
take the antibiotic. o o o
3. This hospital is strict when
it comes to prescribing
antibiotics. o o o
4. This hospital provides
information on antibiotic
resistance. o o o
5. My hospital stay improved
my awareness of antibiotic
resistance.
o o o
Thank you for completing this survey.
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درﺟﺔ ﻣﻌرﻓﺔ و وﻋﻲ اﻟﻣرﺿﻰ ﻓﻲ اﻟﻣﺳﺗﺷﻔﯾﺎت اﻟﺳﻌودﯾﺔ ﺑﺧﺻوص اﺳﺗﺧدام اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ و ﻣﻘﺎوﻣﺗﮭﺎ.
ﻣﻌرﻓﺔ و وﻋﻲ اﻟﻣرﺿﻰ ﻓﻲ اﻟﻣﺳﺗﺷﻔﯾﺎت اﻟﺳﻌودﯾﺔ ﺑﺧﺻوص اﺳﺗﺧدام اﻟﮭدف ﻣن ھذا اﻹﺳﺗﺑﯾﺎن ھو ﺗﻘﯾم 
اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ و ﻣﻘﺎوﻣﺗﮭﺎ. اﻟرﺟﺎء ﻋدم اﻟﺗﻌرﯾف ﺑﻧﻔﺳك أو أي ﺷﺧص اﺧر.
إﻛﻣﺎل و إﻋﺎدة ھذا اﻹﺳﺗﺑﯾﺎن ﯾﻌﺗﺑر ﻣواﻓﻘﺔ ﻣﻧﻛم ﻋﻠﻰ اﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ و ﻋﻠﻰ اﺳﺗﺧدام ردودﻛم ﻓﻲ ھذا 
اﻟﻣﺷروع اﻟﺑﺣﺛﻲ.
دﻗﺎﺋﻖ.01ﯾﺳﺗﻐرق إﻛﻣﺎل ھذا اﻹﺳﺗﺑﯾﺎن ﻣﺎ ﯾﻘﺎرب ﻣن اﻟﻣﺗوﻗﻊ أن
اﻟﺟزء اﻻول
ذﻛر        أﻧﺛﻰ. اﻟﺟﻧس؟1
. ﻣﺎ ھﻲ اﻟﻔﺋﺔ اﻟﻌﻣرﯾﺔ اﻟﺧﺎﺻﺔ ﺑك؟2
ﺳﻧﺔ03-12o
ﺳﻧﺔ04–13o
ﺳﻧﺔ05–14o
ﺳﻧﺔ06–15o
ﺳﻧﺔ07–16o
ﺳﻧﺔ08–17o
.................................................. ﻣﺎ ھو ﻣﺳﺗواك اﻟﺗﻌﻠﯾﻣﻲ؟3
. ﺳﺑب اﻷﺳﺗﺧدام اﻟﺣﺎﻟﻲ ﻟﻠﻣﺿﺎد اﻟﺣﯾوي؟ .........................................4
اﻟﺟزء اﻟﺛﺎﻧﻲ
اﻟرﺟﺎء ﻗراءة ﻛل ﻋﺑﺎرة ﺑﺧﺻوص اﻟﺣﺻول ﻋﻠﻰ اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ . اﻟﺣﺻول ﻋﻠﻰ اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ: ب
وإﺧﺗﯾﺎر: 
أواﻓﻖ / ﻻ أواﻓﻖ / ﻻ أﻋﻠم.
ﻻ أﻋﻠمﻻ أواﻓﻖأواﻓﻖ
. اﻹﺑﻘﺎء ﻋﻠﻰ اﻟﻣﺿﺎدات 1
اﻟﺣﯾوﯾﺔ اﻟزاﺋدة ﻋن اﻟﺣﺎﺟﺔ 
ﻣﻔﯾد ﻓﻲ ﺣﺎﻟﺔ اﻟﺣﺎﺟﺔ ﻟﮭﺎ 
ﻓﻲ وﻗت اﺧر.
ooo
. ﻓﻲ ﺣﺎﻟﺔ ﻣرض أﺣد 2
أﻓراد اﻟﻌﺎﺋﻠﺔ ﺳوف أﻗوم 
ﺑﺈﻋطﺎﺋﮫ اﻟﻣﺿﺎد اﻟﺣﯾوي 
اﻟﺧﺎص ﺑﻲ.
ooo
. ﻣن اﻟﻣﻔﯾد اﻟﺣﺻول 3
oooﻋﻠﻰ اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ 
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ﻣن اﻷﺻدﻗﺎء أو اﻷﻗﺎرب 
اﻟﺻﯾدﻟﯾﺔ ﺑدون اﻟﺣﺎﺟﺔ او 
ﻟرؤﯾﺔ اﻟطﺑﯾب.
. ﺳوف اﻗوم ﺑﺈﻋطﺎء 4
اﻟﻣﺿﺎد اﻟﺣﯾوي اﻟﺧﺎص ﺑﻲ 
ﻷﺣد أﻓراد اﻷﺳرة ﻋﻧد 
ﻣرﺿﮫ.
ooo
اﻟرﺟﺎء ﻗراءة ﻛل ﻋﺑﺎرة ﺑﺧﺻوص ﺗﺄﺛﯾر اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ وإﺧﺗﯾﺎر: أواﻓﻖ / ﻻ أواﻓﻖ / ﻻ . ﺗﺄﺛﯾر اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ: س
أﻋﻠم.
ﻻ أﻋﻠمﻻ أواﻓﻖأواﻓﻖ
. ﻋﻧدﻣﺎ أﺻﺎب ﺑﺎﻟزﻛﺎم 1
ﺳوف أﻗوم ﺑﺗﻧﺎول اﻟﻣﺿﺎد 
اﻟﺣﯾوي ﻣن أﺟل اﻟﺷﻔﺎء 
ﺑﺳرﻋﺔ.
ooo
. ﻋﻧدﻣﺎ ﺗﺗﺣﺳن ﺣﺎﻟﺗﻲ ﺑﻌد 2
ﻋدة أﯾﺎم ﺳوف اﻗوم 
ﺑﺎﻟﺗوﻗف ﻋن إﻛﻣﺎل اﻟﻛﻣﯾﺔ 
اﻟﻣﺗﺑﻘﯾﺔ ﻣن اﻟﻣﺿﺎد 
اﻟﺣﯾوي.
ooo
. اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ 3
ﺗﺳﺗﺧدم ﻟﻣﻌﺎﻟﺟﺔ اﻻﻻم و 
اﻹﻟﺗﮭﺎﺑﺎت.
ooo
اﻟﺣﯾوﯾﺔ . اﻟﻣﺿﺎدات 4
ﺗﺳﺗﺧدم ﻟﻣﻌﺎﻟﺟﺔ ارﺗﻔﺎع 
درﺟﺔ اﻟﺣرارة.
ooo
. اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻓﻌﺎﻟﺔ 5
oooﺿد اﻟﺑﻛﺗﯾرﯾﺎ.
. اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻓﻌﺎﻟﺔ 6
oooﺿد اﻟﻔﯾروﺳﺎت.
. ﻣﻘﺎوﻣﺔ اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ )ﻗدرة اﻟﻛﺎﺋن اﻟﺣﻲ اﻟدﻗﯾﻖ اﻟﻣﻌروف ﺑﺎﻟﺑﻛﺗﯾرﯾﺎ ﻋﻠﻰ ﺗﺣﻣل ﻣﻔﻌول اﻟﻣﺿﺎد اﻟﺣﯾوي ﻣﻣﺎ د
اﻟرﺟﺎء ﻗراءة ﻛل ﻋﺑﺎرة ﺑﺧﺻوص ﻣﻘﺎوﻣﺔ اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﯾؤدي ﻋﻠﻰ ﻋدم ﻓﻌﺎﻟﯾﺔ اﻟﻣﺿﺎد اﻟﺣﯾوي ﻓﻲ ﺟﺳم اﻹﻧﺳﺎن(: 
وإﺧﺗﯾﺎر: أواﻓﻖ / ﻻ أواﻓﻖ / ﻻ أﻋﻠم.
ﻻ أﻋﻠمﻓﻖﻻ أواأواﻓﻖ
. ﻣﻘﺎوﻣﺔ اﻟﻣﺿﺎدات 1
اﻟﺣﯾوﯾﺔ ﻗد ﺗﻛون ﺑﺳﺑب 
إﺳﺗﺧدام اﻟﻣﺿﺎد اﻟﺣﯾوي 
ﻋﻧدﻣﺎ ﻻ ﯾﻛون ھﻧﺎك ﺣﺎﺟﺔ 
ﻟذﻟك.
ooo
. ﻣﻘﺎوﻣﺔ اﻟﻣﺿﺎدات 2
oooاﻟﺣﯾوﯾﺔ ﻗد ﺗﻛون ﺑﺳﺑب ﻋدم 
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ﻻ أﻋﻠمﻓﻖﻻ أواأواﻓﻖ
ﺗﻧﺎول اﻟﻣﺿﺎد اﻟﺣﯾوي ﺣﺗﻰ 
ﻧﮭﺎﯾﺔ اﻟﻔﺗرة اﻟﻣوﺻوﻓﺔ ﻣن 
اﻟطﺑﯾب.
. ﻣﻘﺎوﻣﺔ اﻟﻣﺿﺎدات 3
ﺑﺳﺑب اﻟﺣﯾوﯾﺔ ﻗد ﺗﻛون 
إﺳﺗﺧدام اﻟﻣﺿﺎد اﻟﺣﯾوي 
ﺑدون وﺻﻔﺔ طﺑﯾﺔ )اﻟﻌﻼج 
اﻟذاﺗﻲ(.
ooo
. ﻣﻘﺎوﻣﺔ اﻟﻣﺿﺎدات 4
اﻟﺣﯾوﯾﺔ ﻗد ﺗﻛون ﺑﺳﺑب 
إﺳﺗﺧﺎدم ﻧﻔس اﻟﻣﺿﺎد 
اﻟﺣﯾوي ﻟﻛن ﻣن ﺷرﻛﺔ 
ﻣﺧﺗﻠﻔﺔ.
ooo
. ﻣﻘﺎوﻣﺔ اﻟﻣﺿﺎدات 5
اﻟﺣﯾوﯾﺔ ﺗﻌﺗﺑر أﺣد اﻟﻣﺷﺎﻛل 
اﻟﺻﺣﯾﺔ ﻓﻲ اﻟﺳﻌودﯾﺔ ﻓﻲ 
اﻟوﻗت اﻟﺣﺎﻟﻲ.
ooo
ﻣﻘﺎوﻣﺔ اﻟﻣﺿﺎدات . 6
اﻟﺣﯾوﯾﺔ ﺗﻌﺗﺑر أﺣد اﻟﻣﺷﺎﻛل 
اﻟﺻﺣﯾﺔ ﻓﻲ اﻟﻌﺎﻟم ﻓﻲ 
اﻟوﻗت اﻟﺣﺎﻟﻲ.
ooo
. اﻟرﺟﺎء ﻗراءة ﻛل ﻋﺑﺎرة ﺑﺧﺻوص ﻋﺎدات اﻷطﺑﺎء و ﻋﻼﻗﺔ اﻟﻣرﯾض و اﻟطﺑﯾب وإﺧﺗﯾﺎر: أواﻓﻖ / ﻻ أواﻓﻖ / ﻻ أﻋﻠم.ي
ﻻ أﻋﻠمﻻ أواﻓﻖأواﻓﻖ
. أﺛﻖ ﻓﻲ ﻗرار اﻟطﺑﯾب 1
ﻋﻧدﻣﺎ ﻻ ﯾوﺻف ﻣﺿﺎد
ﺣﯾوي.
ooo
. أﺛﻖ ﻓﻲ ﻗرار اﻟطﺑﯾب 2
ﻋﻧدﻣﺎ ﯾوﺻف ﻣﺿﺎد 
ﺣﯾوي.
ooo
. ﻏﺎﻟﺑﺎ ﯾﺄﺧذ اﻷطﺑﺎء وﻗﺗﮭم 3
ﻓﻲ اﻟﺗﺎﻛد اذا ﻛﺎن اﻟﻣرﯾض 
ﯾﺣﺗﺎج او ﻻ ﯾﺣﺗﺎج اﻟﻣﺿﺎد 
اﻟﺣﯾوي.
ooo
. ﻏﺎﻟﺑﺎ ﯾوﺻف اﻷطﺑﺎء 4
اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻷن 
اﻟﻣرﺿﻰ ﯾﺗوﻗﻌون اﻟﺣﺻول 
ﻋﻠﯾﮭﺎ.
ooo
. اﻟطﺑﯾب اﻟذي ﻻ ﯾﺳﺗﺟﯾب 5
oooﻟطﻠب اﻟﻣرﯾض ﺑوﺻف 
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اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﯾﻌﺗﺑر 
طﺑﯾﺑﺎ ﺳﯾﺋﺎ.
. أﺳﺗﺷﯾر طﺑﯾﺑﺎ اﺧر 6
ﻟوﺻف اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ 
oooﻋﻧدﻣﺎ ﻻ ﯾوﺻﻔﮭﺎ طﺑﯾﺑﻲ.
. اﻟرﺟﺎء ﻗراءة ﻛل ﻋﺑﺎرة ﺑﺧﺻوص إﺳﺗﺧدام اﻟﻣرﯾض ﻟﻠﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﺧﻼل ﻓﺗرة اﻟﺗﻧوﯾم ﻓﻲ ف
إﺧﺗﯾﺎر: أواﻓﻖ / ﻻ أواﻓﻖ / ﻻ أﻋﻠم.اﻟﻣﺳﺗﻔﺷﯾﺎت و 
ﻻ أﻋﻠمﻻ أواﻓﻖأواﻓﻖ
. ﯾﻘوم اﻟطﺑﯾب / اﻟﺻﯾدﻟﻲ 1
ﺑﺈﺧﺑﺎري ﺑﺄﻧﮫ ﯾﺗم ﻋﻼﺟﻲ 
ﺑﺎﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ.
ooo
. اﻟطﺑﯾب/اﻟﺻﯾدﻟﻲ 2
أﺧﺑرﻧﻲ ﻋن طرﯾﻘﺔ إﺳﺗﺧدام 
اﻟﻣﺿﺎد اﻟﺣﯾوي.
ooo
. ھﻧﺎك ﺗﺷدد ﻓﻲ ﺻرف 3
اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻓﻲ ھذا 
oooاﻟﻣﺳﺗﺷﻔﻰ.
. ھذا اﻟﻣﺳﺗﺷﻔﻰ ﯾزود 4
اﻟﻣرﺿﻰ ﺑﻣﻌﻠوﻣﺎت ﻋن 
اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ و 
ﻣﻘﺎوﻣﺗﮭﺎ.
ooo
. إﻗﺎﻣﺗﻲ ﻓﻲ ھذا اﻟﻣﺳﺗﺷﻔﻰ 5
زادت ﻣﻌﻠوﻣﺎﺗﻲ ﺑﺧﺻوص 
اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ و 
ﻣﻘﺎوﻣﺗﮭﺎ.
ooo
ﺷﻛرا ﻹﻛﻣﺎﻟك ھذا اﻹﺳﺗﺑﯾﺎن.
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Appendix 17: Patients questionnaires Invitation Letter
Subject: Invitation to participate in a research study
Dear Sir/Madam
I am a PhD student at the University of Hertfordshire in the UK. I am conducting
research into infection prevention and control in Saudi hospitals.
I will be grateful if you agree to complete a questionnaire regarding your
perceptions and awareness of infection control and antimicrobial use in
hospital. The information you provide in this questionnaire is strictly
confidential. Further information on my study is available in the attached information
sheet. This research has been approved by my university and this hospital.
The questionnaire will take approximately (10) minutes to complete. Please note that
there is no incentive for completing this questionnaire, and you have the right to
withdraw from the study at any time.
If you agree to participate in this study, please sign the attached consent form and
complete the questionnaire.
Truly yours,
Saleh Alghamdi
PhD student
Department of Pharmacy, Pharmacology and Postgraduate Medicine
University of Hertfordshire
College Lane Campus
Hatfield, United Kingdom
AL10 9AB
s.alghamdi2@herts.ac.uk
772
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إﺳﺗﻣﺎرة اﻟﻣواﻓﻘﺔ ﻟﻠدراﺳﺎت اﻟﺗﻲ ﺗﺣﺗوي ﻋﻠﻰ ﻣﺷﺎرﻛﺔ ﺑﺷرﯾﺔ
اﻧﺎ...................................... ﺑﻣوﺟب ھذه اﻻﺳﺗﻣﺎرة ﻋﻠﻰ اﻟﻣﺷﺎرﻛﺔ ﺑﺣرﯾﺔ ﻓﻲ اﻟدراﺳﺔ ﺑﻌﻧوان ) أﺗﻌﮭد 
اﻋﺗﻣﺎد ﺑراﻣﺞ ﻣراﻗﺑﺔ اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻓﻲ اﻟﻣﺳﺗﺷﻔﯾﺎت اﻟﺳﻌودﯾﺔ(.
واﺻل أؤﻛد ﺑﺎﻧﮫ ﺗم اﻋطﺎﺋﻲ ﻣﻠﻌوﻣﺎت ﻋن اﻟدراﺳﺔ و ﺗﺷﻣل: اﻟﮭدف, طرق ﺟﻣﻊ اﻟﺑﯾﺎﻧﺎت, اﺳﻣﺎء و ارﻗﺎم اﻟﺗ-1
ﻣﻊ اﻟﻘﺎﺋﻣﯾن ﻋﻠﻰ اﻟدراﺳﺔ وﺗم ﺷرح ﻓواﺋد و ﻧﺗﺎﺋﺞ ھذه اﻟدراﺳﺔ. وﺗم إﺑﻼﻏﻲ ﺑدوري ﻓﻲ ھذه اﻟدراﺳﺔ. ﻛﻣﺎ أﻧﮫ ﺗم 
إﺑﻼﻏﻲ أﻧﮫ و ﻓﻲ ﺣﺎﻟﺔ أي ﺗﻐﯾر ﻣﮭم ﻋﻠﻰ اﻟﮭدف او ﺗﺻﻣﯾم اﻟدراﺳﺔ ﺳوف ﯾﺗم إﺑﻼﻏﻲ و ﺳوف ﯾطﻠب ﻣﻧﻲ إﻋﺎدة 
ﺗﻌﺑﺋﺔ إﺳﺗﻣﺎرة اﻟﻣﺷﺎرﻛﺔ.
ﺣﻖ ﺑﺎﻹﻧﺳﺣﺎب ﻣن اﻟدراﺳﺔ ﺧﻼل أي وﻗت و ﺑدون أي ﺳﻠﺑﯾﺎت و ﺑدون اﻟﺣﺎﺟﺔ ﺗم اﻟﺗﺄﻛﯾد ﻟﻲ ﺑﺄﻧﮫ ﻟﻲ اﻟ-2
ﻹﻋطﺎء اي ﺳﺑب.
ﻟﻘد ﺗم إﺑﻼﻏﻲ ﻋن طرﯾﻘﺔ اﻟﺗﻌﺎﻣل ﻣﻊ ﺑﯾﺎﻧﺎﺗﻲ, و ﻛﯾف ﺳوف ﺗﺣﻔظ ﺑﺄﻣﺎن, وﻣن ﯾﺳﺗطﯾﻊ اﻟوﺻول إﻟﯾﮭﺎ و ﻛﯾف -3
ﺳوف ﯾﺗم إﺳﺗﺧداﻣﮭﺎ.
............................ﺗوﻗﯾﻊ اﻟﻣﺷﺎرك ............................ اﻟﺗﺎرﯾﺦ....
ﺗوﻗﯾﻊ اﻟﺑﺎﺣث اﻟرﺋﯾﺳﻲ ......................... اﻟﺗﺎرﯾﺦ ..............................
إﺳم اﻟﺑﺎﺣث اﻟرﺋﯾﺳﻲ ............................... اﻟﺗﺎرﯾﺦ ................................ 
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Appendix 19: Patients' questionnaires participant information sheet
UNIVERSITY OF HERTFORDSHIRE
ETHICS COMMITTEE FOR STUDIES INVOLVING THE USE OF HUMAN PARTICIPANTS
(‘ETHICS COMMITTEE’)
FORM EC6: PARTICIPANT INFORMATION SHEET
Title of study
The Adoption of Antimicrobial Stewardship Programmes in Saudi Arabia hospitals
Introduction
You are being invited to take part in a study.  Before you decide whether to do so, it
is important that you understand the research that is being done and what your
involvement will include.  Please take the time to read the following information
carefully and discuss it with others if you wish.  Do not hesitate to ask us anything
that is not clear or for any further information you would like to help you make your
decision.  Please do take your time to decide whether or not you wish to take part.
Thank you for reading this.
What is the purpose of this study?
The aim of this study is to evaluate the perceptions and awareness regarding
antimicrobial use and resistance among patients in Saudi hospitals.
Do I have to take part?
It is completely up to you whether or not you decide to take part in this study.  If you
do decide to take part you will be given this information sheet to keep and be asked
to sign a consent form.  Agreeing to join the study does not mean that you have to
complete it.  You are free to withdraw at any stage without giving a reason.  A
decision to withdraw at any time, or a decision not to take part at all, will not affect
any treatment/care that you may receive (should this be relevant).
Are there any age or other restrictions that may prevent me from participating?
You can participate in the study if you are:
 A hospital patient taking antibiotics.
 18 years old and more.
How long will my part in the study take?
If you decide to take part in this study, you will be involved in it for around (10)
minutes. You are free to withdraw at any stage without giving a reason.
What will happen to me if I take part?
If you decide to take part in this study, you will be given this information sheet to keep
and be asked to sign a consent form. You will then complete the questionnaire. Your
approval to participate in the study does not mean that you have to complete it. You
are free to withdraw at any stage without giving a reason. Withdrawing from the study
will not be held against you in any way.
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What are the possible disadvantages, risks or side effects of taking part?
There will be no risks or side effects.
What are the possible benefits of taking part?
You will contribute to realize the current situation about the perceptions and
awareness regarding antimicrobial use and resistance among hospital patients in
Saudi MOH general hospitals in order to improve antimicrobial practice and use.
How will my taking part in this study be kept confidential?
The data you provide will be confidential and only used for research purposes. Data
reporting will also ensure that you remain anonymous and that your right of
confidentiality is consistently respected. To achieve this, your name, address and other
details will be excluded from the research. Storage and usage of personal information
will be undertaken in accordance with the Data Protection Act 1998 and the EU
Directive 95/46 on Data Protection. All files will be stored in locked drawers and
electronic files (password protected) stored on computer to which only the
researcher/supervisors will have access. Electronic/paper files will be destroyed 3
years after completion of the writing of thesis.
What will happen to the data collected within this study?
The data you provide will be confidential and only used for research purposes. Data
reporting will also ensure that you remain anonymous and that your right of
confidentiality is consistently respected. To achieve this, your name, address and other
details will be excluded from the research. Storage and usage of personal information
will be undertaken in accordance with the Data Protection Act 1998 and the EU
Directive 95/46 on Data Protection. All files will be stored in locked drawers and
electronic files (password protected) stored on computer to which only the
researcher/supervisors will have access. Electronic/paper files will be destroyed 3
years after completion of the writing of thesis.
Who has reviewed this study?
This study has been reviewed by:
The University of Hertfordshire Health and Human Sciences Ethics Committee with
Delegated Authority
The UH protocol number is LMS/PGR/UH/02344
Who can I contact if I have any questions?
If you would like further information or would like to discuss any details personally,
please get in touch with me, in writing, by phone or by email:
Saleh Alghamdi / Principal investigator, s.alghamdi2@herts.ac.uk 00447799914477
or 0550465081
Dr Ilhem Berrou / Principal supervisor / i.berrou@herts.ac.uk
Although we hope it is not the case, if you have any complaints or concerns
about any aspect of the way you have been approached or treated during the
course of this study, please write to the University’s Secretary and Registrar.
Thank you very much for reading this information and giving consideration to
taking part in this study.
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ﻓﻲ اﻟدراﺳﺔﻧﻣوذج إرﺷﺎدات ﻟﻠﻣﺷﺗرﻛﯾن 
ﻋﻧوان اﻟدراﺳﺔ
اﻋﺗﻣﺎد ﺑراﻣﺞ ﻣراﻗﺑﺔ اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ ﻓﻲ اﻟﻣﺳﺗﺷﻔﯾﺎت اﻟﺳﻌودﯾﺔ
ﻣﻘدﻣﺔ
أﻧت ﻣدﻋو ﻟﻠﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ. وﻗﺑل إﺗﺧﺎذ اﻟﻘرار ﺑﺎﻟﻣﺷﺎرﻛﺔ ﻣن اﻟﻣﮭم أن ﺗﻌرف ﻋن ھذا اﻟﺑﺣث و طﺑﯾﻌﺔ 
ﻣﻧﺎﻗﺷﺗﮭﺎ ﻣﻊ اﻻﺧرﯾن ﻋﻧد اﻟﺣﺎﺟﺔ ﻟذﻟك.اﻟﻣﺷﺎرﻛﺔ. اﻟرﺟﺎء أﺧذ اﻟوﻗت اﻟﻛﺎﻓﻲ ﻟﻘراءة اﻟﻣﻌﻠوﻣﺎت اﻟﻣرﻓﻘﺔ و 
اﻟرﺟﺎء ﻋدم اﻟﺗردد ﺑﺎﻟﺳؤال ﻋن أي ﺷﻲ ﻏﯾر واﺿﺢ أو ﻣن أﺟل أي ﻣﻌﻠوﻣﺎت إﺿﺎﻓﯾﺔ ﻟﻣﺳﺎﻋدﺗك ﻓﻲ إﺗﺧﺎذ ﻗرار 
اﻟﻣﺷﺎرﻛﺔ. اﻟرﺟﺎء أﺧذ اﻟوﻗت اﻟﻛﺎﻓﻲ ﻹﺗﺧﺎذ اﻟﻘرار ﺑﺎﻟﻣﺷﺎرﻛﺔ ﻣن ﻋدﻣﮭﺎ.
ﻣﺎ ھو اﻟﻐرض ﻣن ھذه اﻟدراﺳﺔ؟
ﺗﺻورات و وﻋﻲ اﻟﻣرﺿﻰ ﻓﻲ اﻟﻣﺳﺗﺷﻔﯾﺎت اﻟﺳﻌودﯾﺔ ﺑﺧﺻوص اﺳﺗﺧدام إن اﻟﮭدف ﻣن ھذه اﻟدراﺳﺔ ھو ﺗﻘﯾﯾم 
اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ و ﻣﻘﺎوﻣﺗﮭﺎ.
ھل ﯾﺟب ﻋﻠﻲ اﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ؟
ﻋطﺎﺋك ﻟدﯾك اﻟﺣﻖ ﻓﻲ اﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ ﻣن ﻋدﻣﮭﺎ. ﻋﻧد إﺗﺧﺎذك اﻟﻘرار ﺑﺎﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ ﺳوف ﯾﺗم إ
ھذه اﻟورﻗﺔ و ﺳوف ﯾﺗطﻠب ﻣﻧك ﺗوﻗﯾﻊ ﺗﻌﮭد اﻟﻣﺷﺎرﻛﺔ. ﻣواﻓﻘﺗك ﻋﻠﻰ اﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ ﻻ ﯾﻌﻧﻲ ﺑﺎﻟﺿرورة وﺟوب 
إﻛﻣﺎﻟﮭﺎ. ﻟدﯾك اﻟﺣﻖ ﻓﻲ اﻹﻧﺳﺣﺎب ﻣن اﻟدراﺳﺔ ﻓﻲ أي وﻗت و ﺑدون إﺑداء أي ﺳﺑب. ﻋدم اﻟﻣﺷﺎرﻛﺔ أو اﻹﻧﺳﺣﺎب ﻣن 
ﺗك.اﻟدراﺳﺔ ﻓﻲ أي وﻗت ﻟن ﯾؤﺛر ﻋﻠﻰ ﻋﻼﺟك أو رﻋﺎﯾ
ھل ﯾوﺟد ھﻧﺎك أي ﻋﻣر ﻣﺣدد أو ﻏﯾرھﺎ ﻣن اﻟﻘﯾود اﻟﺗﻲ ﻗد ﺗﻣﻧﻌﻧﻲ ﻣن اﻟﻣﺷﺎرﻛﺔ؟
ﺗﺳﺗطﯾﻊ اﻟﻣﺷﺎرﻛﺔ ﻓﻲ اﻟدراﺳﺔ إذا ﻛﻧت:
ﻣرﯾض ﻣﻧوم
ﺳﻧﮫ أو أﻛﺑر81
ﻣﺎ ھﻲ ﻣدة ﻣﺷﺎرﻛﺗﻲ ﻓﻲ اﻟدراﺳﺔ؟
ﻛﻣﺎ ﯾﺣﻖ ﻟك دﻗﺎﺋﻖ.01ﻓﻲ ﺣﺎﻟﺔ ﻣواﻓﻘﺗك ﻋﻠﻰ اﻟﻣﺷﺎرﻛﺔ ﻓﻲ اﻟدراﺳﺔ, ﺳوف ﯾﺳﺗﻐرق زﻣن اﻟﻣﺷﺎرﻛﺔ ﻋﻠﻰ ﻣﺎ ﯾﻘﺎرب 
اﻹﻧﺳﺣﺎب ﻣن اﻟدراﺳﺔ ﻓﻲ أي وﻗت ﺑدون إﺑداء أي ﺳﺑب.
ﻣﺎذا ﺳوف ﯾﺣﺻل ﻋﻧد اﻟﻣﺷﺎرﻛﺔ ﻓﻲ اﻟدراﺳﺔ؟
ﻋﻧد إﺗﺧﺎذك اﻟﻘرار ﺑﺎﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ, ﺳوف ﯾﺗم إﻋطﺎﺋك ھذه اﻟورﻗﺔ و ﺳوف ﯾﺗطﻠب ﻣﻧك ﺗوﻗﯾﻊ ﺗﻌﮭد اﻟﻣﺷﺎرﻛﺔ, 
رﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ ﻻ ﯾﻌﻧﻲ ﺑﺎﻟﺿرورة وﺟوب إﻛﻣﺎﻟﮭﺎ. ﻟدﯾك اﻟﺣﻖ ﺛم ﯾﺗوﺟب ﻋﻠﯾك إﻛﻣﺎل اﻹﺳﺗﺑﯾﺎن. ﻣواﻓﻘﺗك ﻋﻠﻰ اﻟﻣﺷﺎ
ﻓﻲ اﻹﻧﺳﺣﺎب ﻣن اﻟدراﺳﺔ ﻓﻲ أي وﻗت و ﺑدون إﺑداء أي ﺳﺑب. ﻋدم اﻟﻣﺷﺎرﻛﺔ أو اﻹﻧﺳﺣﺎب ﻣن اﻟدراﺳﺔ ﻓﻲ أي وﻗت ﻟن 
ﯾؤﺛر ﻋﻠﻰ ﻋﻼﺟك أو رﻋﺎﯾﺗك.
ھذه اﻟدراﺳﺔ؟ﻣﺎ ھﻲ اﻟﻣﺳﺎوء , اﻟﻣﺧﺎطر أو اﻻﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ اﻟﻣﺗوﻗﻌﮫ ﻣن اﻟﻣﺷﺎرﻛﺔ ﻓﻲ
ﻻ ﯾوﺟد ھﻧﺎك أي ﻣﺧﺎطر أو اﺛﺎر ﺟﺎﻧﺑﯾﺔ ﻣن ھذه اﻟدراﺳﺔ
ﻣﺎ ھﻲ اﻟﻔواﺋد اﻟﻣﺗوﻗﻌﮫ ﻣن ھذه اﻟدراﺳﺔ؟
و وﻋﻲ اﻟﻣرﺿﻰ ﻓﻲ اﻟﻣﺳﺗﺷﻔﯾﺎت اﻟﺳﻌودﯾﺔ ﺑﺧﺻوص ﺳوف ﺗﺳﺎﻋد ﻋﻠﻰ ﻓﮭم و ﺗﻘﯾم اﻟوﺿﻊ اﻟﺣﺎﻟﻲ ﻟﺗﺻورات
دات اﻟﺣﯾوﯾﺔ وﺗﺣﺳﯾن ﺑﯾﺋﺔ اﻟﻌﻣل.اﺳﺗﺧدام اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ و ﻣﻘﺎوﻣﺗﮭﺎ ﻣن أﺟل ﺗﺣﺳﯾن إﺳﺗﺧدام اﻟﻣﺿﺎ
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ﻛﯾف ﺳوف ﯾﺗم ﺣﻔظ ﺳرﯾﺔ ﻣﺷﺎرﻛﺗﻲ ﻓﻲ ھذه اﻟدراﺳﺔ؟ و ﻣﺎذا ﺳوف ﯾﺣدث ﻟﻠﺑﯾﺎﻧﺎت اﻟﺗﻲ ﺳوف ﯾﺗم اﻟﺣﺻول 
ﻋﻠﯾﮭﺎ ﻓﻲ ھذا اﻟدارﺳﺔ؟
اﻟﻣﻌﻠوﻣﺎت اﻟﺗﻲ ﺳوف ﺗﻘوم ﺑﺗزوﯾدھﺎ ﺳﺗﻛون ﺳرﯾﺔ و ﺗﺳﺗﺧدم ﻓﻘط ﻣن أﺟل أھداف اﻟﺑﺣث. ﻋرض و ﻧﻘل اﻟﺑﯾﺎﻧﺎت 
وإﺑﻘﺎﺋك ﻏﯾر ﻣﻌرف ﺑﺈﺳﺗﻣرار. و ﻣن أﺟل ﺗﺣﻘﯾﻖ ذﻟك : إﺳﻣك و ﺑﯾﺎﻧﺎﺗك اﻟﺷﺧﺻﯾﺔ ﻟن ﺳوف ﯾﺣﻔظ ﺧﺻوﺻﯾﺗك
ﺗذﻛر ﻓﻲ اﻟﺑﺣث. ﻛﻣﺎ أن ﺗﺧزﯾن و إﺳﺗﺧدام اﻟﻣﻌﻠوﻣﺎت ﺳوف ﯾﺗﺑﻊ ﻗواﻧﯾن ﺣﻔظ اﻟﺑﯾﺎﻧﺎت. ﺟﻣﯾﻊ اﻟﻣﻠﻔﺎت ﺳوف 
ﺗﺧدﻣﮫ اﻻ ﺗﺣﻔظ ﻓﻲ أدراج ﻣﻘﻔﻠﺔ وﻣﻠﻔﺎت إﻟﻛﺗروﻧﯾﺔ )ﻣﺣﻣﯾﺔ ﺑﺄرﻗﺎم ﺳرﯾﺔ( ﻣﺣﻔوظﺔ ﻓﻲ ﺟﮭﺎز ﺣﺎﺳب اﻟﻲ ﻻ ﯾﺳ
ﺳﻧوات ﻣن ﻧﮭﺎﯾﺔ ﻛﺗﺎﺑﺔ ھذا 3اﻟﺑﺎﺣث و اﻟﻣﺷرﻓﯾن اﻟدراﺳﯾﯾن. اﻷوراق واﻟﻣﻠﻔﺎت اﻹﻟﻛﺗروﻧﯾﺔ ﺳوف ﺗﺗﻠف ﺑﻌد 
اﻟﺑﺣث.
ﻣن ﻗﺎم ﺑﻣراﺟﻌﺔ ھذه اﻟدارﺳﺔ؟
erihsdroftreHﻗﺎم ﺑﻣراﺟﻌﺔ ھذه اﻟدراﺳﺔ ﻟﺟﻧﺔ أﺧﻼﻗﯾﺎت اﻟﻌﻠوم اﻟﺻﺣﯾﺔ و اﻹﻧﺳﺎﻧﯾﺔ ﺑﺟﺎﻣﻌﺔ 
رﻗم اﻟطﻠب ﻓﻲ اﻟﺟﺎﻣﻌﮫ:
44320/HU/RGP/SML
ﻣﻊ ﻣن أﺳﺗطﯾﻊ اﻟﺗواﺻل ﻓﻲ ﺣﺎﻟﺔ وﺟود أي إﺳﺗﻔﺳﺎر؟
إذا ﻛﻧت ﻓﻲ ﺣﺎﺟﺔ ﻣﻌﻠوﻣﺎت إﺿﺎﻓﯾﺔ أو ﺗود ﻣﻧﺎﻗﺷﺔ أي أﻣور ﺷﺧﺻﯾﺔ, اﻟﻣرﺟو اﻟﺗواﺻل ﻣﻌﻲ ﻣن ﺧﻼل:
او 1805640550/ ku.ca.streh@2idmahgla.sﺻﺎﻟﺢ اﻟﻐﺎﻣدي / اﻟﺑﺎﺣث اﻟرﺋﯾﺳﻲ / 
77441999774400
ku.ca.streh@uorreb.iد. اﻟﮭﺎم ﺑرو / اﻟﻣﺷرف اﻟرﺋﯾﺳﻲ / 
ﻓﻲ ﺣﺎﻟﺔ وﺟود أي ﺷﻛوى أو ﻣﺧﺎوف ﻣن طرﯾﻘﺔ اﻟوﺻول أو اﻟﺗﻌﺎﻣل ﻣﻌك ﺧﻼل ھذه اﻟدراﺳﺔ اﻟﻣرﺟو اﻟﺗواﺻل ﻣﻊ إدارة 
اﻟﺟﺎﻣﻌﮫ أو اﻟﻣﺳﺗﺷﻔﻰ.
ه اﻟﻣﻌﻠوﻣﺎت و اﻟﺗﻔﻛﯾر ﻓﻲ اﻟﻣﺷﺎرﻛﺔ ﻓﻲ ھذه اﻟدراﺳﺔ.ﺷﻛرا ﺟزﯾﻼ ﻟﻘراءة ھذ
